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Wee, sleekit, cowran, tim'rous beastie,  
O, what a panic's in thy breastie!  
Thou need na start awa sae hasty,  
Wi' bickering brattle!  
I wad be laith to rin an' chase thee,  
Wi' murd'ring pattle! 
I'm truly sorry Man's dominion  
Has broken Nature's social union,  
An' justifies that ill opinion,  
Which makes thee startle,  
At me, thy poor, earth-born companion,  
An' fellow-mortal! 
I doubt na, whyles, but thou may thieve;  
What then? poor beastie, thou maun live!  
A daimen-icker in a thrave 'S a sma' request:  
I'll get a blessin wi' the lave,  
An' never miss't! 
Thy wee-bit housie, too, in ruin!  
It's silly wa's the win's are strewin!  
An' naething, now, to big a new ane,  
O' foggage green!  
An' bleak December's winds ensuin,  
Baith snell an' keen! 
Thou saw the fields laid bare an' wast,  
An' weary Winter comin fast,  
An' cozie here, beneath the blast,  
Thou thought to dwell,  
Till crash! the cruel coulter past  
Out thro' thy cell. 
That wee-bit heap o' leaves an' stibble,  
Has cost thee monie a weary nibble!  
Now thou's turn'd out, for a' thy trouble,  
But house or hald.  
To thole the Winter's sleety dribble,  
An' cranreuch cauld! 
But Mousie, thou are no thy-lane,  
In proving foresight may be vain:  
The best laid schemes o' Mice an' Men,  
Gang aft agley,  
An' lea'e us nought but grief an' pain,  
For promis'd joy! 
Still, thou art blest, compar'd wi' me!  
The present only toucheth thee:  
But Och! I backward cast my e'e,  
On prospects drear!  
An' forward, tho' I canna see,  
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The increasing prevalence of Alzheimer’s disease poses a considerable socio-
economic challenge in the years ahead. There are few clinical treatments available 
and none capable of halting or slowing the progressive nature of the condition. 
Despite decades of experimental research and testing over 300 interventions in 
transgenic mouse models of the condition, clinical success has remained elusive. 
Deepening our understanding of how such studies have been conducted is likely to 
provide insights which could inform future preclinical and clinical research. 
Therefore I performed a systematic review and meta-analysis on interventions 
tested in transgenic mouse models of Alzheimer’s disease. 
 
My systematic search was performed by electronically searching for publications 
reporting the efficacy of interventions tested in transgenic models of Alzheimer's 
disease. Across these publications I extracted data regarding study characteristics 
and reported study quality alongside outcome data for pathology (i.e. plaque 
burden, amyloid beta species, tau, cellular infiltrates and neurodegeneration) and 
neurobehaviour. From these data I calculated estimates of efficacy using random 
effects meta-analysis and subsequently investigated the potential impact of study 
quality and study characteristics on observed effect size.  
 
My search identified 427 publications, 357 interventions and 55 transgenic models 
representing 11, 688 animals and 1774 experiments. There were a number of 
principal concerns regarding the dataset: (i) the reported study quality of such 
studies was relatively low; less than 1 in 5 publications reported blinded assessment 
of outcome or random allocation to group and no studies reported a sample size 
calculation, (ii) the depth of data on any individual intervention was relatively poor- 
only 16 interventions had outcomes described in 5 or more publications and (iii) 
publication bias analyses suggested 1 in 5 pathological and 1 in 7 neurobehavioural 





Where I inspected relationships between outcomes, meta-regression identified a 
number of notable associations. Changes in amyloid beta 40 were reflective of 
changes in amyloid beta 42 (R2 = 0.84, p<0.01) and within the Morris water maze 
changes in the ‘training’ acquisition phase could explain 44% of the changes in the 
probe ‘test’ phase (p<0.05). Additionally, I identified measures of neurodegeneration 
as the best pathological predictors of changes in neurobehaviour (R2 = 0.72, p<0.01). 
Collectively this work identifies a number of potential weaknesses within in vivo 
modelling of Alzheimer’s disease and demonstrates how the use of empirical data 
























Chapter 1 Introduction 
 
 
1.1 Brief Introduction 
 
Alzheimer’s disease (AD) has been a subject of curiosity for over two millennia. The 
ancient Greek philosophers Pythagoras, Hippocrates and Plato appreciated that 
mental deterioration is a feature of ageing and saw a mental state of infancy in old 
age was something ‘common to all men’ (Berchtold & Cotman 1998). Our first 
appreciation of dementia itself may have been as early as the 2nd century B.C. The 
Roman philosopher Cicero suggested that mental deterioration does not affect all 
old men equally, but those ‘weak in will’. He eloquently demonstrated his 
appreciation of the delicacy of the aged mind, simultaneously suggesting 
preventative strategies for mental failure; 
 
“it is our duty to resist old age; to compensate for its defects by a watchful care; to fight 
against it as we would fight against disease… . Much greater care is due to the mind and 
soul; for they, too, like lamps, grow dim with time, unless we keep them supplied with oil…. 
Intellectual activity gives buoyancy to the mind…. Old men retain their mental faculties, 
provided their interest and application continue…” (Berchtold & Cotman 1998). 
 
Some two millennia later, in 1901 Bavarian psychiatrist Aloysius Alzheimer met 
Auguste Deter, a patient with an array of distressing symptoms. Once a relatively 
healthy individual, Auguste could not remember the simplest of memory tasks, had 
trouble sleeping and suffered from frequent delusional episodes (Maurer, Volk S., & 
Gerbaldo H. 1997). Alzheimer was curious, not only of her behaviour but also of the 




of common features: amyloid plaques, neurofibrillary tangles and 
neurodegeneration. One hundred years later our understanding of the differences 
between normal brain ageing and AD have advanced (Table 1.1) but there are a 
number of critical questions remain concerning; (i) causation, (ii) progression and  
(iii) potential methods of intervention (see later).  
 








A degree of cognitive decline over 
the age of  65 is expected as a 
normal feature of ageing 
(Andrews-Hanna et al. 2007). 
However, effects are often subtle 
and do not generally impact on day 
to day living. 
A gradual increase in the magnitude and 
frequency of memory loss. Typically presents 
with subtle semantic memory deficits and 
memory acquisition. Later stages of the 
condition are associated with poor general 
comprehension, severe memory 
impairments and loss of independent living 











While older non-demented 
individuals do not frequently 
present widespread plaques or tau 
tangles; evidence suggests some 
restricted AD pathology 
particularly in areas such as the 
neocortex, allocortex and basal 
ganglia (Morris et al. 1996;Thal, Del 
Tredici, & Braak 2004). 
Staging of AD pathology defined by Braak 
stages. Amyloid plaque pathology originates 
from the neocortex and as disease 
progresses tau tangles and amyloid plaque 
pathology can be found across the brain 
including regions such as the hippocampus, 
cortex, midbrain and lower brain stem  
(Thal, Del Tredici, & Braak 2004). 
There is some evidence for both 
regional and widespread neuronal 
loss, however the impact is small in 
magnitude (Schuitemaker et al. 
2012). 
Ultimately AD causes extensive cell 
destruction and death (neurodegeneration). 
Neurodegeneration is overall non selective 
(Coleman & Flood 1987)  but can impact 
greater on some brain regions greater than 
others (e.g. neocortex and hippocampal 
formation) (D'Amelio & Rossini 2012). 
Table 1.1: A comparison of those features of Alzheimer’s disease compared to 





1.2 The prevalence and impact of Alzheimer’s disease 
 
Today, Alzheimer’s disease is estimated to affect more than 35 million individuals 
worldwide (Prince, 2009) and cases are typically observed in patients above 65 years 
of age. Estimates are that every 20 years these rates will double, meaning by the 
year 2050 Alzheimer’s disease will affect 114 million individuals (Wimo et al. 2003). 
With one new case every seven seconds, we face an unprecedented social challenge; 
patients frequently need increasing assistance for daily activities which progresses 
to round the clock care in the later stages. The sacrifice caregivers make cannot be 
understated- managing the care of another who is consistently dependent can 
impact on entire families and the wider community. Equal to such social demands 
are the economics. The cost of dementia in a single year across Europe is currently 
thought to be more than €177 billion (Wimo et al. 2003).  and the annual cost of a 
dementia patient is €20,000- exceeding the cost for both cancer and cardiovascular 
disease (Hampel et al. 2011). 
1.3 Disease causation- genes or environment? 
 
 
Much has been learnt from the 5% of the AD population where symptoms of the 
condition appear earlier in life (i.e. <65 years). While such patients are 
symptomatically indistinguishable from their older counterparts with AD, early 
onset is associated with a number of autosomal dominant mutations. Genetic 
linkage studies have identified three specific genes which are associated with the 




21, presenilin-1 (PS-1) on chromosome 14 (Sherrington et al. 1995) and presenilin-2 
(PS-2) on chromosome 1 (Levy-Lahad et al. 1995) (Rogaev et al. 1995). The high 
prevalence of AD in Downs’ syndrome (trisomy of chromosome 21) provides 
further evidence of the genetic component of the disorder. 
 
For late onset Alzheimer’s disease (>65 years), there is no definitive link between 
disease prevalence and environment or genetics (Alzheimer's Association Report 
2012) however a number of risk factors have been identified; the greatest risk being 
advancing age. Others include: a family history of the condition, type II diabetes 
and lower attainment in education (Alzheimer's Association Report 2012).  Genetic 
risk factors have also been identified, such as the apolipoprotein E (apoE) gene on 
chromosome 19. Those who inherit the E4 allele of apoE are at a greater risk of 
developing late onset of the condition compared to the general population, and 
have an earlier age of onset compared to those who inherit the E2 or E3 alleles 
(Corder et al. 1993;Saunders et al. 1993). Conversely the inheritance of the E2 allele 










1.4 The symptoms of Alzheimer’s disease: a 
progressive neurodegenerative disorder 
 
 
Alzheimer’s disease is a slowly progressive neurodegenerative condition of the 
brain where the frequency and severity of behavioural and pathological 
abnormalities increase over time. Pathological changes are thought to precede 
behavioural changes, and thus numerous intervention strategies specifically target 




Prominent pathologies of AD include: an increase in amyloid levels which 
aggregate as amyloid plaques, tau neurofibrillary tangles, neuroinflammation and 
neurodegeneration. The slow progressive onset of such features is complex, 
multifactorial and our understanding is incomplete. The most widely accepted 
theory connecting the most prominent features of AD is the ‘amyloid cascade 
hypothesis’ (see Figure 1.1). This model is based on the rare autosomal inheritance 
of the condition but it is also thought to represent sporadic AD.  
1.4.1 Amyloid cascade hypothesis and amyloid plaque 
pathology 
 
Amyloid precursor protein (APP) is a single transmembrane peptide which 
undergoes post-translational modification by various secretase enzymes as part of 




normal route of metabolism for APP involves non-amyloidogenic cleavage by α-
secretase- producing an 83-residue C-terminal fragment (C83, [See Figure 1.1]) 
which upon further cleavage by γ-secretase leads to the accumulation of a small 
amyloid species known as p3 (Nunan & Small 2000). p3 is not thought to contribute 
to AD pathology and is relatively obscure.  
 
An alternative sequence of events is thought to occur in AD. First, β-site APP 
cleaving enzyme (BACE) cleaves APP producing C99 and subsequent cleavage by 
γ-secretase (at the 42/43 site) produces amyloid species which aggregate in the 
extracellular space, forming ‘amyloid plaques’. Amyloid species 40 and 42 amino 
acids long (amyloid beta 40 and amyloid beta 42 respectively) are thought to form 
the main constituent of such plaques, and amyloid beta 42  in the insoluble form is 
hypothesised to be particularly neurotoxic: with an ability to ‘seed’ the amyloid 
plaque (McGowan, Eriksen, & Hutton 2006). In recent years, there has been 
considerable interest in the impact of other amyloid assemblies  such as monomers 
and oligomers; for example the 56-kDa soluble amyloid-β assembly has been shown 
correlate well with behavioural deficits in animal models of the condition (Lesne et 
al. 2006). Over time, plaque pathology is thought to become incrementally more 
robust. It remains unclear whether the causation of plaques is due to an increase in 
amyloid production or a reduction in clearance. Nevertheless, the widely accepted 
‘amyloid cascade hypothesis’ (Hardy & Selkoe 2002) suggests that the resultant net 










1.4.2 Tau neurofibrillary tangles 
 
Tau is a multifunctional protein which is most commonly found localised to axons 
that stabilises microtubules. There are six isoforms of tau in the adult brain 
generated by alternative mRNA splicing and the protein has either three or four 
Figure 1.1: Amyloid precursor protein (APP) is normally cleaved by and 
secretase leading to the formation of soluble APP (sAPP In Alzheimer’s disease 
sequential cleavage by and  secretase leads to the aggregation of amyloid and the 
build of plaques. The ‘amyloid cascade hypothesis’ attributes the causation of 
Alzheimer’s disease to an accumulation of amyloid beta aggregates, subsequently 
forming plaques and leading to the downstream phosphorylation of tau, 
progressive neurodegeneration and dementia. Diagram provides a simplified linear 




sites (splicing dependent) capable of binding to microtubules (Johnson & Stoothoff 
2004). Normal cell functionality permits various protein kinases (e.g. Cdk2, MAP 
kinase, GSK3) to phosphorylate tau protein (Baumann et al. 1993) which reduces the 
likelihood of tau binding to microtubules. In AD, this dynamic becomes destabilised 
and the hyperphosphorylation of tau (through one or numerous kinases) leads to an 
abundance of large non-membrane-bound abnormal fibres which occupy much of 
the perinuclear cytoplasm. Such fibres typically self-aggregate and form dense cores 
of insoluble tau in the form of 10-nm helices of ‘paired helical filaments’ (PHF) 
(Selkoe 2001). This aggregation severely impairs the ability of tau to bind to 
microtubules. Consequently, microtubules lose normal functionalities regarding 
structure and transport, and tau aggregates become sequestered elsewhere: by glial 
tangles, astrocytes and oligodendroglia. Hyperphosphorylation of tau is not unique 
to AD pathology. It is a common feature of Picks disease, frontotemporal dementia, 
progressive supranuclear palsy and corticobasal degeneration (Rademakers et al., 
2004). 
1.4.3 Neuroinflammation; microgliosis and astrocytosis 
 
Chronic neuroinflammation is a hallmark feature of Alzheimer’s disease; typically 
characterised by increased activity of both astrocytes and microglia Fuller (Fuller et 
al., 2010). Astrocytes are non-neuronal cells within the brain which support neurons 
with nutrients, monitor ion balance and induce neuronal repair after cell damage 




damage, neuroglial damage and the build up of extracellular amyloid (Verkhratsky 
et al. 2010;Wegiel et al. 2000). Astrocytes are frequently found activated in close 
proximity to plaques and are capable of inducing plaque clearance  by recruiting 
amyloid degrading enzymes to plaque deposits (Verkhratsky, Olabarria, Noristani, 
Yeh, & Rodriguez 2010). Similar to astrocytosis, the presence of AD pathologies can 
cause microglial activation. In healthy brain tissue, microglia extensively survey 
neurons for damage, triggering repair, extracellular signalling or phagocytosis as 
required. AD pathologies activate microglia and thus become frequent components 
of amyloid plaques; where they are proposed to accumulate fragmented DNA.  
 
Despite beneficiary roles, the precise role of astrocytosis and microgliosis in AD 
remains unclear. For example the positive effects of astrocyte activation may be 
short lived- it has been proposed that a build up of amyloid species can cause 
swelling and eventual lysis (Nagele, Andrea, Lee, Venkataraman, & Wang 2003). 
 
Microgliosis has also been associated with detrimental effects such as the 
production of neurotoxic species which instigate neurodegeneration (McGeer & 
McGeer 1995;Streit 2010). It also could be that astrocytes and microglia, when 
activated represent opposing forces. Evidence from post mortem AD brains has 
suggested that microglia may be responsible for plaque formation but astrocytosis is 





Notwithstanding such uncertainties, it must be emphasised that the inflammatory 
response in AD pathology is both chronic and widespread and the impact (positive 
or negative) could influence behavioural outcomes. It is thought that such an extent 
of neuroinflammation is capable of impairing the integration neuronal signals 
(Nagele et al. 2003;Vincent, Gasperini, Foa, & Small 2010) and recent evidence 
suggests that the extent of microgliosis in the brain correlates well with cognitive 




Collectively, the disturbances across AD pathology are thought to cause 
neurodegeneration; the incremental inhibition of normal cell function, connectivity 
and consequential programmed cell death. The manifestation of AD symptoms are 
thought to initially decrease neuronal cell functionality and plasticity; such as the 
capacity for long term potentiation (LTP) within hippocampal cells (Chen et al. 
2000) or the prevalence of those proteins required for synaptic integrity (such as 
synaptophysin); both of which are likely contributors to the subsequent neuronal 
loss. While the brain may be 100 billion neurons strong before the presence of AD 
pathologies take hold (D'Amelio & Rossini 2012) sustained ubiquitous neuronal loss 
(opposed to selective loss observed in neurodegenerative Parkinson’s disease) over 
time, can severely disrupt neuronal networks- and have impact in regions critical 
for semantic memory such as the cerebral cortex and hippocampus. Precisely how 
this occurs is unclear; one proposed mechanism is that damage sensors present on 




neuronal cell death signals, ‘caspases’ through both extrinsic and intrinsic pathways 
(Bredesen 2009). A summary of neurodegeneration features is shown in Figure 1.2. 
 
 
Figure 1.2: A representative selection of the outcome measures related to end points 
include features such as: DNA damage, caspase activity, the loss of synapses and 
neurons,  axonal degeneration, DNA fragmentation, cell death signalling (through 
Caspase-3 and Caspase-9), synaptic anchoring proteins (snaptoyphysin, SNAP 25) 
and post synaptic receptor number or subunit composition. NMDA; N-methyl-D-




1.5 Behavioural symptoms 
 
The progression of Alzheimer’s disease can take years if not decades to manifest 
and is characterised clinically by specific stages (See Figure 1.3). Early diagnosis of 
the condition remains difficult and progression from one phase to the next may not 




1.5.1 Prodromal Alzheimer’s disease (mild cognitive 
impairment) 
 
The earliest stages of AD are associated with difficulties in acquiring new 
information and the use of semantic memory (Förstl & Kurz 1999). Diagnosis is 
often difficult; symptoms can be subtle and may be overcome through memory aids 
or coping strategies- even well established behavioural assessment techniques such 
as the activities of daily living (ADL) can be incapable of detecting such changes. 
Figure 1.3: The progression of Alzheimer disease (AD) in clinical terms reflects the 
progressive loss of normal behavioural functions. While a degree of cognitive decline 
is expected in the older ages of life in AD patients may ultimately have impaired 







In the clinic, the earliest phase at which behavioural symptoms can be identified is 
mild cognitive impairment (MCI). Briefly, a diagnosis of MCI is based on; (1) 
changes in cognition observed by either the individual or an observer; (2) object 
impairment in one or more cognitive domains; (3) independent in functional 
activities and the diagnosis must be made the absence of dementia (Morris 2012). As 
the condition develops (notably, MCI may never progress to AD within a patients’ 
lifetime) subtle memory issues become more prominent (e.g. increased frequency of 
recognition or finance errors) and progress towards symptoms of Alzheimer’s 
disease. 
1.5.2 Mild Alzheimer’s disease 
 
The diagnostic criteria for suspected Alzheimer’s disease are variable and there are 
numerous scales currently in use: the most common criteria stipulate deficits both in 
memory and in at least one other cognitive domain (Alves et al. 2012). Methods for 
assessing AD behaviour through cognitive function include the Mini-mental state 
examination (MMSE) (Folstein, Folstein, & McHugh 1975),  The Alzheimer's Disease 
Assessment Scale Cognitive Behaviour Section (ADAS-cog) (Cano et al. 2010), the 
Clinical dementia rating (CDR), Adenbrooke’s cognitive examination (ACE)(Kipps 
and Hodges, 2005)  and the Montreal cognitive assessment (MoCA) (Freitas et al., 
2012). In practical terms, diagnosis is not always straight forward; successful 
diagnosis rates of AD vary from 50% outside specialised centres to 95% with 
experienced clinicians (Mayeux et al. 2011) and the true diagnosis of AD can only be 




1.5.3 Severe Alzheimer’s disease 
 
 
The behavioural capabilities of the AD patient diminish progressively as the disease 
advances. Later stages of the disease are associated with difficulties in performing 
daily activities and general comprehension. Frequent symptoms include; aimless or 
restless activity, sleeplessness and aggressive episodes. One fifth of patients are also 
thought to suffer from hallucinations. While AD is unlikely to directly cause death, 
the presence of the condition will reduce life expectancy by one third (Förstl & Kurz 
1999) . Death most often occurs due to complications such as myocardial infarction 
and septicaemia. 
1.6 Linking the progression of pathology to behaviour 
 
 
One aim of AD research is to link the molecular progression with the behavioural 
phenotype. Despite comprehensive studies regarding the progressive staging of AD 
pathology at autopsy (Braak & Braak 1991) and the widely accepted ‘amyloid 
cascade hypothesis’ there is no universal agreement as to which species is 
responsible for instigating the process. Further, despite a number of studies 
correlating  specific pathologies with cognitive decline I are yet to conclusively 
define which pathological feature(s) of AD correlate with cognitive decline 
(Parvathy et al. 2001;Matthews 2006;McGowan, Eriksen, & Hutton 2006;Nelson, 





In spite of this limitation, it is understood that pathological changes precede the 
clinical diagnosis of dementia by years if not decades (Morris 2005). As we cannot 
predict who will develop AD, current clinical trials are based on reducing well 
established AD pathologies. Such a limitation may have important implications, as 
neurodegeneration is often well established in the later stages of condition. This 
issue has encouraged extensive efforts into developing successful biomarkers for 
AD such as Pittsburgh compound B (Klunk et al. 2004) in order to allow early 














1.7 The search for novel clinical candidates 
1.7.1 Clinical treatments 
 
 
Despite our best effects as a research community, there are no clinical treatments 
capable of halting (or even slowing) the progression of AD. A small number of 
treatments are available which can provide limited cognitive benefits such as 
Donepezil and tetrahydroaminoacridine. These interventions work by increasing 
acetylcholine levels in the synaptic cleft thus increase the likelihood of action 
potential propagation. In more severe stages the NMDA antagonist Memantine may 
be prescribed which acts as a nicotinic acetylcholine receptor antagonist, ultimately 
causing an up-regulation of the receptor. Collectively, these interventions do not 
address the causation of the disorder; benefits are frequently short lived, and some 
patients may see no benefit at all (Selkoe 2001). Thus the search for novel cognitive 
stimulants and treatments capable of slowing or stopping the underlying pathology 
is an urgent unmet medical need. 
 
Clinical trial design over the last two decades has generally been based around 
targets identified from the amyloid cascade hypothesis. For example, promoting 
amyloid beta clearance has been an area of focus through both active and passive 
immunisation strategies which solubilise amyloid, promote phagocytosis or use 
antibodies to remove amyloid deposits from the brain (Mangialasche et al. 2010). 




control clinical trial of AN-1972(QS-21), where immunisation with the A-beta-42 
peptide induced significant levels of anti-amyloid titres. While the trial had to be 
halted early due to aseptic meningoencephalitis which developed in around 6% of 
patients, numerous follow up studies found reduced AD pathology in treated 
patients, and many speculate that the adverse reaction was due to the adjuvant -not 
the peptide (Tabira 2010). 
 
Preventing amyloid production and its aggregation is another strategy which 
underpins clinical trial design. Non-steroidal anti inflammatory drugs (NSAIDS) 
used to target the γ-secretase cleavage site of APP and β-secretase inhibitors such as 
Rosiglitazone or Pioglitazone have been used to attempt to lower the initial 
production of amyloid beta. Targeting tau protein has been another key area of 
research and both in vitro and in vivo investigations using Minocycline have 
identified that the intervention can modulate tau phosphorylation, aggregation and 
decrease neuronal death and cognitive decline (Noble et al. 2009).  
1.8 Animal models of Alzheimer’s disease 
 
Across Alzheimer’s disease the identification of clinical candidates (and aspects of 
clinical trial design) owe much to the animal modelling of the condition. Numerous 
animal models have been developed; capturing aspects of the human condition, 
each with specific attributes. Drosophila melanogaster (D. melanogaster) models have 
emerged as particularly useful tools for studying AD neurodegeneration. With a 




experiments have provided insights into the development of both plaque and tau 
pathology (Van Dam & De Deyn 2011). Similarly, Canorhabditis elegans (C.elegans) 
have a number of genetic homologues with humans (notably PSEN1), and both 
aspects of plaque and tau pathology can be recaptured in transgenic models. 
Despite their successes both of these organisms have substantial differences in brain 
anatomy from humans and behavioural assessments are often limited (Gotz et al. 
2004).  Rodent models with pathological and behavioural features of AD have also 
been developed through the injection of amyloid fragments to induce the AD 
phenotype (Frautschy et al. 1996;Nitta et al. 1994) but faithful replication of such 
models has proved difficult. The most frequently used animal model of AD for 
testing interventions is undoubtedly, the transgenic mouse model (see next). 
1.8.1 Transgenic mouse models of Alzheimer’s disease 
 
Following the identification of familial AD and those mutated genes responsible, 
transgenic mouse models were engineered with the aim to recapture aspects of AD 
in vivo. The first transgenic mouse model was engineered in 1995 (Games et al. 1995) 
where the over expression of a mutated APP (V717F mutation driven by the platelet 
derived growth factor promoter) produced a phenotype of amyloid plaques and 
neuronal loss. Subsequently, there has been an array of models produced, including 
models based on the expression of transgenic presenilin (PS) (Janus et al. 2000); or 
both APP and PS each with specific AD like pathologies alongside behavioural 
deficits (Bridget et al. 2002). Collectively, such work culminated in crossing APP, PS 




tau neurofibrillary tangles, aggressive amyloid plaques and cognitive deficits (Oddo 
et al. 2003). The molecular success of transgenic mouse models has been well 
reflected by extensive use to test candidate intervention strategies before reaching 
the clinical trial stage (Zahs & Ashe 2010). Both behavioural end points (e.g. 
paradigms such as the Morris water maze (Morris 1984)) and pathological end 
points (e.g. Enzyme-linked immunosorbent assay (ELISA) for amyloid levels, 
immunohistochemistry for plaques) can be quantified and efficacy determined by 
comparing  control and treatment groups. 
1.9 Translational failure in Alzheimer’s disease 
 
The prospect of testing candidate intervention strategies in animal models capable 
of capturing aspects of AD provides two main advantages, an opportunity to: (i) 
demonstrate efficacy in vivo and (ii) investigate molecular mechanisms. While 
transgenic mouse models have considerably advanced our understanding of AD, 
issues have arisen regarding reproducibility of efficacy in the clinical trial stage. 
This issue was well illustrated by Ashe and colleagues (Zahs & Ashe 2010) who 
demonstrated that over 300 interventions had been tested in the Tg2576 mouse 
alone without clinical success. Indeed, no novel clinical treatments have emerged in 
AD despite over a decade of testing therapeutics in these transgenic animals. 
1.10 Issues in the use of transgenic mouse models of 
Alzheimer’s disease 
 
The translational road block observed in AD has caused many concerns regarding 




For example, there are numerous concerns regarding the way in which transgenic 
mice are produced; over-expression of APP is not a clinical feature of the condition 
and the rapid onset of pathology in transgenic mice may take more than 60 years to 
manifest in humans. Despite the advances in our ability to produce an array of 
different models, none of these have been identified as the ‘gold standard’; each 
transgenic model captures a specific array and severity of symptoms.  
 
While model criticisms may question the overall use of transgenic mice in order to 
predict clinical efficacy, there are a number of noteworthy alternative explanations 
regarding translational failure. For example, as interventions are frequently given 
early in the mouse lifespan, this may mean that we are learning how to prevent AD 
opposed to treating it (Zahs & Ashe 2010). Further, methodological variation within 
pre-clinical AD studies is anticipated to be high (Vorhees & Williams 2006); if 
studies do not reflect the design of the clinical trial we  may be reducing the 
likelihood of clinical success.  
 
In pre-clinical studies of AD there have been no systematic studies of methodology 
or quality concerning transgenic mouse models of the condition. Further, it is not 
known whether there is evidence of publication bias in the pre-clinical literature 
(the lack of published papers with negative or neutral findings) which could 






Collectively, we have to accept the possibility that biological truths are not being 
reflected in experimental results at either the preclinical (Figure 1.4) or clinical trial 
stage (Figure 1.5) . Altenatively it could be that translational failure occurs because 
the biological truths from animal experiments do not equal those found in humans 
(Table 1.6). A deeper understanding of transgenic model studies may provide 
evidence to help address such questions while simultaneously aiding the design of 



























Positive preclinical trial results are a 
faithful representation of the 
biological truth. 
Preclinical trials are falsely negative. 
Possible reasons for this may include 
inappropriate outcome measure 
selection, random chance, selection bias 














Preclinical studies are falsely 
positive where no true efficacy 
exists. Plausible reasons for this 
include: random chance, 
publication bias or a study quality 
bias 
Negative preclinical trial results are a 
faithful representation of the biological 
truth. 
Figure 1.4: The reported results from preclinical trials many be biologically 
untrue. This could be one explanation of the translational failure observed for 
internvetions in Alzheimer’s disease. Each of the possible scenarios of biological 









   















Positive clinical trial results are a 
faithful representation of the 
biological truth. 
Clinical trials are falsely negative. 
Possible reasons for this may include 
issues regarding the selection of the 
trial population, outcome measure 
based issues, compliance or other 














Clinical trials are falsely positive. 
Possible reasons may include: 
insufficient sample size, random 
chance, outcome measure selection, 
publication bias and study quality bias 
Negative clinical trial results are a 
faithful representation of the 
biological truth. 























Positive preclinical trial results are a 
faithful representation of the 
biological truth in clinical trials. 
Transgenic mice are good predictors 
of clinical efficacy. 
Preclinical studies are falsely negative. 
Plausible reasons for this may include: 
construct validity issues, inappropriate 
outcome measure selection, random 
























Preclinical studies demonstrate 
efficacy which is not reported in 
clinical trials. Plausible reasons for 
this could include: random chance, 
publication bias, study quality bias 
or construct validity issues. 
Negative preclinical trial results are a 
faithful representation of the 
biological truth in clinical trials.  
Transgenic mice are good predictors of 
clinical efficacy. 
Figure 1.5: The reported results from clinical trials could be biologically untrue. 
This could be one explanation of the translational failure observed for 
internvetions in Alzheimer’s disease. Each of the possible scenarios of 
biological vs. experimental truth is explained further. 
Figure 1.6: The reported results from preclinical trials may not reflect those 
results fom the clinical trial stage. This could be one explanation of the 
translational failure observed for internvetions in Alzheimer’s disease. Each of 




1.11 Systematic review and meta-analysis 
 
The issue of translational failure is not unique to AD; such a challenge has been 
identified in other neurological disorders (e.g. ischemic stroke, Parkinson’s disease, 
multiple sclerosis) and beyond (e.g. myocardial infarction). For a number of these 
conditions, systematic review and meta-analysis techniques have proved useful 
tools in order to improve our understanding of translational failure (Rooke et al. 
2011;Sena et al. 2007a;Vesterinen et al. 2010).  
 
A systematic review provides a transparent method by which to identify how much 
literature exists within a given field of research. Studies generally state: the pre-
specified inclusion criteria, specific search terms used, databases searched and how 
the number of included studies was achieved which makes the method 
reproducible. Where multiple experiments have been conducted meta-analysis can 
provide a method of pooling data together in order to summarise how well 
interventions perform.  Using these pooled estimates of effect; meta-analysis can 
also inspect relationships between variables (e.g. does the age at administration 
affect observed outcomes?). 
 
Thus, performing a systematic review and meta-analysis of those interventions 
tested in transgenic mouse models of AD is likely to provide a number of benefits, 
such as a comprehensive summary of:  interventions tested, transgenic mouse 




techniques used may help identify gaps in knowledge (e.g. a promising intervention 
has not been tested for efficacy against a key feature of AD); or suggest new 
hypotheses for exploration (e.g. two separate interventions are likely to provide 
effective combination therapy). Additionally, data collected could be used to help 
provide a framework on which to separate ‘moderate’ from ‘excellent’ behavioural 
performance for different experimental groups (e.g. control transgenic or wild type) 
when testing emerging clinical candidates. 
 
In animal models of focal ischemia systematic review work has previously 
identified that the reported study quality in pre-clinical studies is relatively low 
(such as presence of blinding, randomisation) (Macloed 2008) .Subsequent meta-
analysis suggested that experiments with low study quality were associated with 
higher estimates of efficacy and it is likely I can address similar questions within 
preclinical AD  
 
Meta-analysis can also provide useful insights into whether aspects of study 
methodologies can impact on observed outcome. For example, a frequent finding in 
animal models of stroke is that delays in time to treatment are associated with lower 
estimates of efficacy (Sena et al. 2007b). For models in AD, analyses could inspect 
model specific features such as whether age and/or specific transgenes are 
associated with greater or lesser estimates of efficacy. Further, meta-regression can 




behavioural training ability determine behavioural test performance?) and between 
outcome measures (i.e. can changes in plaque burden explain changes in tau?).   
Meta-analysis can also be used in order to investigate whether publication bias 
exists in preclinical literature and the potential magnitude of impact. For example, 
‘trim and fill’ techniques have been used previously to impute the extent of missing 
papers and the magnitude of revised efficacy (Sena et al., 2010b). Collectively, 
systematic review and meta-analysis work in stroke has culminated in the 
production of ‘Good laboratory practice (GLP) guidelines’ which provide guidelines 
for robust pre-clinical trial design (Macleod et al. 2009). While there have been some 
guidelines recently published for performing pre-clinical studies in AD (Shineman 
et al. 2011) these have been based primarily on an expert panel opinion. Therefore, 
this work will provide the first evidence based approach in order to improve the 
design of trials AD. 
 
1.12 Aims and objectives 
 
The applicability and utility of systematic review and meta-analysis have been well 
demonstrated in recent years. Building on such use, this thesis is written with the 
primary aim of using existing data to provide evidence to develop evidence based 
GLP guidelines in order to make best use of transgenic mouse models of 
Alzheimer’s disease. 
 
This thesis is laid out with particular focus on the cardinal behavioural and 




review and meta-analyses performed are first explained (Chapter 2) and Chapter 3 
summarises the results of our systematic search by outcomes, interventions and 
transgenic models. For meta-analyses results, chapters are organised into specific 
objectives including analyses on: individual outcome measures (Chapter 4); 
transgenic mouse models (Chapter 5) and interventions (Chapter 6). Chapter 7 
addresses our objective to understand the impact of study quality and publication 
bias on observed results. During the course of study I have worked on a number of 
other significant (and published) projects within translational failure and Chapter 8 
summarises some prominent pieces of work. Finally, Chapter 9 brings together 
findings across all chapters and provides a further narrative critique. 
 
Additionally there a number of appendices attached to this thesis. Appendix I 
provides the comprehensive list of those studies included in the systematic review, 
Appendix II describes the reported study quality of such articles whereas Appendix 
III describes the methodology of experiments included in meta-analyses. Further, I 
include notes from my experimental work in the Morris laboratory in Appendix IV. 
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Chapter 2 Methods 
 
In this chapter I discuss how the systematic search was performed and subsequent 
data extraction. The methodologies of meta-analysis are explained including effect 
size calculations, weighting and how data were used to provide summary estimates 
and assess sources of heterogeneity. The various methodological techniques used to 
assess publication bias are also discussed.   
2.1 Systematic search 
 
Studies testing interventions in transgenic mouse models in AD were identified  
from Pubmed, EMBASE and ISI Web of knowledge with the search terms [‘targeted 
deletion’ OR ‘overexpression’ OR ‘knock out’ OR ‘vector’ OR ‘transgenic’] AND 
[‘dementia’ OR ‘tau’ OR ‘mild cognitive impairment’ OR ‘Alzheimer’s disease’] 
within the limit ‘animals’. The search was conducted in January 2009 and 
publications limited to 1995 onwards (the year the first transgenic AD mouse model 
was published). 
2.2 Inclusion and exclusion criteria  
 
 
Titles and abstracts of identified publications were screened by two independent 
reviewers (KE and MM). We retained studies that reported the testing of any 
intervention in any amyloid, tau or presenilin based transgenic mouse model of AD. 
Mice with additional genetic manipulations (e.g. COX-2 knockout) were not 
included in the systematic search as I envisaged that they have limited relevance to 
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the clinical setting.  MM and I excluded publications without an appropriate 
control, and did not include combination therapies. Ovariectomised transgenic mice 
were considered a mechanism of model development and thus MM and I included 
such studies in the review. For studies reporting active immunisation with amyloid 
beta peptides, I categorised interventions based on the fragments of Aβ used and 
also extracted additional details regarding of vectors and/or modifications.  
2.3 Data extraction 
 
 
From the publications included in our review I extracted details regarding: author, 
year of publication and journal. I assessed study quality using a five item checklist 
where studies were given one point for each criterion met. As this is the first study 
of its kind of the AD field, selected checklist items were those which had 
demonstrated significant impact on observed outcomes in preclinical studies 
elsewhere (blinding and randomisation- Macleod, 2008) and those crucial for 
statistical power (sample size calculations). Alongside these I chose to include (i) 
compliance with animal welfare legislation (to identify whether the overall 
treatment of the animals might impact on observed effects) and (ii) a statement 
regarding conflicts of interest (to identify whether alternative motives might be 









I also extracted details on the model used, intervention and outcome assessed. 
Model details included: background strain of mouse, transgenic model, promoter 
and sex. Intervention details included: intervention name, dose, route of 
administration, frequency of administration (i.e. single, multiple, continuous), and 
the age of the animal at intervention administration and outcome assessment (days). 
 
For outcomes of interest I extracted the number of animals used, mean and 
corresponding variance for control, treatment and wild type values wherever 
present. I preferentially used data values given in text or tables and where these 
were not available, I extracted data from graphs using Universal Desktop Ruler 3.2; 
calibrated for each individual graph. Where a single control group serves multiple 
treatment groups, the size of the control group was adjusted by division by the 
number of treatment groups served for meta-analysis. 
 
A common occurrence in experimental science is that multiple controls are used                                    
and I needed to ensure continuity across data extraction. Therefore I used a priority 
rule wherever more than one ‘control’ exists. I preferentially extracted control data 
in the order; (i) where part of the delivery mechanism is included (e.g. example an 
adjuvant or empty vector), (ii) saline or non-treated controls. If no suitable control 
existed within a given publication then it was excluded from the systematic review. 
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2.3.1 Pathological outcomes 
 
Pathological outcomes of interest were: (1) plaque burden, (2) amyloid beta species, 
(3) tau NFT, (4) neurodegeneration, and (5) cellular infiltrates;  
 
(1) I included all plaque staining related outcomes regardless of staining 
technique or methodology of counting used (number, density and area). As 
plaque pathology is typically extracellular, I did not include intracellular 
plaques in our analyses (Gimenez-Llort et al., 2007) 
 
(2)  I extracted details regarding all amyloid species including: amyloid beta 40, 
amyloid beta 42, total amyloid and oligomers. I extracted data regardless of 
solubility or method of quantification. Where data were recorded as short 
term transient changes (i.e. across 24 hours) I took the largest reduction of 
amyloid observed in order to prevent unduly punishing proof of concept 
studies where amyloid levels are allowed to return to normal. Due to the 
transient nature of CSF amyloid levels I did not extract such data (Bateman 
et al., 2007). 
 
(3) For tau NFT, I extracted both overall changes in tau and phosphorylation 
states. I included all data regardless of method of quantification (e.g. ELISA, 
immunohistochemistry, western blot).  
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(4) Irrespective of staining technique or method of quantification I extracted 
data regarding both astrocytosis and microgliosis, hereafter referred to as, 
“Cellular infiltrates”. Where data regarding cellular infiltrates were 
presented with other features such as plaques, I preferentially extracted 
cellular infiltrate outcome measures in isolation opposed to co-staining 
techniques.  
 
(5)  I extracted all outcome measures of neuronal degeneration, including direct 
markers (e.g. the loss of neurons) and indirect markers (e.g. capspase-3, See 
Chapter 3 for a summary). I also included neuronal regeneration (i.e. 
neurogenesis) under the comprehension that the outcome measure provides 
an alternative perspective regarding neuronal plasticity (Chuang, 2010, 




2.3.2 Neurobehavioral outcomes 
 
I extracted data from all behavioural paradigms identified within the literature and 
for each I extracted data regarding the last identifiable time point for each paradigm 
(clinically, longer term outcomes are likely to be of greater interest). Where a single 
paradigm had multiple components which address different questions (e.g. cued 
and contextual learning with fear conditioning paradigm) I extracted the last time 
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point given for each individual question addressed. I did not extract reversal task 
behaviour as I  perceived this to be a secondary objective of behavioural paradigms. 
 
Where experiments were performed in the (1) Morris water maze (MWM), (2) novel 
object recognition test and (3) radial arm water maze (RAWM) there were additional 
data extraction rules made; 
 
(1) For MWM outcomes I captured data from both the acquisition and probe 
phase. For the acquisition phase I extracted all time points providing the 
position of the platform remains constant throughout the test for path length 
and latency outcomes. For the probe test where MWM outcomes were 
reported serially I only include data for the last time point (unless 
experiments only provide a summary estimate of probe performance where 
this would be taken forward). I did not include data for reversal task 
behaviour or for time in opposite or adjacent quadrants.  
(2) I included a number of alternations to the novel object recognition test 
including object replacement test and object shape test (variations 
summarised in Chapter 3). Methods of assessment in the novel object 
recognition task include a number of outcomes which share 
interdependency with each another (e.g. time with new object and time with 
old object). To avoid over representing of experimental data (which would 
cause increased weight) I preferentially extracted one outcome in the order; 
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(i) discrimination index, (ii) time with novel object and (iii) time with 
familiar object.  
 
(3) Similar to the novel object recognition test, the RAWM can be assessed using 
parameters which have a degree of interdependence (e.g. reference memory, 
working memory). Therefore I preferentially extracted total error opposed to 
reference and working memory components. 
 




Meta-analysis provides a statistical method whereby results from multiple trials can 
be combined to provide summary estimates of effect. Such estimates can be used in 
order to analyse the potential impact methodology has on observed outcomes. 
There are a number of stages in performing meta-analyses presented (see Figure 2.1 
for overview). First, individual estimates of effect size must be obtained. Studies are 
then combined and weighted (to ensure smaller imprecise studies do not contribute 
equally to the overall estimate as larger precise studies).  
  
Figure 2.1: There are a number of stages performed in meta-analyses calculation. 
Estimates of efficacy are first calculated at the individual study level. Data are 
subsequently either  entered into  the fixed or random effects model. The random 
and fixed effects models make different assumptions on data (see section 2.4.3, 
adapted from (Borenstein et al., 2009)) 




Where;     CMean= The mean value of all the curve data points 
     CFTP  = The first data point of curve 
       CLTP  = The last data point of curve 
2.4.1 Definition of a comparison 
 
I defined a comparison as an outcome measured in a group of treated transgenic 
animals compared with outcome in a group of untreated control transgenic animals. 
Where there is more than one estimate present for the same structural or 
behavioural outcome of interest within the same cohort of animals, I first combine 
data using fixed effects meta-analysis to give an overall estimate of efficacy.  
 
For calculating effect sizes within the acquisition phase of the MWM I made an 
exception to the last time point rule (extracting behavioural data at the last time 
point) for behavioural paradigms. This was because selecting a single time point 
within the acquisition phase may not provide a faithful representation of overall 
training performance. Therefore, I combined multiple measurements within the 
acquisition phase of the MWM to estimate efficacy. For these, I limited calculations 
made to ‘latency’ or ‘path length’ (as these were the most frequently reported- See 
chapter 3.10) and calculated the area under the curve using the trapezoidal rule for 
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Where;      = The mean value of all the curve data points 
       = Individual point estimates of data points 
        i = Standard deviation of each data point within curve 
Where I calculate the variance accounting for both within and between study 









2.4.2 Individual effect size estimates 
 
 
There are three principle methods for calculating effect size; a simple difference in 
means meta-analysis (MD), a normalised difference in means (NMD) and a 
standardised difference in means (SMD). The choice of method is dependent on the 
dataset in question. For example, difference in means estimates can be used where 
outcomes are measured on the same scale. While this technique is advantageous 
because effect sizes directly relate to experimental results, the likelihood of all 
experiments using the same scale in preclinical science is relatively limited. An 
alternative method is NMD where experiments using different scales can be 
combined by estimating the effect relative to the difference between a disease model 
and wild type animal. Again, this technique is fairly straight forward to 
comprehend but wild type behaviour must be stated (or imputed) for the technique 
to work. Finally, SMD estimates of effect can also combine data using different 
scales by basing the effect size on the variance of a given study. The technique does 
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Where             cm = mean in control group                          
Rxm = mean in treatment group 
   
Where             cSD  = Standard deviation in treatment 
            RxSD  = Standard deviation in control 
    cn   = number of control animals 
                          cn   = number of treatment animals 
 
   
   
   
not require knowledge of wild type performance and assumes differences in 
variance between trials are a reflection of differences in measurement scales- not the 
study population (Borenstein et al., 2009). 
(i) Difference in means meta-analysis (MD) 
 
 
Difference in means effect size (see Equations 2.3 and 2.4) is calculated by the 
difference between an intervention mean (mRx) minus the control mean (mc). Such 
methodology is particularly suited to data where all data are on the same scale and 





























Where;    cm   = Mean in control group 
     Rxm = Mean in treatment group 
     wtm  = Mean in wild type group 
   
(2.6) 
Where             RxSD  = Standard deviation in treatment 
              CSD  = Standard deviation in control 
   
(ii) Normalised mean difference (NMD) meta-analysis 
 
 
Normalised mean difference meta-analysis express individual effect sizes as a 
percentage improvement (Equations 2.5 and 2.6). The estimation of effect size is 
underpinned by the difference between the lesion model and wild type behaviour. 
An improvement which reached that of wild type performance would have an effect 
size of 100. 
    
                  
        





































(iii) Standardised mean difference meta-analysis 
 
Standardised mean difference (SMD) meta-analysis calculation of effect size can be 
particularly useful where numerous different scales are used to assess the same 
outcome (Egger M, 2002). SMD calculates effect sizes according to the variance of 
the sample and assumes differences in variance between trials are a reflection of 
differences in measurement scales. While there are three commonly used variations 
of calculating SMD I conduct analyses using the Hedges’ adjusted g variation (see 
Equations 2.8 and 2.9) which incorporate corrections for small sample bias (defined 
as a comparison between the expected value of a small sample opposed to the 
expected value of an infinite sample).  
 
Therefore Hedges’ adjusted g is calculated by taking the differences in means 


















































Where;     cm = mean in control group 
      
Rx
m = mean in treatment group 
       cn  = number in control group 
      Rxn = number in treatment group 
       iN = cRx nn   



















One issue with using SMD calculations of effect size in practice is that the technique 
does not alter estimates according to the direction of effect. Therefore, for each 
comparison I recorded in which direction improvements were associated and effect 
sizes were adjusted accordingly (i.e. *1 or *-1). 
 
2.4.3 Weighted mean difference models 
 
When combining different studies to gain an overall estimate of effect, it is 
frequently the case that one desires less contribution from some studies than others 
(for example estimates of efficacy from smaller populations are likely to be less 
reliable than those from larger studies and thus I may wish these to have less impact 
on the overall estimate of efficacy). To address this issue I weighted experiments 
using the inverse variance method where the greater the variance of effect size 
















I combined individual study estimates in order to calculate the population effect 
size. Generally speaking, this can be performed by two main methods; fixed and 
random effects meta-analysis. The choice of technique depends on how much 
variation is expected across all individual studies. For example, it could be that all 
experiments represent one ‘true’ biological effect size, and therefore observed 
variance represents sampling error. In such a case, then the fixed effects model is the 
most appropriate because it weights studies with the goal of minimising within 
study error. In practice, it is more common that studies compared are not identical, 
due to systematic differences. This variation (or heterogeneity) can be assessed 
using a random effects model where individual studies are hypothesised to form a 
normal distribution around a global estimate. Individual effect sizes are first placed 
into the fixed effects model, which is then used to derive the random effects meta-
analysis. 
 
(i) Fixed effects model 
 
In the fixed effects model, individual effect sizes are weighted using the inverse 
variance method by calculating a weighted average of the treatment effects from the 
individual trials ((Egger M, 2002), see Equations 2.10 to 2.13).The inverse variance 
method weights each study by the inverse of the squared variance; 
 














The effect sizes are pooled, which provides a weighted average of treatment effect 







 = effect size estimate 





The fixed effects model will give studies with greater variability smaller weights 
(and thus low influence) whereas in the random effects model the impact of weights 
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2)(  IViiQ 
(2.15) 





(ii) Random effects model 
 
 
As the random effects model assumes study estimates will vary, calculations of 
effect size differ from the fixed effects model in that they take account of between 
study variation (τ2).  Thus, in the random effects model, effect sizes ( i) are assumed 
to have a Normal distribution around a global estimate with a variance τ2. The value 
of τ2  is calculated using the DerSimmonian  and Laird estimate (DerSimonian and 









Therefore, if the heterogeneity statistic (Q) is smaller than k-1 (for example if there 
were no observed variance of effect size) then τ2 becomes zero and the random 
























Q = Heterogeneity statistic  
k = number of comparisons 






























































SEIV *96.1)(  SEIV *96.1)( to 




2.4.4 Assessing heterogeneity 
 
 
For stratified analysis, I assessed whether a particular variable accounts for a 
significant proportion of the observed heterogeneity. To achieve this I used the Q 
statistic (which is assumed to follow a χ2 distribution with k-1 degrees of freedom) 
under the null hypothesis that the true treatment effect is the same for all trials. The 
Q statistic examines whether the observed heterogeneity is greater than that 
expected by chance alone. For continuous independent variables (e.g. age at 
treatment, duration of treatment) I defined strata using inter-quartile ranges to 
establish four groups within the variable of interest.  To account for the number of 
comparisons I adjusted our critical value using Bonferroni correction (see Section 
2.4.5). 
2.4.5 Bonferroni corrected p values 
 
While exploring datasets and generating hypotheses it is an expectation that each 
individual dataset may be used multiple times for each hypothesis tested. While a 
critical p value (termed “α value”) of 0.05 may be appropriate for a given individual 
analysis, multiple comparisons increase the likelihood of false positives. One way to 
account for this systematically is to use Bonferroni correction (see Equation 2.20). 
This methodology decreases the alpha value (and therefore the likelihood of 





Where:               n= number of comparisons   
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Thus the null hypothesis (that there is no statistical difference between groups) can 
only be rejected where p< α . As I planned multiple analyses across different 
variables and datasets, α values which can be found stated in tables and within the 





Number of hypotheses tested



























Figure 2.2: The Bonferroni correction corrects the α level according to the number 
of hypotheses tested. The critical value of p for significance (α level on y axis) 
becomes more stringent as the number of comparisons made increases (x axis). 
Multiple values of α will be used across the work conducted. 
Bonferroni Correction 
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2.4.6 Meta-regression  
 
 
Meta-regression is an alternative method of assessing the impact of particular study 
covariates by examining statistical heterogeneity. Meta-regression has particular 
advantages over stratified meta-analysis in the respect that it accounts for both 
between and within study variation and it is possible to enter more than one 
covariate into the model. However, the sensitivity of the approach is likely to differ 
from stratified meta-analysis.  As there is currently no consensus on which 
technique is most suitable for our given datasets I prespecified that I would use 
stratified techniques for primary analysis whereas meta-regression techniques 
(performed using STATA version 10) were used to investigate relationships both 
between and within outcomes.  
 
Similar to stratified meta-analysis, meta-regression uses individual effect sizes to 
derive summary data which are weighted by the inverse variance method 
previously described. There are a number of key differences from stratified meta-
analysis; variables are assessed for their ability to fit a linear regression model, data 
are not required to be stratified and the heterogeneity unit of interest is τ (see 2.14 
above). Our use of meta-regression is strictly limited to investigating relationships 
within and between outcome measures. As the effect size estimates are continuous 
variables these do not need to be modified further before entering the model. 
 




For meta-regression analyses STATA outputs provide information regarding the 
number of studies, tau squared, I squared and the adjusted R2. The value of the 
adjusted R2 represents the strength of the relationship between the variance in a 
covariate of interest and variance in effect size.  
Uni-variate meta-analysis 
 
Where I examined the impact of one variable on another I used uni-variate meta-
regression. Uni-variate meta-regression analyses were performed to inspect the 
impact a single dependent variable had on the observed independent effect size. 
The following command was used to investigate both relationships between 
outcomes using STATA  
 
Metareg  QDV QIV, WSSE (SEDV) 
 
Where; 
QDV =Effect size of dependent variable  
QIV = Effect size of independent variable 












2.4.7 Interpreting meta-regression analyses  
 
Where I performed simple linear meta-regression  I used adjusted R2 values to 
identify how much of the variance in the dependent variable can be explained by 
the independent variable. The adjusted R2 represents the proportion of between 





Similar to linear regression, it is possible for the R2 value to be negative in the 
circumstance where covariates explain less of the heterogeneity than would be 
expected by chance. The significance level of meta-regression analyses was adjusted 
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2.5 Assessing publication bias 
 
 
The identification of missing negative or neutral studies is assessed using three 
different techniques: Egger regression (Egger et al., 1997), funnel plots and Trim and 
Fill models (Duval and Tweedie, 2000). For inputting data into such models, where 
more than one outcome was measured in a single cohort of animals I used all of 
these outcomes in the publication bias analysis, rather than the summary outcome 
data for each cohort used in the meta-analysis. Therefore I took estimates of effect 
size within pre-nested data. 
 
It should be stressed that while these analyses are designed to asses publication bias 
it could be that this is suggested from analyses due to other reasons. For example, it 
could be that studies were methodologically different from larger ones, or that the 
disparity could be explained because only the best interventions are taken forward 
at each stage of drug discovery. 
2.5.1 Egger regression 
 
Egger regression works under the principle that smaller studies have increased 
random error and are therefore likely to have a greater variance around the mean. 
To perform Egger regression one must plot effect size divided by the standard error 
on the Y-axis which is plotted against precision (inverse of the variance) on the X-
axis. If the intercept of the regression line and its 95% confidence limits do not cross 
the origin then this indicates a presence of publication bias. 
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2.5.2 Funnel plot 
 
 
Funnel plots are scatterplots designed to allow the visual assessment of publication 
bias through plotting calculated effect sizes against precision (the inverse of the 
variance for individual studies). Small studies generally have greater variance and 
tend to scatter widely at the bottom of the graph whereas large studies form a much 
narrower distribution of effect size. If a given dataset has no publication bias, the 
data should form a symmetrical inverted ‘funnel’ shape with its line of symmetry 
centred on the global estimate of efficacy. For publication bias to exist, I may expect 
a number missing imprecise studies with negative or neutral effect sizes.  
2.5.3 Trim and fill 
 
While the funnel plot can be used for visual assessment of publication bias, there are 
a number of notable weaknesses: interpretation is subjective and there is no way of 
quantifying missing studies. To address such issues ‘Trim and fill’ is a particularly 
useful technique which uses an iterative method to identify hypothetically missing 
studies (Duval and Tweedie, 2000). If  publication bias was found within datasets, 
Trim and Fill methods would compare the right hand side of the funnel plot to the 
left hand side and calculate the number of asymmetrical  studies (k0, see Figure 3.3). 
Those studies on the right hand side which are asymmetrical are trimmed until 
there are only symmetrical studies left and the ‘true’ pooled effect size is calculated. 
Those studies which were removed and their missing counterparts (on the left hand 
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Figure 2.3: Trim and fill estimates were used to quantify the number of missing 
studies. (a), (b)The methodology ‘trims’ asymmetrical studies within funnel 
plots (where effect size is plotted against precision, asymmetry shown in 
purple). (c) The process then adds missing studies on the left hand side (in red) 
and recalculates the pooled estimate. This process is repeated until the pooled 
effect size stabilises. 
(a) (b) 
(c) 




Chapter 3: Systematic Search Results; describing the 
literature and planning meta-analyses 
 
A systematic search provides an unbiased, comprehensive collection of published 
literature. Collating studies of interventions tested in transgenic mouse models has a 
number of key advantages: (1) to consolidate understanding of how we assess 
efficacy in animal models; (2) to help identify gaps in our knowledge; and (3) to 
plan effective meta-analysis. Thus, this chapter describes the literature on transgenic 
mouse models of Alzheimer’s disease through outcomes, models, interventions and 
study quality.  
3.1 Systematic search results 
 
From our initial search, I identified 8360 publications. From these, we (MM and KE) 
identified 427 publications where a single intervention was tested in a transgenic 
mouse model (see Figure 3.1 for flow diagram). I identified that since 1998 there has 
been an increase in the number of publications per year testing interventions in 
transgenic mouse models of Alzheimer’s disease (Figure 3.2). Five publications were 










Figure 3.2: The search results identified that there has been an increase in the total 
number of publications reporting the testing of interventions in transgenic mouse 








































Figure 3.1: Publications were identified from systematic search were screened for 
possible inclusion. A notable exclusion the systematic search was the Senescence 
Accelerated (SAMP8) mouse. 




Figure 3.3: From 427 publications I identified a number of main pathological 
outcomes including, plaque burden, amyloid beta 40, amyloid beta 42, tau, cell 
infiltrates and neurodegeneration (Neurodeg*). The number of publications 
reported each of these outcomes is reported alongside the details of publications 
excluded. See methods for further details of data inclusion. 
3.2 Summary of outcome measures  
 
From 427 publications, I identified six main pathological outcome measures 
(amyloid plaque burden, amyloid beta 40, amyloid beta 42, tau, cell infiltrates and 
neurodegeneration (See Figure 3.3) alongside neurobehavioural outcomes (Figure 
3.4). 
  




Figure 3.4: From 427 publications I identified 144 publications which reported 
neurobehavioural outcomes. Of these, 122 publications were taken forward to 
meta-analysis stage and the number of excluded publications is explained above. 
See methods for details regarding extraction of MWM acquisition data and see 

















3.3 Pathological outcome measures 
 
3.3.1 Plaque burden 
 
 
Amyloid plaque was the most commonly reported outcome found in 53% (228/427) 
of publications, representing 5613 mice. Over 90% of experiments were quantified 
using immunohistochemical methods (using antibodies such as a 6E10 or 4G8). To a 
lesser extent, Congo red (8.9%) and Thioflavin S (15.2%) staining techniques were 
also used (see Figure 3.5 for overview). In summary, sufficient data were available 
for reliable estimates of efficacy for each staining method and to investigate 
associations between immunohistochemistry and congo red, and 








Figure 3.5: 414 experiments were identified which quantified changes in plaques. 
The number of experiments using immunohistochemistry, congo red and thioflavin 
S can be found in each respective circle. Those cohorts where more than one 
technique was used can be found where circles overlap. *NB for calarity these 
estimates do not include those experiments where less than 3.5 animals exist as 
these could not be used in analyses. 
* 




3.3.2 Amyloid beta species 
 
Overall, 202 publications reported amyloid beta species representing 6545 animals 
and 475 experiments. Of these, 177 publications (88%) report amyloid beta 42 levels, 
165 (82%) report amyloid beta 40 levels  and 37 publications report total amyloid 
beta (see Figure 3.6 for number of experiments). As both monomer, oligomer and 
trimer species of amyloid all represented specific amyloid aggregates I combined 
such data for exploratory analyses (Table 3.1 for summary and Section 4.2 for 
analyses). The most prominently used immunoassay technique was the ELISA; used 
in 90% (187/208) of publications. The methodology of the ELISA was considerably 









Figure 3.6: 475 experiments were identified which quantified changes in amyloid. 
The number of experiments assessing amyloid beta 40, amyloid beta 42 and total 
amyloid beta can be found in each respective circle. Those cohorts where more than 
one technique was used can be found where circles overlap. 
























Solubility of amyloid species 
 
Within each of the main amyloid outcomes (amyloid beta 40, amyloid beta 42 and 
total amyloid beta) I quantified the solubility of amyloid species wherever possible 
(Figure 3.7). Of the 388 experiments which examined amyloid beta 40, 276 stated 
solubility, most commonly examining both soluble and insoluble species. For 
amyloid beta 42, 295 of 389 experiments reported solubility where again 
experiments most frequently recorded both soluble and insoluble species. For total 
amyloid 60 experiments reported the solubility of amyloid species where the ‘total’ 




species Specificity Solubility 
Total number of 
experiments 
Oligomer 
Non specific soluble 17 
  Unknown 14 
6-mer soluble 2 
3-mer soluble 3 
3-mer unknown 1 
12-mer soluble 1 
24-mer soluble 1 
4-mer soluble 1 
9-mer soluble 1 
Ab*56 soluble 1 
40-mer soluble 1 
  Unknown 1 
Monomer 
Non specific soluble 1 
  Unknown 2 
Monomers &dimers Unknown 1 
Total   48 
Table 3.1: Amyloid aggregates were assessed in a number of different methods 
including the specific amyloid aggregate assessed and species solubility. 

































Figure 3.7: The number of experiments which reported the solubility of each of the 
main amyloid beta outcomes (amyloid beta 40, amyloid beta 42 and amyloid beta 
total) is summarised in Venn diagrams. Totals differ from those stated previously as 
data were only included if they stated solubility. 




Figure 3.8: 84 experiments were identified which quantified changes in tau. The 
number of experiments assessing overall tau and the phosphorylation state of tau 
can be found in each respective circle. Those cohorts where more than one technique 
was used can be found where circles overlap. 
3.3.3 Tau  
 
Intracellular neurofibrillary tangles were reported in 38 publications, representing 
84 experiments and 984 animals. The extent of tau pathology was quantified by both 
the phosphorylation state of tau (59 publications) and the overall levels of tau (53 
experiments, Figure 3.8). Within such categories, there was substantial 
methodological heterogeneity (see Figure 3.9 for phosphorylation antibodies 
identified). Both overall levels of tau and phosphorylation levels provide different 
assessment techniques for tau abnormalities in AD. Therefore, I grouped each of 
these together for overall analyses, and 28 comparisons could be used to examine 



























3.3.4 Cell infiltrates 
 
Astrocytosis was reported in 36 publications (representing 43 cohorts, 633 animals) 
and was almost universally (34 publications) stained using Glial fibrillary acidic 
protein (GFAP). Microgliosis was reported in 46 publications (representing 82 
cohorts and 823 animals) most commonly stained with CD45 (see Table 3.2 for 
breakdown of staining techniques used). 
Figure 3.9: A number of different phosphorylation sites for tau were described in 
the literature. The antibody used, and the epitope target alongside the number of 
publications using each staining technique are described. 
 
Number of cohorts which are stained with various antibodies (and 





Phosporylation sites of tau  
















Phosphotyrosine  1 
IA/IE 1 
IB4+ 1 
MAC-3  1 
Macrosialin 1 
PT-stained 1 
Tomato-lectin staining 1 
unknown 1 

















Table 3.2: Various antibodies and staining techniques were used to describe microglia. 
Table describes such data; the most common of which was CD45 antibody staining. 
Figure 3.10: 90 experiments were identified which quantified changes in cellular 
infiltrates. The number of experiments assessing microgliosis and the astrocytosis 
can be found in each respective circle. Those cohorts where more than one 















Outcome measures of neurodegeneration were reported in 41 publications 
representing 64 experiments and 958 animals. Measures of neurodegeneration were 
represented by a continuum of impaired cell and synapse functionality and cell 
death. Data regarding all potential outcome measures of neurodegeneration were 
captured which included measures of neurogenesis with the interpretation that 
down regulation of neurogenesis is a feature of the global neurodegeneration 
present. Figure 3.11 summaries the number of publications which measured direct 
or indirect measures whereas Table 3.3 explains the abundance of each direct (e.g. 









Figure 3.11: 64 experiments were identified which quantified changes in 
neurodegeneration. The number of experiments assessing overall direct and indirect 
measures can be found in each respective circle. Those cohorts where more than one 
technique was used can be found where circles overlap. 




Table 3.3: Both direct and indirect measures were of interest for 
neurodegeneration outcomes. Indirect measures were more frequently 
identified opposed to direct ones, of which the most commonly reported 
outcome of interest was synaptophysin. 
Mode Outcome measure 
Number of 
publications 
Indirect Synaptophysin staining 26 
 BrdU Neurogenesis 9 
 DCX Neurogenesis 5 
 Caspase-3 4 
 Bax proteins 3 
 DNA fragmentation 3 
 Synaptic density 3 
 Calretinin-positive cells 2 
 SNAP-25 2 
 AchR 1 
 BrdU/GFAP 1 
 BrdU/NeuN 1 
 Caspase 9 1 
 Cytochrome C 1 
 Dynamin-1 1 
 GABAA receptor a1 subunit 1 
 NeuN Neurogenesis 1 
 Neuogenesis BrdU/NeuN 1 
 Neurogenesis 1 
 NR2B subunit 1 
 Par-4 1 
 p-NR2B subunit 1 
 pNR2B/NR2B 1 
 PSD-95 1 
 Ubiquitin-positive particles 1 
Total indirect   73 
Direct Neuritic dystrophy 7 
 Axonal degeneration 6 
 Apoptotic neurons 3 
 Degenerating Neurons 3 
 Neuronal count 3 
 Synapse number 3 
 Curvature ratio 1 
 Dystrophy size 1 
 Fluoro Jade 1 
 Mean number of dystrophic neurites 1 
 Mean total area of dystrophic neurites 1 
 Apoptotic count 1 
Total direct   31 
 
  




Table 3.4: The specific brain regions used for experiments are shown across all 
five pathological outcome measures. A single cohort may be represented 
numerous times (n.d. no data) 
3.3.6 Pathological outcomes by brain region 
 
For each pathological outcome extracted additional details were also captured 
regarding the specific brain region assessed. The most commonly assessed brain 
regions were the hippocampus (422 experiments) and the cortex (390 experiments). 
Table 3.4 summarises the specific brain regions used in experiments across all five 




























































Amygdala n.d. n.d. n.d. n.d. 3 6 
Brain  266 251 24 25 163 38 
Brainstem n.d. n.d. n.d. n.d. n.d. 6 
Cerebellum 2 3 n.d. n.d. n.d. n.d. 
Cingulate gyrus n.d. n.d. n.d. n.d. 2 n.d. 
Cortex 82 81 42 23 162 9 
Forebrain 9 12 n.d. n.d. 2 n.d. 
Frontal lobe n.d. n.d. n.d. n.d. 1 n.d. 
Frontal section n.d. n.d. n.d. n.d. 1 n.d. 
Hippocampus 65 81 50 30 196 42 
Olfactory tract n.d. n.d. n.d. n.d. 1 n.d. 
Parietal lobe n.d. n.d. n.d. n.d. 1 n.d. 
Spinal cord n.d. n.d. n.d. 1 n.d. 10 
Spinal ventral roots n.d. n.d. n.d. 2 n.d. n.d. 
Striatum 1 n.d. n.d. n.d. n.d. n.d. 
Subiculum n.d. n.d. 1 n.d. n.d. n.d. 
Thalamus n.d. n.d. 1 1 n.d. n.d. 
Ventricles of walls n.d. n.d. n.d. 1 n.d. n.d. 
Totals 425 428 118 83 532 111 
 
  




3.4 Neurobehavioural paradigms 
 
144 out of 427 publications (33.7%) reported neurobehavioural outcomes. In total, 
thirty different neurobehavioural paradigms were described within the literature; of 
which the MWM was the most frequently used (83 publications). Table 3.6 
summarises the frequency of behavioural paradigms most commonly used. 
Methodological variations extended to apparatus used, conduct and choice of 
outcomes assessed. I planned to take forward data for individual paradigm analyses 
wherever paradigms featured in ten or more publications (Figure 3.12 for 
summary). While this was possible for data from the MWM, RAWM, fear 
conditioning, Novel object recognition task (NORT) and Y/T maze there were 
continuity issues with direction of effect for the open field test which are explained 









Figure 3.12: The six most commonly used behavioural paradigms and number of 
publications (in brackets) were the Morris water maze (MWM), Radial arm water 
maze (RAWM), Fear conditioning, open field test, Y-maze and T-maze. A number 














3.4.1 Morris water maze 
 
The MWM was the most commonly used behavioural paradigm, and outcomes 
were reported from 83 publications. More specifically, this included 130 control and 
treatment acquisition curves (2151 animals) and 113 experiments from the probe 
phase (2018 animals).  
(i) Acquisition phase of the Morris water maze 
 
Methods of quantification within the acquisition phase included ‘latency’ (107 
experiments), ‘path length’ (57 experiments), ‘trials to criterion’ (2 publications), 
‘search error’ (2 experiments) ‘cumulative distance to platform’ (1 experiment) ‘time 
in outer zone’ (1 experiment) and ‘difference in path length’ (1 experiment).  
 
I observed that the methodology of studies described was highly variable; including 
parameters such as the temperature of water used (temperatures ranged from 16 to 
28 °C), the size of the pool (85 to 200 cm), number of trials per day (2 to 12) and 












Water temperature of Morris water maze
 (Degrees celcius)





































































































































Figure 3.14: The use of the Morris water maze (MWM) varied considerably 
with respect the size of the pool used (A), water temperature (B), the number 
of training trials per day and number of days trained (C). For figure C symbol 
size represents the number of experiments. 
Figure 3.13 (previous page): Outcomes commonly reported from the Morris water 
maze were predominantly ‘latency’ and ‘path length’. Other methods included 
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Frequency of Number of days training and trials per day
Number of Days Training















































(ii) Probe phase of the Morris water maze 
 
The probe phase was also extremely variable in its use. Twelve principle methods 
were used for illustrating efficacy and within the 57 studies which used the probe 
phase of the MWM there were 59 different approaches used to demonstrate efficacy 
(See Table 2 and Table Legend for details). Such methodological heterogeneity 
would be the focus of subsequent meta-analysis techniques. 
  

















Time in target quadrant no no no yes 31 to 60 13 
          61 to 120 3 
          unknown 2 
      yes no 31 to 60 6 
          61 to 120 2 
      unknown unknown 31 to 60 2 
          61 to 120 1 
          unknown 2 
      Yes
 
* no 31 to 60 1 
    yes no yes 31 to 60 1 
      yes no 31 to 60 2 
          unknown 1 
        yes 31 to 60 1 
      no  yes 31 to 60 1 
      Yes
*
 no 0 to 30 1 
          31 to 60 2 
  yes no no yes 31 to 60 2 
    yes yes yes 31 to 60 1 
Time in target quadrant Total           44 
Number of platform crosses no no no yes 31 to 60 7 
          61 to 120 3 
          unknown 1 
      yes no 31 to 60 2 
          61 to 120 1 
          unknown 1 
      unknown unknown 61 to 120 1 
    yes Yes
 
* no 31 to 60 1 
        yes 31 to 60 1 
  yes yes yes yes 31 to 60 2 
          unknown 2 
Number of platform crosses Total           22 
Speed no no no yes 31 to 60 2 
          61 to 120 1 
          unknown 1 
      yes no 31 to 60 1 
    yes no yes 31 to 60 1 
      yes no 31 to 60 2 
      Yes
 
* no 0 to 30 1 
          31 to 60 1 
Speed Total           10 
Latency to cross platform no no no yes 31 to 60 1 
    yes no yes 31 to 60 1 
      yes no 31 to 60 1 
  yes yes yes yes 31 to 60 4 
          unknown 2 
Latency to cross platform Total           9 
Distance travelled to platform
1
 no no no yes 31 to 60 1 
          61 to 120 2 
    yes no yes 31 to 60 1 
      yes no 31 to 60 1 
Distance travelled to platform Total           5 
Number of entries to target quadrant no no no yes unknown 1 
      unknown unknown unknown 1 
    yes yes no unknown 1 
  yes yes yes yes 31 to 60 1 
Number of entries to target quadrant Total         4 
Distance travelled in target quadrant no no no yes 31 to 60 1 
      yes no 31 to 60 1 
    yes yes yes 31 to 60 1 
Distance travelled in target quadrant Total         3 
Number of entries to target zone no no no yes 61 to 120 1 
          unknown 1 
Number of entries to target zone Total         2 
Average distance to platform yes no no yes 31 to 60 2 
Average distance to platform Total           2 
Time at platform no no no yes 61 to 120 1 
Time at platform Total           1 
Time in target zone no no no yes 61 to 120 1 
Time in target zone Total           1 
Search Ratio yes no no yes 31 to 60 1 
Search Ratio Total           1 




Figure 3.15: Outcome from the Fear conditioning paradigm were described as 
contextual or cued memory assessments. Number shown describe the number of 






3.4.2 Fear conditioning 
 
Contextual and cued fear conditioning provide a classic example of Pavlovian 
associative learning and the paradigm was used in 19 publications (45 experiments). 
The test typically trains mice to associate an auditory cue with a paired electric 
shock, and then tests mice for their contextual freezing ability after initial training 
sessions (Contextual behaviour assessed in 19 publications, see Table 3.5 for more 
details). Frequently, cued fear conditioning is also assessed (7 publications) where 
the environment changes but an original cue for the stressor (e.g. auditory cue is 




Table 3.5 (previous page): 12 principle methods were used to assess Morris 
water maze probe performance. Within these assessments studies varied by 
whether they; trained the mice to criterion, preformed multiple trials, assessed 
probe performance less than (<24) or greater than (>24) 24 hours after training, 
and the total number of seconds. 




3.4.3 Radial arm water maze 
 
The radial RAWM was used in 23 publications, however as one publication did not 
state error on data I only describe 22 publications in summary statistics.  
Use of the RAWM is considerably varied and I identified different uses where arms 
were baited with food or had a hidden platform. Hidden platform constructs 








Figure 3.16: The Radial arm water maze has two principal forms, baited and 
hidden arm constructs. For one experiment it was not clear which methodology 
was used. 




3.4.4 T-maze & Y-maze 
 
The T and Y maze were used in 7 (11 experiments) and 14 (17 experiments) 
publications respectively. The T- maze and Y-maze assess the ability of mice to 
identify the most recently explored arm and to enter the novel arm. I identified 
percentage alternation as the most common unit of assessment which featured in 6 






Figure 3.17: 19 publications examined either the T-maze or Y maze and each 
could be assessed using a variety of methods. T-maze was assessed using 
‘correct choices’, ‘latency’ or ‘spontaneous alternation’. Y-maze was assessed 
using ‘number of entries’, ‘percentage novel entries’ and ‘spontaneous 
alternation’ 




3.4.5 Novel object recognition tasks 
 
Novel object tasks featured in 15 publications (25 experiments, Figure 3.18). Within 
this term I included a number of similar studies.  The majority of data extracted 
included the conventional use of the Novel object recognition task where mice were 
given a familiarisation ‘training’ period with two blocks, with one of the blocks 
changed for a novel object (21 experiments).  Two experiments were described 
regarding object placement, whereas one experiment identified performed object 
context assessment. For units of the outcome measures extracted I applied our 
prioritisation rule (see methods), taking forward data from 9 experiments regarding 


















Figure 3.18: 25 publications examined Object recognition tasks and these included 
a number of variations. Data were extracted for the object context task, object 
placement task and object recognition task. Where not described, numbers refer to 
experiments and some experiments examine more than one outcome. 




3.4.6 Other neurobehavioural tests  
 
Across all analyses, there are two notable exclusions from the dataset: the open field 
test and elevated plus maze. For the open field test there were sufficient data to be 
investigated as an individual paradigm whereas the elevated plus maze (EPM) 
would be included for a specific publication bias analyses (see Chapter 7). Such 
paradigms were excluded because transgene effects were not consistent and thus I 
could not reliably determine the direction of effect (improvement or worsening). 
 
Open field test 
 
I found 15 publications reporting 24 experiments using the open field test of which 
18 reported wild type performance. Of these 18 experiments, in seven transgenic 
mice were less active than controls and in 11 they were more active. I therefore 
could not be confident in assigning the transgenic direction of effect (Figure 3.19). 
 
Elevated plus maze 
 
Six publications reported eight experiments using the EPM. Similar to the issues 
outlined with the open field test the dataset suggested inconsistencies regarding the 
direction of impact of a transgene (Figure 3.20).  Where I compared the percentage 
time in open arms I observed that the presence of a transgene could both increase 









Difference in distance travelled/ambulation 
(normalised to mean value of control)
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Figure 3.19: For outcomes from the open field test, the presence of a transgene 
was associated with both an increase and decrease ambulation. Data were 
‘normalised’ whereby control transgenic outcomes equated to 100%. Error 
represents standard deviation of each estimate and colour represents transgenic 
model group used. 
 
Figure 3.20: For outcomes from the elevated plus maze, the presence of a 
transgene was associated with both an increase and decrease time in open 
arms. Data were ‘normalised’ whereby control transgenic outcomes equated to 
100%. Error represents standard deviation of each estimate and colour 
represents transgenic model group used. 
 






Description #  
pub 
Attack latency 
Mice are exposed to a particular stressor (e.g. rat) and latency or frequency of attacks is recorded. Transgenic animals are likely to have increased 
aggression compared to wild type counterparts. 
3 
Balance beam Two support columns are connected with a beam above a padded surface. The ability (usually by speed) of the mouse to cross the beam is assessed. 3 
Barnes maze 
The Barnes maze is a circular, open platform elevated above the floor with a number of dark holes evenly spaced around the perimeter. One of these 
holes has a hidden platform, and mice are trained to find such a platform using visio-spatial cues (thus similar to the Morris water maze). Transgenic mice 




Used for the first time in 2008 the cheeseboard maze provides a dry land version of the Morris water maze, where the mouse is trained to find a food 




The circular platform task assesses reference memory to identify a hidden escape hole within a group of many others (i.e. 16 others). Conditions during 
the experiment may be made aversive for the mice by using a high speed fan and/or high lighting and over a number of days the ability of the mouse to 





The closed field symmetrical maze challenges mice to navigate from a startbox to an end box within a walled maze construct. Mice are given a reward for 




Mice are exposed to a particular odour, and then exposed to a novel odour. In a similar method to that of the novel object recognition task, the ability of 




The elevated plus maze is commonly used neurological paradigm used to assess anxiety and consists of four arms in a cross shape, where two arms are 
enclosed by walls and two open. Time spent in both the open and closed arms can be used representing efficacy. Wild type mice typically spend less time 




Exploratory activity can be measured through numerous methods infrared beam break counts. The 2 publications examining exploratory activity 
performed analyses while in cages and thus separates it from open field activity. 
2 







Fear conditioning is a frequently used paradigm in mice which can assess both contextual and cued fear response in a Pavlovian associative learning task. 
Mice are given training sessions whereby a treatment is given which elicits an innate fear response (e.g. small electric foot shock causing freezing 
behaviour). Such a fear response is commonly accompanied by a auditory tone or olfactory cue and behavioural assessment may be designed to 




The food preference test is used to assess both olfactory and spatial memory. Briefly, the paradigm involves ‘demonstrator’ mice which are exposed to 
transgenic mice after consuming mixed chow with a given aroma. The ability of the transgenic mice to remember the aromatic chow from this exposure is 





A functional observation battery can be used to assess a large number of behavioural outcomes including sensorimotor events, muscle tone, and central 
nervous system activity and excitability. 
1 
Habituation task 
The Habituation task as described in Matsuoka, 2008 provides an olfactory assessment similar to the novel object recognition test in experimental design. 




Similar in design to the Barnes maze, the hole board learning task was used to assess the ability of a mouse to remember which out of sixteen holes were 










The Morris water maze is the most widely used behavioural paradigm in transgenic mouse models of Alzheimer’s disease. Mice are trained to find a 
hidden platform in a cloudy pool of water thought to be found using extra visual cues. Mice generally take less time to find the platform as the 





Removal of the platform from the pool is required for the probe ’test’ phase of the Morris water maze. Mice are assessed for their ability to determine 




The novel object recognition task assesses the innate tendency that mice will explore a novel, replaced or displaced object whenever presented with one 
Commonly this paradigm is designed with the mice being exposed to a number of unfamiliar objects for a given period of time (i.e. 5 to 10 minutes). From 
30 minutes to 24 hours later, mice are exposed once again to the same environment with one of the objects displaced or replaced and the ability of the 
mouse to comprehend such a change is quantified by the time spent near the novel or displaced object. 
15 




Table 3.6: Thirty different neurobehavioral paradigms were identified across publications identified. Each is briefly described and 
the number of publications describing each is given. 
Open field test 
The open field test examines both anxiety and locomotion rodent models by their spontaneous ambulation. Innate behavioural such as grooming or 




Passive avoidance paradigms commonly involve exposing mice to an electric shock in a specific environment (e.g. a dark compartment of apparatus). The 




The platform recognition task uses the same apparatus as the Morris water maze (circular pool with external cues) and varies the location of a raised 
visible platform. If Morris water maze has been used previously, this forces mice to change from visio spatial technique to recognition memory 
6 
Radial arm water 
maze 
The Radial arm water maze (RAWM) assesses memory through visio-spatial recognition and can assess both working and reference memory. The 
paradigm consists of a number of different arms (usually six or 8) centred on a central circular pool of water. There are a number of specific set ups in use 
including; baiting all or half of the arms of the maze or placing a hidden platform within one arm. Transgenic mice are expected to have slower latencies 
and increased errors finding goal arms. 
23 
Rotarod The rotarod is assesses coordination and balance through the use of a spinning rod. 2 
Spontaneous 
behaviour 
Spontaneous behaviour was measured within cages of mice. Such assessment does not require any specific paradigm apparatus and assesses the 
presence of stereotypical behaviour. 
1 
String agility String agility can be used to assess both forepaw grip capacity and agility, typically measured by the time. 2 
Tail suspension 
test 
Mice are suspended from the tail and videotaped. The ability of the mice to clasp is assessed through a clasping score. 2 
T-maze 
The T maze consists of 3 goal arms (A,B,C) in a T shape. The most commonly assessed parameter is spontaneous alternation- the ability of the mouse to 
enter an arm which it has not just visited previously. Behaviour in the T maze is thought to reflect the natural tendency mice have to explore novel 
environments. Transgenic mice typically have lower rates of alternation. 
7 
Traverse beam 




Almost identical to the T maze, The Y maze consists of 3 goal arms (A,B,C) in a Y shape. Behaviour in the Y maze is thought to reflect the natural tendency 
mice have to explore novel environments (in this case the unexplored arm). Transgenic mice commonly have lower rates of alternation. 
14 
 




3.5 Transgenic mouse model use 
 
Fifty-five individual transgenes were described; each with a unique description of 
those mutations used to capture aspects of AD. I found the most commonly 
reported transgenic group was the APP group, reported in 298 publications. More 
specifically, the Tg2576 mouse was the most commonly reported single transgenic-
reported in 34% (149/427) of publications. Eighty-five publications tested both male 
and female mice. Where a single sex was used, females were more commonly used 
than males (56 vs. 45 publications). Fifty five percent of publications (236/427) did 
not state the sex of the animal used.   The number of publications describing each 
specific mutation, alongside transgenic model group and sex can be found in Table 
3.8. 
 
The zygosity of transgene expression and promoter used can often be a determining 
factor a given transgenic phenotype. I identified that 68.9% of publications did not 
describe the zygosity of the transgenic mouse. For those publications that did, 
where multiple mutations were present it was not possible to accurately identify 
whether the described zygosity referred to both or one of the mutations. Within the 
published literature, 249/427 (58%) publications made specific reference to the 
promoter used. To improve the statistical power of meta-analyses I decided to cross-
check referenced literature wherever possible in order to deduce how transgenes 
were established. I identified the promoter used for 80% of publications. Four major 




Table 3.7 Simplified summary of use of promoters in transgenic model groups 
used. Most studies use a single type of promoters to direct transgene expression, 
but a number used different promoters to promote different mutations.  
promoters were used (Thy-1 gene promoter, ], PDGF [Platelet derived growth 
factor] and HPP [hamster prion promoter]) which were commonly associated with 
specific strains of transgenic mice. Those promoters identified remained difficult to 
categorise. For these reasons I took the decision not to take promoter attributes 
forward for meta-analyses. Table 3.7 provides a simplified summary listing 

























































HPP   153 3         156 
Thy-1 24 50 11  1 2  88 
unknown 4 20 42 1 3 5 7 82 
PDGF   43   2 2  47 
Mouse prion protein promoter   2 21  1 6  30 
Syrian HPP   29    1  30 
Human cytomegalovirus (CMV)      4    4 
Neuron specific enolase       2  2 
Forebrain-specific calmodulin kinase II    1    1  2 
Thy1 (Human)   2      2 
CamKII        1  1 
Cytomegalovirus enhancer/b-actin      1    1 
Rat specific enolase    1      1 
Prion protein gene complex     1     1 
hAPP    1      1 







HPP/PDGF      18     18 
PDGF/PDGF    2     2 
HPP/unknown     1     1 
 Total number of multiple promoter driven transgenic cohorts 21 
Grand Total 28 302 99 6 7 20 7 469 






Group Transgene Both Female Male Unknown 
Number of 
Publications 
3xTgAD 3xTgAD 11 3 5 13 32 
3xTgAD Total   11 3 5 13 32 
APP APP 1     3 4 
  APP23   2 7 6 15 
  APP51/16     1   1 
  APP695       1 1 
  APP695lon/swe       1 1 
  APP751lon/swe 2 1 1 13 17 
  APParc (E22G) 1       1 
  APPlon 3   1 8 12 
  APPlon/swe 1   1 2 4 
  APPswe 4 4 2 9 19 
  APPV717F 4 6 2 16 28 
  APPV717F (APOE KO)       1 1 
  APPV717I       1 1 
  APPV717I-CT100       1 1 
  APP-YAC       2 2 
  CamKII ttA x tet APPswe/ind 1       1 
  J20 APPSWE/IND 2   2 11 15 
  Tg2576 32 33 16 70 151 
  TgCRND8 5 5 4 17 31 
  tgNORBA       1 1 
  TG-SwDI       2 2 
APP Total   56 51 37 165 309 
APPPS APP23/PS45       1 1 
  APP24   1     1 
  APP695K594N,M595L/PS1de9       1 1 
  APPPS1       3 3 
  APPswe/PS1 2   1 4 7 
  APPswe/PS1A246E   1 3 1 5 
  APPswe/PS1dE9 9 10 11 20 50 
  APPswe/PS1L166P       2 2 
  APPswe/PS1M146L 6 1 4 12 23 
  APPswe/PS1M146V 2 1 1 1 5 
  APPswe/PS1P246L       1 1 
  APPswe/PS2N141I       2 2 
  APPV717F/PS1M146L 1     2 3 
  APPV717I/PS1A246E 2 1   1 4 
APPPS Total   22 15 20 51 108 
Other AD11 1     3 4 
  Nse/ps2m       1 1 
  Tg13592       1 1 
Other Total   1     5 6 
PS1 PS1 1       1 
  PS1dE9   1     1 
  PS1-L235P   1     1 
  PS1M146L     1 1 2 
  PS1M146V 2       2 
PS1 Total   3 2 1 1 7 
Tau GSK-3/VLW       1 1 
  GSK3betaS9A       1 1 
  NFT P301S/K257T       1 1 
  NSE/APPsw       1 1 
  p25       2 2 
  P301S/K257T       1 1 
  pNSE/htau23 1       1 
  T44       4 4 
  tau V337M       2 2 
  tgP301L 3 4 1   8 
Tau Total   4 4 1 13 22 
Unknown unknown       7 7 
Unknown Total         7 7 
Grand Total   97 75 64 255 491 





3.5.1 Age specific parameters 
 
 
Across all outcomes the median age at intervention administration was 168 days 
[IQR 84 to 311] and the median age at outcome assessment was 308 days [IQR 175 to 
420]. The early age at which interventions are administered in transgenic mouse 
models has been proposed as a potential explanation for translational failure (Zahs 
& Ashe 2010). As a representative sample I examined the four most commonly 
tested transgenic mouse models (Tg2576, TgCRND8, APPswe/PS1de9 and 3xTgAD) 
in order to inspect the age of intervention administration and outcome assessment 
by medians and inter-quartile ranges (Figure 3.21). For the Tg2576 and 3xTgAD 
models, the majority of interventions were given before the onset of plaque 
pathology but it is interesting to note that intervention administration in the 
APPswe/PS1de9 transgenic commonly occurs after the onset of plaques. TgCRND8 
mice were also interesting in the respect that they offer a relatively quick onset of 
the phenotype- which may explain why the majority of interventions administered 
before three months of age. The age disparity identified between transgenics may be 























Figure 3.21: The age at which interventions are administered and assessed has 
been increasing interest in terms of clinical relevance. I examined the four most 
commonly tested transgenic models (TgCRND8, Tg2576, 3xTgAD, 
APPswe,/PS1de9) in box and whisper plots for both the age at intervention 
administration and outcome assessment. Also shown is the onset of behavioural 
deficits and robust plaque pathology. (Garcia-Alloza et al. 2006;Janus et al. 
2000;Sterniczuk et al. 2010;Savonenko et al. 2005) 




3.6 Intervention use 
 
357 different interventions were identified within the described literature. I faced 
significant challenges in classifying most interventions into intervention groups; 
intervention attributes are not always known and they can have multiple targets. 
Nonetheless, for illustrative purposes I identified a number of intervention groups 
including; ‘anti-inflammatory interventions’ (including gamma secretase inhibitors, 
97 publications), ‘active immunisation’ (99 publications), ‘passive immunisation’ 
(102 publications), ‘health improvements’ (e.g. dietary supplements or exercise, 86 
publications), ‘beta-secretase Inhibitors’, (13 publications) ‘pro-inflammatory 
interventions’ (10 publications), ‘metals/metal chelators’ (26 publications) and 
‘cholinergic function enhancers’ (29 publications). While selected intervention 
groups and interventions may be subsequently investigated in greater detail, meta-
analyses were not planned to compare intervention classifications. For those 
interventions which report outcomes in 5 or more publications (16 interventions, see 
Figure 3.22 for further details) I provide further estimates of effect information on 








Figure 3.22: The sixteen most commonly tested interventions where outcomes 
were reported and the number of publications they feature in. Such interventions 



























































































































































3.6.1 Active immunisation summary  
 
Due to the considerable data, I explored active immunisation experiments in further 
detail.  I noted 24 unique lengths of amyloid beta tested across 77 publications and 
observed that amyloid beta 1-42 was the most commonly investigated intervention 
(41 publications). 
 
In terms of the mode of administration, amyloid beta was most frequently 
administered as a peptide (19 publications) and it was also administered pre-
transcription genetic coding in seven publications. The diversity of how amyloid 
was packaged for active immunisation was considerable. There were 62 uniquely 
described adjuvants or vectors (such as Freund's adjuvant or the Adeno-viral vector 
[AVV]). A summary of the diverse nature of amyloid beta active immunisation can 
be found in Figure 3.23. 
 
 




Figure 3.23: The administration of amyloid beta as an active immunisation strategy is truly diverse: through the fragment 
of amyloid administered, the mode of administration (genetic or peptide) and whether an adjuvant or peptide has a role 
in administration. AVV: Adeno-virus Vector, Aβ Amyloid beta. 
 














































































80 Blinded assessment of outcome 
Random allocation to group 
Sample size calculation 
Statement regarding conflict of interest 
Complaince with animal welfare legislation 
3.7 Study quality 
 
3.7.1 Study quality items 
 
Reported study quality score was assessed across the 427 publications. Random 
allocation to group was reported by 67 of 427 publications (16%), blinded 
assessment of outcome by 94/427 (22%), a statement of potential conflict of interest 
by 54/427 (13%), compliance with animal welfare regulations by 239/427 (56%); and 
no publication described how the group size of the experiment was determined. I 
examined how study quality changed over time where the only criterion which 
demonstrated consistent improvement was reporting of compliance with animal 











Figure 3.24: Percentage of publications meeting each of the five study quality 
criteria. Total number of publications per year is described in brackets. 




3.7.2 Outcomes reported 
 
 
The use of the study quality item list was a pre-specified attempt to assess study 
quality. There were also other notable study quality markers from working with the 
published literature; four percent of authors (16/427) were contacted due to 
inadequate description of fundamental study methodology such as the number of 
animals used or the age at intervention administration. Furthermore, for every 15 
articles read, one would fail to state whether error bars represented standard error 
or standard deviation and emailing authors aided subsequent interpretations (7% of 
literature).  




3.8 Overview of existing literature 
 
Our systematic review has identified a dataset with extensive methodological 
variation, particularly with respect to the transgenic models used, interventions 
tested, the age at intervention administration and outcome assessment. 
 
Seven major outcome measures were reported from publications (plaque burden, 
amyloid beta 40, amyloid beta 42, tau, cellular infiltrates, neurodegeneration and 
neurobehaviour) and I will summarise overall estimates of efficacy wherever 
possible. Further, wherever data permit I will investigate relationships within and 
between outcomes. 
 
Over the next three chapters I describe such analyses: in Chapter 4 I examine 
individual outcome measures and relationships between outcome measures; in 
Chapter 5 I examine relationships between observed efficacy and age and sex, 
alongside inspecting the impact of the transgene within models. In Chapter 6 I 
provide summary analyses inspecting individual interventions.  
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Chapter 4: Outcome measure specific meta-analyses 
 
In this chapter I perform meta-analyses on each of the main pathological and 
neurobehavioural outcomes extracted. To quantify the impact across all 
interventions on a given outcome, I derive overall summary estimates of efficacy. To 
ensure I account for fundamental differences between models I also stratify outcome 
estimates by the transgenic group used. I then explore methodologies within each 
outcome and where data are sufficient I investigate relationships within a given 
outcome measure. To address limitations in our understanding of how different 
outcome measures relate to one another I investigate relationships between 
outcomes wherever data permit. Throughout, analyses conducted are not designed 
specifically around a specific disease hypothesis; they are conducted to reflect 





For pathological outcomes I initially planned to use normalised meta-analysis 
estimates of effect size (see Methods). However, only 9% of publications described 
wild type data and because some AD like pathology was present in such estimates, 
this ruled out the use of the technique. Methodologies were too diverse to allow 
difference in means estimates and thus I decided to use standardised mean 
difference meta-analysis. 
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Table 4.1: Estimates of standardised effect size according to each staining method 
used. Columns represent different staining techniques (immunohistochemistry 
[immunohist], congo red, Thioflavin S) and end column indicates summary 
estimates , *as different outcomes can be represented in the same cohort of 
animals some are represented more than once. Brackets provide 95 percent 
confidence limits and lower number indicates the number of experiments (n).  
 
4.1 Plaque burden 
 
I identified 414 experiments (representing 5157 animals) which reported changes in 
plaque burden and overall interventions reduced plaque pathology by 0.98 SD (95% 
CI 0.87 to 1.08). Ipartitioned heterogeneity in order to assess whether there was an 
association between the staining technique used and reported outcome but this did 
not account for a significant proportion of the observed heterogeneity (χ2 =0.5). I 
identified that publications most commonly referred to immunohistochemical 
staining methods (91%, [378/414]) where the overall reduction in plaque pathology 
was estimated at 0.98 SD (0.87 to 1.10). Thirty-nine experiments used congo red 
staining which had an estimated reduction of 0.98 SD (0.56 to 1.41). For the 65 
experiments which used Thioflavin S  Iestimated a 0.91 SD (0.67 to 1.14) reduction in 















Effect size 0.98 SD 0.98 SD 0.91 SD 0.97 
95% CI (0.87 to 1.10) (0.56 to 1.41)  (0.67 to 1.14) (0.87 to 1.07) 
n 378 39 65 482 
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Table 4.2: Estimates of standardised effect size according to each combination 
of staining method used for plaque burden. Columns represent different 
staining techniques (immunohistochemistry, congo red, Thioflavin S) and end 
column indicates combined estimates. Brackets give 95 percent confidence 
limits and lower number indicates the number of experiments. 
I identified that sufficient data were present to explore relationships further:  
between antibody stained plaques, congo red (32 experiments) and Thioflavin S (36 






95% CI and n 
Congo red 
Effect size 
95% CI and n 
Thioflavin S 
Effect size 
95% CI and n 
Combined  
Effect size 
95% CI and n 
Antibody stained only 0.95 SD 
 (0.83 to 1.08) 
310   
0.95 SD 
 (0.83 to 1.08) 
310 
Congo stained only 
 
0.57 SD 
 (-0.01 to 1.15) 
7  
0.57 SD 
(-0.01 to 1.15) 
7 




(0.82 to 1.43) 
 29 
1.13 SD 
(0.82 to 1.43) 
 29 
Antibody and Congo 
red stained 
1.27 SD 
(0.76 to 1.78) 
32 
1.09 SD 
(0.58 to 1.60)  
32  
1.17 SD 
(0.68 to 1.65) 
32 
Antibody and 
Thioflavin S stained 
0.94 SD 
(0.57 to 1.32)  
36  
0.73 SD 
(0.40 to 1.06) 
 36 
0.84 SD 
(0.51 to 1.17) 
36 
Congo red and 
Thioflavin S stained  No data No data No data 
Antibody. Congo red 
and Thioflavin S 
stained 










(0.87 to 1.10) 
378 
0.98 SD 
(0.56 to 1.41) 
39 
0.91 SD 
 (0.67 to 1.14) 
65 
0.98 SD 
 (0.87 to 1.08) 
414 




4.1.1 Plaque burden outcomes and transgenic model group  
 
In order to understand transgene effects on observed effect size I stratified plaque 
burden data according to the transgenic group used. I assessed heterogeneity for 
data overall and for antibody stained plaques due the high prevalence of reported 
experiments (representing 91% of cohorts). Where I stratified plaque burden data 
overall I identified that estimates were generally similar and this accounted for a 
significant proportion of the observed heterogeneity (χ2 =12.04, df=4, p<0.05). Where 
I stratified antibody stained plaque burden data only according to the transgenic 
model group used I also found that this did account for a significant proportion of 










95% CI and n 
Congo red 
Effect size 
95% CI and n 
Thioflavin S 
Effect size 
95% CI and n  
Combined   
Effect size 
95% CI and n 
APP 
0.99 
(0.86 to 1.12) 
268 
0.79 
(0.18 to 1.41) 
18 
0.94 
(0.63 to 1.24) 
48 
0.99 




(0.65 to 1.17) 
79 
1.11 
(0.54 to 1.68) 
21 
0.86 
(0.42 to 1.3) 
13 
0.89 








(-0.03 to 1.94) 
3 
1.05 
(0.46 to 1.64)  
26 
Tau No data No data 
0.41 
(-0.53 to 1.35) 
1 
0.41 




(1.05 to 2.49) 
7 
No data No data 
1.77 








estimate Global estimate 
0.98 SD 
(0.87 to 1.10) 
378 
0.98 SD 
(0.56 to 1.41) 
39 
0.91 SD 
 (0.67 to 1.14) 
65 
0.98 SD 
 (0.87 to 1.08) 
414 






Table 4.3 (Previous page): Estimates of standardised effect size for plaque 
burden staining methods according to each transgenic model group used. 
Columns represent different staining techniques (immunohistochemistry, congo 
red, Thioflavin S) and end column indicates combined estimates. Brackets give 
95 percent confidence limits and lower number indicates the number of 
experiments. (N.B. some experiments are represented more than once). 
Figure 4.1: I stratified plaque burden data according to transgenic model group 
used. Error bars represent 95% confidence intervals (CI) and grey bar represents 
95% CI of global estimate, bar width represents the log of the number of animals. 
Transgenic Model Group
















































3.0 Plaque burden 
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4.1.2 Relationships within different plaque staining 
techniques  
 
Wherever sufficient data were present (>10 experiments) I performed meta-
regression in order to identify potential relationships between the different staining 
techniques of plaque burden. For 32 experiments I identified that changes in plaque 
burden stained by congo red could explain 89% of the changes in antibody stained 
plaques (Figure 4.2). Likewise, 36 experiments suggested that changes in plaque 
burden stained by Thioflavin S stained plaques could explain 91.1% changes in 























 95% CI 
N Adj. R2 
0.792 0.088 8.99 0 0.612 0.972 32 0.89 
Adj. R2= 0.89 




Figure 4.2 (upper) and Table 4.4 (lower): 88.7% of changes of 
immunohistochemically stained plaques could be explained by changes in congo 
red stained plaques. Each symbol represents an individual experiment and symbol 
size represents the inverse variance for each estimate of effect size. For each 
comparison table provides co-efficient, standard error, tau (τ), significance level, 
95% confidence limits, number of experiments (N) and adjusted R2 (Adj. R2) 












4.1.3 Plaque burden summary 
 
In summary, estimates of efficacy did not differ according to the staining technique 
used and but I identified differences between transgenic groups where stratifying 
immunohistochemically stained plaque burden. Immunohistochemistry techniques 
were the most commonly assessed and were associated with smaller variances on 
estimates of efficacy. For these reasons I decided to limit subsequent analyses to 













 95% CI 
N Adj. R2 
0.839 0.094 8.92 0 0.648 1.03 36 0.91 
Figure 4.3 (upper) Table 4.5 (lower): 91.1% of changes in immunohistochemically 
stained plaques could be explained by changes in thioflavin S. Each symbol 
represents an individual experiment and symbol size represents the inverse 
variance for each estimate of effect size. For each comparison table provides co-
efficient, standard error, tau (τ), significance level, 95% confidence limits, number of 
experiments (N) and adjusted R2 (Adj. R2) 
Adj. R2=0.91 
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Table 4.6: Estimates of standardised effect size according to each species of amyloid 
assessed. End column indicates combined estimates, *as different outcomes can be 
represented in the same cohort of animals some are represented more than once. 
Brackets give 95 percent confidence limits and lower number indicates the number 
of experiments. 
4.2 Amyloid beta species 
 
I identified 483 experimental cohorts which examined amyloid species (amyloid 
beta 40, amyloid beta 42, total amyloid beta or oligomer species) representing 6525 
animals. From 483 experiments the overall estimated reduction in amyloid was 0.79 
SD (0.70 to 0.87).  
 
I partitioned heterogeneity in order to assess whether the amyloid species assessed 
impacted on observed outcome but this did not account for a significant proportion 
(χ2 =11.21, df=3, Table 4.6). Interventions reduced amyloid beta 40 by 0.68 SD (0.57 to 
0.79), amyloid beta 42 by 0.78 (0.67 to 0.88), total amyloid beta by 0.83 SD (0.62 to 















(0.57 to 0.79) 
388 
0.78 SD 
(0.67 to 0.88) 
389 
0.83 
(0.62 to 1.05) 
81 
0.79 
(0.42 to 1.17) 
33 
0.74 
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Table 4.7: Estimates of standardised effect size according to each amyloid species 
assessed. Columns represent different species including amyloid beta 40, amyloid 
beta 42, total amyloid and oligomer species. End column indicates combined 
estimates. Brackets give 95 percent confidence limits and lower number indicates 
the number of experiments. >10 experiments were sufficient for meta-regreesion*. 
 I explored this dataset further and identified that there were sufficient data to 
investigate number of potential relationships between different amyloid species as 



















95% CI and n 
Combined 
Effect size 
95% CI and n 
Amyloid beta 40 only 1.42 












(0.92 to 1.91) 
54 
Amyloid beta 42 only 
 
0.56 









(0.3 to 0.83) 
34 
Total amyloid only 
  
0.94 






(0.62 to 1.05) 
79 






(0.04 to 1.16) 
8 
0.60 
(0.04 to 1.16) 
8 
Amyloid beta 40 and 
amyloid beta 42 
0.62 
(0.51 to 0.73) 
334* 
0.74 




(0.62 to 0.82) 
334 
Amyloid beta 40 and total 
amyloid  
0.47 








(0.2 to 0.85) 
28* 
Amyloid beta 40 and 
oligomers 
0.61 







(0.36 to 1.31) 
24* 
0.68 
(0.31 to 1.04) 
24* 
Amyloid beta 42 and total 
amyloid  
1.15 
(0.79 to 1.52) 
49 
0.78 






(0.64 to 1.19) 
49 
Amyloid beta 42 and 
oligomers  
0.74 






(0.36 to 1.31) 
24* 
0.73 
(0.38 to 1.09) 
24* 
Total amyloid and 
oligomers   
1.69 
(-0.2 to 3.58) 
3 
2.50 
(0.46 to 4.54) 
3 
2.17 













(0.57 to 0.79) 
388 
0.78 SD 
(0.67 to 0.88) 
389 
0.83 
(0.62 to 1.05) 
81 
0.79 
(0.42 to 1.17) 
33 
0.78 SD 
(0.69 to 0.87) 
483 
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4.2.1 Amyloid beta outcomes stratified transgenic model 
group  
 
As 93% of experiments were represented by either amyloid beta 40 or amyloid beta 
42 I decided to focus analyses on these two species individually (Table 4.8). I 
additionally provide estimates of efficacy for total amyloid and all amyloid species 
with the exception of oligomers due to limited data. 
 
Overall, I identified that stratifying all amyloid data according to the transgenic 
model used accounted for a significant proportion of the observed heterogeneity (χ2 
= 38.4, p<0.05, Table 4.8). Where I analysed changes in amyloid beta 40 outcomes 
according to transgenic model group this accounted for a significant proportion of 
the observed heterogeneity (χ2 = 25.34, p<0.01): higher estimates of effect size were 
associated with the tau transgenic group, 3.06 SD (1.68 to 4.43) compared to the 
'other transgenic model groups assessed (Figure 4.4). For amyloid beta 42 outcomes, 
stratifying data by transgenic model group used also accounted for a significant 
proportion of the observed heterogeneity (χ2 = 22.42, p<0.01) where higher estimates 
of efficacy were found in the Tau, PS and the other transgenic group compared to 
















Amyloid beta 40 
Effect size 
(95% CI) and N 
Amyloid beta 42 
Effect size 
(95% CI) and N 
Total amyloid beta 
Effect size 
(95% CI) and N 
Combined 
Effect size  
(95% CI) and N 
APP 
0.76 
 (0.63 to 0.89)  
292 
0.88 
 (0.75 to 1)  
288 
0.84 
(0.63 to 1.05) 
71 
0.86 




 (0.31 to 0.8)  
61 
0.61 
 (0.37 to 0.84)  
67 
0.79 
 (-1.19 to 2.76)  
8 
0.62 




 (0.05 to 0.6)  
33 
0.31 
 (0.03 to 0.59)  
31 
0.43 
 (0.02 to 0.83)  
2 
0.35 




 (1.68 to 4.43)  
1 
1.9 










 (-1.52 to 0.98)  
1 
2.13 



















 (0.33 to 4.12)  
1 
 
Summary estimate Summary estimate Summary estimate Global estimate 
0.68 
(0.57 to 0.79) 
388 
0.78 
(0.67 to 0.88) 
389 
0.83 
(0.62 to 1.05) 
81 
0.79 
(0.7 to 0.88) 
475 
Table 4.8: Changes in amyloid species stratified according to the transgenic 
model group used. Columns represent different standardised effect sizes of 
amyloid species (amyloid beta 40, amyloid beta 42, total amyloid beta) and end 
column indicates combined estimates. Brackets give 95 percent confidence 
limits and lower number indicates the number of experiments. As different 
outcomes can be represented in the same cohort of animals some are 
represented more than once. 





































































































Figure 4.4: I stratified amyloid beta 40 data according to transgenic model group 
used which accounted for a significant proportion of heterogeneity. Error bars 
represent 95% confidence intervals (CI) and grey bar represents 95% CI of global 
estimate, bar width represents the log of the number of animals. 
Figure 4.5: I stratified amyloid beta 42 data according to transgenic model group 
used which accounted for a significant proportion of heterogeneity. Error bars 
represent 95% confidence intervals (CI) and grey bar represents 95% CI of global 
estimate, bar width represents the log of the number of animals. 
Amyloid beta 42 
Amyloid beta 40 
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4.2.2 Relationships between different amyloid fragments 
 
Where sufficient data permitted, I examined different amyloid species for potential 
relationships (see Table 4.9 for overview).  334 experiments reported changes in 
amyloid beta 40 and amyloid beta 42 and meta-regression suggested that changes in 















Figure 4.6: 88.4% of changes in amyloid beta 40 could be explained by the observed 
changes in amyloid beta 42. Cohorts where both were measured are represented 




Adj. R2= 0.88 
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For the 28 experiments which examined both amyloid beta 40 and total amyloid 
beta meta-regression identified strong correlation between variables, where changes 














For the 24 experiments which reported changes in amyloid beta 40 alongside 
oligomer species meta-regression suggested 34% correlation (Figure 4.8) but this did 
not prove statistically significant. For the 49 experiments which examined both 
amyloid beta and total amyloid levels, meta-regression identified that 50.3% of the 
variation in total amyloid could be explained by the variation observed in amyloid 
beta 42 (p<0.01, Figure 4.9) 
 
Adj. R2= 0.74 
Figure 4.7: 73.7% of changes in total amyloid beta could be explained by the 
observed changes in amyloid beta 40. Cohorts where both were measured are 
represented with symbol size representing the inverse of the variance for each 
estimate of effect size. 
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Figure 4.9: 50.3% of changes in total amyloid could be explained by the observed 
changes in amyloid beta 42. Cohorts where both were measured are represented 









Figure 4.8: 34.0% of changes in amyloid beta 40 could be explained by the 
observed changes in oligomers. Cohorts where both were measured are 
represented with symbol size representing the inverse of the variance for 
each estimate of effect size. 
 
  
Adj. R2= 0.50 
Adj. R2= 0.417 
Adj. R2= 0.34 
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Figure 4.10: 25.7% of changes in oligomers could be explained by the observed 
changes in amyloid beta 42. Cohorts where both were measured are 
represented with symbol size representing the inverse of the variance for each 
estimate of effect size. 
  
Twenty four experiments reported changes in amyloid beta 42 and oligomer species. 
Meta-regression identified that changes in oligomers could explain 25.7 % of 
changes in amyloid beta 42 although this did not prove statistically significant for 
































95 CI% N Adj. R2 
Amyloid beta 40 vs. 42 0.580 0.032 18.09 0 0.517 0.643 334 0.88 
Oligomers vs. amyloid beta 40 0.335 0.122 2.74 0.012 0.082 0.589 24 0.34 
Amyloid beta 40 vs. total 0.607 0.135 4.5 0 0.33 0.884 28 0.74 
Amyloid beta 42 vs. total 0.169 0.041 4.14 0 0.087 0.252 49 0.5 
Oligomers vs. amyloid beta 42 0.317 0.138 2.29 0.032 0.03 0.604 24 0.26 
Adj. R2= 0.26 
Table 4.9: Wherever there were sufficient data I investigated potential relationships 
between amyloid species. For each comparison co-efficient is given (in terms of 
standardise mean difference effect size [SMD ES], standard error, tau (τ), significance 
level, 95% confidence limits, number of experiments (N) and Adjusted R2 (Adj. R2)  
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4.2.3 Solubility of amyloid species 
 
 
Within amyloid species I explored the data to identify the number of experiments 
and estimates of effect across the different solubilities of amyloid (Table 4.10).  This 
was possible for 71% (276/388) amyloid beta 40 experiments which revised the 
overall effect size to 0.66 SD (0.54 to 0.78). 76% (295/389) of amyloid beta 42 
experiments stated solubility which revised the overall effect size to 0.76 SD (0.64 to 
0.88). For total amyloid 77% (62/81) experiments stated solubility which revised the 
overall effect size to 0.75 (0.52 to 0.99). For oligomer species, 48% (16/33) of 
experiments described soluble experiments where the estimated effect size was 1.68 
























Soluble Insoluble  Total Combined   
Effect size  Effect size  Effect size  Effect size 
 (95% CI) and N (95% CI) and N (95% CI) and N  (95% CI) and N 
Amyloid beta 40 
0.58 
(0.42 to 0.73) 
196 
0.63 
(0.48 to 0.79) 
166 
0.79 
(0.49 to 1.08) 
66 
0.66 
(0.54 to 0.78) 
276 
Amyloid beta 42 
0.56 
(0.4 to 0.72) 
187 
0.63 
(0.47 to 0.79) 
162 
0.55 
(0.26 to 0.83) 
52 
0.76 
(0.64 to 0.88) 
295 
Amyloid beta total 
1.01 
(0.43 to 1.59) 
20 
1.01 
(0.43 to 1.59) 
20 
0.79 
(0.5 to 1.09) 
44 
0.75 




(1.09 to 2.21) 
16 
No data No data 
1.65 







estimate Global estimate 
0.70 
(0.57 to 0.84) 
233 
0.73 
(0.59 to 0.86) 
209 
0.89 
(0.69 to 1.09) 
110 
0.77 
(0.67 to 0.87) 
348 
Table 4.10: Summary of the solubility of amyloid species examined. For each 
outcome (amyloid beta 40, amyloid beta 42 total amyloid beta and oligomer species) 
soluble, insoluble, total and combined estimates of standardised effects sizes are 
given. The combined effect size for each species where solubility is stated the end 
column whereas overall solubility is shown in the end row. 
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I therefore explored amyloid beta 40 outcomes to identify the spread of data. 
Sufficient data were present to examine the relationship between soluble and 
insoluble species (144 experiments) however there were insufficient data to examine 
any other solubility relationships (Table 4.11). 
 
 
 Soluble Insoluble  overall Combined  
 Effect size  
(95% CI) and N 
 Effect size  Effect size  Effect size  




 (0.27 to 0.99)  
45     
0.63 





 (0.57 to 1.46)  
22   
1.01 




     
0.78 
 (0.44 to 1.11)  
58 
0.78 






 (0.38 to 0.73)  
144 
0.57 
 (0.41 to 0.74)  
144   
0.59 
 (0.45 to 0.74)  
144 
Soluble and overall 
0.91 
 (0.03 to 1.79)  
8   
0.97 
 (0.59 to 1.34)  
8 
0.89 





















estimate Global estimate 
0.58 
 (0.42 to 0.73)  
196 
0.63 
 (0.48 to 0.79)  
166 
0.79 
 (0.49 to 1.08)  
66 
0.66 
 (0.54 to 0.78)  
276 
Table 4.11: Summary of the solubility of amyloid beta 40. Soluble, insoluble, total 
and combined estimates of effects size are given. The end column represents the 
combined effect size across all solubilities and the end row provides summary 
estimate for each solubility. 
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Likewise, I explored estimates of effect regarding the solubility of amyloid beta 42. 
Sufficient were present to examine the relationship between soluble and insoluble 
















Effect size  
(95% CI) and N 
Insoluble  
Effect size  
(95% CI) and N 
Overall 
Effect size  
(95% CI) and N 
Combined  
 Effect size  




 (0.51 to 1.36)  
36     
0.93 





 (0.6 to 1.17)  
42   
0.89 




    
1.02 
 (0.69 to 1.35)  
66 
1.02 






 (0.39 to 0.77)  
144 
0.63 
 (0.46 to 0.81)  
144   
0.63 
 (0.48 to 0.78)  
144 
 
Soluble and  overall 
0.91 
 (-0.1 to 1.91)  
6   
0.85 
 (0.4 to 1.3)  
6 
0.89 
 (0.26 to 1.53)  
6 
 






 (-0.07 to 0.97)  
3 
0.43 
 (-0.05 to 0.91)  
3 
0.44 







estimate Global estimate 
0.56 
 (0.4 to 0.72)  
187 
0.63 
 (0.47 to 0.79)  
162 
0.55 
 (0.26 to 0.83)  
52 
0.76 
 (0.64 to 0.88)  
295 
Table 4.12: Summary of the solubility of amyloid beta 42. Soluble, insoluble, total 
and combined estimates of effects size are given. The end column represents the 
combined effect size across all solubilities and the end row provides summary 
estimate for each solubility. 
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Amyloid beta total 
 
Finally, I explored estimates of efficacy by solubility within total amyloid beta 
levels.  Experiments were most likely to report the overall level of amyloid 
regardless of solubility (31 experiments) and there were too few data to allow 
comparison of soluble and total amyloid (6 experiments) or insoluble and total 
amyloid beta (1 experiment). There were however sufficient data to examine the 
relationship between soluble and insoluble species of total amyloid beta (18 
experiments, Table 4.13). 
 
 Soluble 
Effect size  
(95% CI) and N 
Insoluble  
Effect size  
(95% CI) and N 
overall 
Effect size  
(95% CI) and N 
Combined  
 Effect size  
(95% CI) and N 
Soluble only 0.68 
 (-0.78 to 2.15)  
1     
0.68 





 (-1.11 to 1.59)  
3   
0.24 
 (-1.11 to 1.59)  
3 
Overall only 
    
0.95 
(0.61 to 1.29) 
35 
0.95 





(0.23 to 1.08) 
16 
1.22 
(0.51 to 1.93) 
16  
0.85 





(-0.57 to 0.7) 
8  
0.09 
(-0.63 to 0.81) 
8 
0.14 








(0.04 to 1.25) 
3 
0.57 
(0.12 to 1.01) 
3 
0.47 












(0.12 to 0.87) 
23 
1.01 
(0.43 to 1.59) 
20 
0.79 
(0.5 to 1.09) 
44 
0.75 








Table 4.13: Summary of the solubility of amyloid beta 40. Soluble, insoluble, total 
and combined estimates of effects size are given. The end column represents the 
combined effect size across all solubilities and the end row provides summary 
estimate for each solubility. 
 
                                                    Chapter 4: Outcome measure specific meta-analyses 
116 
 
4.2.4 Relationships between different solubilities of amyloid 
 
For the 144 studies which measured both changes in soluble and insoluble amyloid 
beta 40 I performed meta-regression to identify potential relationships. Data 
suggested that changes in soluble amyloid could explain a significant proportion of 
the changes in insoluble amyloid (adjusted R2 value of 0.59, p<0.02, Figure 4.11, 
Table 4.14). Similarly, 144 experiments suggested that changes in soluble amyloid 
beta 42 could explain 35.3 of changes in insoluble amyloid beta 42 (Figure 4.12, 
Table 4.14, p<0.02). For amyloid beta total, 16 experiments suggested that 62.9% of 
changes in insoluble amyloid could be explained by changes in soluble amyloid 



















Figure 4.11: I performed meta-regression in order to investigate the relationship 
between changes in soluble and insoluble amyloid beta 40. Symbol size denotes the 
inverse of the variance for each estimate of effect size.  
Adj. R2= 0.59 
Amyloid beta 40 





Figure 4.12: I performed meta-regression in order to investigate the relationship 
between changes in soluble and insoluble amyloid beta 42. Symbol size denotes 
the inverse of the variance for each estimate of effect size.  
Figure 4.13: I performed meta-regression in order to investigate the relationship 
between changes in soluble and insoluble amyloid beta total. Symbol size 
denotes the inverse of the variance for each estimate of effect size.  
Adj. R2= 0.35 
Adj. R2= 0.63 
Amyloid beta 42 
Amyloid beta total  






4.2.5 Amyloid beta summary 
 
In summary experiments were almost five times more likely to report amyloid beta 
40 or amyloid beta 42 opposed to total amyloid. I observed that estimates of efficacy 
for amyloid differed according the transgenic group assessed, for data overall and 
more specifically within both amyloid beta 40 and amyloid beta 42. Collectively the 
data suggest that there may be a number of strong relationships between amyloid 
species, most prominently between changes in amyloid beta 40 and 42. As amyloid 
beta 40 and 42 datasets represented the majority of amyloid beta, I limit subsequent 














95 CI% N Adj. R2 
Sol. 40 vs. Insol. 40 0.489 0.0568 8.6 0 0.3763 0.601 144 0.59 
Sol. 42 vs. Insol. 42 0.400 0.0568 7.06 0 0.288 0.512 144 0.35 
Sol. total vs. Insol. total 1.087 0.346 3.14 0.007 0.344 1.831 16 0.63 
Table 4.14: Relationships between soluble and insoluble amyloid beta outcomes 
were analysed using meta-regression techniques. For each comparison co-efficient 
is given (in terms of standardise mean difference effect size [SMD ES], standard 
error, tau (τ), significance level, 95% confidence limits, number of experiments 
(N) and Adjusted R2 (Adj. R2)  
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Table 4.15: Estimates of standardised effect size according to whether tau was 
measured quantatively or the phosphorylation state of tau was assessed. Brackets give 
95 percent confidence limits and lower number indicates the number of experiments, 
*as different outcomes can be represented in the same cohort of animals some are 
represented more than once 
4.3 Tau neurofibrillary tangles 
 
Eighty four experiments measured changes in tau (984 animals) where data 
suggested a baseline efficacy of 0.55 SD (0.38 to 0.72). I partitioned heterogeneity to 
assess whether estimates of tau overall or the phosphorylation state of tau differed 
where this accounted for a significant proportion (χ2 =10.0, p<0.05). Estimates 
suggested interventions were more effective at reducing overall levels of tau 0.60 SD 
(0.38 to 0.81) compared to improving the phosphorylation state of tau, 0.44 SD (0.20 










 Overall Tau 
levels  
Phosphorylation 
state of  tau 
Summary 
estimate* 
Effect size 0.44 0.60 0.53 
95 % CI (0.20 to 0.69) (0.38 to 0.81) (0.36 to 0.69) 
n 59 53 112 
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Exploring data further, I identified 31 experiments which reported overall changes 
in tau without the phosphorylation state of tau whereas 25 experiments reported 
vice versa (Table 4.16). 28 experiments reported both overall tau and 





(95% CI) and N 
Phospho tau 
Effect size 
(95% CI) and N 
All tau species 
Effect size 
(95% CI) and N 
Overall tau only 1.10 
(0.57 to 1.64) 
31  
1.10 
(0.57 to 1.64)  
31 
Phosphorylation 
state of tau only 
 
0.64 
(0.31 to 0.97) 
25 
0.64 
(0.31 to 0.97) 
25 
Both tau and 
phosphorylation 
state of tau 
0.18 
(-0.06 to 0.43) 
28 
0.57 
(0.29 to 0.85) 
 28 
0.40 





estimate Global estimate 
0.44 
(0.2 to 0.69) 
59 
0.60 
(0.38 to 0.81) 
53 
0.55 
(0.38 to 0.72) 
84 
 
4.3.1 Tau outcomes and transgenic model group estimates 
 
I partitioned heterogeneity for tau outcomes according to the transgenic model used 
which accounted for a significant proportion (χ2= 16.14, df=4, p<0.01). Estimates of 
efficacy were higher in the ‘other’ transgenic group; however wide confidence 
intervals and few limited our ability to identify associations (Table 4.17 and Figure 
4.14). 
Table 4.16: Estimates of standardised effect size according to each tau species 
assessed. Columns represent the different forms of tau reported, overall tau and 
phosphorylation state of tau (phosphorylated tau). End column indicates 
combined estimates. Brackets give 95 percent confidence limits and lower number 
indicates the number of experiments. 



















(95% CI) and N 
Phos. state of tau 
Effect size 
(95% CI) and N 
Combined 
Effect size  
(95% CI) and N 
APP 
-0.65 
 (-1.34 to 0.05)  
3 
0.62 
 (-0.08 to 1.31)  
7 
0.03 







 (-0.24 to 2.34)  
4 
1.05 




 (0.27 to 0.9)  
42 
0.45 
 (0.15 to 0.74)  
29 
0.56 




 (0.07 to 0.75)  
14 
0.83 
 (0.43 to 1.23)  
9 
0.63 
 (0.36 to 0.90)  
20 






 (-0.13 to 2.79)  
4 
1.33 





Summary estimate Summary estimate Global estimate 
0.44 
 (0.2 to 0.69)  
59 
0.6 
 (0.38 to 0.81)  
53 
0.55 
 (0.38 to 0.72)  
84 
Table 4.17 Estimates of standardised effect size according to each transgenic 
model group used. Columns represent different tau species (overall tau and 
phosphorylation state of tau [Phospho tau]). End column indicates combined 
estimates. Brackets give 95 percent confidence limits and lower number indicates 
the number of experiments. (N.B. some experiments may be represented more 
than once), phos. (phosphorylation). 
Figure 4.14: I stratified tau data according to transgenic model group used where 
this accounted for a significant proportion of the observed heterogeneity. Error 
bars represent 95% confidence intervals (CI) and grey bar represents 95% CI of 
global estimate and  bar width represents the log of the number of animals. 
Transgenic Model Group











































                                                    Chapter 4: Outcome measure specific meta-analyses 
122 
 
4.3.2 Relationships within different tau species 
 
For the 28 experiments which examined both tau and phosphorylated tau species I 
performed a meta-regression to identify potential relationships.  Our analysis 
suggests that changes in the phosphorylation state of tau were not reflective of 
changes observed in overall tau (See Figure 4.15 and Table 4.18). The negative 
adjusted R squared value reflects data where variables explain less of the 





















95 CI% N Adj. R
2 
Phospho tau vs. 
tau 0.18 0.18 1.01 0.32 -0.19 0.55 28 -0.13 
Figure 4.15 (upper) and Table 4.18 (lower): I investigated whether changes in the 
phosphorylation state of tau (phosphor tau) could explain a significant 
proportion of the changes in tau. Meta-regression output provides co-efficient, 
standard error, τ and the lower and upper 95% confidence limits of the co-
efficient estimate alongside the number of experiments (N) and adjusted R 




Phos. tau v. tau  
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Table 4.19: Estimates of standardised effect size for astrocytosis and microgliosis 
overall and end column indicates the overall estimate. Brackets give 95 percent 
confidence limits and lower number indicates the number of experiments, *as 
different outcomes can be represented in the same cohort of animals some are 
represented more than once 
4.3.3 Summary of tau species 
 
Our analyses identified that estimates of efficacy for overall tau were smaller than 
estimates for the phosphorylation state of tau. The transgenic model group used I 
associated with differences in efficacy but these were for the most part subtle 
differences. In respect of the limited data I decided to include all tau when 
performing subsequent analyses.  
 
4.4 Cell infiltrates 
 
Eighty nine cellular infiltrate experiments (representing 1099 animals) suggested an 
overall reduction in cell infiltrates of 0.40 SD (0.13 to 0.68, 89 experiments). I 
partitioned heterogeneity in order to assess differences between cellular infiltrate 
species and identified smaller estimates of efficacy for microgliosis opposed to 














(0.68 to 1.45) 
43 
0.24 
(-0.08 to 0.56) 
72 
0.56 
(0.31 to 0.81) 
115 
                                                    Chapter 4: Outcome measure specific meta-analyses 
124 
 
I explored this dataset further (Table 4.20) and identified 17 experiments which 
examined astrocytosis in isolation, whereas 46 experiments examined microgliosis 
without astrocytosis. Twenty six experiments examined both astrocytosis and 





Effect size  
(95% CI) and N 
Microgliosis 
Effect size  
(95% CI) and N 
Combined   
Effect size and N 


















 (-0.70 to -0.04)  
46 
-0.37 







 (0.42 to 1.57)  
26 
1.25 
 (0.79 to 1.72)  
26 
1 
 (0.42 to 1.57)  
26 
 
Summary estimate Summary estimate Global estimate 
1.07 
 (0.68 to 1.45)  
43 
0.24 
 (-0.08 to 0.56)  
72 
0.40 
(0.13 to 0.68) 
89 
Table 4.20: Estimates of standardised effect size according to the different 
measures of cellular infiltrates assessed. Columns represent astrocytosis and 
microgliosis. End column indicates combined estimates. Brackets give 95 
percent confidence limits and lower number indicates the number of 
experiments. 
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Table 4.21: Estimates of standardised effect size according to each transgenic model 
group used and the different measures of cellular infiltrates assessed. Columns 
represent astrocytosis and microgliosis. End column indicates combined estimates. 
Brackets give 95 percent confidence limits and lower number indicates the number 
of experiments. (N.B. some experiments may be represented more than once). 
 
4.4.1 Cellular infiltrates and transgenic model group 
estimates 
 
I stratified cellular infiltrates overall by the transgenic mouse model group used but 
estimates were relatively similar and this did not account for a significant 
proportion of heterogeneity (Table 4.21, χ2= 5.52). Similarly where I stratified 
astrocytosis outcomes this did not account for a significant proportion of the 
heterogeneity (Table 4.21, χ2= 5.76). Where I stratified microgliosis outcomes 
according to the transgenic group used this did account for a significant proportion 
of the observed heterogeneity (Table 4.21, χ2= 11.1) however for the majority of data 










(95% CI) and N 
Microgliosis 
Effect size 
(95% CI) and N 
Combined 
Effect size and N 




 (0.58 to 1.65)  
28 
0.15 
 (-0.24 to 0.54)  
50 
0.34 





 (0.41 to 1.67)  
12 
0.36 
 (-0.21 to 0.94)  
21 
0.51 





 (-0.16 to 2.2)  
1 
2.69 
 (1.08 to 4.29)  
1 
1.61 











(-0.55 to 1.08)  
2 
PS no data no data no data 




Summary estimate Summary estimate Global estimate 
1.07 
 (0.68 to 1.45)  
43 
0.24 
 (-0.08 to 0.56)  
72 
0.40 
 (0.13 to 0.68)  
89 


















4.4.2 Relationships within cellular infiltrates 
 
Subsequently, I performed meta-regression in order to further our understanding of 
the potential relationship between astrocytosis and microgliosis for the 26 cohorts 
which reported both. I found a relatively strong correlation (Adjusted R squared= 
0.71, p<0.05) between changes in both outcomes (Figure 4.17 and Table 4.22) 
 
 
Figure 4.16: I stratified cellular infiltrate outcomes according to transgenic model group 
used where this did not account for a significant proportion of the observed 
heterogeneity. Error bars represent 95% confidence intervals (CI) and grey bar represents 
95% CI of global estimate, bar width represents the log of the number of animals. 
Transgenic Model Group







































































4.4.3 Summary of cellular infiltrates 
 
Our analyses at both the global level and transgenic model level suggested 
differences between intervention estimates on astrocytosis and microgliosis, 
however changes in astrocytes were generally good predictors of changes in 
microgliosis. I took both outcomes forward together as ‘cellular infiltrates’ to 












CI% N Adj. R2 
Astrocytosis vs. 
microgliosis 0.527 0.094 5.58 0 0.332 0.722 26 0.71 
Figure 4.17 & (upper) Table 4.22 (lower): Investigating the relationship between 
astrocytosis and microgliosis using meta-regression techniques. Symbol size 
denotes the inverse of the variance for each estimate of effect size. Meta-
regression output describes co-efficient, standard error, t value and the lower and 
upper 95% confidence limits of the co-efficient estimate. 
Adj. R2= 0.71 
Astrocytosis vs. microgliosis  





Sixty four neurodegeneration experiments representing 962 animals suggested an 
overall improvement of 0.91 SD ([0.69 to 1.12], χ2= 192).  I partitioned heterogeneity 
in order to assess whether assessing direct or indirect neurodegeneration outcomes 
impacted on observed outcome and found that this accounted for a significant 
proportion of the observed heterogeneity (χ2 =6.80, p<0.05). I observed smaller 
estimates of effect size for direct measures of neurodegeneration opposed to indirect 





I explored this dataset further and calculated estimates of efficacy wherever, 
indirect, direct or both were reported and identified that no experiments examined 














(0.22 to 0.97) 
22 
1.03 
(0.78 to 1.29) 
42 
0.91 
(0.69 to 1.12) 
64 
Table 4.23: Estimates of standardised effect size according to measures of 
neurodegeneration were direct or indirect. End column indicates summary 
estimate, Brackets give 95 percent confidence limits and lower number indicates 
the number of experiments, *as no experiments examined both measures animals 
are not represented more than once. 


















































4.5.1 Neurodegeneration and transgenic model group 
estimates 
 
I stratified data overall according to the transgenic mouse model used but this did 
not account for a significant proportion of the observed heterogeneity (χ2 =9.51, 
























(95% CI) and N 
Indirect 
Effect size 
(95% CI) and N 
Combined 
Effect size 
(95% CI) and N 
Direct only 0.60 
(0.22 to 0.97) 
22  
0.60 





(0.78 to 1.29)  
42 
1.03 
(0.78 to 1.29) 
42 
Both direct and 









Summary estimate Summary estimate Global estimate 
0.60 
(0.22 to 0.97) 
22 
1.03 
(0.78 to 1.29) 
42 
0.91 
(0.69 to 1.12) 
64 
Table 4.24: Estimates of standardised effect size according to the different 
combinations of neurodegeneration measures reported. End column 
indicates combined estimates. Brackets give 95 percent confidence limits and 
lower number indicates the number of experiments. 
Neurodegeneration 
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Table 4.25: Estimates of standardised effect size according to each transgenic model 
group used and the different measures of neurodegeneration assessed. Columns 
represent direct and indirect measures. End column indicates combined estimates. 
Brackets give 95 percent confidence limits and lower number indicates the number 

























(95% CI) and N 
Indirect 
Effect size 
(95% CI) and N 
Combined 
Effect size and N 
(95% CI) and N 
APP 
0.41 
 (-0.02 to 0.85)  
12 
0.98 
 (0.67 to 1.28)  
31 
0.82 




 (0.91 to 2.33)  
4 
1.42 
 (0.8 to 2.04)  
7 
1.47 







 (0.55 to 1.86)  
1 
1.21 




 (-0.43 to 1.12)  
7 
0.77 
 (-0.5 to 2.05)  
3 
0.52 
























Summary estimate Summary estimate Global estimate 
0.59 
 (0.22 to 0.97)  
23 
1.03 
 (0.78 to 1.29)  
42 
0.91 
 (0.69 to 1.12)  
65 
Figure 4.18(previous page): I stratified cellular infiltrate outcomes according to 
transgenic model group used. Error bars represent 95% confidence intervals (CI) 
and grey bar represents 95% CI of global estimate, bar width represents the log of 
the number of animals. 
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4.5.2 Relationships within neurodegeneration outcomes 
 
No experiments examined both direct and indirect measures of neurodegeneration 
thus I could not investigate relationships. 
4.5.3 Summary of neurodegeneration outcomes 
 
I identified that interventions successfully improved neurodegeneration overall and 
also specifically within direct and indirect outcome measures. Where I stratified 
data according to whether data were direct or indirect measures, indirect measures 
were associated with higher estimates of efficacy. I did not identify a significant 
impact of the transgenic model group used. 
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4.6 Summary of pathological outcomes and potential 
relationships  
 
Improving our understanding of how different pathologies are connected in 
transgenic mouse models would be an asset to translational research. Across all 
pathological outcomes included I identified 725 experimental cohorts which had a 
global improvement of 0.78 SD (0.71 to 0.65, Table 4.26).  
 
I then inspected how much data were present across different pathological 
outcomes within the same cohort of transgenic mice (Table 4.27). Overall I identified 
sufficient data (i.e. >10 experiments) for 12 other relationships to be investigated, 
however the relationship between amyloid beta 40 and 42 (334 experiments) had 








































































Effect size 0.98 0.68 0.78 0.55 0.40 0.91 0.78 
95% CI (0.87 to 1.1) (0.57 to 0.79) (0.67 to 0.88) (0.38 to 0.72) (0.13 to 0.68) (0.69 to 1.12) (0.71 to 0.85) 
n 378 388 389 84 89 64 725 
Table 4.26: Estimates of standardised effect size according to the different 
measures of neurodegeneration assessed. Columns represent direct and 
indirect measures. End column indicates combined estimates. Brackets give 95 
percent confidence limits and lower number indicates the number of 
experiments. 





























ES (95% CI) and 
N 
0.89 
 (0.7 to 1.09)  
145* 
0.72 















 (0.65 to 0.97)  
145 
0.84 


















 (0.72 to 1.03)  
165 
1.28 

















 (0.55 to 1.33)  
30 
1.18 

















 (0.53 to 1.03)  
62 
1.18 















 (0.62 to 1.16)  
29* 
0.99 

























   
0.38 







































 (0.58 to 1.64)  
12* 
0.89 




   
0.47 
 (0.13 to 0.81)  
32* 
0.33 
















































 (0.77 to 1.45)  
19* 
1 












 (0.03 to 0.95)  
1 
1.61 
























 (0.57 to 1.52)  
8 
0.33 















 (0.43 to 0.92)  
13* 
1.13 
 (0.64 to 1.62)  
13* 
0.92 
 (0.58 to 1.25)  
13 




 (0.87 to 1.1)  
378 
0.68 
 (0.57 to 0.79)  
388 
0.78 
 (0.67 to 0.88)  
389 
0.55 
 (0.38 to 0.72)  
84 
0.4 
 (0.13 to 0.68)  
89 
0.91 
 (0.69 to 1.12)  
64 
0.78 











Table 4.27: Estimates of standardised effect size where single cohorts were used 
to assess more than one pathological outcome. End column indicates combined 
estimates. Brackets give 95 percent confidence limits and lower number 
indicates the number of experiments. (N.B. some experiments are represented 
more than once). 
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4.6.1 Relationships between different pathological outcomes 
 
I identified four statistically significant relationships of the 12 analyses, all of which 
involved plaque burden (where α= 0.004, Table 4.28, Figures 4.19 to 4.30). 145 
experiments suggested that changes in amyloid beta 40 could explain a significant 
proportion (18.6%) of changes in plaque burden and similarly 165 experiments 
suggested that 19.1% of changes in amyloid beta 42 could explain changes in plaque 
burden. Changes in plaque burden were suggested to change 53.79% of changes in 
























Figure 4.19: Changes in amyloid beta 40 could explain a significant proportion of 
changes in plaque burden.  Symbol size denotes the inverse of the variance for 




Amyloid beta 40 vs. plaque burden 







Figure 4.20: Changes in amyloid beta 42 could explain a significant proportion of 
changes in plaque burden.  Symbol size denotes the inverse of the variance for 




Amyloid beta 42 vs. plaque burden 
Figure 4.21: Changes in plaque burden could explain a significant proportion of 
changes in tau pathology.  Symbol size denotes the inverse of the variance for 
each estimate of effect size. 








Plaque burden vs. cellular infiltrates 
Figure 4.22: Changes in plaque burden could explain changes in cellular 





Plaque burden vs. neurodegeneration 
Figure 4.23: Changes in plaque burden could explain a significant proportion of 
changes in neurodgeneration.  Symbol size denotes the inverse of the variance for 












































Figure 4.24: Changes amyloid beta 40 did not explain a statistically significant 
proportion of changes in tau.  Symbol size denotes the inverse of the variance for 




Amyloid beta 40 vs. tau 




Figure 4.25: Changes amyloid beta 42 did not explain a statistically significant 
proportion of changes in tau.  Symbol size denotes the inverse of the variance for 
each estimate of effect size 




Figure 4.26: Changes amyloid beta 40 did not explain a statistically significant 
proportion of changes in cellular infiltrates.  Symbol size denotes the inverse of 
the variance for each estimate of effect size 
Figure 4.27: Changes amyloid beta 42 did not explain a statistically significant 
proportion of changes in cellular infiltrates.  Symbol size denotes the inverse of 
the variance for each estimate of effect size 
Amyloid beta 40 vs. cellular infiltrates 











Amyloid beta 40 vs. neurodegeneration 
Figure 4.28: Changes amyloid beta 40 did not explain a statistically significant 
proportion of changes in neurodegeneration.  Symbol size denotes the inverse of 
the variance for each estimate of effect size 
Figure 4.29: Changes amyloid beta 42 did not explain a statistically significant 
proportion of changes in neurodegeneration.  Symbol size denotes the inverse of 







Amyloid beta 42 vs. neurodegeneration 




















Aβ 40 vs. plaques 0.201 0.046 4.41 0 0.111 0.291 145 0.19 
Aβ 42 vs. plaques 0.202 0.044 4.56 0 0.114 0.289 165 0.19 
Plaques vs. tau 0.186 0.057 3.25 0.003 0.069 0.303 30 0.54 
Plaques vs. cell Infiltrates -0.021 0.104 -0.2 0.845 -0.229 0.188 61 -0.02 
Plaques vs. neurod. 0.48 0.153 3.14 0.004 0.166 0.794 29 0.83 
Aβ 40 vs. tau 0.117 0.056 2.08 0.046 0.002 0.231 33 0.25 
Aβ 42 vs. tau 0.184 0.100 1.84 0.075 -0.02 0.388 32 0.14 
Aβ 40 vs.  cell Infiltrates 0.694 0.311 2.23 0.033 0.059 1.328 32 0.04 
Aβ 42 vs.  cell Infiltrates 0.259 0.239 1.08 0.287 -0.227 0.745 35 0.03 
Aβ 40 vs. neurod. -0.023 0.354 -0.07 0.949 -0.811 0.765 12 -0.24 
Aβ 42 vs. neurod. 0.152 0.206 0.74 0.47 -0.282 0.586 29 0.13 
Cell infiltrates vs. neurod. 1.304 0.482 2.71 0.02 0.244 2.364 13 0.43 
Table 4.28: Summary of meta-regression data inspecting relationships between 
pathological outcomes. For each comparison co-efficient is given (in terms of 
standardised mean difference effect size [SMD ES], standard error, tau (τ), significance 




Cellular infiltrates vs. neurodegeneration 
Figure 4.30: Changes amyloid beta 42 did not explain a statistically significant 
proportion of changes in neurodegeneration.  Symbol size denotes the inverse of 










































For calculating the effect size of neurobehavioural paradigms I inspected weighted 
mean difference estimates where I identified a number of extreme effect sizes. At the 
individual outcome level, estimates of neurobehavioural effect estimates of effect 
ranged from -8600% to 1113% and 29.5% of estimates calculated worsening or 
improvement greater than 100% (Figure 4.31).  I identified that this effect was 
caused by the close approximation of means in wild type and control transgenic 
mice, therefore representing a weaknesses in the NMD approach. While this may 
raise concerns about the neurobehavioural impact of transgenes (see Chapter 5) I 
could not alter the dataset without introducing potential bias and thus could not use 










Figure 4.31: Histogram of normalised mean difference effect sizes for 
neurobehavioural data. While the majority of data lay between 100% 
improvement or worsening, 29.5% of pre-nested data lay outside such values. 
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As data were not similar enough to use difference in means estimates, I chose to 
perform analyses using standardised mean difference estimates. Therefore from the 
259 neurobehavioural experiments identified (representing 4325 animals) I 
estimated that interventions improved outcomes by 0.61 SD (0.54 to 0.69). I explored 
each of the individual paradigms used within this estimate which are  

























 (0.4 to 0.58)  
130 
0.63  
(0.5 to 0.76)  
113 
0.86 
(0.61 to 1.10) 
41 
0.70 
 (0.51 to 0.89)  
45 
0.95  
 (0.63 to 1.27)  
25 
0.46 
 (0.21 to 0.71)  
28 
Table 4.29: I calculated estimates of effect in standardised effect size according to 
each paradigm used. Brackets represents 95% confidence limit and n represents the 
number of experiments 


















































4.7 Acquisition phase of the Morris water maze 
 
Overall, I estimated from 130 experiments that interventions improved 
neurobehavioral deficits in acquisition phase of the MWM by 0.49 SD (0.40 to 0.58). 
4.7.1 Acquisition phase and transgenic model group 
estimates 
 
I first stratified data according to the transgenic model group used which did not 
account for a significant proportion of heterogeneity (χ2 =1.13, Figure 4.32, Table 



















Figure 4.32: I stratified acquisition data according to transgenic model group 
used. Error bars represent 95% confidence intervals (CI) and grey bar represents 
95% CI of global estimate, bar width represents the log of the number of animals. 
Acquisition phase of the MWM 





(95% CI) and N 
APPPS 
Effect size 
(95% CI) and N 
3xTgAD 
Effect size 
(95% CI) and N 
PS1 
Effect size 
(95% CI) and N 
GLOBAL 
Effect size 
(95% CI) and N 
0.52 0.48 0.48 0.57 0.49 
(0.42 to 0.63) (0.23 to 0.72) (0.21 to 0.74) (-1.13 to 2.28) (0.41 to 0.58) 







4.7.2 Stratified acquisition phase analyses 
 
Experiments performed within the acquisition phase of the MWM varied in terms of 
the size of the pool, temperature of water used and the total number of trials. I 
performed stratified analyses on each of these to gain estimates of effect size for 
each quartile. For acquisition outcomes I stratified estimates of effect according to 
the size of the pool used (109 experiments) but I did not identify a relationship 
between pool size and intervention effect (Figure 4.33a, (χ2 =4.16). For outcomes 
where the pool temperature was stated (76 experiments) I again stratified estimates 
of effect but this did not account for a significant proportion of the observed 
heterogeneity (χ2=3.03, Figure 4.33b). Where I could calculate the total number of 
trials (109 experiments) I found higher effect sizes associated with fewer total trials 
but this did not explain a significant proportion of the observed heterogeneity 
(χ2=2.43, Figure 4.33c). 
  
Table 4.30: Estimates of efficacy according to the transgenic mouse model group 
used. Estimates are given in Standardised mean difference estimates (SD), brackets 
represent 95% confidence limits of this estimate and N represents the number of 
experiments. 
 




Tempeature of water (Degrees Celcius)
















































Acquisition size of pool
Size of pool (cm)

















































Total number of training trials
Total number of trials

































































Figure 4.33: I stratified acquisition data according to the size of the pool used (a), 
temperature of water (b) and total number of training trials (c). Error bars 
represent 95% confidence intervals (CI) and grey bar represents 95% CI of global 
estimate, bar width represents the log of the number of animals. 
Methodology of the MWM: Acquisition phase 
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4.7.3 Summary of acquisition phase of the Morris water maze 
 
Overall, I found that interventions successfully improved deficits in the acquisition 
phase of the MWM. Stratifying data according to the transgenic model used 
accounted for a significant proportion of the observed heterogeneity but this was 
not reflected by differences in estimates of effect. Stratifying data by size of pool, 
water temperature used or total number of training trials did not explain a 
significant proportion of the heterogeneity. 
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4.8 Probe phase of the Morris water maze 
 
 
Overall, 113 experiments suggested that interventions successfully improved 
neurobehavioral deficits in the MWM by 0.63 SD, (0.50 to 0.76). 
4.8.1 Probe phase and transgenic model group estimates 
 
I first stratified data according to the transgenic model group used where estimates 
of effect were broadly similar and this did not account for a significant proportion of 











Figure 4.34: I stratified data from the probe phase of the Morris water maze 
(MWM) according to transgenic model group used. Error bars represent 95% 
confidence intervals (CI) and grey bar represents 95% CI of global estimate, bar 
width represents the log of the number of animals. 
Transgenic Model Group














































Probe phase of the MWM 





(95% CI) and N 
APP 
Effect size 
(95% CI) and N 
APPPS 
Effect size 
(95% CI) and N 
PS1 
Effect size 
(95% CI) and N 
Other 
Effect size 
(95% CI) and N 
Tau 
Effect size 
(95% CI) and N 
0.6 0.69 0.59 0.46 0.21 1.16 
 (-0.85 to 2.05)   (0.53 to 0.84)   (0.24 to 0.94)   (0.07 to 0.84)  (-0.49 to 0.92)  (0.34 to 1.98)  






4.8.2 Stratified probe phase analyses 
 
Experiments in the MWM varied in terms of the size of the pool, temperature of 
water used and the total number of trials. I performed stratified analyses on each of 
these to gain estimates of effect size for each quartile. I stratified results from the 
probe phase of the MWM by pool size where estimates of effect were relatively 
similar and this did not account for a significant proportion of the observed 
heterogeneity (96 experiments χ2=2.05, Figure 4.35a). Where temperature of the 
MWM pool was stated (76 experiments) I found that the higher the temperature of 
the water used, the lower the estimate of efficacy (χ2=36.3, p<0.02, Figure 4.35b).  I 
stratified experiments by the total number of trials wherever stated (91 
experiments). While, this accounted for a significant proportion of observed 
heterogeneity estimates of efficacy did not suggest a particular relationship 
(χ2=21.96, p<0.02, 91 experiments, Figure 4.35c). 
Table 4.31: Estimates of efficacy in the probe phase of the MWM according to 
the transgenic mouse model group used. Estimates are given in Standardised 
mean difference estimates (SMD), brackets represent 95% confidence limits of 
this estimate and N represents number of experiments. 
 
                                                    Chapter 4: Outcome measure specific meta-analyses 
149 
 
Figure 4.35: I stratified data from the probe phase of the Morris water maze (MWM) 
according to the size of the pool used (a), temperature of water (b) and total number of 
training trials (c). Error bars represent 95% confidence intervals (CI) and grey bar 
represents 95% CI of global estimate, bar width represents the log of the number of 
animals. 
Size of Morris water maze pool
Size of MWM pool (cm)


















































Temperature of water in MWM
Temperature of water (Degrees celcius)



















































(c) Total number of training trials
Total number of trials
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Table 4.32: Estimates of standardised effect size according to whether the fear 
conditioning paradigm was used in the cued or contextual set up. End column 
indicates combined estimates Brackets provide 95 percent confidence limits and 
lower number indicates the number of experiments *as different outcomes can be 
represented in the same cohort of animals some are represented more than once. 
4.8.3 Summary of probe phase of the Morris water maze 
 
Overall, interventions successfully improved outcomes from the probe phase of the 
MWM and I did not observe differences in estimates according to different 
transgenic mouse model groups. For stratified analyses, smaller estimates of efficacy 
were with higher water temperatures and while stratifying by the total number of 
training trials accounted for a significant proportion of the observed heterogeneity, 
relationships were difficult to define.  
4.9 Fear conditioning 
 
Overall, data from 678 animals suggested that interventions improved fear 
conditioning outcomes by 0.70 SD (0.51 to 0.89, 45 comparisons). I identified that 
cued assessment of behaviour was associated with smaller effect sizes than 
contextual assessment (Table 4.32 and for further details see Chapter 3) and 
stratification accounted for a significant proportion of the observed heterogeneity 
(χ2=8.79). 
 








(0.01 to 0.60) 
15 
0.81 
(0.57 to 1.05) 
45 
0.69 
(0.5 to 0.89) 
60 
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I explored fear conditioning data further to identify whether I could examine 
potential relationships . For the 15 experiments which examined both cued and 















4.9.1 Fear conditioning transgenic model groups 
 
I stratified fear conditioning outcomes according to the transgenic model group 
used and found that this did not account for a significant proportion of the observed 
heterogeneity (χ2=3.04, Figure 4.36). For informative purposes only I also describe 
transgenic model group estimates of efficacy within the cued and contextual 




(95% CI) and N 
Contextual 
Effect size 
(95% CI) and N 
Combined 
Effect size 




















(0.57 to 1.01) 
30 
0.79 
(0.57 to 1.01) 
30 




 (0.01 to 0.6)  
15 
0.79 
(0.17 to 1.42) 
15 
0.56 






estimate Global estimate 
0.30 
 (0.01 to 0.6)  
15 
0.81 
(0.57 to 1.05) 
45 
0.7 
(0.51 to 0.89) 
45 
Table 4.33: Estimates of effect size for fear conditioning and more specifically 
the cued and contextual learning tasks. For each, the standardised effect size 
is given with 95% confidence limits and the number of experiments. 
 
 





Transgenic model Group 
Cued  
Effect size 
(95% CI) and N 
Contextual  
Effect size 
(95% CI) and N 
Combined 
Effect size and N 
(95% CI) and N 
APP 
0.35 0.84 0.73 
(0 to 0.7) (0.47 to 1.21) (0.45 to 1.02) 
13 29 29 
APPPS 
0.19 0.81 0.68 
(-0.38 to 0.75) (0.52 to 1.1) (0.43 to 0.94) 
2 9 9 
3xTgAD 
  0.46 0.46 
No data (-0.18 to 1.1) (-0.18 to 1.1) 
  6 6 
Tau 
  1.58 1.58 
No data (0.29 to 2.88) (0.29 to 2.88) 
  1 1 
PS1 
      
No data No data No data 
      
Other 
      
No data No data No data 
      
  
Summary estimate Summary estimate Global estimate 
0.3 0.81 0.70 
(0.01 to 0.6) (0.57 to 1.05) (0.51 to 0.89) 







4.9.2 Relationships between fear conditioning outcomes 
 
For the 15 experiments where both contextual and cued fear conditioning were 
assessed I performed meta-regression to identify potential relationships. However 
the value of tau (study heterogeneity) was insufficient for an R2 value to be 
calculated.  
 
Table 4.34: Estimates of effect size by transgenic model group for fear 
conditioning and more specifically the cued and contextual learning tasks. For 
each, the standardised effect size is given with 95% confidence limits and the 
number of experiments. 
 
 













4.9.3 Summary of fear conditioning outcomes 
Overall, interventions successfully improved outcomes in the fear conditioning 
paradigm, and also more specifically when examining the cued and contextual 
learning in isolation. Stratifying data according to the transgenic model group used 
identified that estimates were relatively similar and this did not account for a 
significant proportion of the observed heterogeneity. 
Figure 4.36 (previous): I stratified data from the fear conditioning paradigm 
according to the transgenic model group used which did not account for a 
significant proportion of heterogeneity. Error bars represent 95% confidence 
intervals (CI), grey bar represents 95% CI of global estimate, bar width represents 
the log of the number of animals. 
Fear conditioning
Transgenic model group
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Table 4.35: Estimates of standardised effect size according to how the radial arm 
maze paradigm was used. End column indicates the overall estimate Brackets 
provide 95 percent confidence limits and lower number indicates the number of 
experiments. 
4.10 Radial arm water maze 
 
 
Overall, interventions improved outcomes in the radial arm water maze by 0.86 SD 
(0.61 to 1.10, 41 comparisons n=678 animals, χ2 = 98.66). I explored the sensitivity of 
different methodological set ups and while estimates of efficacy differed, this did 
not account for a significant proportion of the observed heterogeneity (χ2 = 5.88, 
p<0.05, Table 4.35). As each methodology could only be used for a single experiment 

















(95% CI)  
 N 
1.01 
(0.7 to 1.32) 
29 
0.59 
(0.13 to 1.04) 
10 
0.68 
(-0.4 to 1.75) 
2 
0.86 
(0.61 to 1.1) 
41 
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4.10.1 RAWM transgenic model group estimates 
 
I stratified RAWM outcomes according to the transgenic model group used where 
this did not account for a significant proportion of the observed heterogeneity 
(χ2=2.68, Figure 4.37). For informative purposes only I also describe transgenic 

















(95% CI) and N 
Combined 
 
Effect size  
(95% CI) and N 
APP 
1 
(0.6 to 1.4) 
11 
0.72 
(-0.04 to 1.48) 
7 
  
No data  
  
0.91 




(0.54 to 1.41) 
17 
0.37 
(0.07 to 0.67) 
3 
0.68 
 (-0.4 to 1.75) 
2 
0.8 




No data  
  
  
No data  
  







No data  
  
  
No data  
  







 (0.28 to 2.55) 
1 
  
No data  
  No data  
1.41 




No data  
  
  
No data  
  
  















(0.7 to 1.32) 
29 
0.48 
 (-0.04 to 1.01) 
10 
0.68 
 (-0.4 to 1.75) 
2 
0.86 












Table 4.36: Estimates of efficacy according to the transgenic mouse model group used. 
Estimates are given in Standardised mean difference estimates (SD), brackets 
represent 95% confidence limits of this estimate and N represents number of 
experiments. 
 


















4.10.2 Summary of RAWM 
 
Overall, interventions successfully improved outcomes within the RAWM. 
Methodologies differed in overall estimates of effect size and I identified that the 
transgenic model group accounted for a significant proportion of the observed 
heterogeneity. 
Figure 4.37 I stratified data from the radial arm water maze (RAWM) according 
to the transgenic model group used but this did not account for a significant 
proportion of the observed heterogeneity. Error bars represent 95% confidence 
intervals (CI) and grey bar represents 95% CI of global estimate, bar width 
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4.11 Novel object recognition task 
 
Overall interventions improved outcomes by 0.95 SD (95% CI 0.63  to 1.27, N=460 
animals). I explored the sensitivity of different methodological set ups but did not 
identify potential areas for stratification. Thus, I first stratified data according to the 
transgenic model group used. 
 
4.11.1 NORT and transgenic model groups 
 
Estimates of efficacy across different transgenic model groups were notably 
different and stratification accounted for a significant proportion of the observed 
heterogeneity (Table 4.37, Figure 4.38, χ2=13.33, p<0.05) however interpretation was 




























(95% CI) and N (95% CI) and N (95% CI) and N (95% CI) and N (95% CI) and N (95% CI) and N 
1.23 0.82 0.29 -0.22 0.63 0.95 
(0.77 to 1.68) (0 to 1.63) (-0.7 to 1.28) (-1.02 to 0.59) (0.19 to 1.07) (0.63 to 1.27) 
15 5 1 1 3 25 
Table 4.37: Estimates of efficacy according to the transgenic mouse model 
group used. Estimates are given in Standardised mean difference estimates), 
brackets represent 95% confidence limits of this estimate and N represents 
number of experiments. 
 














4.11.2 Relationships within NORT outcomes 
 
While I explored the NORT dataset for potential ways to stratify data, this was not 
possible within the dataset extracted.  
4.11.3 NORT summary 
 
Compared to other neurobehavioural tasks data were few for the novel object 
recognition task (25 experiments). Nevertheless, I identified that interventions 
successfully improved NORT outcomes, and stratifying by the transgenic model 
used accounted for a significant proportion of the observed heterogeneity. 
Figure 4.38: I stratified data from the novel object recognition task (NORT) 
according to the transgenic model group used. Error bars represent 95% 
confidence intervals (CI) and grey bar represents 95% CI of global estimate, bar 
width represents the log of the number of animals. 
NORT
Transgenic model group












































4.12 T maze & Y maze 
 
Due to similarities between the T and Y maze I merged the two datasets together in 
order to increase overall statistical power. Across the two paradigms I estimated 
that interventions improved outcomes by 0.46 SD (0.21 to 0.71, 28 experiments). I 
first derived estimates of efficacy and assessed heterogeneity by stratifying data 
according to each paradigm. I identified broadly similar estimates between the T 
and Y maze with improvements of 0.56 SD (0.17 to 0.95) and 0.39 SD (0.06 to 0.72) 
respectively (Table  4.38) and this did not account for a significant proportion of the 









I explored data further and identified that no mice were assessed in both the T maze 
and Y maze and thus I could not investigate potential relationships between the two 
paradigms (Table 4.39). 
 
 





Effect size 0.56 0.39 0.46 
95 CI (0.17 to 0.95) (0.06 to 0.72) (0.21 to 0.71) 
n 11 17 28 
Table 4.38: Estimates of standardised effect size were assessed according to 
whether mice were tested in the T-maze or Y-maze, 95% confidence limits (95% 
CI) and number of experiments. End column indicates the overall estimate *as no 
experiments examined both measures animals are not represented more than 
once.  











4.12.1 Transgenic model groups and T and Y maze  
 
I stratified data according the transgenic mouse model used and found higher 
estimates of efficacy with the APP transgenic model group 0.89 SD (0.25 to 1.53) 
compared to the APPPS transgenic group 0.20 SD (-0.11 to 0.51 (or the 3xTgAD 
transgenic group 0.69 SD (0.20 to 1.18) where this account for a significant 
proportion of the observed heterogeneity (χ2=7.91, df=2,p<0.05). For informative 
purposes I also describe transgenic model group specific estimates of efficacy for the 
T and Y maze individually (Table 4.40). 
 
 T maze Y maze Combined 
 Effect size Effect size Effect size 
 (95% CI) and N (95% CI) and N (95% CI) and N 
T maze only 0.56  0.56 
  (0.17 to 0.95)  (0.17 to 0.95) 
  11  11 
Y maze only  0.39 0.39 
   (0.06 to 0.72) (0.06 to 0.72) 
   17 17 
Y and T maze    
  No data No data No data 
     
Summary estimate Summary estimate Global estimate 
0.56 
(0.17 to 0.95) 
11 
0.39 
(0.06 to 0.72) 
17 
0.46 
(0.21 to 0.71) 
28 
Table 4.39: Estimates of effect size for the T and Y maze as individual paradigms 
and a combined single outcome measure. For each, the standardised effect size is 
given with 95% confidence limits and the number of experiments. 
 
 







(95% CI) and N 
Y maze 
Effect size 
(95% CI) and N 
Combined 
Effect size and N 
(95% CI) and N 
APP 
0.73 
(-0.51 to 1.97) 
2 
1.02 
(0.21 to 1.82) 
4 
0.89 




(-0.19 to 1.2) 
5 
0.05 
(-0.26 to 0.36) 
10 
0.20 




(0 to 1.09) 
4 
0.91 
(-0.1 to 1.92) 
3 
0.69 

































Summary estimate Summary estimate Global estimate 
0.56 
(0.17 to 0.95) 
11 
0.39 
(0.06 to 0.72) 
17 
0.46 





Table 4.40: Estimates of effect size by transgenic model group for the T and Y 
maze individually, and combined. For each, the standardised effect size is given 
with 95% confidence limits and the number of experiments. 
 
 
Figure 4.39: I stratified data from the T and Y maze by the transgenic model 
group used but this did not account for significant proportion of the observed 
heterogeneity. Error bars represent 95% confidence intervals (CI); grey bar 
represents 95% CI of global estimate, bar width represents the log of the number 
of animals. 
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4.12.2 Summary of Y and T maze 
 
Overall, interventions successfully improved outcomes both within the Y and T 
maze individually and collectively. Our estimates of efficacy did not suggest it 
might be inappropriate to combine the two datasets. Although I observed 
differences in estimates of efficacy across different transgenic mouse models this 
was not reflected in terms of heterogeneity. 
 
 
4.13 Summary of neurobehavioral outcomes and 
potential relationships 
 
Understanding potential relationships between different behavioural paradigms is 
likely to provide insights which could assist preclinical trial design. Therefore, I 
used the six principle behavioural paradigms to investigate potential relationships 
between different behavioural tests. Despite a potential 15 comparisons I could only 
identify sufficient data to inspect the relationship between the acquisition and probe 
phase of the MWM (>10 outcomes, for summary see Table 4.41) 
 
Therefore, I performed meta-regression in order to identify whether variance in the 
acquisition phase of the MWM could be a reliable predictor for variance in the probe 
phase. Using data from 78 experiments, performance across the acquisition phase 
could explain 44% of the variation in the probe phase (Figure 4.20a).  
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I explored this dataset further to identify whether different stages of the acquisition 
phase correlated better with the probe phase than others. Therefore I calculated 
individual estimates of effect and segregated data into: (i) first, (ii) between first and 
last, and (iii) last time points. Meta-regression identified that the proportion of 
variation in the probe which could be explained by acquisition phase variation 
sequentially increased with a respective R2 of (i)13%, (ii) 57% and 59% (See Table 
4.42 and Figure 4.20b-d). 
  
Table 4.41 (next page): Estimates of standardised effect size according to where single 
cohort was used to assess more than one behavioural outcome measures.  Columns 
represent the acquisition and probe phase of the Morris water maze (MWM), Radial arm 
water maze (RAWM), Fear conditioning, Novel object recognition task (NORT) and Y/T-
maze. End column indicates combined estimates. Brackets give 95 percent confidence 
limits and lower number indicates the number of experiments. (N.B. some experiments 
may be represented more than once). 
 






Probe phase RAWM  Fear NORT T/Y-maze  Combined 
ES (95% CI) ES (95% CI)  ES (95% CI) ES (95% CI) ES (95% CI) ES (95% CI) ES (95% CI)  
 and N  and N   and N   and N   and N   and N  and N  
0.38 
          
0.38 




        
0.54 
(0.3 to 0.78) (0.3 to 0.78) 
24 24 
    
0.88 
      
0.88 
(0.49 to 1.26) (0.51 to 1.26) 
24 24 
      
0.65 
    
0.7 
(0.38 to 0.93) (0.45 to 0.95) 
33 33 




(0.3 to 1.18) (0.47 to 1.2) 
16 16 
          
0.34 0.34 
(0.05 to 0.64) (0.05 to 0.64) 
12 12 
0.55 0.70 
        
0.65 
 (0.45 to 0.66)   (0.53 to 0.87)  (0.52 to 0.77) 




      
0.73 
 (0.27 to 0.94)  (0.41 to 1.14) (0.42 to 1.04) 
8 8 8 
0.46 
    
0.69 
    
0.57 
 (0.07 to 0.86)   (0.15 to 1.23)  (0.21 to 0.93) 
5 5 5 
0.46 




(-0.01 to 0.93) (-1.18 to 4.75) (0.02 to 1.35) 
2 2 2 
0.39 
        
0.30 0.32 
 (0.11 to 0.66)  (-0.17 to 0.77) (0.01 to 0.63) 
9 9 9 
  
0.38 0.78 
      
0.58 
 (-0.07 to 0.84)  (0.45 to 1.11) (0.22 to 0.93) 





    
0.82 
(0.52 to 1.35) (0.29 to 1.1) (0.53 to 1.12) 
6 6 6 
  
0.71 




 (0.38 to 1.04)   (0.43 to 1.79)  (0.56 to 1.15) 
8 8 8 
  
0.59 
      
0.34 0.45 
 (-0.03 to 1.2)  (-0.16 to 0.84) (-0.03 to 
0.92) 9 9  
    
1.22 0.72 
    
0.92 
(0.19 to 2.24) (0.36 to 1.08) (0.39 to 1.45) 
3 3 4 
    No data     No data    No data  
    
0.46 
    
0.33 0.43 
(0.19 to 0.73) (-0.38 to 1.03) (0.2 to 0.65) 
6 6 6 




 (0.6 to 1.63)   (-1.18 to 
4.75)  
(0.24 to 2.03) 
2 2 2 




(-0.36 to 1.7) (0.16 to 1.37) (0.02 to 1.47) 
3 3 3 
        
1.07 1.44 1.25 
 (-0.33 to 
2.48)  
(-0.06 to 2.95)  (0.22 to 2.27) 















0.49 0.63 0.86 0.7 0.95 0.46 0.61 
 (0.41 to 0.58)  (0.5 to 0.76)  (0.61 to 1.1) (0.51 to 0.89) (0.63 to 1.27) (0.21 to 0.71) (0.54 to 0.69) 
130 113 41 45 25 28 259 
   















































Acquisition curve vs. probe phase 
0.826 0.14 5.89 0 0.547 1.105 78 0.44 
First time point of acquisition vs. 
probe phase 
0.414 0.114 3.62 0.001 0.186 0.642 78 0.13 
Between first and last time point 
of acquisition vs. probe phase 
0.601 0.087 6.94 0 0.428 0.773 78 0.57 
last time point of acquisition vs. 
probe phase between 
0.325 0.047 6.95 0 0.232 0.418 78 0.59 
Figure 4.40: Meta-regression comparing probe phase with acquisition curves, first  
and last time point of acquisition curve and sections in between. For each comparison 





Acquisition curves vs. probe phase First time point of curve vs. probe phase 
Between first and last time points of 
curve vs. probe phase 









= 0.57 Adj. R
2
= 0.59 
Table 4.42: Meta-regression comparing probe phase with acquisition curves, first  
and last time point of acquisition curve and sections in-between. For each 
comparison co-efficient is given, standard error, tau (τ), significance level, 95% 
confidence limits, number of experiments (N) and Adjusted R2 (Adj. R2).  
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The overall estimates of efficacy for structural and behavioural outcomes were 0.78 
SD (0.71 to 0.85, 725 experiments) and 0.61 SD (0.54 to 0.69, 259 experiments). I was 
interested whether changes in structural pathology could explain changes in 
neurobehavioural function and identified that 146 experiment measured both of 





Structural outcome Functional outcome 
Effect size Effect size 
(95% CI) and N (95% CI) and N 
Structural outcomes only 
0.84 
  (0.75 to 0.92) 
579 
Functional outcomes only   
0.61 
(0.50 to 0.72) 
113 
Both structural and 
functional outcomes 
0.63 0.61 
(0.51 to 0.75) (0.51 to 0.71) 
146 146 
  
Summary estimate Summary estimate 
0.78 0.61 
(0.71 to 0.85) (0.54 to 0.69) 
725 259 
Table 4.43: Estimates of effect size for changes in pathological structural outcomes 
and neurobehavioural function. For each, the standardised effect size is given with 
95% confidence limits and the number of experiments. 
 
                                                    Chapter 4: Outcome measure specific meta-analyses 
167 
 
Pathology vs. neurobehaviour: Summary analysis 
4.14.1 Overall relationship between pathology and 
neurobehaviour  
 
Therefore I took forward estimates of effect from 147 experiments to identify 
whether structural changes could explain and functional changes. Our meta-
regression identified that 20.6% of the overall variation in behaviour could be 





























N Adj. R2 
All pathology vs. 
all neurobehaviour 
0.155 0.039 3.93 0 0.077 0.232 146 0.21 
Figure 4.41 (upper) and Table 4.44 (lower): I performed meta-regression in 
order to understand whether changes in pathological outcomes could explain 
changes in neurobehavioural outcomes. Symbol size represents the inverse of 
variance, For comparison co-efficient is given (in terms of standardise mean 
difference effect size [SMD ES], standard error, tau (τ), significance level, 95% 




Change in pathology vs. change in neurobehaviour 
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4.14.2 Relationships between specific pathologies and 
neurobehaviour 
 
 To identify whether individual pathologies might have greater or lesser impacts on 
neurobehaviour I explored the spread of the data (Table 4.40). I identified that 
sufficient data were present to investigate each of the individual pathologies in 










For meta-regression analyses (see Table 4.46) 100 experiments suggested that 
changes in plaque pathology could explain 31% of changes in neurobehaviour 
(Figure 4.42a). 89 experiments suggested that amyloid beta 40 could explain 12% of 
the variation in neurobehavioural outcomes but this did not prove statistically 
significant (Figure 4.42b) whereas changes in amyloid beta 42 explained 22% of 






























































100* 88* 94* 17* 24* 20* 
Table 4.45: I explored cohort datasets to identify where individual pathological 
experiments were performed alongside neurobehavioural assessment *sufficient 
data were present to allow analyses across all pathologies. 
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Amyloid beta 40  
Amyloid beta 42 * Tau  
Cellular infiltrates  Neurodegneration * 
Plaque burden *  
For the 17 tau experiments where neurobehavioural outcomes were measured I did 
not identify a correlation between changes (Figure 4.42d). Similarly changes in 
cellular infiltrates [24 experiments] did not explain changes in neurobehaviour 
(Figure 4.42e). For outcomes regarding neurodegeneration however, 20 experiments 
suggested that changes in pathology could explain 71.93% of the changes in 

















































 95% CI 
N Adj. R2 
Plaque burden vs. NBS 0.196 0.047 4.19 0 0.103 0.289 100 0.31 
Aβ 40  vs. NBS 0.094 0.038 2.5 0.014 0.019 0.169 88 0.12 
Aβ 42  vs. NBS 0.13 0.035 3.68 0 0.06 0.2 94 0.22 
Tau vs. NBS 0.09 0.165 0.54 0.594 -0.261 0.441 17 -0.06 
Cellular infiltrates vs. NBS -0.2 0.151 -1.32 0.2 -0.513 0.114 24 0.07 
Neurodegeneration vs. NBS 0.265 0.076 3.47 0.003 0.104 0.426 20 0.72 
Table 4.46: I investigated potential relationships between each pathological 
outcome and neurobehaviour. For each comparison co-efficient is given (in terms 
of standardise mean difference effect size [SMD ES], standard error, tau (τ), 
significance level, 95% confidence limits, number of experiments (N) and 
Adjusted R2 (Adj. R2) 
 
Figure 4.42 (previous page): I performed meta-regression in order to 
understand whether changes in pathological outcomes could explain changes in 
neurobehavioural outcomes. For each comparison adjusted R2 (Adj. R2) is given. 
Symbol size represents the inverse of variance. 
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4.14.3 Relationships between pathologies and 
neurobehaviour by transgenic model group 
 
Although I maximised statistical power by pooling all transgenic models in order to 
define relationships between pathological and neurobehavioural outcomes the 
approach does not consider differences in pathologies between the models. 
Therefore, I examined how much data were present within individual transgenic 
model groups for possible further analyses. I identified that there were sufficient 
data to analyses relationships between a number of transgenic model group 















































































APP 72* 57* 61* 2 15* 14* 
APPPS 21* 21* 21* 1 8 5 
3xTgAD 7 10* 10* 14* 1 0 
Tau 0 0 1 0 0 1 
PS1 0 0 0 0 0 0 
Other 0 0 1 0 0 0 
All Transgenic model groups 100* 88* 94* 17* 24* 20* 
Table 4.47: Table describes number of individual experiments where 
pathological outcomes were examined alongside neurobehavioural 
outcomes,*sufficient data for analyses. 
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Plaque burden vs. neurobehaviour 
APPPS transgenic models APP transgenic models 
Therefore, I was able to examine the relationship between plaque burden and 
neurobehaviour for both the APP and APPPS transgenic model groups (Table 4.48). 
For APP transgenic models meta-regression suggested that 30.6% of the variation in 
neurobehaviour could be explained by variation in plaque burden (Figure 4.23a).  
However, where I examined APPPS mice I identified that reductions in plaque 








































N Adj. R2 
APP 0.144 0.048 2.98 0.004 0.047 0.240 72 0.31 
APPPS     0.290 0.149 1.95 0.066 -0.021 0.602 21 0.17 
Figure 4.43 (upper) and Table 4.48 (lower): I assessed whether changes in plaque 
burden could explain changes in neurobehaviour within the APP and APPPS 
transgenic model groups. Symbol size represents the inverse of variance. 
For each comparison co-efficient is given (in terms of standardise mean difference 
effect size [SMD ES], standard error, tau (τ), significance level, 95% confidence 
limits, number of experiments (N) and Adjusted R2 (Adj. R2). 
Adj. R
2
= 0.31 Adj. R
2
= 0.17 




For amyloid beta 40 I was able to perform meta-regression analyses on the APP, 
APPPS and 3xTgAD groups respectively (Table 4.49). Our meta-regression analyses 
suggested that 13% of the variation in pathology could explain variations in 
neurobehaviour (Figure 4.24a). I did not identify a statistically significant 
relationship between variation in amyloid beta 40 and neurobehaviour in APPPS 
models (Figure 4.24b) or within 3xTgAD models (Figure 4.24c). 
Figure 4.44 (next page): I assessed whether changes in amyloid beta 40 (a,b,c) and 
amyloid beta 42 (d,e,f) could explain changes in neurobehaviour within the APP 
APPPS and 3xTgAD. transgenic model groups. For each comparison Adjusted R2 
(Adj. R2) is given. Symbol size represents the inverse of variance. 
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3xTgAD transgenic models 
Amyloid beta 40 vs. neurobehaviour 
APP transgenic models 
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For amyloid beta 42 I was able to perform meta-regression analyses on the APP, 
APPPS and 3xTgAD groups respectively (Table 4.49). 62 APP experiments 
suggested that changes in amyloid beta 42 could explain 21% of changes in 
neurobehaviour (Figure 4.23d). I did not identify a statistically significant 
relationship within the APPPS transgenic group (Figure 4.23e).  Where I examined 
10 3xTgAD experiments I identified a strong correlation between changes in 


















N Adj. R2 
    Amyloid beta 40 
APP 0.08 0.043 1.87 0.067 -0.006 0.166 57 0.13 
APPPS 0.073 0.105 0.7 0.493 -0.146 0.293 21 -0.06 
3xTgAD 0.302 0.191 1.59 0.151 -0.137 0.742 10 0.19 
Amyloid beta 42 
APP 0.1 0.039 2.56 0.013 0.022 0.179 61 0.21 
APPPS 0.115 0.11 1.05 0.307 -0.114 0.345 21 -0.01 









Table 4.49:  I assessed whether changes in amyloid beta 40 and amyloid beta 42 
could explain changes in neurobehaviour within the APP, APPPS and 3xTgAD 
transgenic model groups. For each comparison co-efficient is given (in terms of 
standardise mean difference effect size [SMD ES], standard error, tau (τ), 
significance level, 95% confidence limits, number of experiments (N) and Adjusted 
R2 (Adj. R2) 
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For tau neurofibrillary tangles, I assessed whether changes in 14 tau experiments 
could explain changes in neurobehaviour within the 3xTgAD mouse model. 
However, I did not identify a significant correlation between tau and 
neurobehaviour (Table 4.50, Figure 4.25).  
 
For cellular infiltrates 15 APP experiments suggested a potential correlation 
between changes in cellular infiltrates and neurobehaviour however this did not 
reach statistical significance (Table 4.50, Figure 4.25). Finally, 14 APP experiments 
suggested that changes in neurodegeneration could explain 60% of changes in 

























N Adj. R2 
              Tau 
3xTgAD 0.119 0.336 0.35 0.729 -0.612 0.85 14 -0.11 
Cellular infiltrates 
APP -0.325 0.134 -2.43 0.03 -0.614 -0.037 15 0.67 
Neurodegeneration 
APP 0.25 0.09 2.76 0.017 0.053 0.447 14 0.60 
Table 4.50: I assessed relationships between pathological outcomes and 
neurobehaviour within specific transgenic model groups wherever sufficient 
data were present. Data included Tau outcomes within 3xTgAD mice, cellular 
infiltrates within APP mice, and neurodegeneration outcomes within APP mice. 
For each comparison co-efficient is given (in terms of standardise mean 
difference effect size [SMD ES], standard error, tau (τ), significance level, 95% 
confidence limits, number of experiments (N) and Adjusted R2 (Adj. R2) 
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APP transgenic models 
APP transgenic models 
APP transgenic models 
3xTgAD transgenic models 
Neurdogeneration Cellular infiltrates 
Tau 
Figure 4.45: I assessed relationships between pathological outcomes and 
neurobehaviour within specific transgenic model groups wherever sufficient data 
were present. Data included Tau outcomes within 3xTgAD mice (a), cellular 
infiltrates within APP mice (b), and neurodegeneration outcomes within APP mice. 
(c) For each comparison Adjusted R2 (Adj. R2) is given. Symbol size represents the 
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4.15 Interpreting outcome measure analyses 
 
4.15.1 Summary of findings 
 
I identified a number of interesting relationships both within and between outcome 
measures. Changes in antibody stained plaque burden correlated well with both 
Thioflavin S and congo red stained plaques which is reassuring in terms of external 
validity. For measuring changes in amyloid species I noted a number of 
correlations, in particular that changes in amyloid beta 40 reflected changes amyloid 
beta 42. For outcomes regarding tau, I did not identify a correlation between 
improvements in the extent of phosphorylated tau and reductions and overall tau 
which was somewhat surprising. While estimates of efficacy for microgliosis were 
much greater than those identified for astrocytosis the two species of cellular 
infiltrates had a strong correlation with one another.  For outcomes in the MWM I 
found a strong correlation between changes in the acquisition and probe phase 
which sequentially increased at later acquisition stages.  
 
For relationships between pathological outcomes, changes in plaque pathology were 
present in all significant relationships, where correlations were found with changes 
in amyloid beta 40, amyloid beta 42, tau and neurodegeneration. I identified a 
medium strength correlation between changes in pathology and neurobehaviour 
and while plaque burden, amyloid beta 40 and amyloid beta 42 could all explain a 
significant proportion of changes, there may be value in the hypothesis that  
neurodegeneration provides the best predictor of changes in neurobehaviour.  
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Overall this chapter provides estimates of efficacy across 12 outcomes and within 
these  I was frequently able to estimate efficacy for individual transgenic groups and 
specific methodologies. While a number of stratified analyses suggested that 
methodologies do not impact on observed outcomes (e.g. plaque staining technique, 
length of amyloid species assessed, size of pool in the MWM) there were also 
methodologies used which were associated with differences in observed outcomes. 
For example, data suggested that indirect assessment of neurodegeneration 
outcomes were associated with greater estimates of effect than direct measures 
which may be an important consideration to clinical trial design. Perhaps the 
finding with the greatest continuity was the impact of the transgenic model group 
used across pathological outcomes (where 4 of a possible 6 stratifications proved 
significant). Such findings suggest that a deeper understanding of transgenic 
models themselves may provide insights into intervention efficacy.  
 
Therefore, our next chapter explores the impact of age and sex across the different 
transgenic mouse models. I also perform analyses specifically on transgenic control 
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4.15.2 Implications of findings 
 
Where I inspected relationships within outcomes I identified a number of 
particularly strong relationships (e.g. plaque burden, amyloid beta 40, cellular 
infiltrates). I must be cautious in interpretation as observed relationships imply 
associations, not causations. Nonetheless, it is reassuring with regard to external 
validity that despite a multitude of methodologies available there, measurements of 
amyloid and plaques generally correlated extremely well together.   
 
For relationships between pathological outcomes, it is interesting that all statistically 
significant associations involved plaque burden. Such findings could imply that 
specific pathological targeting of ‘early’ amyloid cascade hypothesis targets could 
have particularly widespread knock on effects.  However, one might also expect 
dominant influences from other outcomes which were not observed: in particular 
tau pathology. Associations between amyloid and other outcomes may be also be 
influenced by the prominence of amyloid bearing models.  
 
While there were a number of associations identified between pathological and 
neurobehavioural outcomes the strongest relationship observed was for 
neurodegeneration. Few models are capable of capturing such features which is 
reflected by a low number of publications which report neurodegeneration 
outcomes. Such data suggest that if I are to assess pathological outcomes as 
surrogate measures of improvement in behaviour, selecting models capable of 
capturing neurodegeneration may provide the greatest likelihood of clinical success. 
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Chapter 5: Age and transgene analyses 
 
Understanding the impact study characteristics exert on observed efficacies is a 
fundamental aim of this thesis. In this chapter I examine three age related 
parameters for their observed impact on effect size: (i) the age of mice at 
intervention administration, (ii) assessment and (iii) the difference between the age 
at administration and assessment.  I additionally assess the impact of sex on 
observed outcomes. 
 
For age specific analyses I analyse outcome measures datasets overall and I then 
perform analyses on the specific transgenic model group. For neurobehavioural 
data I chose to analyse data overall, as I envisaged this would be the most clinical 
relevant approach, opposed to stratifying data according to the individual paradigm 
used. I looked to further inform analyses conducted on interventions by assessing 
the impact of the transgene itself and where age related analyses are conducted 
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5.1 Age specific analyses for pathological outcomes 
 
For each outcome, I stratify data into inter-quartile ranges to assess the impact of the 
age at intervention administration, outcome assessment, and the difference between 
intervention administration and outcome assessment. For age specific analyses, I 
stratify all data for a given outcome and then explore individual transgenic model 
groups; to reflect differences in pathologies of the transgenic used. For all analyses, 
as I must stratify data into four categories, I took a conservative approach and 
stratify data wherever there were 20 or more experiments. Table 5.1 describes the 
number of experiments performed across each of the main pathological outcomes 
according to the transgenic group used. For each outcome, I plot data overall and 
the most commonly used transgenic, and tabulate others. 
 Transgenic model group 
 
 APP APPPS 3xTgAD Tau PS1 other Total 
Plaque burden 268* 79* 24* no data no data 7 378 
Amyloid beta 40 292* 61* 33* 1 1 no data 388 
Amyloid beta 42 288* 67* 31* 1 1 1 389 
Tau 8 4 48* 20* no data 4 84 
Cellular infiltrates 61* 25* 1 2 no data no data 89 
Neurodegeneration 43* 11 1 9 no data no data 64 
Table 5.1: The number of experiments measuring different pathological outcomes 
according by transgenic model group Where sufficient data were present (> 20 
experiments I stratified outcomes according to the transgenic model group used (shown 
by *). 
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5.1.1 Age at intervention administration 
Plaque burden  
 
For all 378 experiments where plaque burden was stained using 
immunohistochemically methods it was possible to stratify data according to the 
age of transgenic at intervention administration. Overall, estimates of effect 
suggested an inverse relationship between effect size and age at intervention but 
this did not account for a signification proportion of the observed heterogeneity (χ2 
=2.70, Figure 5.1a, Table 5.2). I inspected the dataset to identify whether there were 
sufficient experiments (≥20) for further exploration within each transgenic group. 
 
Plaque burden individual transgenic model groups 
 
As 268/378 of experiments were performed on APP models I stratified data by 
interquartile ranges and while the same relationship was observed, this did not 
account for a significant proportion of the observed heterogeneity (χ2 =0.36, Figure 
5.1b).  Sufficient data were also present within the APPPS group where 79 
experiments were stratification accounted for a significant proportion of the 
observed heterogeneity although a linear relationship could not be identified 
(p<0.02, χ2 = 28.7, Table 5.2). For the 3xTgAD group, stratifying 24 experiments did 
account for a significant proportion of the observed heterogeneity (χ2 =25.6, p<0.02, 
Table 5.2) although data were few, particularly in the second quartile and third 
quartiles (3 experiments respectively). 
 













(0.96 to 1.67) 
65 
1.02 
(0.75 to 1.28) 
70 
0.88 
(0.63 to 1.14) 
48 
0.86 
(0.65 to 1.08) 
83 
0.99 
(0.86 to 1.12) 
268 
Non sig.  





(0.1 to 1.07) 
21 
1.12 
(0.62 to 1.63) 
18 
1.12 
(0.51 to 1.73) 
22 
0.85 
(0.39 to 1.31) 
18 
0.91 
(0.65 to 1.17) 
79 
 Sig. 





(0.44 to 1.88) 
9 
-0.28 
(-1.99 to 1.43) 
3 
1.72 
(-1.19 to 4.64) 
3 
1.98 
(0.58 to 3.38) 
9 
1.11 
(0.46 to 1.75) 
24 
 Sig  





(0.83 to 1.32) 
104 
1 
(0.71 to 1.29) 
75 
0.96 
(0.75 to 1.18) 
98 
0.91 
(0.70 to 1.11) 
100 
0.98 
(0.87 to 1.1) 
378 
 Non sig 
(11.3 crit).  











Amyloid beta 40 
 
For 96% (374/388) of amyloid beta 40 experiments it was possible to stratify data 
according to the age of transgenic at intervention administration. Overall, stratifying 
amyloid beta 40 by the interquartile range did accounted for a significant proportion 
of the observed heterogeneity (χ2 = 13.2, Figure 5.1c), but I did not identify a specific 
relationship between point estimates and age. I inspected the dataset to identify 
whether there were sufficient experiments (≥20) for further exploration within each 
transgenic group. 
Table 5.2: Plaque burden outcomes were stratified by the age at administration 
overall, and by specific transgenic model groups (APP, APPPS and 3xTgAD). 
Estimates of efficacy are given in standardised effect size, brackets give 95% CI and 
number in bold represents the total number of experiments. 
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Amyloid beta 40 individual transgenic model group analyses 
 
As 278/374 experiments were performed on APP models I stratified data according 
to the age at intervention administration but this did not account for a significant 
proportion of the observed heterogeneity (χ2 =8.55, Figure 5.1d). For the 61 
experiments which were performed on APPPS mice I stratified data by age at 
administration but this did not explain a significant proportion of observed 
heterogeneity. (χ2 =7.32, Table 5.3). There were also sufficient data to stratify 
3xTgAD outcomes (33 experiments) although there was no clear relationship 
between age at intervention administration and effect size (p<0.02, χ2=13.6, Table 
5.3). 
 
  Quartiles 









(0.52 to 1.31) 
64 
0.74 
(0.49 to 0.99) 
71 
0.77 
(0.53 to 1.01) 
76 
0.49 







Quartiles (days) 0 to 77 84 to 140 168 to 280 294 to 672   
APPPS 
0.56 
(-0.03 to 1.15) 
17 
0.74 
(0.32 to 1.16) 
14 
0.55 
(0.12 to 0.98) 
17 
0.37 
(-0.15 to 0.9) 
13 
0.55 
(0.31 to 0.8) 
61 
Non. sig.  




(-0.53 to 1.71) 
3 
0.46 
(0.19 to 0.72) 
14 
-0.09 
(-0.77 to 0.58) 
8 
0.36 
(-0.23 to 0.96) 
8 
0.32 
(0.05 to 0.6) 
33 
Sig. 





(0.51 to 1.07) 
96 
0.56 
(0.36 to 0.75) 
86 
0.73 
(0.51 to 0.96) 
84 
0.53 








Quartiles (days) 0 to 70 77 to 126 140 to 263 280 to 672   
Table 5.3 Amyloid beta 40 outcomes were stratified by the age at administration 
overall, and by specific transgenic model groups (APP, APPPS and 3xTgAD). 
Estimates of efficacy are given in standardised effect size, brackets give 95% CI and 
number in bold represents the total number of experiments. 
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Amyloid beta 42 
 
For 99.7% (388/389) of amyloid beta 42 experiments it was possible to stratify data 
according to the age of transgenic at intervention administration. Overall, stratifying 
amyloid beta 42 data according to the age at intervention administration did not 
account for a significant proportion of the observed heterogeneity, although there 
did appear to be a modest inverse relationships between effect size and age (χ2 
=7.21, Figure 5.1e). I inspected the dataset to identify whether there were sufficient 
experiments (≥20) for further exploration within each transgenic group. 
 
Amyloid beta 42 individual transgenic model groups 
 
 
When I inspected data from the APP transgenic group I observed higher estimates 
of efficacy at earlier ages of intervention administration and this accounted for a 
significant proportion of the observed heterogeneity (χ2 = 12.7, p<0.02, Figure 5.1f). 
Where I stratified APPPS and 3xTgAD according to the age at intervention 
assessment this did not account for a significant proportion of the observed 
heterogeneity (χ2 = 9.91, and χ2 =4.5 respectively). 
  




  Quartiles 








(0.99 to 1.67) 
79 
0.8 
(0.59 to 1.02) 
64 
0.79 
(0.58 to 1.01) 
76 
0.7 
(0.48 to 0.92) 
68 
0.88 
(0.75 to 1) 
287 
Sig. 




(0.15 to 1.14) 
18 
0.69 
(0.31 to 1.06) 
14 
0.84 
(0.27 to 1.4) 
16 
0.36 
(-0.06 to 0.77) 
19 
0.61 
(0.37 to 0.84) 
67 
 Non. sig. 





(-0.23 to 1.07) 
3 
0.19 
(-0.07 to 0.46) 
13 
0.19 
(-0.85 to 1.24) 
7 
0.44 
(0.07 to 0.81) 
8 
0.31 
(0.03 to 0.59) 
31 
Non. sig.  




(0.59 to 1.1) 
81 
0.87 
(0.66 to 1.07) 
120 
0.72 
(0.51 to 0.93) 
94 
0.67 
(0.49 to 0.85) 
93 
0.78 




Quartiles (days) 0 to 77 84 to 140 168 to 280 294 to 672   
Figure 5.1 (next page): I stratified pathological outcomes according to the age at 
which interventions were administered. Stratified summary estimates are given for 
each quartile for plaque burden, amyloid beta 40 and amyloid beta 42 for all 
transgenic models (A, C, E) and for the most frequently used transgenic models (B, 
D,F). Bar width represents extremes within each quartile, error bars represent 95 % 
confidence limits and grey bar denotes 95% confidence limit of global estimate. 
Table 5.4 Amyloid beta 42 outcomes were stratified by the age at administration 
overall, and by specific transgenic model groups (APP, APPPS and 3xTgAD). 
Estimates of efficacy are given in standardised effect size, brackets give 95% CI and 
number in bold represents the total number of experiments. 
 







Amyloid beta 40: all transgenic models
Age at intervention administration (days)











































Plaque burden: all transgenic models
Age at intervention administration (days)











































Plaque burden: APP models
Age at intervention administration (days)














































Amyloid beta 40: APP transgenic models
Age at intervention administration (days)














































(E) (F)Amyloid beta 42: all transgenic models
Age at intervention administration (days)











































Amyloid beta 42: APP transgenic models
Age at intervention administration (days)


















































Overall, stratifying tau outcomes did not account for a significant proportion of the 
observed heterogeneity (χ2 =10.17, Figure 5.2a), although there did appear to be an 
inverse relationship between effect size and age at intervention.  
 
Tau individual transgenic model groups 
 
As 48 experiments were performed on the 3xTgAD transgenic model I stratified 
data by interquartile ranges and this did not account for a significant proportion of 
the observed heterogeneity (χ2 = 7.05, Figure 5.2b). For the 20 experiments 
performed using tau transgenics, stratifying data did account for a significant 
proportion of the observed heterogeneity however the overall relationship was 













(-0.39 to 0.75) 
6 
0.89 
(0.41 to 1.36) 
19 
0.87 
(0.29 to 1.44) 
15 
0.21 
(-0.22 to 0.65) 
8 
0.56 
(0.32 to 0.81) 
48 
Non. Sig. 





(-0.1 to 5.69) 
4 
0.35 
(0.11 to 0.58) 
6 
0.53 
(0.19 to 0.86) 
5 
1.21 
(0.18 to 2.23) 
5 
0.63 









(0.08 to 0.62) 
18 
0.62 
(0.25 to 0.99) 
26 
0.54 
(0.25 to 0.83) 
15 
0.7 
(0.33 to 1.08) 
25 
0.55 













Table 5.5 Tau outcomes were stratified by the age at administration overall, and by 
specific transgenic model groups (3xTgAD and tau). Estimates of efficacy are given 
in standardised effect size, brackets give 95% CI and number in bold represents the 
total number of experiments. 
 





 Overall, stratifying cellular infiltrate outcomes by the interquartile accounted for a 
significant proportion of the observed heterogeneity with later ages of intervention 
administration associated with an increase in cell infiltrates (χ2 = 176, p<0.01, Figure 
5.2c).  
 
Cellular infiltrates transgenic model groups 
 
As 61/88 experiments were performed on APP models I stratified data according to 
the age of the mice at intervention administration although relationships were 
difficult to define (χ2 =121, p<0.02, Figure 5.2d). For the APPPS group, 25 
experiments the overall relationship was without a specific direction (data formed a 
V shaped plot, χ2 =82.7, p<0.02, Table 5.6).  
  Quartiles 









(-0.15 to 0.99) 
17 
1.35 
(0.76 to 1.94) 
13 
0.33 
(-0.59 to 1.25) 
14 
-0.58 
(-1.14 to -0.03) 
17 
0.34 









(0.07 to 1.21) 
7 
0.67 
(0.16 to 1.18) 
3 
0.13 
(-1.47 to 1.74) 
9 
0.47 
(-0.17 to 1.11) 
6 
0.51 
(0.02 to 0.99) 
25 
  
     Sig. 





(0.29 to 1.08) 
22 
0.32 
(-0.32 to 0.97) 
22 
1.18 
(0.62 to 1.74) 
22 
-0.59 
(-1.03 to -0.15) 
22 
0.41 
(0.12 to 0.69) 
88 
Sig. 
(11.3 crit).   
Quartiles (days) 14 to 119 140 to 238 252 to 392 406 to 672   
  
Table 5.6: Cellular infiltrate outcomes were stratified by the age at administration 
overall, and by specific transgenic model groups (APP and APPPS). Estimates of 
efficacy are given in standardised effect size, brackets give 95% CI and number in 
bold represents the total number of experiments. 
 





Overall, stratifying neurodegeneration outcomes did not account for a significant 
proportion of the observed heterogeneity, although there did appear to be a modest 
reduction in effect size when interventions were administered within the first 
quartile (χ2 = 7.34, Figure 5.2e).  
 
Neurodegeneration outcomes by transgenic model groups 
 
There were only sufficient data (42 experiments) to inspect data from the APP 
transgenic group for the impact of the age at intervention administration. When I 
inspected data from the APP transgenic group, estimates of efficacy were smaller in 
the first quartile but stratification did not prove significant (χ2 =4.17, Figure 5.2f). 
  Quartiles 









(-0.01 to 0.96) 
12 
1.53 
(0.86 to 2.21) 
11 
0.77 
(0.43 to 1.11) 
13 
0.84 
(0.02 to 1.65) 
6 
0.84 
(0.58 to 1.1) 
42 
 Non.Sig.  





(0.12 to 0.99) 
14 
1.56 
(1 to 2.13) 
17 
0.84 
(0.48 to 1.2) 
9 
0.86 
(0.57 to 1.15) 
22 
0.94 
(0.72 to 1.15) 
62 
Non sig. 
(11.3 crit).  
Quartiles (days) 14 to 84 112 to 224 238 to 308 336 to 616   
Table 5.7: Neurodegeneration outcomes were stratified by the age at administration 
overall, and by specific transgenic model groups (APP only). Estimates of efficacy 
are given in standardised effect size, brackets give 95% CI and number in bold 
represents the total number of experiments. 
 








(B)Tau: All Transgenic models
Age at intervention administration (days)











































Cellular infiltratres: APP models
Age at intervention administration (days)








































Cellular infiltratres: All transgenic models
Age at intervention administration (days)
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Figure 5.2: I stratified pathological outcomes according to the age at which 
interventions were administered. Stratified summary estimates are given for each 
quartile for tau, cellular infiltrates and neurodegeneration for all transgenic models 
(A, C, E) and for the most frequently used transgenic models (B, D,F). Bar width 
represents extremes within each quartile, error bars represent 95 % confidence limits 
and grey bar denotes 95% confidence limit of global estimate. 
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Overall I assessed 99% (376/378) of the plaque burden dataset for the impact of age 
of outcome assessment. Overall, stratifying data according to the age at which 
outcomes were assessed did not account for a significant proportion of the observed 
heterogeneity. I inspected the dataset to identify whether there were sufficient 
experiments (≥20) for further exploration within each transgenic group. 
 
Plaque burden individual transgenic model groups 
 
I assessed the impact of the age at outcome assessment for the 266 experiments 
which used APP mice, but this did not account for a significant proportion of the 
observed heterogeneity (χ2 =6.51). In contrast, for the 79 experiments reported from 
APPPS mice, stratifying data according to the age at outcome assessment did 
account for a significant proportion of the heterogeneity (χ2 =43.3, p<0.02, Table 5.8) 
but relationships were difficult to define .Twenty-four plaque burden experiments 
were performed within the 3xTgAD group and our stratified analysis suggested that 
very early estimates were lower than others, crossing the line of no effect (χ2 =35.2, 
p<0.02, Table 5.8).  
  














Amyloid beta 40 
 
373/388 amyloid beta 40 experiments stated the age at outcome assessment and 
were taken forward to stratified analysis. Stratifying data according to the age at 
outcome assessment did not account for a significant proportion of the observed 
heterogeneity but I observed smaller estimates of efficacy at later ages of assessment 
(χ2 =35.2, p<0.01, Figure 5.3). I inspected the dataset to identify whether there were 




  Quartiles 
df=3 
α=0.02  
Critical  χ2 
value 





(0.97 to 1.61) 
68 
0.68 
(0.44 to 0.93) 
68 
1.07 
(0.83 to 1.31) 
65 
0.98 
(0.72 to 1.25) 
65 
0.99 










(0.68 to 1.6) 
20 
0.27 
(-0.13 to 0.68) 
20 
1.1 
(0.57 to 1.64) 
19 
0.89 
(0.31 to 1.47) 
20 
0.91 










(-0.6 to 1.19) 
8 
1.25 
(-0.65 to 3.15) 
4 
2.54 
(1.08 to 3.99) 
8 
1.23 
(0.56 to 1.89) 
4 
1.11 










(0.94 to 1.46) 
96 
0.82 
(0.59 to 1.05) 
85 
1.01 
(0.76 to 1.25) 
101 
0.91 
(0.71 to 1.11) 
94 
0.98 





Quartiles (days) 65 to 210 211 to 322  336 to 434  435 to 721   
Table 5.8: Plaque burden outcomes were stratified by the age at outcome assessment 
overall, and by specific transgenic model groups (APP, APPPS and 3xTgAD). 
Estimates of efficacy are given in standardised effect size, brackets give 95% CI and 
number in bold represents the total number of experiments. 




Amyloid beta 40 and individual transgenic model groups 
 
I identified that amyloid beta 40 was most commonly assessed in APP transgenic 
models (277 experiments) and stratifying data according to the age at outcome 
assessment accounted for a significant proportion of the observed heterogeneity 
although there was no clear relationship(χ2 =22.8, p<0.02, Figure 5.3).  
There were also sufficient data present in both APPPS and 3xTgAD transgenic 
groups, but stratifying data according to the age at outcome assessment did not 





α=0.02   
Critical χ2 
Value   
 





(0.28 to 0.94) 
68 
1.01 
(0.74 to 1.28) 
69 
0.73 
(0.47 to 0.99) 
71 
0.53 
(0.34 to 0.72) 
69 
0.72 
(0.59 to 0.84) 
277 
Sig.  





(0.34 to 1.53) 
16 
0.64 
(0.26 to 1.01) 
15 
0.47 
(-0.19 to 1.13) 
15 
0.24 
(-0.13 to 0.62) 
15 
0.55 
(0.31 to 0.8) 
61 
Non. Sig.  





(-0.22 to 0.56) 
9 
0.29 
(-0.52 to 1.09) 
8 
0.35 
(-0.14 to 0.83) 
8 
0.54 
(-0.11 to 1.2) 
8 
0.32 
(0.05 to 0.6) 
33 
 Non. Sig.  





(0.44 to 0.97) 
92 
0.75 
(0.53 to 0.97) 
98 
0.66 
(0.44 to 0.88) 
93 
0.51 
(0.35 to 0.68) 
90 
0.65 















Table 5.9: Amyloid beta 40 outcomes were stratified by the age at outcome assessment 
overall, and by specific transgenic model groups. Sufficient data were present to 
examine APP, APPPS and 3xTgAD transgenic groups in further detail. Estimates of 
efficacy are given in standardised effect sizes, brackets give 95% CI and with number 
of experiments. 
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Amyloid beta 42 
 
For 387/389 amyloid beta 42 experiments it was possible to stratify data according to 
the age at outcome assessment. Overall, I identified that stratifying data by the age 
at outcome assessment did not account for significant proportion of the observed 
heterogeneity (χ2 =7.5, Figure 5.3). I inspected the dataset to identify whether there 
were sufficient experiments (≥20) for further exploration within each transgenic 
group. 
 
Amyloid beta 42 and individual transgenic model groups 
I stratified data according to the age of outcome assessment in APP mice and 
identified that smaller estimates of efficacy were associated with later ages at 
outcome assessment (χ2 =21.3, p<0.02, Figure 5.3).  Conversely, for the 3xTgAD 
group 31 experiments suggested that higher estimates of efficacy were associated 
with later ages of assessment (χ2 =12.9, p<0.02, Table 5.10). I also stratified APPPS 
(67 experiments) but this did not account for a significant proportion of the 









  Quartiles 
df=3 
α=0.02   
 Critical 
χ2 value  
Amyloid beta 
42 





(0.99 to 1.66) 
72 
1.02 
(0.77 to 1.28) 
71 
0.63 
(0.4 to 0.85) 
79 
0.72 
(0.51 to 0.94) 
64 
0.88 
(0.76 to 1.01) 
286 
Sig.  





(0.24 to 1.13) 
17 
0.56 
(0.3 to 0.82) 
17 
0.37 
(-0.24 to 0.99) 
16 
0.79 
(0.22 to 1.36) 
17 
0.61 
(0.37 to 0.84) 
67 
Non. Sig.  





(-0.48 to 0.48) 
9 
0.3 
(-0.52 to 1.12) 
6 
0.14 
(-0.23 to 0.52) 
8 
0.85 
(0.24 to 1.45) 
8 
0.31 
(0.03 to 0.59) 
31 
 Sig.  





(0.77 to 1.29) 
97 
0.74 
(0.53 to 0.94) 
97 
0.63 
(0.41 to 0.85) 
94 
0.78 
(0.6 to 0.95) 
99 
0.78 
(0.67 to 0.88) 
387 
 Non. sig.  
(11.3 crit) 




Figure 5.3 (next page): I stratified pathological outcomes according to the age at 
which outcomes were assessed. Stratified summary estimates are given for each 
quartile for  plaque burden, amyloid beta 40 and amyloid beta 42 for all 
transgenic models (A, C, E) and for the most frequently used transgenic models 
(B, D,F). Bar width represents extremes within each quartile, error bars 
represent 95 % confidence limits and grey bar denotes 95% confidence limit of 
global estimate. 
Table 5.10 Amyloid beta 42 outcomes were stratified overall, and by specific 
transgenic model groups. Sufficient data were present to examine APP, APPPS and 
3xTgAD transgenic groups in further detail. Estimates of efficacy are given in 
standardised effect sizes, brackets give 95% CI and with number of experiments 









Amyloid beta 40: all transgenic models
Age at outcome assessment (days)












































Amyloid beta 42: all transgenic models
Age at outcome assessment (days)













































Amyloid beta 40: APP models
Age at outcome assessment (days)












































Plaque burden: APP models
Age at outcome assessment (days)















































Amyloid beta 42: APP models
Age at outcome assessment (days)















































Plaque burden: all transgenic models
Age at outcome assessment (days)





















































I stratified the 84 tau experiments to assess the impact of the age at outcome 
assessment but this did not account for a significant proportion of the observed 
heterogeneity (χ2 =9.14, Figure 5.4) 
 
 
Tau and individual transgenic model groups 
 
 
 For the 3xTgAD group there were sufficient data to allow stratification of data by 
the age at outcome assessment (48 experiments) but this did not account for a 
significant proportion of the observed heterogeneity (χ2 =7.65, Figure 5.4). 
Conversely, stratifying data from the tau transgenic group did account for a 
significant proportion of the observed heterogeneity (χ2 =12.37, p<0.02, Table 5.11), 





  Quartiles 
df=3 
α=0.02   
Critical  χ2 
value 




(0.02 to 1.48) 
12 
0.75 
(0.27 to 1.23) 
12 
0.94 
(0.22 to 1.66) 
12 
0.31 
(-0.05 to 0.66) 
12 
0.56 
(0.32 to 0.81) 
48 
Non. sig.  
Quartiles (days) 120 to 231 252 to 336 339 to 381  420 to 672   
Tau 
0.33 
(-0.16 to 0.82) 
5 
0.37 
(0.1 to 0.63) 
7 
0.65 
(0.33 to 0.98) 
3 
1.21 
(0.18 to 2.23) 
5 
0.63 
(0.36 to 0.9) 
20 
Sig.  





(0.14 to 0.9) 
22 
0.67 
(0.36 to 0.97) 
20 
0.45 
(0.06 to 0.84) 
21 
0.57 
(0.24 to 0.91) 
21 
0.55 




Quartiles (days) 71 to 224 231 to 320  336 to 381 389 to 672   
Table 5.11 Tau outcomes were stratified overall, and by specific transgenic model 
groups. Sufficient data were present to examine the 3xTgAD and tau transgenic 
groups in further detail. Estimates of efficacy are given in standardised effect sizes, 
brackets give 95% CI and with number of experiments 





For outcome regarding cellular infiltrates it was possible to determine the age at 
outcome assessment for 87/89 experiments. Where I stratified such data according to 
the age at outcome assessment, later ages of assessment were associated with 
smaller estimates of effect size (χ2 =30.7, p<0.01, Figure 5.4).I inspected the dataset to 
identify whether there were sufficient experiments (≥20) for further exploration 
within each transgenic group. 
 
Cellular infiltrates and individual transgenic model groups 
 
 
I inspected the APP group for the impact the age of assessment has on outcomes 
and  identified that earlier ages of outcome assessment were associated with greater 
reductions of cellular infiltrate species (χ2 =82.7, p<0.02, Figure 5.4). I did not 





  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  





(0.31 to 1.44) 
16 
0.49 
(-0.09 to 1.07) 
14 
-0.12 
(-0.61 to 0.37) 
17 
0.04 
(-1.19 to 1.26) 
13 
0.35 
(-0.01 to 0.72) 
60 
Sig. 





(0.38 to 1.13) 
7 
0.55 
(-0.25 to 1.35) 
5 
-0.34 
(-1.31 to 0.63) 
8 
1.67 
(0.13 to 3.22) 
5 
0.51 
(0.02 to 0.99) 
25 
Non. sig. 





(0.37 to 1.17) 
24 
0.73 
(0.13 to 1.32) 
20 
0.02 
(-0.42 to 0.46) 
21 
0.09 
(-0.72 to 0.89) 
22 
0.42 




Quartiles (days) 35 to 252 258 to 364 371 to 483 493 to 714   
Table 5.12 Cellular infiltrates outcomes were stratified overall, and by specific 
transgenic model groups. Sufficient data were present to examine APP and APPPS 
transgenic groups in further detail. Estimates of efficacy are given in standardised 
effect sizes, brackets give 95% CI and with number of experiments. 





For 62 out of 64 neurodegeneration experiments it was possible to assess the impact 
of the age at outcome assessment but this did not account for a significant 
proportion of the observed heterogeneity (χ2 =3.08, Figure 5.4). I inspected the 
dataset to identify whether there were sufficient experiments (≥20) for further 
exploration within each transgenic group. 
 
 
Neurodegeneration and individual transgenic model groups 
 
For neurodegeneration outcomes, APP was the only transgenic group where 
sufficient data were present to allow stratification by the age at outcome assessment. 
Stratifying such data did not account for a significant proportion of the observed 
heterogeneity (χ2 =6.09, Figure 5.4) and estimates of efficacy within each quartile did 
not suggest any particular relationships. 
  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  





(0.39 to 2) 
12 
0.58 
(0.31 to 0.84) 
9 
1 
(0.46 to 1.54) 
6 
0.76 
(0.43 to 1.08) 
15 
0.84 
(0.58 to 1.1) 
42 
 Non. Sig.  





(0.63 to 1.97) 
16 
0.88 
(0.49 to 1.28) 
15 
0.88 
(0.56 to 1.2) 
15 
0.79 
(0.46 to 1.12) 
16 
0.94 
(0.72 to 1.15) 
62 
 Non. Sig.  
(11.3 crit).  









Table 5.13 Neurodegeneration outcomes were stratified overall, and by specific 
transgenic model groups. Sufficient data were present to examine the APP 
transgenic group in further detail. Estimates of efficacy are given in standardised 
effect sizes, brackets give 95% CI and with number of experiments. 








Cellular infiltrates: All transgenic models
Age at outcome assessment (days)












































Tau: All transgenic models
Age at outcome assessment (days)












































Neurodegeneration: All transgenic models
Age at outcome assessment (days)











































Age at outcome assessment (days)










































(D) Cellular infiltrates: APP models
Age at outcome assessment (days)













































Age at outcome assessment (days)

















































Figure 5.4: I stratified pathological outcomes according to the age of outcome 
assessment. Stratified summary estimates are given for each quartile for tau, 
cellular infiltrates and neurodegeneration for all transgenic models (A, C, E) 
and for the most frequently used transgenic models (B, D,F). Bar width 
represents extremes within each quartile, error bars represent 95 % confidence 
limits and grey bar denotes 95% confidence limit of global estimate. 
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For plaque burden outcomes, it was possible to stratify 376/378 of experiments 
according to the difference between age at administration and assessment. 
Stratifying data accounted for a significant proportion of the observed heterogeneity 
and estimates of efficacy showed a modest inverse relationship with the difference 
between age at administration and assessment (χ2 =18.7, p<0.01, Figure 5.5).  
 
Plaque burden and individual transgenic model groups 
 
I stratified the 266 APP experiments according to the difference between age at 
administration and assessment but this did not account for a significant proportion 
of heterogeneity (χ2 =0.24, Figure 5.5). Similarly, stratifying the 79 APPPS transgenic 
experiments did not account for a significant proportion of the observed 
heterogeneity (χ2 =5.49, Table 5.14). I stratified 24 3xTgAD experiments where there 
was no clear relationship between estimates of efficacy and the difference between 
age at administration and assessment (χ2 =47.5, p<0.02, Table 5.14). 
 
Amyloid beta 40 
 
For amyloid beta 40 outcomes it was possible to stratify 373 experiments according 
to the difference between age at administration and assessment. Stratifying data 
overall did not account for a significant proportion of the observed heterogeneity (χ2 
=8.12). I inspected the dataset to identify whether there were sufficient experiments 
(≥20) for further exploration within each transgenic group. 
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  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  





(0.67 to 1.25) 
72 
1.05 
(0.78 to 1.32) 
62 
1 
(0.71 to 1.28) 
50 
0.97 
(0.73 to 1.2) 
82 
0.99 
(0.85 to 1.12) 
266 
Non. Sig.   





(0.41 to 1.23) 
22 
1.1 
(0.52 to 1.68) 
18 
0.88 
(0.22 to 1.53) 
20 
0.68 
(0.31 to 1.06) 
19 
0.91 
(0.65 to 1.17) 
79 
Non. Sig.   





(1.64 to 7.4) 
8 
-0.4 
(-1.54 to 0.74) 
4 
1.21 
(0.34 to 2.08) 
7 
1.31 
(0.55 to 2.06) 
5 
1.11 
(0.46 to 1.75) 
24 
Sig. 




(0.89 to 1.42) 
95 
0.92 
(0.69 to 1.16) 
97 
1.02 
(0.83 to 1.22) 
109 
0.86 
(0.61 to 1.11) 
75 
0.98 














Amyloid beta 40 and individual transgenic model groups 
 
 
For the 277 experiments which reported amyloid beta 40 outcomes from APP 
transgenic models I identified a modest increase in effect size with greater 
differences between the age at administration and outcome assessment (χ2 =12.38, 
p<0.02, Figure 5.5). Stratifying 61 APPPS experiments accounted for a significant 
proportion of heterogeneity but this was not reflected by a relationship between 
effect size and difference between age at administration and assessment (χ2 =11.39, 
p<0.02, Table 5.15). Stratifying 33 3xTgAD experiments did not account for 
significant proportion of heterogeneity (χ2 =3.63, Table 5.15). 
 
 
Table 5.14 Plaque burden outcomes were stratified overall, and by specific transgenic 
model groups. Sufficient data were present to examine APP, APPPS and 3xTgAD 
transgenic groups in further detail. Estimates of efficacy are given in standardised 
effect sizes, brackets give 95% CI and with number of experiments. 
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  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  
Amyloid beta 
40 





(0.39 to 0.95) 
65 
0.5 
(0.26 to 0.73) 
74 
0.89 
(0.63 to 1.15) 
67 
0.78 
(0.53 to 1.03) 
71 
0.72 
(0.59 to 0.84) 
277 
 Sig.  





(0.04 to 1.22) 
15 
0.9 
(0.47 to 1.33) 
17 
0.36 
(-0.04 to 0.76) 
14 
0.29 
(-0.26 to 0.85) 
15 
0.55 
(0.31 to 0.8) 
61 
 Sig.  





(-0.29 to 0.39) 
8 
0.47 
(-0.27 to 1.21) 
9 
0.44 
(-0.27 to 1.15) 
8 
0.54 
(0 to 1.08) 
8 
0.32 
(0.05 to 0.6) 
33 
 Non. Sig. 




(0.36 to 0.83) 
95 
0.52 
(0.32 to 0.71) 
90 
0.77 
(0.57 to 0.97) 
97 
0.67 
(0.45 to 0.9) 
91 
0.65 
(0.54 to 0.75) 
373 
 Non. Sig. 
(11.3 crit).  











Amyloid beta 42 
 
Stratifying 387 amyloid beta 42 experiments according to the difference between age 
at administration and outcome assessment did not account for a significant 
proportion of the observed heterogeneity(χ2 =4.50, Figure 5.5). I inspected the 
dataset to identify whether there were sufficient experiments (≥20) for further 








Table 5.15 Amyloid beta 40 outcomes were stratified overall, and by specific 
transgenic model groups. Sufficient data were present to examine APP, APPPS and 
3xTgAD transgenic groups in further detail. Estimates of efficacy are given in 
standardised effect sizes, brackets give 95% CI and with number of experiments 
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Amyloid beta 42 and individual transgenic model groups 
 
Stratifying APP transgenic models (286 experiments) was weakly associated with 
smaller estimates of efficacy (χ2 =21.2, p<0.02, Figure 5.5). For APPPS models, I 
stratified 67 studies according to the difference between age at intervention 
administration and outcome assessment but this did not account for a significant 
proportion of the observed heterogeneity (χ2 =4.78, Table 5.16). For the 31 
experiments examining amyloid beta 42 in 3xTgAD models, larger differences 
between intervention administration and outcome assessment were weakly 
associated with higher estimates of efficacy but this was not statistically significant 
(χ2 =9.24, p<0.02,  Table 5.16) 
  
  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  





( 0.93 to 1.56 ) 
71 
0.52 
( 0.28 to 0.76 ) 
65 
1.01 
( 0.77 to 1.25 ) 
78 
0.78 
( 0.55 to 1.02 ) 
72 
0.88 
(0.76 to 1.01) 
286 
Sig.  





( -0.02 to 0.8 ) 
19 
0.82 
( 0.47 to 1.18 ) 
16 
0.52 
( 0.21 to 0.84 ) 
15 
0.7 
( 0.02 to 1.39 ) 
17 
0.61 
(0.37 to 0.84) 
67 
Non. Sig. 





( -0.49 to 0.29) 
8 
0.76 
( 0.02 to 1.49 ) 
8 
0.18 
( -0.2 to 0.55 ) 
7 
0.52 
(-0.22 to 1.27) 
8 
0.31 
(0.03 to 0.59) 
31 
Non. Sig. 





( 0.64 to 1.13 ) 
98 
0.7 
( 0.52 to 0.89 ) 
106 
0.84 
( 0.64 to 1.04 ) 
86 
0.72 
( 0.5 to 0.93 ) 
97 
0.78 




Quartiles (days) 0 to 21  28 to 84  88 to 154  155 to 420   
Table 5.16 Amyloid beta 42 outcomes were stratified overall, and by specific 
transgenic model groups. Sufficient data were present to examine APP, APPPS and 
3xTgAD transgenic groups in further detail. Estimates of efficacy are given in 
standardised effect sizes, brackets give 95% CI and with number of experiments 
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Amyloid beta 40: All transgenic models
Difference between age at administration and outcome assessment (days)











































Amyloid beta 42: All transgenic models
Difference between age at administration and outcome assessment (days)












































Amyloid beta 42: APP models
Difference between age at administration and outcome assessment (days)










































Plaque burden: APP models
Difference between age at administration and outcome assessment (days)













































Plaque area: All transgenic models
Difference between age at administration and outcome assessment (days)














































Amyloid beta 40: APP models
Difference between age at administration and outcome assessment (days)
















































Figure 5.5: I stratified pathological outcomes according to the difference between 
the age at administration and assessment. Stratified summary estimates are given 
for tau, cellular infiltrates and neurodegeneration for all transgenic models (a, c, e) 
and for the most frequently used transgenic models (b,d,f). Bar width represents 
extremes within each quartile, error bars represent 95 % confidence limits and 
grey bar denotes 95% confidence limit of global estimate. 





I stratified the 84 tau experiments into quartiles but this did not account for a 
significant proportion of the observed heterogeneity and the overall relationship 
was unclear (χ2 =2.56, p<0.01,  Figure 5.6) I inspected the dataset to identify whether 
there were sufficient experiments (≥20) for further exploration within each 
transgenic group. 
 
Tau and individual transgenic model groups 
 
For both 3xTgAD and tau transgenic groups there were sufficient data for 
transgenic group specific analyses, however these did not account for a significant 






α=0.02   
  Critical  
χ2 value  





(0.2 to 1.82) 
12 
0.68 
(0.22 to 1.14) 
15 
0.62 
(-0.03 to 1.28) 
10 
0.34 
(0.09 to 0.6) 
11 
0.56 
(0.32 to 0.81) 
48 
Non. sig. 





(0.37 to 2.12) 
5 
0.41 
(0.01 to 0.81) 
6 
0.4 
(0.13 to 0.67) 
6 
1.03 
(-0.2 to 2.27) 
3 
0.63 
(0.36 to 0.9) 
20 
Non. sig. 





( 0.53 to 1.43 ) 
24 
0.53 
( 0.24 to 0.83 ) 
24 
0.38 
( -0.06 to 0.83 ) 
14 
0.37 
( 0.13 to 0.61 ) 
22 
0.55 

















Table 5.17 Tau outcomes were stratified overall, and by specific transgenic model 
groups. Sufficient data were present to examine 3xTgAD and tau transgenic groups 
in further detail. Estimates of efficacy are given in standardised effect sizes, brackets 
give 95% CI and with number of experiments 





I stratified the 87 cellular infiltrates experiments and identified that larger 
differences between the age at intervention administration and outcome assessment 
were associated with smaller estimates of effect size (χ2 =98.2, Figure 5.6c). I 
inspected the dataset to identify whether there were sufficient experiments (≥20) for 
further exploration within each transgenic group. 
 
Cellular infiltrates and individual transgenic model groups 
 
For APP experiments I stratified data and identified an increase of cellular infiltrates 
where there were smaller differences between the age at administration intervention 
and outcome assessment  (χ2 =69.1, p<0.02, Figure 5.6d).  For the APPPS1 group 
stratification by quartiles accounted for a significant proportion of the observed 
heterogeneity (χ2 =29.5, p<0.02, Table 5.18). Estimates of efficacy did not suggest a 
clear relationship between the difference between age at administration and 
assessment and effect size. 
 
  
  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  





(-0.96 to 0.43) 
16 
0.82 
(0.02 to 1.62) 
16 
0.18 
(-0.26 to 0.62) 
14 
0.73 
(-0.09 to 1.56) 
14 
0.35 
(-0.01 to 0.72) 
60 
 Sig. 





(-0.34 to 1.21) 
7 
0.84 
(0.52 to 1.17) 
7 
-0.33 
(-1.32 to 0.66) 
6 
1.1 
(-0.28 to 2.48) 
5 
0.51 
(0.02 to 0.99) 
25 
 Sig.  





(-0.86 to 0.33) 
22 
0.88 
(0.41 to 1.34) 
25 
0.02 
(-0.41 to 0.44) 
20 
0.87 
(0.22 to 1.52) 
20 
0.42 
(0.13 to 0.7) 
87 
 Sig.  
(11.3 crit). 
Quartiles (days) 1 to 21 28 to 84 87 to 140 147 to 420   













For 62 neurodegeneration experiments I assessed the impact of the duration 
between the age at intervention administration and outcome assessment but this did 
not account for a significant proportion of the observed heterogeneity (χ2 =8.61, 
Figure 5.6e). I inspected the dataset to identify whether there were sufficient 
experiments (≥20) for further exploration within each transgenic group. 
 
Neurodegeneration and individual transgenic model groups 
 
I stratified data in the APP transgenic model group, and identified that smaller 
differences between the age at intervention administration and outcome assessment 
were associated with higher estimates of effect size (χ2 =22.1, p<0.02, Figure 5.6f) 
  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  





(0.8 to 2.03) 
11 
0.8 
(0.08 to 1.53) 
10 
0.65 
(0.36 to 0.94) 
16 
0.85 
(0.46 to 1.24) 
5 
0.84 
(0.58 to 1.1) 
42 
Sig.  





(0.47 to 1.48) 
15 
1.41 
(0.95 to 1.87) 
16 
1.03 
(0.2 to 1.86) 
10 
0.70 
(0.47 to 0.94) 
21 
0.94 
(0.72 to 1.15) 
62 
Non. Sig. 
(11.3 crit).  
Quartiles (days) 3 to 28 35 to 92  112 to 154  168 to 321   
 
  
Table 5.18 (pervious page): Cellular infiltrate outcomes were stratified overall, and 
by specific transgenic model groups. Sufficient data were present to examine APP, 
APPPS and 3xTgAD transgenic groups in further detail. Estimates of efficacy are 
given in standardised effect sizes, brackets give 95% CI and with number of 
experiments 
Table 5.19 Neurodegeneration outcomes were stratified overall, and by specific 
transgenic model groups. Sufficient data were present to examine APP, APPPS and 
3xTgAD transgenic groups in further detail. Estimates of efficacy are given in 
standardised effect sizes, brackets give 95% CI and with number of experiments 








Difference between age at administration and outcome assessment (days)










































Cellular infiltrates: All transgenic models
Difference between age at administration and outcome assessment (days)












































Cellular infiltrates: APP models
Difference between age at administration and outcome assessment (days)













































Difference between age at administration and outcome assessment (days)










































Neurodegeneration: All transgenic models
Difference between age at administration and outcome assessment (days)











































Difference between age at administration and outcome assessment (days)















































































Figure 5.6: I stratified pathological outcomes according to the difference between 
the age at administration and assessment. Stratified summary estimates are given 
for each quartile for tau, cellular infiltrates and neurodegeneration for all transgenic 
models (a, c, e) and for the most frequently used transgenic models (b,d,f). Bar 
width represents extremes within each quartile, error bars represent 95 % 
confidence limits and grey bar denotes 95% confidence limit of global estimate. 








For each outcome I stratify data into inter-quartile ranges to assess the impact of the 
age at intervention administration, outcome assessment, and the difference between 
intervention administration and outcome assessment. For age specific analyses, I 
stratify all data for a given outcome and then explore individual transgenic model 
groups separately wherever there are sufficient data to reflect differences in 
pathologies of the transgenic used. As I must stratify data into four categories, I took 
a conservative approach and stratify data wherever there were 20 or more 
experiments present within a single transgenic group. Table 5.20 describes the 
number of experiments performed across each of the main behavioural outcomes 
according to the transgenic group used. However, while sufficient data were 
present in order to investigate individual paradigms I envisaged that performing 











 Transgenic model group 
 
 APP APPPS 3xTgAD Tau PS1 Other Total 
Acquisition phase 86 22 20 0 2 0 130 
Probe phase 70 18 19 1 3 2 113 
Other 67 40 10 3 1 2 123 
Total 156* 56* 36* 3 4 4 259 
Table 5.20: The number of experiments measuring different neurobehavioural 
outcomes according by transgenic model group. Where sufficient data were 
present for data overall (≥ 20 experiments) I stratified outcomes according to the 
transgenic model group used (shown by *). 
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5.2.1 Age at intervention administration 
 
I first stratified neurobehavioral data overall to assess the impact age at intervention 
administration had on observed effect sizes which was possible for 256/259  
experiments.  Stratification accounted for a significant proportion of the observed 
heterogeneity where later ages of intervention administration were associated with 
higher estimates of efficacy (χ2 =18.7, p<0.01, Figure 5.7a).  
 
Neurobehaviour and individual transgenic model groups 
 
Stratification by the age at administration did not account for a significant 
proportion of the observed heterogeneity for APP mice (χ2 =2.10 Figure 5.7b) and 
clear relationships could not be identified with stratifying APPPS neurobehavioural 
outcomes (χ2 =11.6, Table 5.21). Stratification of 3xTgAD outcomes suggested that 
higher estimates of efficacy were found at later ages of intervention administration 
(χ2 =13.1, p<0.02, Table 5.21). 
 
  Quartiles 
df=3 
α=0.02   
  Critical  
χ2 value  
NBS data Q1 Q2 Q3 Q4 All quartiles 10.2 
APP 
0.56 
(0.38 to 0.74) 
35 
0.64 
(0.42 to 0.86) 
35 
0.69 
(0.52 to 0.85) 
45 
0.81 
(0.6 to 1.03) 
40 
0.67 
(0.57 to 0.76) 
155 
Non. Sig. 





(-0.08 to 0.62) 
12 
0.54 
(0.32 to 0.76) 
16 
0.45 
(0.07 to 0.83) 
11 
0.8 
(0.45 to 1.14) 
17 
0.54 
(0.38 to 0.69) 
56 
Sig. 





(-0.23 to 0.54) 
9 
0.58 
(0.29 to 0.87) 
12 
0.89 
(0.26 to 1.52) 
4 
0.67 
(0.21 to 1.14) 
11 
0.55 
(0.35 to 0.76) 
36 
 Sig.  





(0.26 to 0.59) 
58 
0.61 
(0.48 to 0.74) 
75 
0.6 
(0.44 to 0.77) 
58 
0.82 
(0.66 to 0.99) 
65 
0.61 




Quartiles (days) 14 to 82 84 to 140 168 to 252  280 to 672     
 
 











5.2.2 Age at outcome assessment 
 
I first stratified neurobehavioral data overall to assess the impact age at outcome 
assessment had on observed effect size, which was possible for 255/259 experiments.  
Stratifying data overall, did not account for a significant proportion of the observed 
heterogeneity although I did observe that higher estimates of effect size were 
associated with later ages of outcome assessment (χ2 =6.68, Figure 5.7c). 
 
Neurobehaviour and individual transgenic model groups 
 
APP transgenic models were the most commonly assessed transgenic model group 
(154 experiments) where estimates of efficacy were greater and later ages of 
assessment and this accounted for a significant proportion of the observed 
heterogeneity (χ2 =13.2). Where I stratified APPPS transgenic experiments, data did 
not suggest a direction of effect and for 3xTgAD stratification did not account for a 
significant proportion of heterogeneity χ2 =13.4 and χ2 =9.59 respectively). 
  
Table 5.21 (previous page): I stratified neurobehavioural outcomes according to the 
age at intervention administration overall, and by specific transgenic model groups. 
Sufficient data were present to examine APP, APPPS and 3xTgAD transgenic 
groups in further detail. Estimates of efficacy are given in standardised effect sizes, 
brackets give 95% CI and with number of experiments. 


















5.2.3 Difference between age at administration and age at 
assessment 
 
I first stratified neurobehavioral data overall to assess the impact the difference 
between age at administration and age at assessment had on observed effect size. 
Overall, 255 experiments suggested longer durations between administration and 
assessment were associated with larger effect sizes, however this did not account for 




  Quartiles    
df=3 
α=0.02   
  Critical  
χ2 value  





(0.27 to 0.58) 
40 
0.71 
(0.55 to 0.88) 
38 
0.78 
(0.55 to 1.02) 
38 
0.79 
(0.58 to 1) 
38 
0.67 
(0.58 to 0.77) 
154 
Sig.  





(0.53 to 0.95) 
14 
0.37 
(0.01 to 0.73) 
14 
0.56 
(0.23 to 0.89) 
13 
0.46 
(0.13 to 0.8) 
15 
0.54 
(0.38 to 0.69) 
56 
Sig.  





(-0.11 to 0.74) 
9 
0.59 
(0.23 to 0.95) 
9 
0.72 
(0.43 to 1.01) 
9 
0.58 
(0.02 to 1.14) 
9 
0.55 
(0.35 to 0.76) 
36 
Non 
Sig.   





(0.36 to 0.6) 
66 
0.61 
(0.45 to 0.77) 
62 
0.7 
(0.54 to 0.86) 
63 
0.69 
(0.52 to 0.86) 
64 
0.62 





Quartiles (days) 35 to 196 197 to 313 314 to 434 444 to 721     
Table 5.22 I stratified neurobehavioural outcomes according to the age at 
outcome assessment overall, and by specific transgenic model groups. Sufficient 
data were present to examine APP, APPPS and 3xTgAD transgenic groups in 
further detail. Estimates of efficacy are given in standardised effect sizes, brackets 
give 95% CI and with number of experiments. 




Neurobehaviour and individual transgenic model groups 
 
I stratified APP data where higher estimates of efficacy were associated with longer 
durations between intervention administration and outcome assessment (χ2 =25.9). 
Stratifying APPPS experiments also accounted for a significant proportion of 
observed heterogeneity (χ2 =34.6, p<0.02), however there was no clear trend present. 
For 3xTgAD mice, stratification of data did not account for a significant proportion 






α=0.02   
  Critical  
χ2 value  
NBS data Q1 Q2 Q3 Q4 All quartiles 10.2 
APP 
0.58 
(0.39 to 0.77) 
42 
0.55 
(0.37 to 0.72) 
35 
0.56 
(0.36 to 0.75) 
38 
0.95 
(0.77 to 1.14) 
39 
0.67 
(0.58 to 0.77) 
154 
Sig.  





(0.64 to 1.09) 
14 
0.45 
(0.08 to 0.82) 
15 
0.69 
(0.41 to 0.96) 
13 
0.11 
(-0.16 to 0.39) 
14 
0.54 
(0.38 to 0.69) 
56 
  Sig.   





(-0.03 to 0.84) 
9 
0.75 
(0.34 to 1.15) 
10 
0.53 
(0.19 to 0.86) 
10 
0.43 
(-0.19 to 1.05) 
7 
0.55 
(0.35 to 0.76) 
36 
Non sig.  





(0.46 to 0.75) 
64 
0.56 
(0.42 to 0.71) 
61 
0.65 
(0.5 to 0.81) 
67 
0.63 
(0.46 to 0.8) 
63 
0.62 
(0.54 to 0.69) 
255 
 Non Sig. 
(10.8 crit). 
Quartiles (days) 0 to 33 35 to 111 112 to 172 172 to 452     
Table 5.23: I stratified neurobehavioural outcomes according to the difference 
between age at administration and outcome assessment overall, and by specific 
transgenic model groups. Sufficient data were present to examine APP, APPPS 
and 3xTgAD transgenic groups in further detail. Estimates of efficacy are given 
in standardised effect sizes, brackets give 95% CI and with number of 
experiments. 









Difference between age at intervention and assessment
All transgenic models APP transgenic models
All transgenic models  APP transgenic models
All transgenic models APP transgenic models
Age at outcome assessmet (days)








Difference between age at administration and outcome assessment (days)








Age at administration (days)
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Difference between age at administration and outcome assessment (days)































































































































Age at outcome assessmet (days)
Figure 5.7: I stratified neurobehaviour outcomes according to the age at which 
interventions were administered (a,b), assessed (c,d) and the difference between the 
administration and assessment (e,f). Estimates are given overall and for the most 
commonly tested transgenic group (APP). Bar width represents extremes within each 
quartile, error bars represent 95 % confidence limits and grey bar denotes 95% 
confidence limit of global estimate. 
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5.3 Sex analyses 
 
5.3.1 Pathological outcome measures 
 
I stratified the six pathological outcomes according to the sex of the animal used to 
identify whether data suggested an impact on observed outcomes (Table 5.24). For 
plaque burden I observed higher estimates for males opposed to females however 
this did not account for a significant proportion of the observed heterogeneity (χ2 
=11.0, Figure 5.8a). For amyloid beta 40 outcomes I observed moderately higher 
estimates of efficacy in males opposed to females (χ2 = 10.4, Figure 5.8b) but this did 
not reach statistical significance. For amyloid beta 42, females were associated with 
higher estimates of efficacy (χ2 =18.0 p<0.01, Figure 5.8c).  
 
For tau, estimates of efficacy were higher in females opposed to males and this 
accounted for a significant proportion of the observed heterogeneity (χ2 =46.7 
p<0.01, Figure 5.8d). For outcomes regarding cellular infiltrates, I observed that male 
mice were associated with larger estimates than females (χ2 =148, p<0.01, Figure 
5.8e). Finally, neurodegeneration outcomes were greater in male mice than female 
mice but this did not account for a significant proportion of the observed 
heterogeneity (χ2 =7.0, Figure 5.8f). 
  









5.3.2 Neurobehavioural outcome measures 
 
259 neurobehavioural experiments suggested an overall improvement of 0.59 SD 
([0.60 to 0.77], Table 5.25). Stratifying experiments according to the sex used 
accounted for a significant proportion of the observed heterogeneity (χ2 = 25.4, 
p<0.02, Figure 5.9) where female mice were associated with larger estimates of effect 
opposed to males, 0.79 SD (0.62 to 0.97, [38 experiments]) vs. 0.53 SD (0.35 to 0.70, 
[53 experiments]). For the 79 experiments performed where both sexes were used 
there was an estimated effect of 0.41 SD (0.28 to 0.50). For the 89 experiments 
performed where the sex was unclear the overall effect was 0.76 SD (0.63 to 0.89). 
 
Female 
SMD effect size 
(95 % CI) and N 
Male 
SMD effect size 
(95 % CI) and N 
Both 
SMD effect size 
(95 % CI) and N 
Unknown 
SMD effect size 
(95 % CI) and N 
Total 
SMD effect 







0.65 0.85 1.05 1.07 0.98  
(0.34 to 0.95) (0.42 to 1.28) (0.77 to 1.32) (0.93 to 1.21) (0.87 to 1.1) Non. Sig. 




0.47 0.51 0.56 0.96 0.68  
(0.28 to 0.67) (0.20 to 0.81) (0.34 to 0.77) (0.78 to 1.14) (0.57 to 0.79) Non. Sig . 




0.67 0.55 0.53 1.03 0.78  
(0.44 to 0.9) (0.23 to 0.87) (0.34 to 0.72) (0.87 to 1.2) (0.67 to 0.88) Sig. 
74 48 76 191 389  
Tau 
0.48 0.29 0.96 0.28 0.55  
(0.27 to 0.7) (-0.21 to 0.8) (0.63 to 1.29) (0.04 to 0.53) (0.38 to 0.72) Sig. 
7 7 35 35 84  
Cellular 
infiltrates 
1.23 2.39 0.93 0.04 0.4  
(0.15 to 2.31) (0.62 to 4.17) (0.27 to 1.59) (-0.24 to 0.33) (0.13 to 0.68) Sig 
7 4 16 62 89  
Neuro- 
degeneration 
0.31 0.84 0.92 0.97 0.91  
(-0.27 to 0.9) (0.29 to 1.38) (0.39 to 1.46) (0.73 to 1.22) (0.69 to 1.12) Non.Sig. 
2 4 18 40 64  
Table 5.24: I stratified each pathological outcome according to sex of the animal 
used. Estimates are given in terms of standardised effect size, brackets represent 95% 
confidence limits and N provides the number of experiments 




Figure 5.8: I stratified each pathological outcome (A) plaque burden, (B) amyloid 
beta 40, (C) amyloid beta 42, (D) Tau, (E) Cellular infiltrates and (F) 
neurodegeneration according to sex of the animal used. Bar width represents the 
log of the number of animals, error bars represent 95 % confidence limits and grey 
bar denotes 95% confidence limit of global estimate. 
Plaque burden
Sex






























































































































































































































































































































SMD effect size  
(95 % CI) and N 
Male 
SMD effect size 
(95 % CI) and N 
Both  
SMD effect size 
 (95 % CI) and N 
Unknown  
SMD effect size 
(95 % CI) and N 
Overall 
 SMD effect size 
 (95 % CI) and N 
Critical  χ2 
value  10.8 
df= 4 
0.79 
(0.62 to 0.97) 
38 
0.53 
(0.35 to 0.70) 
53 
0.41 
(0.28 to 0.54) 
79 
0.76 
(0.63 to 0.89) 
89 
0.69 




 Sig.  
  
Figure 5.9: I stratified neurobehavioual outcome according to sex of the 
animal used. Bar width represents the log of the number of animals, error bars 
represent 95 % confidence limits and grey bar denotes 95% confidence limit of 
global estimate. 
 
Table 5.25: I stratified neurobehavioural outcomes according to sex of the animal 
used. Estimates are given in terms of standardised effect size, brackets represent 
95% confidence limits and N provides the number of experiments. 
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5.4 Defining the transgenic model 
 
To add greater depth to our analyses where interventions were tested I identified 
the impact of the transgene itself on pathology and neurobehaviour within control 
transgenic mice.  Datasets used for this approach were not considered 
comprehensive as they have not been identified through a systematic approach. 
Without this approach it is not possible to determine how much of published data 
analyses represent (Figure 5.10). Nevertheless analyses are useful in the respect that 
they represent those control transgenic animal s used within analyses described and 











Figure 5.10: I conducted analyses to improve our understanding of 
transgenic models used in analyses. Such models represent an unknown 
proportion of all available literature but their utility is that such data 
represents those transgenic models used in analyses conducted. 
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5.4.1 Calculating effect sizes to assess the impact of 
transgenes 
 
I first required an estimate of effect in order to assess the impact of transgenes. For 
pathological experiments, the reporting of wild type behaviour was relatively rare 
(<5%), and as I could not impute wild type behaviour this restricted the use of SMD 
to calculated effect sizes. As alternative I used z scores to calculate pathological 
effect sizes, by taking the mean value in the control divided by the calculated 
standard deviation. For neurobehavioural outcomes, 185 of the 259 experiments 
(71.4%) of experiments reported wild type performance and thus I could use SMD 










Percentage of experimental cohorts 
where wild type data are reported 
<5% 71.4% 
For assessing the impact of the transgene 
I calculate effect sizes using: Z scores 
Standardised mean 
difference 
Percentage of total dataset contributing 
to estimates  
100% 71.4% 
Table 5.24 I estimated the impact of the transgene through different methods for 
pathology (z-scores) and behaviour (Standardised mean difference) reflecting 
differences in the reporting of wild type animals. 
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I first summarised the number of studies where there was a comparison between 
transgenic and wild type mice. Sufficient data (≥ 20 experiments) were present to 
investigate outcomes overall, and for a number of outcomes within specific 
transgenic model groups (Table 5.8). As our analyses were focused specifically on 
the transgenic models, I was conscious to take into account differences in the extent 
and severity of pathologies across different transgenes. Therefore, I chose to only 





























































































APP 172* 164* 171* 5 45* 27* 
APPPS 66* 47* 53* 3 20* 10 
3xTgAD 18 22* 20* 35* 1 1 
Tau 0 1 1 14 2 6 
PS1 0 1 1 0 0 0 
Other 4 0 1 4 0 0 
All data 260 235 247 61 68 44 
Table 5.25: The number of experiments which compare transgenic performance 
with wild type performance across each pathological outcome and overall. 
Where there were ≥ 20 experiments data could be taken forward to age specific 
analyses (*). 





For outcomes regarding plaque burden, there were sufficient data to investigate the 
impact of age at outcome assessment for both APP and APPPS groups (Table 5.25). 
For APP models I estimated an overall effect of the transgene on plaque pathology 
of 3.72 (3.09 to 4.35).  Stratifying 170 APP experiments using those quartiles defined 
where interventions were tested did not suggest a particular direction of effect (χ2 
=25.1, p<0.05, 170 comparisons,). 
 
For the APPPS transgenic group, 66 experiments suggested a stronger impact of the 
transgene on plaque pathology, with an overall z score effect of 7.28 (3.51 to 11.05). 
Where I stratified data according to the age at outcome assessment I found higher 
estimates of efficacy at later ages of outcome assessment (χ2 =834, p<0.05, 66 
comparisons, Table 5.26).  
 





  Q1 Q2 Q3 Q4 All quartiles 3.84 
APP 
3.95 
(3 to 4.91) 
37 
3.54 
(2.1 to 4.98) 
43 
3.58 
(2.48 to 4.69) 
45 
3.82 
(2.71 to 4.93) 
45 
3.72 
(3.09 to 4.35) 
170 
 Sig.  
Quartiles (days) 66 to 231 252 to 364 368 to 469 476 to 721     
APPPS 
3.17 
(2.07 to 4.26) 
19 
4.19 







(2.96 to 11.90) 
18 
7.28 
(2.06 to 12.5) 
66 
 Sig.   
Quartiles (days) 65 to 210 211 to 252  266 to 336 364 to 560     
 
  
Table 5.26: I stratified plaque burden outcomes according to the age at outcome 
assessment to assess the impact of the transgene.  Sufficient data were present to 
examine APP and APPPS transgenic groups in further detail. Estimates of efficacy are 
given in z scores, brackets give 95% CI and with number of experiments. 
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Amyloid beta 40 
For amyloid beta 40 outcomes there were sufficient data to examine APP, APPPS 
and 3xTgAD in further detail (Table 5.27). 161 APP experiments suggested a z score 
impact of 6.18 (5.04 to 7.33). I observed an inverse association between the age of 
outcome assessment  and transgene effect (χ2 =593, p<0.05, Table 5.27).  
 
For APPPS transgenic models , 47 experiments suggested the overall impact of 
amyloid beta 40 was 3.67 (3.02 to 4.31). Where I stratified data according to the age 
at assessment I identified smaller extents of amyloid beta 40 were associated with 
later ages of assessment (χ2 =34.5 , p<0.05, Table 5.27). For 3xTgAD, 22 experiments 
suggested an overall effect of 3.18 (1.74 to 4.63). Where I stratified such data I 
identified an inverse relationship between age and the degree of amyloid beta 40 
pathology (χ2 =72.1, p<0.05, Table 5.27).   
 





  Q1 Q2 Q3 Q4 All quartiles 3.84 
APP 
8.33 
(5.10 to 11.56) 
20 
7.50 
(4.83 to 10.2) 
46 
6.59 
(4.21 to 8.98) 
47 
3.62 
(2.46 to 4.30) 
48 
6.18 
(5.04 to 7.33) 
161 
  Sig.  
Quartiles (days) 51 to 113 115 to 290 308 to 406  413 to 714     
APPPS 
5.14 
(3.25 to 7.03) 
10 
3.25 
(2.00 to 4.50) 
12 
3.94 
(2.88 to 4.99) 
11 
2.74 
(1.86 to 3.61) 
14 
3.67 
(3.02 to 4.31) 
47 
 Sig.   
Quartiles (days) 56 to 112 120 to 210 224 to 300 301 to 672     
3xTgAD 
4.33 
(-1.30 to 9.96) 
5 
3.82 
(2.43 to 5.21) 
5 
2.66 
(1.20 to 4.13) 
6 
2.28 
(1.69 to 2.87) 
6 
3.18 
(1.74 to 4.63) 
22 
Sig.   




Table 5.27: I stratified amyloid beta 40 outcomes according to the age at outcome 
assessment to assess the impact of the transgene.  Sufficient data were present to 
examine APP and APPPS transgenic groups in further detail. Estimates of efficacy are 
given in z scores, brackets give 95% CI and with number of experiments. 
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Amyloid beta 42 
 
For amyloid beta 42 outcomes there were sufficient data to examine APP, APPPS 
and 3xTgAD in further detail (Table 5.28). 169 APP experiments suggested a z score 
impact of 5.67 (4.55 to 6.79). I stratified data and identified that later ages of outcome 
assessment were associated with lower estimates of impact (χ2 =173, p<0.05, Table 
5.28). 
 
Overall I estimated the amyloid beta 42 impact within APPPS transgenes at 4.50 
(3.51 to 5.49) from 53 experiments. Where I stratified APPPS data according to the 
age at outcome assessment I found this accounted for a significant proportion of the 
observed heterogeneity the overall relationship remained unclear (χ2 =73.0, p<0.05, 
Table 5.28). For 20 3xTgAD experiments the overall impact was 3.76 (2.69 to 4.84) 
and stratification suggested an inverse relationship between age at outcome 
assessment and transgene effect (χ2 =54.0, p<0.05, Table 5.28). 
 
  





  Q1 Q2 Q3 Q4 All quartiles 3.84 
APP 
6.86 
(4.55 to 9.18) 
31 
6.66 
(3.15 to 10.17) 
45 
5.15 
(3.90 to 6.40) 
51 
4.35 
(3.29 to 5.40) 
42 
5.67 
(4.63 to 6.71) 
169 
  Sig.  
Quartiles (days) 42 to 141 142 to 308 317 to 413 420 to 714    
APPPS 
4.02 
(2.70 to 5.35) 
11 
5.97 
(3.19 to 8.74) 
15 
4.95 
(2.89 to 7.01) 
12 
2.99 
(2.11 to 3.88) 
15 
4.50 
(3.51 to 5.49) 
53 
  Sig.  
Quartiles (days) 56 to 112 120 to 224 231 to 300 301 to 627    
3xTgAD 
5.72 
(2.37 to 9.07) 
5 
4.45 
(2.09 to 6.82) 
3 
3.38 
(2.01 to 4.76) 
2 
2.25 
(1.66 to 2.84) 
10 
3.76 
(2.69 to 4.84) 
20 
  Sig.  
Quartiles (days) 112 to 168 210 to 252 336 to 448 450 to 672    














35 experiments reported tau outcomes within the 3xTgAD group and overall, the z- 
score estimated impact was 8.77 (5.72 to 11.82) where there was considerable 
heterogeneity present (χ2 =9913). When I stratified data according to the age at 
outcome assessment I found that this accounted for a significant proportion of the 
observed heterogeneity but the overall relationship was unclear (Table 5.29, χ2 











44 cellular infiltrate experiments were reported from the APP transgenic group and 
I estimated an overall z score effect size of 4.53 (3.59 to 5.46). I stratified data 
according to the age at outcome assessment and found that this explained a 
  Quartiles 
df=3 
α=0.05 
Critical  χ2 
value 
  Q1 Q2 Q3 Q4 All quartiles 3.84 
3xTgAD 
6.23 
(2.95 to 9.51) 
10 
4.31 
(2.17 to 6.44) 
6 
20.04 
(8.26 to 31.83) 
9 
3.79 
(2.38 to 5.2) 
10 
8.77 
(5.72 to 11.82) 
35 
 Sig.  
Quartiles (days) 120 to 231 252 to 336 339 to 381  420 to 672     
Table 5.28 (previous page): I stratified amyloid beta 42 outcomes according to the age at 
outcome assessment to assess the impact of the transgene.  Sufficient data were present 
to examine APP and APPPS transgenic groups in further detail. Estimates of efficacy are 
given in z scores, brackets give 95% CI and with number of experiments. 
Table 5.29: I stratified tau outcomes according to the age at outcome assessment to 
assess the impact of the transgene.  Sufficient data were present to examine the 
3xTgAD in further detail. Estimates of efficacy are given in standardised effect sizes, 
brackets give 95% CI and with number of experiments. 
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significant proportion of the observed heterogeneity, although it was difficult to 
determine relationships (χ2 =218, p<0.05, Table 5.30). 
 
 
  Quartiles 
df=3 
α=0.05 
Critical  χ2 
value 
  Q1 Q2 Q3 Q4 All quartiles 3.84 
APP 
5.13 
(3.34 to 6.92) 
13 
4.68 
(3.31 to 6.05) 
10 
2.89 
(1.79 to 3.98) 
12 
5.67 
(2.91 to 8.42) 
9 
4.53 
















26 experiments were performed in APP transgenic mice which had an estimated 
overall effect of 4.89 (3.50 to 6.29).  Stratifying data according to the age at outcome 
assessment explained a significant proportion of the observed heterogeneity (χ2 =137, 
p<0.05, Table 5.31) where there was a moderate association between increasing 











  Q1 Q2 Q3 Q4 All quartiles 3.84 
APP 
5.57 
(3.33 to 7.82) 
10 
3.07 
(1.49 to 4.66) 
6 
4.24 
(-0.22 to 8.7) 
5 
6.41 
(4.27 to 8.54) 
5 
4.89 
(3.5 to 6.29) 
26 
 Sig.  
Quartiles (days) 112 to 252 260 to 364 371 to 493  504 to 630     
Table 5.30: I stratified APP outcomes according to the age at outcome assessment to 
assess the impact of the transgene.  Estimates of efficacy are given in standardised 
effect sizes, brackets give 95% CI and with number of experiments. 
Table 5.31: I stratified neurodegeneration outcomes from APP control mice according 
to the age at outcome assessment to assess the impact of the transgene.  Estimates of 
efficacy are given in standardised effect sizes, brackets give 95% CI and with number 
of experiments. 
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5.4.3 Defining the neurobehavioural deficits within transgenic 
models 
 
Similar to pathological outcomes, I first summarised how many comparisons 
between wild type and transgenic cohorts (Table 5.32). Sufficient data were present 
within the APP (67 experiments), APPPS (40 experiments) and 3xTgAD (25 
experiments in order to permit further analysis. In order to inform these analyses 
further, I plotted estimates of effect size according to the age at assessment as shown 


























All data 140 
Table 5.32 I summarised the number of experiments which compare transgenic 
neurobehavioural performance with wild type performance overall and within 
each transgenic model group. Where there were >20 experiments data could be 
taken forward to age specific analyses(*). 
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Age at assessment (days)

















































































Figure 5.11: To illustrate the spread of the data I plotted the impact of the 
transgene (standardised effect size) against the age at outcome assessment 
(days) according to the transgenic group used 




For APP experiments I took forward 66 experiments (therefore excluding 1 
experiment) where I could identify the age at assessment and calculated an overall 
impact of 1.12 SD (0.97 to 1.27). Stratification of estimates by the age at outcome 
assessment did not prove significant (χ2 =3.17, p<0.05, Table 5.33). APPPS 
experiments suggested an overall impact of the transgene of 0.68 SD (0.51 to 0.84) 
and stratification proved statistically significant (χ2 =15.0, p<0.05, Table 5.33).  For 
3xTgAD models, I estimated an effect of 1.22 SD (0.90 to 1.53) and while 
stratification did account for a significant proportion of heterogeneity (χ2 =18.5, 
p<0.05, Table 5.33) this was not reflected by a relationship between transgene effect 











NBS data Q1 Q2 Q3 Q4 All quartiles 3.84 
APP 1.23 1.15 0.9 1.14 1.14 
Non sig   (0.95 to 1.51) (0.73 to 1.57) (0.72 to 1.09) (0.72 to 1.09) (0.86 to 1.41) 
  22 17 13 14 66 
Quartiles (days) 56 to 172  173 to 315 332 to 445 448 to 721    
APPPS 0.94 0.53 0.85 0.57 0.68 
Sig.   (0.73 to 1.16) (0.29 to 0.77) (0.33 to 1.36) (0.23 to 0.91) (0.52 to 0.84) 
  7 13 8 12 40 
Quartiles (days) 84 to 224 227 to 268 280 to 322 336 to 547    
  1.47 1.04 0.96 1.46 1.22 
Sig 3xTgAD (1.09 to 1.86) (0.54 to 1.55) (0.14 to 1.78) (0.81 to 2.11) (0.9 to 1.53) 
  5 7 6 7 25 
Quartiles (days) 117 to 201 230 to 345 421 to 486 508 to 656     
Table 5.33: I summarise the number of experiments which compare transgenic 
neurobehavioural performance with wild type performance specific for each transgenic 
group and overall. Where there were >20 experiments data could be taken forward to age 
specific analyses. 




5.4.4 Quantifying the impact of transgene, pathology and 
neurobehaviour 
 
In order to establish whether sufficient data were present to explore potential 
relationships between pathology and neurobehaviour in transgenic control animals 
I summarised data were both outcomes were observed. Overall, I identified 82 
experiments where I could estimate the effect of transgenic for both pathology and 
neurobehaviour. Where I performed meta-regression on such data I observed that 
changes in pathology could explain 11.0% of changes in neurobehaviour (Figure 
5.12).  More specifically I had sufficient data to investigate relationships within APP 












Figure 5.12: I performed meta-regression on the 82 experiments where I could 
estimate the impact of transgenes on pathology and neurobehaviour.  Each 
symbol represents a single experiment and size denotes the inverse variance 
(and therefore weight in analysis). 
Transgenic control animals: Relationship between 
















Where I examined APP mice, I identified a strong positive correlation between 
changes in pathology and neurobehaviour, while I also observed a correlation 
between changes observed in APPPS mice, this did not prove statistically significant 






















All data 82 
Table 5.34: I summarised the number of experiments where I could estimate the 
impact of transgenes on neurobehaviour and pathology overall, and within specific 
transgenic groups. Where there were >20 experiments data could be taken forward 
to age specific analyses. 
Relationship between pathology and neurobehaviour in control transgenic animals 






























Changes in pathology vs. NB 
across all transgenic models 
0.05 0.018 2.77 0.007 0.014 0.087 82 0.11 
Changes in pathology vs. NB in 
APP transgenic models 
0.101 0.023 4.5 0 0.056 0.147 43 0.44 
Changes in pathological vs. NB 
in APPPS transgenic models 
0.027 0.036 0.73 0.472 -0.048 0.102 28 -6.43 
Figure 5.13 (previous): I performed meta-regression on the both APP and APPPS 
transgenic mice where I could estimate the impact of transgenes on pathology and 
neurobehaviour.  Each symbol represents a single experiment and size denotes 
the inverse variance (and therefore weight in analysis). 
Table 5.35: Meta-regression comparing probe phase with acquisition curves, first  
and last time point of acquisition curve and sections in-between. For each 
comparison co-efficient is given, standard error, tau (τ), significance level, 95% 
confidence limits, number of experiments (N) and Adjusted R2 (Adj. R2)  
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5.5 Interpreting transgenic model analyses  
 
5.5.1 Summary of findings  
 
Within this chapter, analyses identified a number of associations between age and 
intervention effect, however interpretation must be made cautiously as there were 
few common trends that proved statistically significant.  
 
For amyloid related outcomes (plaque burden, amyloid beta 40 and 42) I found 
smaller effect sizes associated with later ages of administration and assessment (i.e. 
APP and APPPS mice) suggesting that early intervention could improve observed 
outcomes. Where I assessed age of assessment on the pathological impact of the 
transgene, data suggested that the extent of amyloid beta 40 and 42 lessens over 
time whereas plaque burden becomes more extensive. 
 
For tau, the overall relationship between the age of animals and intervention effect 
was unclear at the overall level and at the transgenic model group level. Further, 
where I assessed control mice for the impact of the transgene there was no specific 
associations identified. For cellular infiltrates perhaps the most interesting  
result was regarding the age at outcome assessment, where later ages were 
associated with smaller effects for (data  overall and within the APP group). 
However, no specific relationships were suggested within our transgene analysis.  
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For neurodegeneration outcomes intervention analyses did not suggest a particular 
direction of effect, but where I inspected the impact of the transgene there was a 
modest increase in the severity for APP mice at later ages of assessment. 
 
For sex analyses, males had higher estimates of efficacy for four out of six 
pathological outcomes but these were frequently marginal, and there was consistent 
overlapping of 95% confidence limits with female mice. Perhaps a more notable 
concern was that 50% (699/1392) of experiments did not state the sex of the animal 
used. For neurobehavioural outcomes female transgenic mice were associated with 
greater improvements than males however where both males and females were 
assessed estimated of effect were considerably smaller, which weakens the strength 
of this hypothesis.   
 
Across age related analyses it is a consideration that the age at outcome assessment, 
duration of treatment or length of follow up may not be entirely independent 
variables. For example the length of treatment possible will be at times determined 
by how long the animal lives (i.e. the age at outcome assessment).Thus the 
interdependency between age at outcome assessment and length of treatment 
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5.5.2 Implications of findings 
 
Stratifying data into inter-quartile ranges did not identify many definitive 
relationships, and where relationships were observed these were frequently specific 
to individual transgenic model groups. Nonetheless, there were a number of 
outcomes where increasing age was associated with difference in effect size (such as 
neurodegeneration and age at intervention administration). Therefore such 
differences reiterate the need for experiments to be performed most reflective of the 
clinical conditions in which it is proposed they will be tested. 
 
The lack of reporting of the sex of the animals used in these studies is concerning 
considering that numerous differences have been identified between different 
transgenic lines. While this limits the statistical power of our analyses to identify 
differences I did find differences between the sex used. Therefore the empirical data 
suggest that identifying (and reporting) efficacy across both male and female mice 
may improve the external validity of findings. 
 








Where I examined the impact of transgenes on pathology there was a suggestion 
that the shift in amyloid over time results in a decrease of amyloid species at the 
same time that plaque burden increases. While this offers a hypothesis of model 
development it is not conclusive. Perhaps the most interesting finding is that 
variation in pathology can only explain 11% of variation in neurobehaviour. This 
value is smaller than the changes observed where interventions are tested. While a 
greater dataset would provide a statistically more powerful analysis I have 
demonstrated the feasibility of this approach. 
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Chapter 6 Intervention specific analyses 
 
Each of the publications included in this review performed experiments to ascertain 
the impact of a given intervention within transgenic models of Alzheimer’s disease. 
From the 427 publications, 357 individual intervention strategies were described 
and I provide estimates of efficacy across pathology and behaviour.  Overall, I 
identified 273 interventions which assessed changes in pathological outcomes, 
whereas 107 interventions assessed changes in neurobehaviour. I estimated that 24 
% (84/357) of interventions were assessed in more than one transgenic model. 
 
To improve our understanding of data regarding individual interventions, where 
outcomes are reported from the most frequently reported interventions (> 5 
publications), I summarised these in greater detail. Additionally, where data permit 
I inspect individual interventions and intervention groups.  
6.1 Interventions reported in 5 or more publications 
 
There were 16 interventions reported in five or more publications and I derived 
estimates of efficacy for each of the pathological outcomes; plaque burden, amyloid 
beta 40, amyloid beta 42, tau, cellular infiltrates and neurodegeneration (Table 6.1). I 
also summarise data regarding neurobehavioural outcomes where I describe 
analyses for neurobehaviour overall, and for the acquisition and probe phase of the 
MWM alongside other behavioural paradigms used. 
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Figure 6.1: Interventions examined in five or more publications are 
stratified according to plaque burden estimates of effect size. Error bars 
represent 95% confidence limits and grey bar represents the 95% confidence 
limit across all interventions, symbol size represents the log of the number 
of animals. Grey bar represents 95% CI across all interventions 
Improvement in pathology (standardised effect size)

































































































6.1.1 Plaque burden 
 
Within the 16 most commonly reported interventions, all 16 assessed changes in 
plaque burden (Table 6.1). Antibody 3d6 was associated with larger estimates of 
effect size where two experiments suggested a reduction of 2.24 SD (1.14 to 3.33)  
The one study which assessed the impact of aluminium suggested a worsening of 
outcome with an effect size of -1.27 SD (-2.07 to -0.47). Across all interventions and 
outcomes tested, the assessment of plaque burden after treatment with amyloid beta 
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Figure 6.2: Interventions which were examined in five or more publications are 
stratified according to amyloid beta 40 estimates of effect size. Error bars represent 
95% Confidence limits of summary estimate and symbol size represents the log of 
the number of animals. Grey bar represents 95% CI across all interventions  
Improvement in pathology (standardised effect size)

























































































6.1.2 Amyloid beta 40 
 
Within the 16 most commonly reported interventions, 15 assessed changes in 
amyloid beta 40 (Figure 6.2). Of 22 LY-411575 experiments, all 22 examined changes 
in amyloid beta 40 levels. Such studies were associated with the largest effect size 
within this group and amyloid beta 40 was reduced by 2.15 SD (1.43 to 2.87). 
Conversely, the use of lipopolysaccharide (LPS) was associated with a worsening of 
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Improvement in pathology (standardised effect size)


























































































6.1.3 Amyloid beta 42 
 
Interestingly, while all 22 LY-411575 experiments assessed amyloid beta 40 levels 
only 9 experiments estimated the effect on amyloid beta 42 where there was an 
overall improvement of 1.67 SD (0.78 to 2.56). Significantly higher estimates of 
efficacy were associated with the use of lithium, which was reduced amyloid beta 42 
by 5.40 SD (2.84 to 7.95).  In accordance with changes in amyloid beta 40, LPS was 









Figure 6.3: Interventions which were examined in five or more publications 
are stratified according to amyloid beta 42 estimates of effect size. Error bars 
represent 95% Confidence limits of summary estimate and symbol size 
represents the log of the number of animals.  Grey bar represents 95% CI 
across all interventions 
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Figure 6.4: Interventions which were examined in five or more publications are 
stratified according to tau estimates of effect size. Error bars represent 95% 
Confidence limits of summary estimate and symbol size represents the log of 
the number of animals. Grey bar represents 95% CI across all interventions. 
6.1.4 Tau 
 
Seven of the 16 most commonly reported interventions reported tau outcomes 
however data were limited (mode 1, Table 6.1). Of the seven interventions, only 
lithium and ibuprofen were associated with an improvement of tau pathologies. 
Higher estimates of efficacy were associated with lithium where 9 experiments 
suggested a reduction the extent of tau pathology by an estimated 0.97 SD (0.51 to 
1.42). Neprilysin and LPS both suggested a worsening of outcome and although 
data were limited (1 experiment for each), nicotine also suggested a worsening of 
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6.1.5 Cellular infiltrates 
 
Within the 16 most commonly reported outcomes, 10 interventions reported 
changes in cellular infiltrates. Cerebrolysin was associated with the greatest 
reduction of cellular infiltrates with an estimated effect size of 1.05 SD (0.17 to 1.93) 
although data were limited (2 experiments). Conversely, one experiment which 
assessed the impact of antibody 10d5 suggested an increase in cellular infiltrates of -





























Figure 6.5: Interventions which were examined in five or more publications 
are stratified according to cellular infiltrates estimates of effect size. Error bars 
represent 95% Confidence limits of summary estimate and symbol size 
represents the log of the number of animals.  Grey bar represents 95% CI 
across all interventions 
 
Improvement in pathology (standardised effect size)
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Figure 6.6: Interventions which were examined in five or more publications 
are stratified according to neurodegeneration estimates of effect size. Error 
bars represent 95% Confidence limits of summary estimate and symbol size 
represents the log of the number of animals.  Grey bar represents 95% CI 




Twelve of the 16 most frequently reported interventions assessed changes in 
neurodegeneration. Antibody 3d6 was associated with the greatest improvement in 
neurodegeneration, with an effect size of 1.80 SD (1.08 to 2.52). Smaller effect sizes 
were associated with Memantime where the overall estimate across 4 experiments 
crossed the line of no effect 0.12 SD (-0.44 to 0.68). Interestingly, while 55 
experiments investigated the use of amyloid beta 42 overall, only 1 experiment 
examined neurodegeneration outcomes where there was an overall improvement of 
1.22 SD (0.39 to 2.04). 
 
  
Improvement in pathology (standardised effect size)
















































































SMD Effect size 
(95 % CI) and N 
Amyloid beta 
40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 
42 
SMD Effect size 
(95 % CI) and N 
TAU 
SMD Effect size 









SMD Effect size 
(95 % CI) and N 
A beta 1-42 1.49 1.48 1.07 0.21 0.99 1.22 
55 experiments (1.18 to 1.80) (0.81 to 2.15) (0.71 to 1.42) (-0.06 to 0.48) (-0.19 to 2.17) (0.39 to 2.04) 
 42 20 28 5 6 1 
LY-411575 1.68 2.15 1.67       
22 experiments (1.15 to 2.21) (1.43 to 2.87) (0.78 to 2.56) No data No data No data 
 1 22 9       
Lithium 3.83 1.48 5.40 0.97   1.26 
15 experiments (-2.19 to 9.86) (-1.5 to 4.45) (2.84 to 7.95) (0.51 to 1.42) No data (-0.03 to 2.55) 
 2 2 7 9   1 
Envir. Enrich 0.4 -0.45 -0.39 0.1 -0.84 0.35 
12 experiments (-0.18 to 0.97) (-1.72 to 0.82) (-1.66 to 0.88) (-0.7 to 0.9) (-1.4 to -0.27) (-0.49 to 1.19) 
 9 5 5 1 1 1 
Antibody 10d5 1.74 0.16 0.14   -1.96 0.82 
10 experiments (0.8 to 2.67) (-0.51 to 0.83) (-0.53 to 0.81) No data (-6.08 to 2.17) (-1.26 to 2.89) 
 8 1 1   1 2 
LPS 0.89 -0.48 -0.32 -0.94 -1.48   
10 experiments (0.16 to 1.63) (-1.19 to 0.23) (-1.02 to 0.38) (-2.1 to 0.22) (-2.07 to -0.9) No data 
 9 1 1 1 2   
Ibuprofen 1.09 0.40 0.21 0.86 0.77 0.85 
9 experiments (0.70 to 1.49) (-0.17 to 0.98) (-0.31 to 0.74) (0.07 to 1.64) (-0.02 to 1.56) (0.29 to 1.4) 
 5 5 6 1 4 1 
Cerebrolysin 1.24 0.23 0.88   1.05 1.05 
8 experiments (0.78 to 1.7) (-0.91 to 1.37) (-0.33 to 2.1) No data (0.17 to 1.93) (0.56 to 1.55) 
 8 1 1   2 5 
Exercise 0.54 0.71 1.08   -0.79 0.92 
8 experiments (-0.39 to 1.46) (-0.1 to 1.52) (-0.24 to 2.39) No data (-1.4 to -0.18) (-0.37 to 2.22) 
 4 2 4   1 2 
Flurbiprofen 0.89 0.21 0.13       
8 experiments (-0.74 to 2.52) (0 to 0.42) (-0.09 to 0.35) No data No data No data 
 2 8 8       
Nicotine 1.28 1.14 1.39 -1.39 0.53 0.7 
7 experiments (0.1 to 2.46) (0.52 to 1.76) (0.46 to 2.33) (-2.42 to -0.35) (0.06 to 1) (-0.25 to 1.65) 
 4 7 7 1 1 3 
Neprilysin 0.99 0.91 1.3 -0.81 0.67 0.78 
6 experiments (0.37 to 1.6) (0.54 to 1.28) (-0.21 to 2.82) (-1.54 to -0.08) (-0.37 to 1.71) (0.05 to 1.51) 
 5 2 2 1 2 1 
A beta 1-15 1.48 0.02 0.15       
5 experiments (0.76 to 2.19) (-0.4 to 0.43) (-0.25 to 0.55) No data No data No data 
 5 4 5       
Memantine 1.54 0.86 0.33   0.83 0.12 
5 experiments (0.94 to 2.15) (-0.72 to 2.43) (-1.67 to 2.33) No data (0.28 to 1.39) (-0.44 to 0.68) 
 4 1 1   1 4 
Aluminium -1.27 -0.21 0.05     0.26 
4 experiments (-2.07 to -0.47) (-1.77 to 1.35) (-1.42 to 1.52) No data No data (-0.24 to 0.75) 
 1 3 3     2 
Antibody 3d6 2.24   1.72     1.8 
1 experiment (1.14 to 3.33) No data (0.72 to 2.72) No data No data (1.08 to 2.52) 













Table 6.1 (previous page): The sixteen most commonly tested interventions were 
assessed for their ability to reduce the most commonly reported pathological 
features of Alzheimer’s disease: plaque burden, amyloid beta 40, amyloid beta 
42, tau, cellular infiltrates and neurodegeneration. Effect sizes are given in 
standardised effect size, brackets give 95% confidence limits and number of 







For neurobehavioural outcomes, I first derived estimates for the sixteen most 
commonly tested interventions collectively across the most commonly used 
paradigms. To account for potential differences in paradigms used I then 
summarise intervention data for the acquisition phase of the Morris water maze, the 
probe phase of the Morris water maze and other behavioural paradigms separately.  
Summaries follow this order to reflect the lesser need to demonstrate 
neurobehavioural improvements by individual outcomes (the need is greater for 
pathological outcomes where targeting specific molecular structures may be 
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Figure 6.7: Interventions with outcomes reported in five or more publications 
were stratified according to overall neurobehavioural estimates of effect size. 
Error bars represent 95% Confidence limits of summary estimate and symbol 
size represents the log of the number of animals. Environmental enrichment 
(Env. Enrich) 
6.1.7 All neurobehavioural outcomes 
 
For neurobehavioural data overall, 13 out of the 16 most commonly assessed 
interventions reported behavioural outcomes (Table 6.2 for overview). Within such 
studies neprilysin was associated with larger effect sizes of 1.36 SD (0.52 to 2.20, 
Figure 6.6) however such estimates were based only two experiments. Interestingly, 
Memantime (which is clinical use) was associated with only a modest benefit in 
behaviour of 0.28 SD (-0.03 to 0.58). The most commonly assessed neurobehavioural 
intervention overall was amyloid beta 1-42 which featured in 23 experiments and 







Improvement in neurobehaviour (standardised effect size)













































































All neurobehavioural data  
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Figure 6.8: Interventions with outcomes reported in five or more publications 
were stratified according to overall  performance in the acquisition phase of 
the Morris water maze (MWM). Error bars represent 95% Confidence limits of 
summary estimate and symbol size represents the log of the number of 
animals. Environmental enrichment (Env. Enrich)  
Improvement in neurobehaviour (standardised effect size)









































































Acquisition phase of the MWM
6.1.8 Acquisition phase of the MWM 
 
Within the most commonly reported interventions twelve reported outcomes within 
the acquisition phase of the MWM (Figure 6.8). Lithium was associated with the 
greatest estimates of effect size of 1.67 SD (0.68 to 2.65, [1 experiment]) whereas the 
use of aluminium was associated with effect sizes which crossed the line of no effect 
0.26 SD (-0.72 to 1.25, [1 experiment]). Memantine, which crossed the line of no 
effect for neurobehaviour overall, was associated with significant improvements of 
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Figure 6.9 : Interventions with outcomes reported in five or more publications 
were stratified according to overall performance in the probe phase of the 
Morris water maze (MWM). Error bars represent 95% Confidence limits of 
summary estimate and symbol size represents the log of the number of 
animals  
Improvement in neurobehaviour (standardised effect size)
































































Probe phase of the MWM
6.1.9 Probe phase of the MWM 
 
Eleven out of the sixteen most commonly reported data from the probe phase of the 
Morris water maze. Amyloid beta 1-15 was associated with the greatest estimates of 
effect size  (1.61 [-0.19 to 3.42], 3 experiments)whereas lithium was associated with a 
modest worsening of outcome (-0.04 (-0.85 to 0.76 [1 experiment]). The most 
commonly reported outcome was amyloid beta 1-42 which featured in 13 
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Figure 6.10: Interventions with outcomes reported in five or more publications 
were stratified according to overall performance across the novel object 
recognition task, fear conditioning, radial am water maze and T/Y maze. Error bars 
represent 95% Confidence limits of summary estimate and symbol size represents 
the log of the number of animals. 
Improvement in neurobehaviour (standardised effect size)
















































6.1.10 Other neurobehavioural data 
 
Seven of the 16 most commonly reported interventions were tested in the RAWM or 
NORT, Fear conditioning or T/Y maze. While data were more limited overall, I 
derived estimates of efficacy and found lower estimates of effect size with lithium of 
0.03 SD (-0.85 to 0.90), [1 experiment]. Amyloid beta 1-15 was associated with 
greater effect sizes of 2.46 SD (0.10 to 4.82).  Similar to the acquisition and probe 
phase of the MWM, the greatest number of experiments were performed on 
amyloid beta 1-42 (7 experiments) which was associated with an improvement of 
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Table 6.2 The sixteen most commonly tested interventions summarised for their 
ability to improve overall neurobehaviour and more specifically, the acquisition and 
probe phase of the Morris water maze (MWM) and other neurobehavioural 
paradigms. Effect sizes are given in standardised effect size, brackets give 95% 
confidence limits and number of experiments.  
Drug 
Acquisition 
SMD Effect size 
(95 % CI) and N 
Probe 
SMD Effect size 
(95 % CI) and N 
Other NBS 
SMD Effect size 
(95 % CI) and N 
Combined 
SMD Effect size 
(95 % CI) and N 
A beta 1-42 
0.63 
(0.32 to 0.94) 
15 
0.88 
(0.53 to 1.24) 
13 
0.62 
(-0.14 to 1.38) 
7 
0.72 




(0.04 to 0.78) 
5 
0.26 
(-0.15 to 0.67) 
4 
0.24 
(-0.45 to 0.93) 
4 
0.28 





(0.35 to 1.17) 
6 
0.79 
(0.22 to 1.36) 
7 
1.37 
(0.96 to 1.78) 
7 
0.94 




(-0.09 to 1.51) 
2 
0.24 
(-0.56 to 1.04) 
4 
0.44 
(-0.12 to 1) 
4 
0.44 
(0.01 to 0.86)  
8 
A beta 1-15 
0.98 
(-0.41 to 2.37) 
3 
1.61 
(-0.19 to 3.42) 
3 
2.46 
(0.1 to 4.82) 
1 
1.60 








No data  
 
0.66 




(-0.15 to 0.68) 
3 
1.60 
(1.13 to 2.07) 
3 
No data  
 
0.86 




(0.11 to 3.21) 
1 
0.79 
(0.32 to 1.26) 
3 
1.41 
(0.62 to 2.19) 
1 
1 
(0.61 to 1.39)  
3 
Flurbiprofen No data  
 
0.19 
(-0.17 to 0.56) 
2 
No data  
 
0.19 




(0.68 to 2.65) 
1 
-0.04 
(-0.85 to 0.76) 
1 
0.03 
(-0.85 to 0.9) 
1 
0.41 




(-0.16 to 1.92) 
1 
1.41 
(0.62 to 2.2) 
2 
No data  
 
1.36 




(-0.72 to 1.25) 
1 
0.01 
(-0.68 to 0.71) 
1 
No data  
 
0.09 




(0.39 to 2.24) 
1 
No data  
 
No data  
 
1.32 




No data  
 
 
No data  
 
 
No data  
 
 




No data  
 
 
No data  
 
 
No data  
 
 




No data  
 
 
No data  
 
 
No data  
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6.2 Analyses regarding individual interventions or 
intervention groups 
 
One advantage of systematic review techniques is the ability to empirically quantify 
the impact of intervention administration study design characteristics such as; the 
dose, number of administrations or route of administration used. However, within 
those interventions which report outcomes in 5 or more publications there were 
generally insufficient data (or detail) to perform such analyses (Table 6.2). Where I 
was able to analyse data was where amyloid fragments had been used as an active 
immunisation strategy. 
 
For active immunisation using amyloid beta fragments there were a number of 
different variations of amyloid experiments used (e.g. gene or peptide, specific 
fragment of amyloid). From our summaries in Chapter 3 I concluded that the 
method of modification of active immunisation fragments was too varied to permit 
reliable analysis to assess whether the different modifications made to amyloid 
fragments are associated with differences in observed efficacy. Sufficient data were 
present I investigated the active immunisation dataset further to address: (i) 
whether I observe differences in efficacy between gene and peptide immunisation 
and (ii) whether N terminal fragments perform better than amyloid beta 1-42 . 
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6.2.1 Dose analyses 
 
 
Intervention Dose Unit     Total 
A beta 1-42 1 ul/350 uM 1 
  35 ul/350 uM 1 
  100 µg 1 
   mg 2 
  200 µg 1 
  Unknown   49 
A beta 1-42 Count    55 
LY-411575 0.1 mg/kg/day 2 
  0.3 mg/kg/day 2 
  1 mg/kg/day 3 
  3 mg/kg/day 3 
  10 mg/kg/day 11 
  25 mg/kg/day 1 
LY-411575 Count    22 
Lithium 1.98 g/kg 1 
  2 LICL/kg 3 
  2.4 mg/kg/day 1 
  10 microlitres per gram 1 
  20 mg/kg/day 1 
  60 mg/kg/day 1 
  200 mg/kg/day 1 
  300 mg/kg/day 3 
  600 mg/kg/day 1 
  Unknown   2 
Lithium Count    15 
Environmental Enrichment Unknown   12 
Environmental Enrichment Count   12 
Antibody 10d5 10 mg/kg/week 2 
  Unknown   8 
Antibody 10d5 Count    10 
LPS 0.5 mg/kg 1 
  4 ug/ul 2 
  10 ug 3 
  25 mg/kg 2 
  Unknown   2 
LPS Count    10 
Ibuprofen 40 mg/kg/day 1 
  50 mg/kg/day 2 
  56 mg/kg/day 1 
  62.5 mg/kg/day 2 
  375 ppm 3 
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Intervention Dose Unit     Total 
Ibuprofen Count    9 
Cerebrolysin 4 mg/kg 1 
  5 mg/kg 2 
   ml/kg 5 
Cerebrolysin Count    8 
Exercise 2520 mins 1 
  4850 mins 1 
  Unknown   6 
Exercise Count    8 
Flurbiprofen 10 mg/kg/day 4 
  25 mg/kg/day 2 
  50 mg/kg/day 1 
  100 mg/kg/day 1 
Flurbiprofen Count    8 
Nicotine 0.42 mg/kg 2 
  30 mg/kg 1 
  195 ug/day 1 
  200 ug/mL 2 
  490 ug/mL 1 
Nicotine Count    7 
Neprilysin 0.6 µl 2 
  2 µl 1 
  3 µl 1 
  4 µl 1 
  15000000 TU 1 
Neprilysin Count    6 
A beta 1-15 Unknown   5 
A beta 1-15 Count    5 
Memantine 5 mg/kg/day 1 
  10 mg/kg/day 3 
  20 mg/kg/day 1 
Memantine Count    5 
Aluminium 0.09 mg/g 2 
  2 mg/kg/diet 1 
  17 mg/kg/day 1 
Aluminium Count    4 
Antibody 3d6 10 mg/kg/week 1 
Antibody 3d6 Count    1 
 
Table 6.2: From the most commonly tested interventions, there were too few 
experiments to power analyses into examining the impact of dose across any 
outcome. Data described represents intervention dose and individual 
experiments conducted.    
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6.2.2 Active immunisation analyses 
 
I stratified individual pathological outcomes according to whether active 
immunisation experiments were performed using amyloid peptides or genes. Our 
analyses suggested that active immunisation strategies successfully reduced the 
extent of plaque burden, amyloid beta 40 and 42, neurodegeneration and 
neurobehaviour in transgenic animals. I observed significantly smaller estimates of 
effect size using peptides for plaque burden, amyloid beta 40, amyloid beta 42 and 
neurodegeneration. For cellular infiltrates both estimates crossed the line of no effect 




SMD Effect size 
(95 % CI) and N 
Gene 
SMD Effect size 
(95 % CI) and N 
Global 
SMD Effect size 




0.98 1.91 1.24  
(0.75 to 1.2) (1.43 to 2.39) (1.02 to 1.46) 160.3 
54 25 79 Sig. 
Amyloid beta 40 
 
0.55 2.09 0.83  
(0.51 to 1.14) (1.02 to 2.42) (0.65 to 1.12) 86.6 
30 12 42 Sig. 
Amyloid beta 42 
 
0.69 1.72 0.88  
(0.47 to 0.92) (1.02 to 2.42) (0.65 to 1.12) 93.8 
42 16 58 Sig. 
Tau 
0.26 0.29 0.28  
(-0.07 to 0.59) (-0.2 to 0.79) (0.05 to 0.51) 0.44 
3 3 6 Non sig. 
Cellular infiltrates 
 
0.5  0.05 0.39  
(-0.28 to 1.28) (-1.32 to 1.42) (-0.26 to 1.05) 75.6 
12 4 16 Sig. 
Neurodegeneration 
 
0.84  0.84  
(0.32 to 1.37) No data (0.32 to 1.37)  
6  6  
Neurobehaviour 
0.97 0.75 0.81  
(0.77 to 1.17) (0.26 to 1.25) (0.51 to 1.12) 2.97 










Table 6.3: I stratified active immunisation outcomes using amyloid fragments 
according to whether they used a gene or peptide Estimates of efficacy are given in 










































































































































































































































































































Reduction in plaque burden (standardised effect size)










































As there a number of different fragments of amyloid used in active immunisation I 
sought to understand whether the specific fragment used would impact on 
observed efficacy for plaque burden. Thus, I dichotomised data into experiments 
which used full length amyloid beta 1-42 and N terminal fragments however I did 
not find observe significant differences between these two groups (Figure 6.12, χ2 
=2.82). 
  
Figure 6.11 (previous page):  I inspected estimates of efficacy for active 
immunisation fragments according to whether amyloid was administered as 
gene or petide. Figure shows stratified estimates across plaque burden, amyloid 
beta 40, amyloid beta 42, tau and cellular infiltrates. Error bars represent 95% CI, 
grey bar denotes 95 CI of global estimate. Chi squared values given in Table 6.3. 








6.3 Summary estimates for interventions  
 
For each intervention assessed in transgenic mouse models of AD I provide 
summary estimates using standardised mean difference across pathology and 
neurobehaviour. Estimates are frequently calculated using few data, and therefore 
results should be interpreted with caution, particularly where estimates are extreme.  
 
Two hundred and seventy three interventions were assessed for their ability to 
improve pathological outcomes (Table 6.3).  While estimates are given for each 
individual pathological outcome, the order of interventions is based on the overall 
reduction of across all pathologies.  107  interventions were assessed for their ability 
for their ability to improve neurobehavioural outcomes (Table 6.4). For 
neurobehavioural outcomes, estimates of efficacy are ordered in terms of overall 
improvements in neurobehaviour, and I provide estimates of efficacy overall and 
summarise individual groups of behavioural data. Whilst this approach is 
informative for assessing potential strengths and weaknesses across the different 
apparatus used, it is unlikely that intervention development is paradigm specific 
and I would regard behaviour overall as the most useful indicator. 
Figure 6.12 (previous page):  I examined estimates of efficacy for amyloid beta 
fragments on plaque burden but did not find significant differences between short 
N terminal fragments (black) and amyloid beta 42 (red). Error bars represent 95% 
confidence limits (CI), grey bar denotes 95% CI of fragments near the N-terminus, 
symbol size represents the log of the number of animals. 
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SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 




(-0.4 to 15.6) 
1 
No data No data No data No data No data 
Antibody 4G8 
13.3 
(0.36 to 26.23) 
1 
No data No data 
5.66 
(-0.04 to 11.35) 
1 
No data No data 
Antibody 
1E11(anti A beta 
1-10) 
6.81 
(-0.43 to 14.05) 
1 
No data No data No data No data No data 
BMS-433796 No data 
6.35 
(3.38 to 9.32) 
1 
No data No data No data No data 
NGF 
6.02  
(0.23 to 11.8) 
2 




(-0.48 to 12.26) 
1 




5.15 to 7.26) 
1 
No data No data No data 
5.44 





(1.87 to 23.25) 
1 
6.46 
 (2.64 to 10.28) 
4 
9.65 
 (2.87 to 16.43) 
4 
2.56 
(-0.21 to 5.34) 
 1 
No data No data 
Antibody 2H4 
(anti A beta 1-10) 
5.75  
(-0.49 to 11.99) 
1 
No data No data No data No data No data 
ST1571 No data No data No data 
4.7  




(-0.09 to 10.09) 
1 
Antibody IgG2b 
(anti A-beta 1-40) 
4.45 
(-0.6 to 9.5) 
1 
No data No data No data No data No data 
Furin  
5.89 
 (3.37 to 8.42) 
2 
3.8 
(-1.04 to 8.64) 
2 
No data No data No data 
Antibody (fusion) 
4.27 
 (1.1 to 7.45)  
1 
No data No data No data No data No data 
KEGV 
4.19  
(-1.11 to 9.48) 
 2 
No data No data No data No data No data 
MRK-560 
0.67  
(0.06 to 1.28) 
 1 
6.12 
(-1.87 to 14.11) 
4 
1.08  




 (-0.64 to 3.74) 
 1 
No data 
H89 No data No data 
3.92  
(2.3 to 5.53) 
 1 
No data No data No data 
Antibody A11 
5.12 
 (2.3 to 7.93) 
 2 
3.42  
(1.34 to 5.51)  
1 
3.16  
(1.18 to 5.14)  
1 
5.24 
 (1.38 to 9.1)  
1 





 (0.16 to 11.45) 
1 
3.08 
(-0.35 to 6.5) 
1 




(-4.12 to 11.09) 
2 





(2.35 to 5.48) 
1 
3.35  
(2.32 to 4.38) 
 1 
3 
 (2.02 to 3.97)  
1 
No data No data No data 
Merk-3 No data 
4.26  
(0.65 to 7.87)  
4 
3.03 
 (1.8 to 4.26) 
 4 
No data No data No data 
Antibody 1560 
4.79  
(1.32 to 8.26) 
 6 
No data No data 
3.5  
(0.78 to 6.22) 
 6 
No data No data 
DADS 
5.13  
(0.48 to 9.77)  
1 
14.52 
 (5.81 to 23.24) 
1 
7.76  
(2.98 to 12.53) 
1 
1 
 (-0.94 to 2.95) 
1 
No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
Alpha- tocopherol No data No data No data 
2.79  
(-0.1 to 5.69) 
 4 






(1.13 to 4.11) 
11 




(-0.39 to 2.94) 
 1 
5.57 
 (1.93 to 9.21) 
 1 
5.4 
 (1.85 to 8.95)  
1 
No data No data No data 
Pravastatin 
1.08  
(-0.43 to 2.6) 
 4 
2.46  
(0.61 to 4.31)  
4 
4.89 
 (2.02 to 7.76)  
4 





(0.71 to 4.6)  
1 
2.17  
(0.43 to 3.91) 
 1 






(0.75 to 3.95) 
 6 
No data No data No data No data 
TTR antibody No data No data No data No data No data 
2.26 
 (0.69 to 3.82) 
 1 
Antibody 16G1 No data No data 
2.22  
(0.12 to 4.31)  
1 
No data No data No data 
Lithium 
3.83 
 (-2.19 to 9.86) 
2 
1.48 
 (-1.5 to 4.45)  
2 
5.4 
 (2.84 to 7.95) 
 7 
0.97  








(-1.75 to 6.9)  
2 
1.85 
 (-1.16 to 4.85)  
2 
1.71 
 (-1.27 to 4.68) 
2 
No data No data No data 
Y-27632 No data No data 
2.12  
(0.98 to 3.26)  
1 
No data No data No data 
A beta 1-6 
3.09 
 (1.2 to 4.97) 
1 
1.06 (-0.19 to 
2.3) 1 
4.48  
(2.02 to 6.94) 
 1 





 (0.83 to 2.88) 
 3 
2.14 
 (1.25 to 3.03)  
3 
No data No data No data 
CNI-1493 
2.01 
 (1.07 to 2.95) 
 1 





(0.81 to 2.81)  
3 
2.14  
(1.29 to 2.98)  
3 
No data No data No data 
Antibody Amy-33 
1.56 
 (0.1 to 3.03) 
 4 
20.43  
(9.74 to 31.12) 
1 
23.43 









 (0.34 to 2.69)  
1 
3.01 
 (1.44 to 4.57)  
1 
1.85 
 (0.6 to 3.1)  
1 
No data No data No data 
SAC 
8.11 
 (1.08 to 15.14) 
1 
15.97  
(6.08 to 25.85) 
1 
1.05 
 (-0.7 to 2.81) 
 1 
2.11  
(-0.38 to 4.6)  
1 
No data No data 
N-acetyl cystine No data 
3.91 
 (1.15 to 6.68) 
 1 
1.23  
(-0.42 to 2.88)  
1 
No data No data No data 
Antibody 3d6 
2.24 




 (0.72 to 2.72)  
1 
No data No data 
1.8  




 (1.36 to 1.87)  
1 
1.31 
 (0.73 to 1.88)  
1 
1.35 









 (0.28 to 2.75) 
 2 
No data No data 
2.07 
 (0.1 to 4.05)  
3 
No data No data 
DAPT No data 
1.6  
(0.43 to 2.76)  
1 
2.08 
 (0.8 to 3.36) 
 1 
No data No data No data 
Ginsenoside Rg3 No data 
1.66  
(0.39 to 2.94)  
1 
1.98 
 (0.63 to 3.34)  
1 
No data No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
LY-411575 
1.68 
 (1.15 to 2.21) 
 1 
2.15 
 (1.43 to 2.87)  
22 
1.67 
 (0.78 to 2.56) 
 9 
No data No data No data 
E64d 
2.69 
 (-1.73 to 7.11) 
2 
1.53 
 (-0.82 to 3.88) 
2 
1.28  
(-1.58 to 4.15) 
 2 




 (1.6 to 2.67)  
3 
0.87  
(-0.49 to 2.23)  
3 
1.66 
(-0.78 to 4.09) 
 2 
No data No data No data 
Antibody scFv 
1.71 (0.3 to 
3.12) 1 
No data No data No data No data No data 
ERC lesion 
3.17  
(1.84 to 4.5) 
 1 
1.46  
(0.5 to 2.42) 
 1 
1.23 
 (0.3 to 2.16)  
1 
No data No data No data 
Leuprolide 
1.7 
 (0.33 to 3.06) 
 1 
No data No data No data No data No data 
Valproic acid 
1.38 




 (4.95 to 9.56)  
1 
No data No data No data 
BRI-Abeta1-40 
4.02 
 (1.99 to 6.05)  
1 
2.76  
(1.14 to 4.39)  
1 
0.38 
 (-0.78 to 1.53) 
1 
No data No data No data 
PAZ-417 No data 
2.03  
(1.01 to 3.05)  
2 
1.35  
(0.46 to 2.23)  
2 




 (-0.55 to 2.67) 
1 
3.03 
 (-1.4 to 7.46)  
2 
2.79  
(1.12 to 4.47)  
2 
No data No data No data 
Caffeine No data 
1.61  
(-0.17 to 3.38) 
 1 
1.64 
 (-0.14 to 3.43) 
1 
No data No data No data 
Testosterone 
1.58 
 (0.79 to 2.37)  
1 
No data No data No data No data No data 
Caloric restriction 
0.95  
(0.13 to 1.77) 
 2 
1.83 
 (-0.2 to 3.86)  
2 
4.4  
(-2.52 to 11.32) 
2 
0.33  
(-0.36 to 1.01) 
 1 
1.05  





 (-0.61 to 0.94) 
2 
0.8 
 (-0.11 to 1.71) 
5 
0.8  
(0.03 to 1.58) 
 5 
No data No data 
4.39 
 (3.19 to 5.59)  
2 
Paroxetine No data 
2.28 
 (1.16 to 3.4)  
3 
0.31 
 (-1.26 to 1.88) 
1 
2.12 
 (-2.23 to 6.48) 
2 
No data No data 
Antibody scFv9 
0.69  
(0.85 to 2.23) 
 1 
1.29 
 (0.27 to 2.3) 
 2 
2.97 
 (1.35 to 4.59) 
 2 
No data No data No data 
CHIP expressing 
lentivirus 
No data No data No data 
1.48 
 (0.83 to 2.13)  
2 
No data No data 
Phenserine No data No data No data No data 
1.46  
(-0.67 to 3.59)  
1 
No data 
Nogo-66 recep tor 
-ec to -Fc 
0.96  
(-0.1 to 2.02) 
 1 
3.39 
 (1.72 to 5.07) 
 1 
1.75  




 (0.06 to 2.24) 
 1 
1.17 




(0.44 to 4.82)  
2 
-0.21 
 (-1.63 to 1.2) 
 1 
-0.14 
 (-2.11 to 1.82) 
1 
No data No data 
1.21 
 (-0.82 to 3.24) 
1 
Ginsenoside Re No data 
1.3 
 (0.26 to 2.34) 
 1 
1.32  
(0.28 to 2.36) 
 1 
No data No data No data 
Nobiletin 
1.32  
(0.24 to 2.4)  
1 
1.18 
 (0.13 to 2.24)  
1 
1.36 
 (0.28 to 2.45) 
 1 
No data No data No data 
Retinoic-acid 
2.19 
 (1.53 to 2.85) 
 1 
No data No data No data 
0.48 
 (-0.1 to 1.07)  
1 
1.43 




 (-0.26 to 2.01) 
1 
No data No data No data 
1.47 
(0.59 to 2.34) 
1 
No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 




(0.89 to 2.48) 
 6 
1.62 
 (0.8 to 2.44) 
 3 
1.22  




(-0.22 to 3.64) 
 3 
1.73 




 (0.1 to 2.46) 
 4 
1.14  
(0.52 to 1.76) 
 7 
1.39 
 (0.46 to 2.33) 
 7 
-1.39 
 (-2.42 to -0.35) 
1 
0.53  
(0.06 to 1)  
1 
0.7  
(-0.25 to 1.65)  
3 
A beta 1-42 
1.49 
 (1.18 to 1.8) 
 42 
1.48 
 (0.81 to 2.15) 
20 
1.07  
(0.71 to 1.42) 
28 
0.21 
 (-0.06 to 0.48) 
5 
0.99 
 (-0.19 to 2.17) 
6 
1.22 
 (0.39 to 2.04) 
 1 
Valsartan No data 
1.17  
(0.45 to 1.89)  
2 
1.25 
 (0.52 to 1.97) 
 2 
No data No data No data 
A beta 1-5 
1.02  




(0.24 to 2.65)  
1 
No data No data 
1.38 
 (0.54 to 2.23) 
 1 
EFRH No data 
1.4  
(0.4 to 2.39)  
3 
1.86  




 (0.24 to 1.46) 
 1 
1.26 






(0.15 to 1.91)  
1 
1.36  
(0.41 to 2.31) 
 1 
No data No data No data 
Fish oil-based diet No data No data 
1.22  




(-0.28 to 2.58) 
 1 
No data 
A beta 5-11 
1.18  
(0.34 to 2.01)  
1 
No data No data No data No data No data 
Lovastatin 
0.88 
 (-0.99 to 2.75) 
6 
0.54 
 (-0.72 to 1.81) 
6 
1.3  
(-0.33 to 2.93) 
 6 
No data No data No data 
Copper 
1.57  
(0.73 to 2.41) 
 2 
1.27  
(-1.9 to 4.44)  
2 
1.89  
(-2.65 to 6.43) 
 2 





(0.61 to 1.7) 
 2 
No data No data No data No data No data 
AR-A014418 No data No data No data 
1.15  
(0.19 to 2.11)  
1 




 (-3.29 to 5.55)  
2 
No data No data No data No data No data 
Antibody Ab3 No data 
1.21 
 (-0.24 to 2.67) 
1 
1.04 
 (-0.34 to 2.41) 
1 
No data No data No data 
Oxybutynin No data No data 
1.09 
 (0.01 to 2.17)  
2 
No data No data No data 
Cerebrolysin 
1.24 
 (0.78 to 1.7)  
8 
0.23 
 (-0.91 to 1.37) 
1 
0.88 




 (0.17 to 1.93)  
2 
1.05 
 (0.56 to 1.55) 
 5 
Bacopa Monniera No data 
1.06  
(0.62 to 1.5) 
 4 
1.1 
 (0.66 to 1.54)  
4 
No data No data No data 
Antibody ab9 
1.63 
 (0.18 to 3.08) 
 2 
0.81 
 (0.25 to 1.36)  
4 
1.19 
 (0.52 to 1.86) 
 4 
No data No data No data 
BM15-766 
0.13 (-0.89 to 
1.14) 1 
1.22 
 (0.42 to 2.03) 
 1 
1.56 
 (0.69 to 2.44)  
1 
No data No data No data 
Insulin-like 
Growth fac to r 1 
1.53 
 (0.02 to 3.04)  
1 
2.06  
(0.36 to 3.76) 
 1 
1.43  




 (0.43 to 1.66)  
1 
0.82 








 (0.48 to 2.85)  
1 




 (0.21 to 1.9)  
1 
No data No data No data No data No data 
BRI2 
4.5  
(2 to 7)  
1 
0.48  
(-2.58 to 3.55) 
 2 
1.46  
(-3.29 to 6.2) 
 2 
No data No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
A beta 3-9 
0.93  




 (0.15 to 2.53)  
1 
No data No data 
1.01 




 (0.07 to 1.19)  
3 
0.62 
 (-0.05 to 1.29) 
3 
1.78 
 (1.2 to 2.37)  
3 
No data No data No data 
Antibody 10d5 
1.74 
 (0.8 to 2.67)  
8 
0.16 
 (-0.51 to 0.83) 
1 
0.14  




(-6.08 to 2.17) 
 1 
0.82 




(-0.15 to 4)  
1 
0.94 
 (0.19 to 1.68) 
3 
0.33 
 (-0.41 to 1.06) 
3 
2.61  









 (-0.91 to 3.63) 
2 
No data No data No data 
-4.59  





 (-0.47 to 1.54) 
1 
No data No data No data No data 
1.45 
 (0.38 to 2.53)  
1 
mHJ5.1 No data No data No data No data 
0.95 
 (-0.9 to 2.8)  
1 
 
Bryostatin 1 No data 
0.96 
(-0.18 to 2.1) 
2 
0.69 
 (-0.05 to 1.43) 
1 
No data No data No data 
A beta 1-11 
1.33 
 (0.57 to 2.08)  
2 
0.89 
 (0.19 to 1.59) 
4 
1.17 
 (-0.31 to 2.65) 
4 
0.49 
 (0.03 to 0.95)  
1 
2.06 





 (0.38 to 1.43)  
3 
0.75  
(-0.12 to 1.62)  
1 
0.64 
 (-0.22 to 1.51) 
1 
No data No data 
1.68 
 (0.57 to 2.8) 
 2 
A beta 2-6 
0.91  
(-0.1 to 1.92)  
2 
No data No data No data No data No data 
Antibody 12B4 
0.9  




 (0.4 to 2.29) 
 1 
No data No data 
0.92 




 (0.75 to 1.65) 
 1 
0.93 
 (0.42 to 1.44)  
1 
0.71 










 (0.07 to 1.82)  
1 
0.83 
 (-0.27 to 1.94) 
1 
No data No data No data No data 
KMI-429 No data 
1.43 
 (-0.4 to 3.27)  
1 
0.56 
 (-0.9 to 2.02)  
1 
No data No data No data 
Resveratrol No data No data No data No data 
0.86 
 (-1.27 to 3)  
1 
0.92 





(0.44 to 1.43)  
3 
0.89 
 (-0.31 to 2.09) 
3 
1.02 









 (0.94 to 2.15)  
4 
0.86 
 (-0.72 to 2.43) 
1 
0.33 




 (0.28 to 1.39) 
 1 
0.12 




 (0.46 to 2.15)  
5 
0.6 
 (-0.2 to 1.4)  
7 
0.85 
 (0.32 to 1.39)  
7 




 (1.16 to 2.95)  
2 
No data No data No data 
-1 
 (-3.38 to 1.38) 
2 
2.48 
 (1.53 to 3.43)  
1 
Ginsenoside Rg1 No data 
0.79 
 (-0.3 to 1.87)  
1 
0.86 
 (-0.24 to 1.96) 
1 
No data No data No data 
Antibody 16E6 No data No data 
0.81 
 (-0.68 to 2.31) 
1 
No data No data No data 
Pioglitazone 
0.43 
 (-0.07 to 0.93) 
3 
0.86 
 (-0.22 to 1.95) 
3 
0.47 













 (-0.48 to 3.04) 
1 
No data No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
m3D6 Fab 
Fragments 
No data No data No data No data 
0.77 








 (0.26 to 2) 
 1 
0.46 
 (-0.35 to 1.27) 
1 
No data No data No data 
Scyllo-inositol 
0.73  
(0.29 to 1.18)  
1 
0.74 
 (0.06 to 1.42)  
1 
0.87 
 (0.17 to 1.57) 
 1 
No data No data No data 
PBT2 
1.92 
 (0.44 to 3.4) 
 1 
0.71 
 (-0.09 to 1.52) 
2 
0.51 
 (-0.1 to 1.11) 
 2 
0.65 




 (0.07 to 1.74)  
2 
a beta 1-16 
0.42  
(-0.28 to 1.12)  
1 
0.78 
 (0.27 to 1.29) 1 
0.89 
 (0.38 to 1.41)  
1 
No data No data No data 
Picro toxin No data No data No data No data No data 
0.74 




(0.04 to 1.58) 
3 
1.76 
 (0.86 to 2.67) 
1 
1.35 




 (-2.29 to 0.37) 
1 
No data 
Antibody Ab5 No data 
0.55 
(-0.76 to 1.85) 
1 
0.94 
 (-0.41 to 2.3) 
1 
No data No data No data 
Physostigmine 
0.72 
 (-0.21 to 1.64) 
1 
No data No data No data No data No data 
Neprilysin 
0.99 
 (0.37 to 1.6) 
 5 
0.91 
 (0.54 to 1.28) 
2 
1.3 
 (-0.21 to 2.82) 
2 
-0.81 
 (-1.54 to -0.08) 
1 
0.67 
 (-0.37 to 1.71) 
2 
0.78 






(-1.39 to 2.7)  
1 
0.74 
(-1.33 to 2.82)  
1 
No data No data No data 
NAP No data 
0.79 
(-0.09 to 1.66) 
 1 
0.71 
(-0.16 to 1.58) 
1 
0.67  
(0.05 to 1.29) 
3 
No data No data 
Exercise 
0.54 
 (-0.39 to 1.46) 
4 
0.71 
 (-0.1 to 1.52) 
 2 
1.08  




 (-1.4 to -0.18) 
1 
0.92 
 (-0.37 to 2.22) 
2 
Antibody 2C1 No data No data No data No data No data 
0.67 




 (-0.28 to 1.88) 
2 
0.48 
 (-0.14 to 1.11) 
3 
0.83  
(-0.22 to 1.87)  
3 
No data No data No data 
DHA-diet 2 
2.18 
 (-0.01 to 4.38) 
1 
0.43 
 (-0.38 to 1.24) 
3 
0.22 
 (-0.6 to 1.03)  
3 
1.34 
 (0.38 to 2.31)  
3 
No data No data 
DP-115 No data 
0.12 
 (-0.67 to 0.91) 
2 
1.69 
 (-0.08 to 3.45) 
2 
No data No data No data 
Corn oil No data No data 
0.11 











(-0.61 to 1.6)  
1 
0.8  
(-0.35 to 1.96) 
 1 
No data No data No data 
DP-109 
1.55 
 (1.05 to 2.05)  
1 
-0.13 
 (-0.78 to 0.53) 
1 
-0.24 
 (-0.9 to 0.43)  
1 




(0.34 to 1.23)  
1 
0.32 
 (-0.15 to 0.8)  
1 
0.75 
 (0.27 to 1.23)  
1 
No data No data No data 
AF267B 
1.78  
(1 to 2.57)  
1 
0.07 
 (-1.02 to 1.17) 
1 
1.89 
 (0.98 to 2.8)  
1 
0.24  
(-0.11 to 0.6)  
1 
No data No data 
Memapsin 2 
0.81 
 (0.35 to 1.27) 
 2 
0.37  
(-0.14 to 0.87) 
 2 
0.65 
 (0.17 to 1.12)  
2 
No data No data No data 
Antibody Ab40.1 
3 
 (0.39 to 5.62)  
1 
0.38 
 (-0.49 to 1.26) 
2 
0.55 
 (-0.76 to 1.86) 
2 
No data No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
Vitamin E 
0.47 
 (-0.33 to 1.26) 
2 
0.63 
 (-0.15 to 1.41) 
2 
0.63 
 (-0.49 to 1.75) 
2 
No data No data No data 
A beta 1-28 
0.55 
 (-0.26 to 1.36) 
1 
No data No data No data 
0.57 





(0.7 to 1.49)  
5 
0.4  
(-0.17 to 0.98) 
 5 
0.21  
(-0.31 to 0.74)  
6 
0.86 
 (0.07 to 1.64)  
1 
0.77 
 (-0.02 to 1.56) 
4 
0.85 
 (0.29 to 1.4)  
1 
Coenzyme Q10 No data 
-0.27 
 (-1.52 to 0.98) 
1 
2.13 
 (0.4 to 3.85)  
1 
No data No data No data 
A beta 40/42 
3.3  
(0.74 to 5.86) 
 2 
0.04 
 (-0.62 to 0.71) 
4 
0.72 
 (0.14 to 1.29)  
4 
No data No data No data 
GSK-188909 No data 
0.44 
 (-0.48 to 1.36) 
2 
0.64 
 (-0.1 to 1.38)  
2 








 (-0.73 to 1.39) 
2 
No data No data No data 
Compound XH1 No data 
0.53 
 (-0.51 to 1.58) 
1 
No data No data No data No data 
A beta 1-30 
0.81 
 (-0.17 to 1.8)  
4 
0.33 
 (-0.08 to 0.73) 
3 
0.69 
 (-0.46 to 1.84) 
3 
No data No data No data 
DHA-diet 3 
3.16 
 (0.46 to 5.86)  
1 
0.22 
 (-0.53 to 0.97) 
3 
0.37  
(-0.42 to 1.15)  
3 
1.02  
(-0.17 to 2.22)  
3 
No data No data 
Antibody D-2H6 
0.67 
 (-0.13 to 1.47) 
3 
No data No data No data 
0.38  





 (0.19 to 3)  
2 
-0.19 
 (-1.71 to 1.34) 
1 
-1.76 




 (-0.88 to 0.55) 
1 
2.65 
 (0.89 to 4.41) 
 1 
A beta 1-40 
0.82 
 (0.28 to 1.36) 
 6 
0.33 
 (-1.21 to 1.87) 
1 
0.36 




 (-1.06 to 0.39) 
1 
No data 
T cells No data 
-0.03 
 (-1.1 to 1.04)  
3 
0.54 










 (-0.85 to 2.02) 
1 
0.27 
 (-0.6 to 1.15) 
 3 
0.88 
 (-0.44 to 2.19) 
3 
No data No data No data 
A beta 1-15 
1.48 
 (0.76 to 2.19)  
5 
0.02 
 (-0.4 to 0.43) 
 4 
0.15 
 (-0.25 to 0.55) 
5 
No data No data No data 
K252a No data No data No data 
0.48 
 (0.24 to 0.71)  
1 
No data No data 
DHA 
0.23 
 (-0.9 to 1.36)  
1 
-0.01 
 (-1.19 to 1.17) 
3 
1.06 
 (0.23 to 1.89)  
3 
No data No data 
0.39 




 (-0.67 to 1.18) 
3 
0.42 
 (0.08 to 0.75)  
8 
0.8 
 (0.04 to 1.57)  
7 
0.78 
 (-0.33 to 1.88) 
1 
No data No data 
Learning 
2.28 
 (0.89 to 3.66) 
1 
-0.19 
(-0.92 to 0.54)  
1 
0.02 
(-0.76 to 0.79) 
 1 
0.74 
 (0.2 to 1.28) 
 1 
No data No data 
GF120918 No data 
0.46 
(-0.31 to 1.23)  
1 
0.42 
(-0.35 to 1.19) 
 1 





(-0.63 to 4.36)  
2 
1.03 
(-0.2 to 2.26)  
2 
0.09 
 (-0.53 to 0.71) 
2 
No data No data 
High Fat diet No data 
0.59 
(-0.1 to 1.28) 
1 
0.28 
(-0.4 to 0.96) 
 1 
No data No data No data 
Antibody HT7 
0.64 
(-1.08 to 2.35)  
1 
No data No data 
0.24 
 (-1.38 to 1.85) 
1 
No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
Antibody 6E10 
0.42 
(-0.31 to 1.15)  
3 
No data No data No data No data No data 
Antibody Ab2 No data 
0.39 
(-0.9 to 1.68) 
1 
0.44 
(-0.84 to 1.73)  
1 
No data No data No data 
Erythromycin No data 
0.16 
(-1.32 to 1.65) 
 1 
0.66 
(-0.87 to 2.2) 
1 
No data No data No data 
Antibody Ib3 
0.4 
 (-1.01 to 1.81) 
1 
No data No data No data No data No data 
OMOO-3 DR9 No data 
0.59 
(-0.19 to 0.98) 
 1 
No data No data No data No data 
Antibody 3A3 No data No data No data No data No data 
0.39 




(0.16 to 1.63)  
9 
-0.48 
(-1.19 to 0.23) 
 1 
-0.32 
(-1.02 to 0.38)  
1 
-0.94 
(-2.1 to 0.22) 
1 
-1.40 
(-2.07 to -0.9) 
2 
No data 
Rosiglitazone No data 
-0.26  
(-1.32 to 0.79) 
 1 
1.16 
 (0 to 2.33) 
 1 




 (0.1 to 4.7) 
 2 
No data No data No data 
-0.3  





 (-0.66 to 1.54) 
1 
0.36 
 (-0.88 to 1.6) 
 1 
0.22 
 (-1.05 to 1.49) 
1 
No data No data No data 
D1 
0  
(-1.09 to 1.09)  
1 
No data No data No data 
0.52 





 (-1.91 to 2.56) 
1 
No data No data No data No data No data 
Tau379–408 No data No data No data 
0.31 
 (0.04 to 0.58)  
4 
No data No data 
40H-GTS-21 
0.3 
 (-0.58 to 1.19) 
1 
No data No data No data No data No data 
Antibody 6C6 No data No data No data No data No data 
0.29 








(0.16 to 1.24)  
1 
No data No data No data 
Clioquinol 
0.8  
(0.01 to 1.59)  
1 
-0.63 
 (-2.07 to 0.81) 
1 
-0.03  
(-1.42 to 1.36) 
 1 
-0.43 




 (0.22 to 4.02) 
1 
Protollin No data 
2.03 
 (0.74 to 3.32) 
 1 
2.19  




(-4.19 to -1.72) 
1 
No data 





(-0.15 to 2.78)  
1 
0.15 
 (-0.15 to 0.45) 
2 
0.14 
 (-0.31 to 0.58) 
2 





 (-0.52 to 0.78) 
3 
0.38 
 (-0.28 to 1.04) 
3 
No data No data No data 
Naproxen No data 
0.31 
 (-0.4 to 1.02) 
 1 
0.18 
 (-0.44 to 0.8) 2 
No data No data No data 
TAPI-I No data 
0.43 
 (-0.66 to 1.53) 
1 
0.04 
 (-1.05 to 1.12) 
1 
No data No data No data 
SMAKEGV 
0.23 
 (-2.39 to 2.86) 
2 
No data No data No data No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
Flurbiprofen 
0.89  
(-0.74 to 2.52)  
2 
0.21  
(0 to 0.42)  
8 
0.13 
 (-0.09 to 0.35) 
8 
No data No data No data 
Antibody 7b6 
0.22 
 (-1.18 to 1.61) 
1 
No data No data No data No data No data 
GSM-1 No data 
-0.11 
 (-0.97 to 0.76) 
6 
1.17  
(-0.43 to 2.77) 
 6 
No data No data No data 
A beta 1-7 
0.19 
 (-1.24 to 1.62) 
1 
No data No data No data No data No data 
 TO 901317 No data 
-0.26  
(-1.31 to 0.79) 
 4 
0.66 
 (0.12 to 1.21)  
4 
No data No data No data 
celecoxib 
0.65 
 (0.02 to 1.28)  
3 
0.04  
(-0.7 to 0.78)  
2 
0.03 








 (FAB fragment) 
No data 
0.08  
(-1.62 to 1.77)  
1 
0.27  
(-1.44 to 1.99) 
 1 
No data No data No data 
Minocycline 
-0.8 
1 (-2.59 to 0.96) 
2 
-0.06 
 (-0.5 to 0.39)  
3 
0.13 




 (0.07 to 1.06) 
 3 
No data 
LY-D No data 
0.63  
(-0.47 to 1.74) 
 3 
-0.36 
 (-1.54 to 0.82) 
2 





(0.45 to 2.77) 
 2 
No data No data No data 
-1.41 
 (-2.58 to -0.24) 
2 
No data 
FK506 No data No data 
0.15 
 (-0.59 to 0.89) 
1 
No data No data No data 
Antibody BBS1 
-0.01 
 (-0.96 to 0.93) 
2 
-0.92 
 (-1.93 to 0.09) 
2 
-0.36 










 (-0.18 to 0.97) 
9 
-0.45 
 (-1.72 to 0.82) 
5 
-0.39 
 (-1.66 to 0.88) 
5 
0.1 
 (-0.7 to 0.9) 
 1 
-0.84 
 (-1.4 to -0.27)  
1 
0.35 




 (0 to 1.93)  
1 
0.16 
 (-0.48 to 0.8)  
1 
-0.32 
 (-0.99 to 0.35) 
1 
No data No data No data 
Gingko Biloba 
0.37 
 (-0.63 to 1.36) 
1 
0.13 
 (-0.57 to 0.83) 
1 
0 
 (-0.7 to 0.7)  
1 
No data No data No data 
MF tricyclic No data 
0.24 
 (-0.47 to 0.95) 
1 
0.02 
 (-0.6 to 0.64)  
2 
No data No data No data 
Progesterone 
-0.28 
 (-0.9 to 0.34) 
 1 
No data No data 
1.97  
(0.61 to 3.32) 
 1 
No data No data 
Antibody BAM-10 No data 
0.05 (-0.33 to 
0.42) 1 
0.11 
 (-0.26 to 0.48) 
1 




 (-2.25 to 2.39)  
1 
No data No data No data No data No data 
DSP-4 
0.07 
 (-1.2 to 1.33) 
 2 
No data No data No data No data No data 
Nimesulide 
0.29  
(-0.41 to 0.99)  
1 
0.09 
 (-0.45 to 0.63) 
1 
-0.11 
 (-0.64 to 0.43) 
1 
No data No data No data 
Simvastatin 
0.14 
 (-0.48 to 0.76) 
1 
-0.04 
 (-0.66 to 0.58) 
1 
0.06 
 (-0.56 to 0.68) 
1 
No data No data No data 
Losartan No data 
0.16 
 (-0.41 to 0.72) 
1 
-0.06 
 (-0.62 to 0.5) 
 1 





(-1.79 to 2.15) 
 1 
-0.09 
 (-2.05 to 1.87) 
1 
No data No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
C1q 
0.04 
 (-1.23 to 1.3)  
1 





(-1.79 to 2.15)  
1 
-0.11 
 (-2.07 to 1.86) 
1 




(-0.64 to 0.85) 
 1 
0.08  
(-0.35 to 0.51)  
1 
-0.05 




(-0.38 to 0.38)  
1 
No data 
e64 No data 
-0.24  
(-1.77 to 1.28) 
 1 
0.3 
 (-1.23 to 1.84) 
1 
No data No data No data 
BDA-410 No data 
-0.13  
(-1.61 to 1.35) 
 1 
0.18 
 (-1.3 to 1.66)  
1 
No data No data No data 
Donepezil 
0.03 
 (-0.85 to 0.9) 
 1 
No data No data No data No data No data 
GM1 ganglioside No data 
0.04 
 (-2.08 to 2.15) 
2 
-0.04 
 (-2.02 to 1.95) 
2 




(-0.97 to 0.99)  
1 
No data No data No data No data No data 
Trolox 
0.01 
 (-0.48 to 0.49) 
1 
No data No data No data No data No data 
hIGF No data No data No data 
0 
 (-0.6 to 0.61)  
2 
No data No data 
Egb- 761 
-0.01 
 (-0.49 to 0.48) 
1 
No data No data No data No data No data 
Aluminium 
-1.27  
(-2.07 to -0.47) 
1 
-0.21 
 (-1.77 to 1.35) 
3 
0.05  
(-1.42 to 1.52) 
 3 
No data No data 
0.26 
(-0.24 to 0.75) 
 2 
Rolipram No data 
-0.11 
 (-0.79 to 0.56) 
1 
0.11  
(-0.77 to 0.99) 
 1 
No data No data No data 
Paclitaxel No data No data No data 
0.03 









No data No data No data No data No data 
-0.05 
(-1.82 to 1.73)  
1 
A beta 25-35 No data No data No data No data No data 
-0.05 
(-1.23 to 1.13) 
 2 
A beta 15-24 
-0.19 




(-1.39 to 0.81) 
 1 
No data No data 
0.24 




 (0.51 to 2.26) 
2 
No data No data No data 
-1.43  
(-1.98 to -0.88) 
2 
No data 
Lipid Neutral Diet No data 
-0.03 
(-1.01 to 0.94) 
 1 
-0.14  
(-1.12 to 0.83)  
1 
No data No data No data 
Sulindac Sulfide No data 
-0.24 
(-0.75 to 0.27)  
2 
0.05 
(-0.46 to 0.56) 
 2 
No data No data No data 
Uch-L1 No data No data 
-0.11 
(-0.64 to 0.43) 
 2 
No data No data No data 
lipoic acid 
-0.22 
 (-0.75 to 0.3)  
1 
0.07  
(-0.66 to 0.8) 
 1 
-0.08 
 (-0.81 to 0.66) 
1 
No data No data No data 
Dexamethasone 
-0.51 
(-2.9 to 1.89) 
2 
-0.4 
(-1.06 to 0.26)  
3 
-0.91 
(-1.73 to -0.09) 
3 
-0.12 
(-0.95 to 0.71)  
2 
1.04  







 (-1.18 to 0.71)  
1 
-0.1  
(-1.04 to 0.85) 
1 
-0.11 
 (-0.78 to 0.56) 
1 
No data No data 





SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
Antibody 2h6 
2.29 
 (1.18 to 3.41) 
 2 
No data No data No data 
-1.15 
(-1.85 to -0.45) 
2 
No data 
Nicotinamide No data 
-0.65 
(-1.22 to -0.08) 
2 
-0.1 
(-0.74 to 0.54) 
2 
0 
(-1.11 to 1.11) 
2 








(-1.15 to 0.93) 
 2 
No data No data No data 
Antibody 12A11 
-0.4  
(-1.53 to 0.73)  
1 
No data No data No data No data 
-0.11 




 (-1.61 to 0.66) 
1 
0.03 
 (-1.09 to 1.15) 
1 
-0.26  
(-1.39 to 0.86)  
1 
No data No data No data 
Mild brain trauma 
-0.5  
(-1.42 to 0.42) 
 4 
-0.24  
(-0.77 to 0.29) 
 2 
-0.16 
 (-0.69 to 0.37) 
2 
No data No data No data 
Captopril 
-0.7 
 (-2.05 to 0.65) 
2 
-0.11 
 (-0.88 to 0.66) 
3 
-0.55 
 (-1.69 to 0.59) 
3 




 (1.09 to 3.29) 
 1 
No data No data No data 
-0.98 









 (-1.99 to 0.92) 
1 
-0.03 
 (-1.41 to 1.36) 
1 
No data No data No data 
A beta 1-9 
12.12 
 (5.18 to 19.05) 
1 
0.4 
(-0.81 to 1.6) 
1 
0.28 











(-1.28 to 0.39)  
1 
-0.3  
(-1.27 to 0.67) 
 1 
No data No data No data 
Sodium butyrate No data 
-0.38 
 (-1.09 to 0.32) 
1 
0.24  
(-0.45 to 0.94) 
 1 
-0.85 
 (-1.45 to -0.25) 
1 
No data No data 
A beta 16-20 
0.5 
 (-0.82 to 1.82) 
1 
No data No data No data 
-0.89 
 (-2.34 to 0.55) 
1 
-0.96 




 (-0.86 to -0.13) 
1 
No data No data No data No data No data 
Metrifonate 
0.31  
(-0.35 to 0.97)  
1 
-0.96 
 (-1.65 to -0.26) 
1 
-1.12 
 (-1.83 to -0.41) 
1 
No data No data No data 
High Cholesterol 
-0.9 
 (-2.28 to 0.48) 
4 
-0.05 
 (-1 to 0.91)  
3 
-0.2 
 (-0.64 to 0.24) 
3 
No data No data No data 
Roscovitine No data No data 
-0.56  
(-1.7 to 0.57)  
2 
No data No data No data 
Dicyclomine 
-0.78  
(-1.48 to -0.08) 
1 
-1.21  
(-2.48 to 0.07)  
1 
-0.75 
 (-1.6 to 0.11)  
1 
-0.46  
(-0.82 to -0.09) 
1 




(-1.53 to 0.22) 
1 
-0.59 
 (-1.58 to 0.4) 
 1 
-0.55  
(-1.54 to 0.44) 
 1 
No data No data No data 
KMI-358 No data 
-0.58 
 (-2.05 to 0.89) 
1 
-0.7 
 (-2.2 to 0.8) 
 1 





 (-2.09 to 0.82) 
3 




 (-1.4 to -0.15) 
 2 
-0.96 
 (-1.5 to -0.42)  
2 
-0.21 
 (-0.72 to 0.3)  
2 








 (-1.93 to 0.39) 
2 






 (-2.24 to 0.78) 
3 
No data No data No data No data 
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Table 6.3: I summarised the effect of interventions across the six principle 
pathological outcomes.  Effect size estimates provided are given in terms of  
standardised mean difference alongside 95% confidence limits and number of 
experiments. Each estimate is assigned a heat map colour as explained in the key. 
Drug 
Plaque area 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 40 
SMD Effect size 
(95 % CI) and N 
Amyloid beta 42 
SMD Effect size 
(95 % CI) and N 
Tau 
SMD Effect size 
(95 % CI) and N 
Cellular infiltrates 
SMD Effect size 
(95 % CI) and N 
Neurodegeneration 
SMD Effect size 
(95 % CI) and N 
Antibody 2286 
5.23 
 (-0.01 to 10.47) 
1 
No data No data No data 
-0.9 
 (-1.73 to -0.07) 
1 
No data 
Kainic acid No data 
-0.87  
(-2.41 to 0.67)  
3 
No data No data No data No data 
A beta 16-22 
-1.24  
(-2.37 to -0.1) 
 1 
No data No data No data 
-0.44  






 (-3.26 to -0.58) 
1 
-0.71 
 (-1.49 to 0.06) 
1 
-0.82  
(-1.63 to 0)  
1 




(-2.62 to 1.76)  
1 
No data No data No data 
-1.99  
(-4.88 to 0.89) 
 1 
No data 
Insulin No data 
-1.06 
 (-2.58 to 0.46) 
3 
No data No data No data No data 
SAP protein 
-1.29 
(-2.83 to 0.24) 
1 
No data No data No data No data No data 
iPF2a-11 (IsoP) 
-1.29 
(-2.46 to -0.12) 
1 
-1.65 
(-3.29 to 0) 
1 
-1.61 
(-3.25 to 0.03) 
1 
No data No data No data 
M3D6 No data No data No data No data 
-2.41 





(-11.07 to -2.85) 
 1 
No data No data No data No data 
-2.61 
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6.3.2 Heat map for neurobehavioural outcomes 
 
 
Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
Amyloid beta-12-28P     2.86 2.86 
  no data no data (1.61 to 4.11) (1.61 to 4.11) 
      1 1 
A beta 36-42 2.11 2.25   2.2 
  (0.32 to 3.89) (0.9 to 3.61) no data (1.12 to 3.28) 
  1 1   1 
A beta 1-11 1.52 2.73   2.13 
  (0.24 to 2.8) (1.45 to 4.01) no data (1.22 to 3.03) 
  1 1   1 
Blueberry supplementation     1.9 1.9 
  no data no data (-0.53 to 4.33) (-0.53 to 4.33) 
      1 1 
Testosterone     1.81 1.81 
  no data no data (0.38 to 3.25) (0.38 to 3.25) 
      1 1 
PBT2 2.01 1.35   1.68 
  (1.16 to 2.86) (0.51 to 2.2) no data (1.08 to 2.28) 
  2 2   2 
Antibody 2h6 
(deglycosylated) 
    1.66 1.66 
  no data no data (-0.08 to 3.4) (-0.08 to 3.4) 
      1 1 
Antibody m266     1.65 1.65 
  no data no data (0.51 to 2.78) (0.51 to 2.78) 
      5 5 
Nogo-66 receptor -ecto-Fc     1.62 1.62 
  no data no data (0.44 to 2.79) (0.44 to 2.79) 
      1 1 
A beta 1-15 0.98 1.61 2.46 1.6 
  (-0.41 to 2.37) (-0.19 to 3.42) (0.1 to 4.82) (0.2 to 3.01) 
  3 3 1 4 
Resveratrol     1.58 1.58 
  no data no data (0.29 to 2.88) (0.29 to 2.88) 
      1 1 
Nobiletin     1.5 1.5 
  no data no data (0.35 to 2.65) (0.35 to 2.65) 
      1 1 
BDA-410     1.43 1.43 
  no data no data (0 to 2.86) (0 to 2.86) 
      2 2 
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Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
Antibody 2h6     1.41 1.41 
  no data no data (-0.36 to 3.19) (-0.36 to 3.19) 
      1 1 
Physostigmine     1.38 1.38 
  no data no data (0.51 to 2.25) (0.51 to 2.25) 
      3 3 
G-CSF 1.37     1.37 
  (-0.09 to 2.82) no data no data (-0.09 to 2.82) 
  1     1 
TO901317     1.36 1.36 
  no data no data (0.31 to 2.42) (0.31 to 2.42) 
      1 1 
Neprilysin 0.88 1.41   1.36 
  (-0.16 to 1.92) (0.62 to 2.2) no data (0.52 to 2.19) 
  1 2   2 
Garlic extract 0.79 2.67 1.16 1.32 
  (0.14 to 1.44) (1.56 to 3.77) (-0.67 to 2.98) (0.33 to 2.31) 
  2 2 2 2 
antibody 10d5 1.32     1.32 
  (0.39 to 2.24) no data no data (0.39 to 2.24) 
  1     1 
epigallocatechin-3- 
gallate 
    1.29 1.29 
  no data no data (0.57 to 2.01) (0.57 to 2.01) 
      2 2 
NAP   1.28   1.28 
  no data (0.61 to 1.94) no data (0.61 to 1.94) 
    1   1 
ST1571 1.27     1.27 
  (-0.19 to 2.74) no data no data (-0.19 to 2.74) 
  1     1 
Rosiglitazone     1.26 1.26 
  no data no data (0.42 to 2.1) (0.42 to 2.1) 
      1 1 
AF267B 0.71 1.57   1.25 
  (-0.41 to 1.83) (0.7 to 2.43) no data (0.56 to 1.93) 
  1 1   1 
e64     1.2 1.2 
  no data no data (0.19 to 2.2) (0.19 to 2.2) 
      1 1 
Lenti-siBACE1-6 0.41 1.79   1.17 
  (-0.85 to 1.67) (0.65 to 2.93) no data (0.33 to 2.02) 
  1 1   1 
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Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
Memapsin 2 0.67 1.72   1.12 
  (-0.26 to 1.61) (-0.58 to 4.02) no data (0.01 to 2.24) 
  2 2   2 
Lipoic acid 0.99 1.55 0.79 1.1 
  (-0.12 to 2.1) (0.69 to 2.41) (0.02 to 1.56) (0.59 to 1.61) 
  1 1 1 1 
Gingko Biloba 0.9 1.16   1.09 
  (-0.15 to 1.95) (0.53 to 1.79) no data (0.55 to 1.63) 
  1 1   1 
Retinoic-acid 0.84 1.35   1.07 
  (-0.37 to 2.04) (0.04 to 2.66) no data (0.19 to 1.96) 
  1 1   1 
Antibody D-2H6     1.06 1.06 
  no data no data (-0.11 to 2.23) (-0.11 to 2.23) 
      3 3 
FK506     1.05 1.05 
  no data no data (0.33 to 1.76) (0.33 to 1.76) 
      1 1 
Glatiramer acetate 1.04     1.04 
  (-0.15 to 2.24) no data no data (-0.15 to 2.24) 
  1     1 
PAZ-417     1.02 1.02 
  no data no data (0.35 to 1.69) (0.35 to 1.69) 
      4 4 
Naproxen   1.02   1.02 
  no data (-0.04 to 2.08) no data (-0.04 to 2.08) 
    1   1 
Ibuprofen 1.66 0.79 1.41 1 
  (0.11 to 3.21) (0.32 to 1.26) (0.62 to 2.19) (0.61 to 1.39) 
  1 3 1 3 
T cells     0.95 0.95 
  no data no data (0.51 to 1.39) (0.51 to 1.39) 
      3 3 
Environmental Enrichment 0.76 0.79 1.37 0.94 
  (0.35 to 1.17) (0.22 to 1.36) (0.96 to 1.78) (0.7 to 1.19) 
  6 7 7 9 
Antibody 2286     0.93 0.93 
  no data no data (-0.33 to 2.18) (-0.33 to 2.18) 
      1 1 
Leuprolide     0.92 0.92 
  no data no data (-0.28 to 2.11) (-0.28 to 2.11) 
      1 1 
 
 
    
     
                                                                      Chapter 6: Intervention specific analyses 
277 
 
Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
Clioquinol 1.43 0.52   0.92 
  (0.29 to 2.57) (-0.49 to 1.53) no data (0.16 to 1.67) 
  1 1   1 
DAPT     0.86 0.86 
  no data no data (0.13 to 1.59) (0.13 to 1.59) 
      5 5 
Nicotine 0.26 1.6   0.86 
  (-0.15 to 0.68) (1.13 to 2.07) no data (0.54 to 1.17) 
  3 3   3 
Grape Polyphenolics 0.98 0.82   0.86 
  (-0.25 to 2.2) (0.07 to 1.57) no data (0.22 to 1.51) 
  1 1   1 
CNI-1493     0.84 0.84 
  no data no data (0.25 to 1.42) (0.25 to 1.42) 
      1 1 
Nicotinamide 0.29 1.39 0.64 0.83 
  (-0.7 to 1.28) (0.6 to 2.19) (-0.08 to 1.37) (0.35 to 1.3) 
  1 1 1 1 
Caffeine 0.98 0.76   0.83 
  (0.3 to 1.66) (0.29 to 1.23) no data (0.44 to 1.22) 
  1 1   1 
Pyrrolidine 
Dithiocarbamate 
0.47 1.23   0.81 
  (-0.29 to 1.22) (0.41 to 2.05) no data (0.26 to 1.37) 
  1 1   1 
Antibody BBS1     0.8 0.8 
  no data no data (-0.21 to 1.8) (-0.21 to 1.8) 
      2 2 
TSG   0.62 0.98 0.78 
  no data (0.2 to 1.03) (0.22 to 1.74) (0.27 to 1.3) 
    4 4 4 
LDN-57444     0.75 0.75 
  no data no data (0.09 to 1.41) (0.09 to 1.41) 
      1 1 
Picrotoxin   1.62 0.13 0.73 
  no data (0.24 to 3) (-1.01 to 1.26) (-0.15 to 1.6) 
    1 1 1 
A beta 1-42 0.63 0.88 0.62 0.72 
  (0.32 to 0.94) (0.53 to 1.24) (-0.14 to 1.38) (0.44 to 1) 
  15 13 7 23 
MF tricyclic   0.71   0.71 
  no data (-0.32 to 1.75) no data (-0.32 to 1.75) 
    1   1 
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Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
Rolipram 0.43 0.59 0.83 0.7 
  (-0.38 to 1.24) (0.01 to 1.17) (0.37 to 1.29) (0.37 to 1.03) 
  1 1 4 5 
Pomegranate juice 0.89 0.3   0.68 
  (0.4 to 1.38) (-0.36 to 0.96) no data (0.29 to 1.08) 
  1 1   1 
Uch-L1     0.66 0.66 
  no data no data (0.14 to 1.19) (0.14 to 1.19) 
      2 2 
Antibody BAM-10   0.66   0.66 
  no data (-0.12 to 1.44) no data (-0.12 to 1.44) 
    1   1 
Cerebrolysin 0.66     0.66 
  (0.17 to 1.14) no data no data (0.17 to 1.14) 
  3     3 
Caloric restriction 0.62 0.72   0.61 
  (-0.07 to 1.31) (0.28 to 1.16) no data (0.29 to 0.92) 
  3 2   4 
Progesterone     0.6 0.6 
  no data no data (-0.56 to 1.76) (-0.56 to 1.76) 
      2 2 
Antibody 20.1 (monoclonal)     0.59 0.59 
  no data no data (-0.43 to 1.62) (-0.43 to 1.62) 
      2 2 
Intermittent Fasting 0.54 0.2   0.49 
  (-0.12 to 1.2) (-0.6 to 1.01) no data (-0.06 to 1.04) 
  3 2   4 
NGF     0.48 0.48 
  no data no data (0.16 to 0.81) (0.16 to 0.81) 
      2 2 
Insulin-like Growth factor 1 0.48     0.48 
  (-0.33 to 1.3) no data no data (-0.33 to 1.3) 
  1     1 
Scyllo-cyclohexanehexol 0.41 0.75   0.47 
  (-0.1 to 0.93) (-0.37 to 1.86) no data (0 to 0.94) 
  7 1   7 
Valsartan 0.7 0.24   0.47 
  (0.03 to 1.37) (-0.43 to 0.91) no data (0 to 0.94) 
  4 2   4 
Exercise 0.71 0.24 0.44 0.44 
  (-0.09 to 1.51) (-0.56 to 1.04) (-0.12 to 1) (0.01 to 0.86) 
  2 4 4 8 
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Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
DSP-4     0.44 0.44 
  no data no data (-0.38 to 1.26) (-0.38 to 1.26) 
      2 2 
Antibody NAB61 0.84 0.32   0.44 
  (0.08 to 1.59) (-0.09 to 0.74) no data (0.08 to 0.81) 
  1 1   1 
Lithium 1.67 -0.04 0.03 0.41 
  (0.68 to 2.65) (-0.85 to 0.76) (-0.85 to 0.9) (-0.17 to 1) 
  1 1 1 2 
Donepezil 0.44 0.25 0.71 0.41 
  (-0.02 to 0.9) (-0.29 to 0.8) (-0.03 to 1.44) (0.1 to 0.72) 
  4 4 3 7 
Valproic acid 0.36 0.51   0.41 
  (0 to 0.72) (0 to 1.03) no data (0.11 to 0.7) 
  1 1   1 
Estrogen 0.36 0.06 0.51 0.4 
  (-0.08 to 0.8) (-0.35 to 0.46) (0.28 to 0.75) (0.15 to 0.64) 
  3 3 4 5 
Epi-cyclohexanehexol 0.36 0.3   0.35 
  (-0.31 to 1.04) (-0.78 to 1.38) no data (-0.23 to 0.92) 
  3 1   3 
Paroxetine 0.71 -0.05   0.32 
  (-0.2 to 1.62) (-0.92 to 0.83) no data (-0.31 to 0.95) 
  1 1   1 
Simvastatin 0.43 0.35 0.14 0.31 
  (-0.01 to 0.88) (-0.09 to 0.79) (-0.3 to 0.58) (0.05 to 0.56) 
  1 1 1 1 
Galantamine 0.36 0.27   0.31 
  (-0.1 to 0.82) (-0.24 to 0.77) no data (-0.11 to 0.73) 
  4 4   4 
Antibody 1560 0.06 0.82 -0.32 0.3 
  (-0.92 to 1.03) (-0.32 to 1.96) (-1.3 to 0.67) (-0.21 to 0.81) 
  2 2 2 2 
MDVFMKGLSMAKE 0.3     0.3 
  (-0.84 to 1.44) no data no data (-0.84 to 1.44) 
  1     1 
A beta 1-30     0.29 0.29 
  no data no data (-0.66 to 1.24) (-0.66 to 1.24) 
      4 4 
Memantine 0.41 0.26 0.24 0.28 
  (0.04 to 0.78) (-0.15 to 0.67) (-0.45 to 0.93) (-0.03 to 0.58) 
  5 4 4 9 
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Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
Bacopa Monniera     0.27 0.27 
  no data no data (-0.19 to 0.72) (-0.19 to 0.72) 
      2 2 
Rivastigmine 0.39 0.09   0.21 
  (-0.38 to 1.17) (-0.55 to 0.73) no data (-0.28 to 0.7) 
  2 2   2 
Flurbiprofen   0.19   0.19 
  no data (-0.17 to 0.56) no data (-0.17 to 0.56) 
    2   2 
PBD150 0.12 0.12 0.25 0.18 
  (-1.16 to 1.41) (-0.93 to 1.17) (-0.62 to 1.11) (-0.41 to 0.77) 
  1 1 4 5 
Metyrapone     0.14 0.14 
  no data no data (-0.61 to 0.89) (-0.61 to 0.89) 
      1 1 
Minocycline 0.13     0.13 
  (-1.75 to 2.01) no data no data (-1.75 to 2.01) 
  2     2 
Learning 0.17 0.08   0.12 
  (-0.39 to 0.73) (-0.25 to 0.41) no data (-0.17 to 0.41) 
  7 8   15 
Typical Western Diet 0.12     0.12 
  (-0.86 to 1.09) no data no data (-0.86 to 1.09) 
  1     1 
Lipid Neutral Diet 0.11     0.11 
  (-0.87 to 1.08) no data no data (-0.87 to 1.08) 
  1     1 
High Fat diet 0.26 0.4 -0.15 0.09 
  (-0.69 to 1.22) (-0.57 to 1.36) (-0.82 to 0.53) (-0.39 to 0.57) 
  1 1 1 1 
Aluminium 0.26 0.01   0.09 
  (-0.72 to 1.25) (-0.68 to 0.71) no data (-0.47 to 0.66) 
  1 1   1 
Metrifonate 0.03     0.03 
  (-0.5 to 0.55) no data no data (-0.5 to 0.55) 
  1     1 
celecoxib     -0.04 -0.04 
  no data no data (-0.43 to 0.35) (-0.43 to 0.35) 
      3 3 
EFRH -0.05     -0.05 
  (-0.64 to 0.55) no data no data (-0.64 to 0.55) 
  3     3 
     
     
                                                                      Chapter 6: Intervention specific analyses 
281 
 
Table 6.4: Summary estimates of effect (standardised effect size), 95% confidence 
limits and number of experiments for each intervention behaviourally tested. Each 
estimate is assigned a heat map colour as explained in the key. 
Drug Acquisition  Probe Other Combined 
  SMD Effect size SMD Effect size SMD Effect size SMD Effect size 
  (95 % CI) and N (95 % CI) and N (95 % CI) and N (95 % CI) and N 
Tau379–408     -0.22 -0.22 
  no data no data (-1.02 to 0.59) (-1.02 to 0.59) 
      1 1 
a beta 1-16     -0.23 -0.23 
  no data no data (-1.76 to 1.3) (-1.76 to 1.3) 
      1 1 
B-vitamin Deprivation -0.25     -0.25 
  (-1.16 to 0.65) no data no data (-1.16 to 0.65) 
  1     1 
Mild brain trauma -0.26     -0.26 
  (-1.02 to 0.49) no data no data (-1.02 to 0.49) 
  2     2 
DHA -0.26     -0.26 
  (-1.24 to 0.72) no data no data (-1.24 to 0.72) 
  1     1 
impoverished housing   -0.56 -0.12 -0.4 
  no data (-1.58 to 0.46) (-1.5 to 1.27) (-1.22 to 0.42) 
    1 1 1 
Pioglitazone -0.22 -0.65   -0.54 
  (-1.61 to 1.17) (-1.51 to 0.2) no data (-1.26 to 0.19) 
  1 1   1 
Dicyclomine 0.13 -1.14   -0.67 
  (-1.03 to 1.29) (-2.03 to -0.24) no data (-1.37 to 0.04) 
  1 1   1 
Sucrose Sweetened Water -0.8 -1.25 -0.37 -0.76 
  (-1.91 to 0.3) (-2.09 to -0.42) (-1.1 to 0.36) (-1.26 to -0.27) 
  1 1 1 1 
Isolation Stress     -1.07 -1.07 
  no data no data (-1.9 to -0.23) (-1.9 to -0.23) 
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6.4 Interpreting intervention analyses 
 
6.4.1 Summary of findings 
 
 
Overall I identified 357 interventions tested in transgenic mouse models of AD. Few 
interventions were tested on more than one occasion and only 4% (16 of 357) report 
outcomes in 5 publications or more. This limits the reliability of individual 
intervention estimates and also prevents us performing dose response analyses. 
Nevertheless, I was able to examine amyloid fragments in further detail where I 
identified that gene immunisation was generally more effective at reducing 
pathological outcomes than peptide immunisation and that N terminal fragments 
were just as effective as full length amyloid beta 1-42. 
6.4.2 Implications of findings 
 
While the breadth of interventions tested is extensive, the depth of knowledge on 
any specific intervention is limited. From the data identified, there are only a 
handful of interventions where preclinical transgenic studies provide sufficient data 
for reliable estimates. Considering that most of these interventions appear to work, 
the field may benefit from exploring how much data remains unpublished, both 
collectively and specifically for each outcome measure. While Chapter 7 investigates 
missing negative or neutral data in further detail, the reader should bear in mind 
that positive studies may also never reach publication.
                                                                Chapter 7: Study quality and publication bias 
283 
 
Chapter 7: Study quality and publication bias  
 
Our understanding of how study quality items or publication bias may influence 
our preclinical trials in AD is relatively unknown. This chapter assesses the impact 
of aggregate study quality and individual study quality items on pathological and 
neurobehavioural outcomes. I subsequently assess an additional study quality item 
to examine whether the presence of a wild type group impacts on behavioural 
outcomes. Data are assessed for the presence of publication bias through Egger 
regression, Funnel plotting and ‘Trim and fill’ techniques.  
7.1 Study quality items 
 
7.1.1 Total Study quality Score 
 
I performed a stratified analysis to assess the potential impact of aggregate study 
quality on pathology and behaviour overall, and for individual outcomes (see Table 
7.1 for overview). For pathological outcomes, I observed that aggregate study 
quality (defined by the individual components of blinding, randomisation, conflict 
of interest, compliance with animal welfare legislation) accounted for a significant 
proportion of the observed heterogeneity (χ 2=142, 725 observations, p<0.01, Table 
7.1) however there was no clear relationship between study quality and effect size. 
Similarly, stratifying neurobehavioral summary data accounted for a significant 
proportion of the observed heterogeneity but a clear relationship could not be 
defined (χ 2=10.4, p<0.01, 259 observations, Table 7.1). 




I observed that stratifying individual outcome measures by overall study quality 
score could explain a significant proportion of the heterogeneity in four out of six of 
the main pathological outcomes (See Table 7.1 and Figure 7.1 for overview of 
individual outcomes). Although stratifications proved significant regarding plaque 
burden (χ 2=110, p<0.01, Figure 7.1a), amyloid beta 40 (χ 2=9.27, p<0.01, Figure 7.1b) 
amyloid beta 42 (χ 2=23.3, Figure p<0.01, 7.1c), tau neurofibrillary tangles (χ 2=13.4, 
p<0.01, Figure 7.1d) it was not possible to identify clear relationships between study 
quality and effect size. Stratifying results from cell infiltrates did however suggest a 
relationship, with greater effect sizes associated with higher study quality (χ 2=129, 
p<0.01, Figure 7.1e). Stratification of neurodegeneration outcomes did not explain a 
significant proportion of the heterogeneity. 
 
For individual behavioural outcomes, stratifying outcomes for the acquisition phase 
of the MWM by study quality suggested a modest inverse relationship between 
study quality and effect size but this did not account for a significant proportion of 
heterogeneity (p<0.01, Figure 7.1g).I observed that for outcomes from the probe 
phase of the MWM, there was an inverse relationship between study quality and 
intervention efficacy (χ 2=13.8, p<0.01, Figure 7.1h). As other neurobehavioral studies 
had fewer studies, I combined data from the Fear conditioning, RAWM, NORT, and 
the Y and T maze to increase power. However this did not account for a significant 
proportion of the observed heterogeneity (123 observations, χ2= 6.4, p<0.01, Figure 
7.1I). 





Outcome measure Aggregate Study Quality Combined 
 0 1 2 3 4 
Plaque burden* 1.07 SD 0.79 SD 0.89 SD 1.67 SD 1.24 SD 0.98 SD 
(antibody stained) (0.85 to 1.29) (0.60 to 0.98)  (0.7 to 1.08) (1.25 to 2.08) (0.52 to 1.97)  (0.87 to 1.1) 
  91 151 99 35 2 378 (χ 2= 110) 
Amyloid beta 40 1 SD 0.72 SD 0.45 SD 0.73 SD -0.13 SD 0.68 SD 
  (0.7 to 1.29) (0.56 to 0.87)  (0.27 to 0.62) (0.34 to 1.12) (-0.78 to 0.53)  (0.57 to 0.79) 
  68 211 81 27 1 388 (χ 2= 9.27) 
Amyloid beta 42* 1.21 SD 0.66 SD 0.72 SD 0.87 SD -0.24 SD 0.78 SD 
   (0.92 to 1.5) (0.51 to 0.8) (0.51 to 0.93) (0.51 to 1.22)  (-0.9 to 0.43)  (0.67 to 0.88) 
  70 201 81 36 1 389 (χ 2= 23.3) 
NFT* 0.49 SD 0.57 SD 0.64 SD 0.73 SD   0.55 SD 
   (0.19 to 0.78) (0.32 to 0.83)  (0.09 to 1.2) (0.31 to 1.14) No studies  (0.38 to 0.72) 
  15 52 6 11   84 (χ 2= 13.4) 
Cell infiltrates*  0.04 SD 0.34 SD 0.23 SD 1.53 SD   0.4 SD 
   (-0.48 to 0.56)  (-0.01 to 0.7)  (-0.3 to 0.77) (0.64 to 2.41) No studies  (0.13 to 0.68) 
  20 30 27 12   89 (χ 2= 129) 
Neurodegeneration  0.54 SD 0.99 SD 0.94 SD 0.91 SD   0.91 SD 
 (-0.25 to 1.33)  (0.6 to 1.38) (0.64 to 1.23) (0.21 to 1.62) No studies  (0.69 to 1.12) 
7 24 25 8   64 (χ 2= 2.8) 
 0.96 SD 0.72 SD 0.65 SD 1.09 SD 0.66 SD 0.78 SD 
Total Pathology  (0.8 to 1.13) (0.62 to 0.82)  (0.52 to 0.78)  (0.82 to 1.37)  (0.35 to 0.97)  (0.71 to 0.85) 
 146 348 164 65 2 725 (χ 2=142) 
Acquisition phase 
of MWM  
0.52 SD 0.59 SD 0.42 SD 0.46 SD   0.49 SD 
 (0.3 to 0.73) (0.41 to 0.77)  (0.27 to 0.57) (0.22 to 0.69) No studies  (0.41 to 0.58) 
25 50 29 26   130 (χ 2= 1.59) 
Probe  phase of 
MWM*  
0.72 SD 0.84 SD 0.4 SD 0.41 SD   0.63 SD 
 (0.4 to 1.03)  (0.6 to 1.07) (0.22 to 0.58) (0.08 to 0.75) No studies  (0.5 to 0.76) 
24 47 26 16   113 (χ 2= 13.8) 
Other NBS studies* 0.78 SD 0.69 SD 0.56 SD 1.05 SD  0.72 SD 
(0.51 to 1.05) (0.49 to 0.89) (0.34 to 0.79) (0.63 to 1.46) No studies  (0.59 to 0.84) 
28 39 38 18  123 (χ 2= 6.4) 
Total Behaviour 
0.65 SD 0.70 SD 0.46 SD 0.64 SD   0.61 SD 
 (0.49 to 0.82)  (0.57 to 0.84)  (0.33 to 0.58)  (0.44 to 0.85) No studies   (0.54 to 0.69) 





Table 7.1: I stratified outcomes to identify whether there was an association between 
effect size and overall study quality. For each outcome, summary estimates are 
provided regarding effect size, 95% confidence limits and number of experiments 
alongside chi squared value (χ2), *represents stratifications which accounted for a 
significant proportion of the observed heterogeneity. 















Plaque burden Amyloid beta 40 Amyloid beta 42
(D)
Tau Cellular infiltrates Neurodegeneration
Quality Score

































































































































































































































































































(G) Acqusition phase of the MWM (H) Probe phase of the MWM
Quality Score








































































































































Figure 7.1: I stratified outcomes to identify whether there was an association between 
effect size and overall study quality. For each outcome, grey bar represents 95% 
confidence limit (CI) of global estimate, error bars represent 95% CI of summary estimates 
and bar width represents the log of the number of animals. 
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7.1.2 Blinded assessment of outcome 
 
 
I performed a stratified analysis in order to assess the impact of blinded assessment 
of outcome on pathological and behaviour overall, and for individual outcomes (see 
Table 7.2 for summary and Figure 7.2 for overview of individual outcomes). 
Stratification of pathological and neurobehavioral outcomes did not account for a 
significant proportion of the observed heterogeneity (725 observations and 259 
observations respectively, Table 7.2).  
 
I observed that stratifying results by the presence of blinding could explain a 
significant proportion of the heterogeneity in one of the six main pathological 
outcomes (See table 7.2 for overview). For cell infiltrates, the presence of blinding 
was associated with higher estimates of efficacy (0.55 SD [95% CI -0.11 to 1.22] vs. 
0.35 SD [0.08 to 0.61], Figure 7.2e). I did not identify any individual behavioural 
outcome measure where stratifying data by the presence of blinding accounted for a 


















Yes No   df=1 
Plaque burden* 1.15 SD 0.91 SD 0.98 SD   
 (antibody stained)  (0.89 to 1.4)  (0.79 to 1.04)  (0.87 to 1.1) χ2 = 0.15 
  93 285 378 Non Sig. 
Amyloid beta 40 0.46 SD 0.75 SD 0.68 SD   
   (0.26 to 0.66)  (0.63 to 0.88)  (0.57 to 0.79) χ2 = 5.17 
  68 320 388 Non Sig. 
Amyloid beta 42 0.58 SD 0.85 SD 0.78 SD   
   (0.39 to 0.77)  (0.72 to 0.97)  (0.67 to 0.88) χ2 = 5.88 
  82 307 389 Non Sig. 
NFT* 0.89 SD 0.51 SD 0.55 SD   
   (0.3 to 1.48)  (0.33 to 0.69)  (0.38 to 0.72) χ2 = 3.16 
  14 70 84 Non Sig. 
Cell infiltrates* 0.55 SD 0.35 SD 0.4 SD   
   (-0.11 to 1.22)  (0.08 to 0.61)  (0.13 to 0.68) χ2= 12.2 
  28 61 89 Sig 
Neurodegeneration  0.80 SD 1 SD 0.91 SD   
 (0.51 to 1.1)  (0.7 to 1.3)  (0.69 to 1.12) χ2 = 0.11 
22 42 64 Non Sig. 
 0.72 SD 0.8 SD 0.78 SD  
Total Pathology  (0.56 to 0.88)  (0.72 to 0.87)  (0.71 to 0.85) χ2= 0.00 
 139 586 725 Non Sig 
Acquisition phase of 
MWM  
0.39 SD 0.51 SD 0.49 SD   
 (0.14 to 0.64)  (0.42 to 0.61)  (0.41 to 0.58) χ2 = 0.73 
18 112 130 Non Sig. 
Probe  phase of MWM 0.36 SD 0.67 SD 0.63 SD   
 (0 to 0.71)  (0.53 to 0.81)  (0.5 to 0.76) χ2 = 3 




0.88 SD 0.68 SD 0.72 SD   
 (0.63 to 1.13)  (0.54 to 0.82)  (0.59 to 0.84) χ2= 4.41 
19 104 123 Non Sig. 
 0.58 SD 0.66 SD 0.61 SD  
Total Behaviour  (0.4 to 0.77)  (0.53 to 0.70)  (0.54 to 0.69) χ2= 0.00 






Table 7.2: I stratified outcomes to identify whether there was an association between 
effect size and blinded assessment of outcome. For each outcome, summary estimates 
are provided regarding effect size, 95% confidence limits and number of experiments 
alongside chi squared value (χ2), *represents stratifications which accounted for a 
significant proportion of the observed heterogeneity. 
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(G) Acqusition phase of the MWM (H) Probe phase of the MWM Other behavioural paridigms
(I)





































































































































































































































































































































































































































































Figure 7.2: I stratified outcomes to identify whether there was an association 
between effect size and blinded assessment of outcome. For each outcome, grey 
bar represents 95% confidence limit (CI) of global estimate, error bars represent 
95% CI of summary estimates and bar width represents the log of the number of 
animals. 




7.1.3 Random allocation to group 
 
 
I performed a stratified analysis in order to assess the impact of random allocation 
to group on pathological and behaviour overall, and for individual outcomes (see 
Table 7.3 and Figure 7.3 for overview of individual outcomes). For pathological 
outcomes, I observed that stratifying data according to whether experimental cohort 
were randomised or not accounted for a significant proportion of the observed 
heterogeneity (χ 2 =41.2, p<0.01, 725 observations, Table 7.3). Stratifying 
neurobehavioral summary data did not account for a significant proportion of the 
observed heterogeneity (259 observations, Table 7.3). 
 
I observed that stratifying data according to the presence of randomisation could 
explain a significant proportion of heterogeneity in two individual pathological 
outcomes, plaque burden and cell infiltrates. For plaque burden marginally smaller 
estimates of effect size were obtained from randomised experiments compared to 
non-randomised experiments (0.96 SD [0.70 to 1.21] vs. 0.99 SD [0.86 to 1.12], 
Figure7.3a). For cell infiltrates the converse was true where higher estimates of 
effect size were found in randomised experiments (Figure 7.3e). For 
neurobehavioral studies the combined data from Fear conditioning, RAWM, NORT, 
stratification by random allocation to group did not account for a significant 
proportion of the observed heterogeneity. 
 

















Yes No  df=1 
Plaque burden* 0.96 SD 0.99 SD 0.98 SD   
 (antibody stained)  (0.7 to 1.21)  (0.86 to 1.12)  (0.87 to 1.1) χ2 = 24.98 
  55 323 378 Sig. 
Amyloid beta 40 0.69 SD 0.68 SD 0.68 SD   
   (0.41 to 0.97)  (0.56 to 0.79)  (0.57 to 0.79) χ2 = 4.53 
  54 334 388 Non sig. 
Amyloid beta 42 1.06 SD 0.73 SD 0.78 SD   
   (0.74 to 1.38)  (0.62 to 0.84) (0.67 to 0.88) χ2 = 1.09 
  55 334 389 Non sig. 
NFT* 0.51 SD 0.56 SD 0.55 SD   
   (0.19 to 0.83)  (0.36 to 0.76)  (0.38 to 0.72) χ2 = 1.02 
  17 67 84 Non sig. 
Cell infiltrates*  1.03 SD 0.3 SD 0.4 SD   
   (0.23 to 1.84)  (0.02 to 0.58)  (0.13 to 0.68) χ2 = 90.8 
  12 77 89 Sig. 
Neurodegeneration  0.67 SD 0.97 SD 0.91 SD   
 (0.27 to 1.08)  (0.73 to 1.22)  (0.69 to 1.12) χ2 = 4.14 
15 49 64 Non sig. 
 0.84 SD 0.77 SD 0.78 SD  
Total pathology  (0.65 to 1.02)  (0.7 to 0.85)  (0.71 to 0.85) χ2 = 41.15 
 114 611 725 Sig 
Acquisition phase 
of MWM  
0.43 SD 0.52 SD 0.49 SD   
(0.28 to 0.59) (0.41 to 0.63) (0.41 to 0.58) χ2 = 0.57 
41 89 130 Non sig. 
Probe  phase of 
MWM  
0.44 SD 0.71 SD 0.63 SD   
 (0.23 to 0.65)  (0.55 to 0.88)  (0.5 to 0.76) χ2 = 3.86 




0.60 SD 0.74 SD 0.72 SD  
 (0.30 to 0.90)  (0.60 to 0.88)  (0.59 to 0.84) χ 2 = 0.13 
23 100 123 Non. sig 
 0.51 SD 0.64 SD 0.61 SD  
Total Behaviour*  (0.36 to 0.66)  (0.56 to 0.73)  (0.54 to 0.69) χ2 = 6.27 
 62 197 259 Non. sig 
Table 7.3: I stratified outcomes to identify whether there was an association 
between effect size and random allocation to group. For each outcome, summary 
estimates are provided regarding effect size, 95% confidence limits and number of 
experiments alongside chi squared value (χ2), *represents stratifications which 
accounted for a significant proportion of the observed heterogeneity. 




Plaque burden Amyloid beta 40 Amyloid beta 42
(D) Tau Cellular infiltrates Neurodegeneration
(E) (F)
(G) Acqusition phase of the MWM
(H) Probe phase of the MWM Other behavioural paridigms(I)
























































































































































































































































































































































































































































Figure 7.3: I stratified outcomes to identify whether there was an association between 
effect size and random allocation to group. For each outcome, grey bar represents 
95% confidence limit (CI) of global estimate, error bars represent 95% CI of summary 
estimates and bar width represents the log of the number of animals. 
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7.1.4 Statement regarding a conflict of interest 
 
I performed a stratified analysis in order to assess the impact of a statement 
regarding a conflict of interest on overall pathological and behaviour, and for 
individual outcomes (see Table 7.4 for summary and Figure 7.4 for overview of 
individual outcomes). For pathological outcomes, I observed that stratifying data 
according to a statement regarding a conflict of interest accounted for a significant 
proportion of the observed heterogeneity (χ 2 =70.4, p<0.01, 725 observations, Table 
7.4). Similarly, stratifying neurobehavioral summary data accounted for a significant 
proportion of the observed heterogeneity where higher estimates of efficacy were 
found with a presence of the study quality item (0.75 SD [0.59 to 0.90] vs. 0.58 SD 
[0.49 to 0.66], χ 2 =8.15). 
 
For individual pathological outcomes stratifying both plaque burden and amyloid 
beta 40 outcomes by a conflict of interest explained a significant proportion of 
heterogeneity where estimates were higher when present opposed not when not (χ 2 
=76.8 [Figure 7.4a], and  χ 2= 10.1 p<0.01 [Figure 7.4b], p<0.01 respectively) . 
Although stratifying amyloid beta 42 data proved significant in terms of 
heterogeneity, I did not identify differences in estimates (χ 2= 6.81).I did not identify 
any individual behavioural outcome measures where stratifying data by a conflict 
of interest could account for a significant proportion of the observed heterogeneity. 
 








Yes No   df=1 
Plaque burden* 1.5 SD 0.84 SD 0.98 SD   
 (antibody stained)  (1.23 to 1.76)  (0.72 to 0.97)  (0.87 to 1.1) χ2 = 76.8 
  72 306 378 Sig. 
Amyloid beta 40* 0.76 SD 0.67 SD 0.68 SD   
   (0.54 to 0.99)  (0.55 to 0.78)  (0.57 to 0.79) χ2 = 10.1 
  57 331 388 Sig. 
Amyloid beta 42 0.8 SD 0.77 SD 0.78 SD   
   (0.58 to 1.01)  (0.66 to 0.89)  (0.67 to 0.88) χ2 = 6.81 
  67 322 389 Sig 
NFT 0.35 SD 0.59 SD 0.55 SD   
   (0.03 to 0.66)  (0.4 to 0.78)  (0.38 to 0.72) χ2 = 0.07 
  5 79 84 Non sig 
Cell infiltrates  0.69 SD 0.31 SD 0.4 SD   
   (0.08 to 1.3) (-0.01 to 0.63)  (0.13 to 0.68) χ2 = 0.01 
  21 68 89 Non sig 
 
Neurodegeneration  
0.97 SD 0.88 SD 0.91 SD   
 (0.55 to 1.39)  (0.63 to 1.13)  (0.69 to 1.12) χ2 = 0.09 
14 50 64 Non sig 
 0.93 SD 0.75 SD 0.78 SD  
Total pathology*  (0.77 to 1.09)  (0.67 to 0.83)  (0.71 to 0.85) χ2 = 70.4 
 118 607 725 Sig 
Acquisition phase of 
MWM  
0.52 SD 0.49 SD 0.49 SD   
 (0.33 to 0.72)  (0.39 to 0.60)  (0.41 to 0.58) χ2 = 0.16 
27 103 130 Non sig 
Probe  phase of 
MWM*  
0.82 SD 0.60 SD 0.63 SD   
 (0.54 to 1.1)  (0.45 to 0.74)  (0.5 to 0.76) χ2 = 4.99 




0.89 SD 0.67 SD 0.72 SD   
 (0.61 to 1.16)  (0.53 to 0.81)  (0.59 to 0.84) χ2 = 5.13 
33 90 123 Non sig 
 0.75 SD 0.58 SD 0.61 SD  
Neurobehaviour*  (0.59 to 0.90)  (0.49 to 0.66)  (0.54 to 0.69) χ2 = 8.15 




   
Yes No Combined 
  
Table 7.4: I stratified outcomes to identify whether there was an association between 
effect size and a statement regarding conflicts of interest. For each outcome, summary 
estimates are provided regarding effect size, 95% confidence limits and number of 
experiments alongside chi squared value (χ2), *represents stratifications which 
accounted for a significant proportion of the observed heterogeneity. 
 




Plaque burden Amyloid beta 40 Amyloid beta 42
(D) Tau Cellular infiltrates Neurodegeneration
(E) (F)
(G) Acqusition phase of the MWM
(H) Probe phase of the MWM Other behavioural paridigms(I)




























































































































































































































































































































































































































































Figure 7.4: I stratified outcomes to identify whether there was an association 
between effect size and statement regarding a conflict of interest. For each outcome, 
grey bar represents 95% confidence limit (CI) of global estimate, error bars 
represent 95% CI of summary estimates and bar width represents the log of the 
number of animals. 
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7.1.5 Compliance with animal welfare legislation 
 
I performed a stratified analysis in order to assess the impact of a compliance with 
animal welfare legislation on overall pathological and behaviour, and for individual 
outcomes (see Table 7.5 for summary and Figure 7.5 for overview of individual 
outcomes). For pathological outcomes overall, I observed that stratifying data 
according to a statement regarding compliance with animal welfare legislation did 
not account for a significant proportion of the observed heterogeneity. Similarly, 
neurobehavioral experiments overall did not account for a significant proportion of 
the observed heterogeneity. 
 
When observing individual pathological outcomes, I identified that amyloid beta 40 
(Table 7.5b) and amyloid beta 42 (Table 7.5c) had lower estimates of efficacy with 
the presence of the study quality feature (χ2 = 7.58 and χ2 = 18.8, p<0.01 respectively). 
Conversely, I observed that for outcomes regarding cell infiltrates and 
neurodegeneration higher estimates of efficacy were present where studies reported 
a compliance with animal welfare legislation feature (χ2 = 57.3 and χ2 = 10.9, p<0.01 
respectively). I did not identify any an associations between neurobehavioural 
estimates of efficacy and whether or not publications stated a compliance with 
animal welfare legislation. 
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(A) (B) (C)Plaque burden Amyloid beta 40
Amyloid beta 42
(D) Tau Cellular infiltrates Neurodegeneration
(E) (F)
(G) Acqusition phase of the MWM





























































































































































































































































































































































































































































Figure 7.5: I stratified outcomes to identify whether there was an association 
between effect size and compliance with animal welfare legislation. For each 
outcome, grey bar represents 95% confidence limit (CI) of global estimate, error 
bars represent 95% CI of summary estimates and bar width represents the log of the 
number of animals. 










Yes No   df=1 
Plaque burden 0.94 SD 1.05 SD 0.98 SD   
(antibody stained)  (0.8 to 1.09)  (0.86 to 1.24)  (0.87 to 1.1) χ2 = 0.96 
 233 145 378 Non Sig. 
Amyloid beta 40* 0.6 SD 0.84 SD 0.68 SD   
   (0.47 to 0.73)  (0.65 to 1.03)  (0.57 to 0.79) χ2 = 7.58 
  263 125 388 Sig 
Amyloid beta 42* 0.71 SD 0.91 SD 0.78 SD   
   (0.58 to 0.83)  (0.73 to 1.09)  (0.67 to 0.88) χ2 = 18.8 
  255 134 389 Sig 
NFT 0.68 SD 0.44 SD 0.55 SD   
   (0.42 to 0.95)  (0.21 to 0.67)  (0.38 to 0.72) χ2= 2.1 
  49 35 84 Non Sig. 
Cell infiltrates*  0.62 SD 0.00 SD 0.4 SD   
   (0.26 to 0.98)  (-0.4 to 0.4)  (0.13 to 0.68) χ2 = 57.3 
  57 32 89 Sig 
Neurodegeneration  1.08 SD 0.53 SD 0.91 SD   
 (0.81 to 1.35)  (0.27 to 0.79)  (0.69 to 1.12) χ2 = 10.9 
44 20 64 Sig 
 0.77 SD 0.81 SD 0.78 SD  
Pathology  (0.68 to 0.85)  (0.7 to 0.93)  (0.71 to 0.85) χ2 = 1.86 
 472 253 725 Non Sig. 
Acquisition phase of 
MWM  
0.47 SD 0.54 SD 0.49 SD   
 (0.38 to 0.57)  (0.35 to 0.73)  (0.41 to 0.58) χ2 = 0.28 
91 39 130 Non Sig. 
Probe  phase of MWM*  0.54 SD 0.85 SD 0.63 SD   
 (0.39 to 0.68)  (0.57 to 1.13)  (0.5 to 0.76) χ2 = 3.03 
77 36 113 Non Sig. 
Other neurobehavioural 
studies 
0.68 SD 0.78 SD 0.72 SD   
 (0.53 to 0.84)  (0.56 to 1)  (0.59 to 0.84) χ2= 0.07 
79 44 123 Non Sig. 
 0.56 SD 0.71 SD 0.61 SD  
Neurobehaviour  (0.48 to 0.65)  (0.57 to 0.86)  (0.54 to 0.69) χ2 = 2.10 










Table 7.5: I stratified outcomes to identify whether there was an association 
between effect size and compliance with animal welfare legislation. For each 
outcome, summary estimates are provided regarding effect size, 95% confidence 
limits and number of experiments alongside chi squared value (χ2), *represents 
stratifications which accounted for a significant proportion of the observed 
heterogeneity. 




7.1.6 Sample size calculation 
 
No publications presented a sample size calculation so it was not possible to 
quantify the impact of this study quality item. 
7.1.7 Peer review publications 
 
For peer reviewed publications it was not possible to quantify impact as no non 
reviewed literature (i.e. abstracts) contained data possible to include in the meta-
analysis.  
7.2 Presence of a wild type group in neurobehavioral 
outcomes 
 
For neurobehavioral paradigms such as the MWM there is no single ceiling effect 
expected in performance. Therefore most (but not all) publications reported data 
from wild type mice to illustrate the maximum behavioural improvement expected 
within a given paradigm. To further our understanding of whether the presence of a 
wild type group might impact on observed effect size I stratified data according to 
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Our analyses are summarised in Table 7.6. I identified that overall, higher estimates 
of efficacy were associated with the absence of a wild type group however the only 
statistically significant difference was for the NORT where estimates were higher 
where there was a wild type group present. For four out of the six outcomes 
assessed I identified smaller estimates of efficacy where a wild type group was 




Outcome measure Wild type animals present Combined χ 2 
Yes No     
Acquisition phase of 
MWM  
0.45 0.63 0.49   
 (0.35 to 0.55)  (0.45 to 0.8) (0.4 to 0.58) χ2 = 3.1 
94 36 130 Non sig 
Probe  phase of 
MWM 
0.57 0.81 0.63   
 (0.42 to 0.72) (0.54 to 1.08) (0.5 to 0.76) χ2 = 3.04 
85 28 113 Non sig 
Fear conditioning 0.67 0.71 0.7   
  (0.25 to 1.1) (0.49 to 0.93) (0.51 to 0.89) χ2 = 0.001 
  35 10 45 Non sig 
Radial arm water 0.9 0.41 0.86  
maze (0.65 to 1.15)  (-0.75 to 1.56) (0.61 to 1.1) χ2 = 4.15 
  37 4 41 Non sig 
Novel object  1.23 0.62 0.95   
recognition test (0.72 to 1.73) (0.27 to 0.97) (0.63 to 1.27) χ2 = 8.38 
  14 11 25 Sig 
Y-maze/T-maze 0.45 0.47 0.46   
(0.19 to 0.72) (-0.37 to 1.31) (0.21 to 0.71) χ2 = 0.003 
24 4 28 Non sig 
 0.59 0.7 0.61   
Total (0.5 to 0.67)  (0.54 to 0.86) (0.54 to 0.69) χ2 = 1.64 
 194 64 259 Non sig 
Table 7.6: I stratified neurobehavioural outcomes to identify whether there was 
an association between effect size and the presence of a wild type group. For each 
outcome, summary estimates are provided regarding: effect size, 95% confidence 
limits, number of experiments alongside chi squared value (χ2), *represents 
stratifications which accounted for a significant proportion of the observed 
heterogeneity. 
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7.3 Publication bias 
 
I assessed the potential impact of publication bias using Egger regression, Funnel 
plot asymmetry and trim and fill techniques. I first derived estimates of the impact 
on pathology and neurobehavioural outcomes overall. I then repeated the analyses 
on subsets of these datasets using: outcome measures, transgenic model groups and 
brain regions (where relevant). These analyses were performed to address concerns 
that a presence publication bias could reflect systematic difference in experimental 
methodology similar to small study effects. 
 
Investigating individual outcome measures (and brain regions) is crucial to ensure 
the integrity of these initial findings. For example, it could be that those techniques 
used to derive estimates of efficacy for plaque burden provide large and precise 
estimates of effect size. If the converse were true for amyloid beta 40 (small 
imprecise measures of effect size) then this would give the impression of publication 
bias. In truth, such differences described are a reflection of those methodologies 
used not missing studies. 
 
I assessed pathological outcomes overall using Egger regression which indicated a 
presence of publication bias (Figure 7.6a).Funnel plot asymmetry also suggested a 
presence of publication bias with a number of missing negative and imprecise effect 
sizes (Figure 7.6b). A further indication of publication bias was found using trim 
and fill where a suggested baseline efficacy of 0.749 SD (95% CI 0.702 to 0.796, 2517 
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experiments) was reduced to 0.419 SD (0.367 to 0.470) after the inclusion of 783 
missing studies (Figure 7.6c). For neurobehavioral outcomes overall I found a 
presence of publication bias with both Egger regression (Figure 7.6d) and 
publication bias (Figure 7.6e) Trim and fill suggested a baseline efficacy of 0.601 SD 
(95% CI 0.538 to 0.664, 561 experiments) which was reduced to 0.405 SD (0.334 to 
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Pathological outcomes Y Y 
0.749 
0.702 to 0.796 
2517 
0.419 









0.538 to 0.664 
561 
0.405 





Table 7.7: Summary table of assessing pathological outcomes for the presence of 
publication bias through Egger regression, Funnel plot asymmetry and Trim and fill 
techniques. Where Trim and fill identified publication bias both the unadjusted and 
adjusted estimates of efficacy are given alongside the percentage of experiments which are 
hypothesised missing. 





Figure 7.6: Summary data for pathological and neurobehavioral outcomes. 
Pathological outcomes are assessed by (a) Egger regression, (b) Funnel plot 
asymmetry and (c) Trim and fill techniques (missing studies shown in red). 
Likewise neurobehavioural data are assessed through Egger regression, (d) 
Funnel plot asymmetry and (e) Trim and fill techniques (f).  
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Individual Pathological outcomes 
 
7.3.1 Plaque burden 
 
For plaque burden data both Egger regression (Figure 7.7a) and Funnel plot 
asymmetry suggested a degree of publication bias (Figure 7.7b). Trim and fill 
analysis of 632 outcomes suggested a baseline efficacy of 0.999 SD (95 CI 0.905 to 
1.093) revised to 0.610 (95% CI 0.508 to 0.712) after correction for the inclusion of 
data from 154 imputed missing studies Figure 7.7c).  
7.3.2 Amyloid beta 40 
 
For amyloid beta 40 data, both Egger regression (Figure 7.7d) and Funnel plot 
asymmetry suggested a presence of publication bias (Figure 7.7e) which was 
confirmed using trim and fill analysis (Figure 7.7f). 625 outcomes suggested a 
baseline efficacy of 0.635 SD (0.579 to 0.724) which was revised to 0.321 SD (0.221 to 
0.421) after the correction of including data from 124 missing studies. 
 
 
7.3.3 Amyloid beta 42 
For amyloid beta 42 data, Egger regression (Figure 7.8a) and Funnel plotting (figure 
7.8b) suggested a presence of publication bias which was confirmed using trim and 
fill techniques. Data from 632 experiments suggested a baseline efficacy of 0.706 SD 
(0.616 to 0.796) which was reduced to 0.351 SD (0.250 to 0.452) after accounting for 
the estimated 136 missing studies (Figure 7.8c). 
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Figure 7.7: Publication bias analyses for plaque burden (a-c) and amyloid beta 40 
(d-f). Each outcome was assessed for publication bias using Egger regression (a,c), 
Funnel plot asymmetry (b,d) and Trim and Fill techniques (c,f). Missing studies 
from Trim and Fill techniques are shown in red. 
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Figure 7.8: Publication bias analyses for amyloid beta 42 (a-c) and tau (d-f). Each 
outcome was assessed for publication bias using Egger regression (a,c), Funnel plot 
asymmetry (b,d) and Trim and Fill techniques (c,f). Missing studies from Trim and 
Fill techniques are shown in red. 
 





Similar to findings in other outcomes, Egger regression (Figure 7.8d), Funnel 
plotting (Figure 7.6e) of changes in tau pathology suggested an absence of negative 
or neutral studies. Further evidence of publication bias was found using trim and 
fill techniques where baseline efficacy of 0.533 SD (95% 0.400 to 0.666) from 273 
experiments was reduced to 0.285 SD (0.141 to 0.430) after the inclusion of 43 
missing studies (Figure 7.8f).  
 
7.3.5 Cellular Infiltrates 
 
For outcomes regarding cellular infiltrates Egger regression suggested a presence of 
publication bias (Figure 7.9a) but this was not replicated in the Funnel plot 
asymmetry (Figure 7.9b). Assessing such 222 experiments using trim and fill 
techniques did not alter the overall estimate of efficacy and thus the estimate of 
efficacy; 0.561 SD (0.367 to 0.755) remained unchanged (Figure 7.9e). 
7.3.6 Neurodegeneration 
 
For neurodegeneration outcomes a presence of publication bias was visible in both 
Egger regression (Figure 7.9d) and Funnel plot asymmetry (Figure 7.9e). From 133 
studies, the baseline efficacy was estimated to be 0.962 SD (0.784 to 1.140) which 
after trim and fill was revised to 0.764 SD (0.566 to 0.961) after the inclusion of 17 
missing studies(Figure 7.9f). 
 










































































































































Figure 7.9: Publication bias analyses for cellular infilatrates (a-c) and 
neurodegeneration (d-f). Each outcome was assessed for publication bias using 
Egger regression (a,c), Funnel plot asymmetry (b,d) and Trim and Fill techniques 
(c,f). Missing studies from Trim and Fill techniques are shown in red. 
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[Standard Deviations, 
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(0.905 to 1.093) 
632 
0.610 









Amyloid beta 40 Y Y 
0.635 
(0.579 to 0.724) 
625 
0.321 









Amyloid beta 42 Y Y 
0.706 
(0.616 to 0.796) 
632 
0.351 









NFT Y Y 
0.533 
(0.400 to 0.666) 
273 
0.285 









Cell infiltrates Y N 
0.561 
(0.367 to 0.755) 
222 
0.561 









Neurodegeneration Y Y 
0.962  
(0.784 to 1.140)  
133 
0.764  













(0.792 to 1.045) 
331 
0.467    









Table 7.8: Summary table of assessing pathological outcomes for the presence of 
publication bias through Egger regression, Funnel plot asymmetry and Trim and fill 
techniques. Where Trim and fill identified publication bias both the unadjusted and 
adjusted estimates of efficacy are given alongside the percentage of experiments which 
are hypothesised missing. 
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Overall pathology by brain region 
 
 
7.3.7 Hippocampus and Cortex estimates of efficacy 
 
From 2517 comparisons used to provide pathological estimates of efficacy, the 
specific brain region was stated in 1314 (52%). Within these, 92% of estimates were 
either for the hippocampus (658 comparisons) or cortex (549 comparisons). 
Therefore I assessed data from both the cortex and hippocampus for a presence of 
publication bias. 
 
For data from the hippocampus I identified a presence of publication bias with 
Egger regression (Figure 7.10a) and funnel plotting (Figure 7.10b) where I identified 
a number of missing negative effect size, low precision estimates. Such findings 
were confirmed using Trim and Fill where a baseline efficacy of 0.747 SD (95 CI 
0.650 to 0.843) which was reduced to 0.370 SD (95 CI 0.263 to 0.477) after the 
inclusion of 125 missing studies (Figure 7.10c). 
 
For data from the cortex I identified a presence of publication bias with Egger 
regression and funnel plotting (Figure 7.10d and e). These findings were also 
confirmed using Trim and Fill where a baseline efficacy of 0.828 SD (95 CI 0.726 to 
0.930) which was reduced to 0.446 SD (95 CI 0.333 to 0.558) after the inclusion of 108 
missing studies (Figure 7.10f). 
 



































































































































Figure 7.10: Publication bias analyses from the hippocampus (a-c) and cortex (d-
f). Each outcome was assessed for publication bias using Egger regression (a,c), 
Funnel plot asymmetry (b,d) and Trim and Fill techniques (c,f). Missing studies 
from Trim and Fill techniques are shown in red. 
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(0.650 to 0.843) 
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Table 7.9: Summary table of assessing pathological outcomes for the presence of 
publication bias through Egger regression, Funnel plot asymmetry and Trim and 
fill techniques. Where Trim and fill identified publication bias both the 
unadjusted and adjusted estimates of efficacy are given alongside the percentage 
of experiments which are hypothesised missing. 
                                                                Chapter 7: Study quality and publication bias 
313 
 
Individual Neurobehavioral Outcomes 
 
7.3.8 Acquisition phase of Morris water maze 
 
Where I assessed acquisition data I identified an indication of publication bias using 
both Egger regression (Figure 7.11a) and funnel plot asymmetry (Figure 7.11b). Trim 
and fill estimates suggested a baseline efficacy 0.489 SD (0.406 to 0.573) which was 
reduced to 0.353 SD (0.264 to 0.441) after the inclusion of 32 missing studies (Figure 
7.11c) 
7.3.9 Probe phase of Morris water maze 
 
 
Similar to acquisition data, both Egger regression and funnel plot asymmetry 
indicated publication bias for outcomes from the probe phase of the MWM (Figures 
7.11d and 7.11e respectively). Trim and fill analysis of 212 outcomes suggested a 
baseline efficacy of 0.623 SD (95 CI 0.503 to 0.744) which was reduced to 0.400 SD (95 
CI 0.262 to 0.539) after the inclusion of 32 missing studies (Figure 7.11f). To ensure 
the presence of publication bias did not reflect differences in the methods of 
behavioural assessment I performed a sensitivity analysis where only data for ‘time 
in target quadrant’ were used. Trim and fill analysis of 80 outcomes suggested a 
baseline efficacy of 0.688 SD (95 CI 0.534 to 0.842) which was revised to 0.498 (95 CI 
0.324 to 0.672) after correction for the inclusion of data from 15 imputed missing 
studies (not shown). 
  





Figure 7.11: Publication bias analyses for the acquisition phase (a-c) and probe 
phase (d-f) of the Morris water maze (MWM). Each outcome was assessed for 
publication bias using Egger regression (a,c), Funnel plot asymmetry (b,d) and 
Trim and Fill techniques (c,f). Missing studies from Trim and Fill techniques are 
shown in red. 
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7.3.10 Fear conditioning  
 
 
For data regarding fear conditioning, Egger regression suggested publication bias, 
but it was difficult to interpret asymmetry on the funnel plot (Figures 7.12a and 
7.12b respectively). Trim and fill analysis of 60 outcomes suggested a baseline 
efficacy of 0.693 SD (0.495 to 0.890) which was reduced to 0.503 SD (0.297 to 
0.709)after the inclusion of 10 missing studies (Figure 7.12c).  This translated to a 
37.8% reduction in global estimate. 
7.3.11 Radial arm water maze 
 
 
For data from the radial arm water maze Egger regression and Funnel plotting both 
suggested a degree of publication bias (see Figure 7.12d and 7.12e respectively). 
Trim and fill analysis of 52 outcome suggested a baseline efficacy of 0.804 SD (0.585 
to 1.204) which was reduced to 0.507 SD (0.279 to 0.735) after the inclusion of 16 
missing studies (See figure 7.12f).  
 
7.3.12 Novel object recognition task 
 
Both Egger regression and funnel plot asymmetry suggested publication bias was 
present within the NORT dataset (Figure 7.13a and 7.13b respectively). Trim and fill 
analysis of 30 outcomes suggested a baseline efficacy of 0.904 SD (0.62 to 1.119) 
which was reduced to 0.629 SD (0.300 to 0.959) after the inclusion of 6 missing 
studies (Figure 7.13c).  
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Figure 7.12: Publication bias analyses for fear conditioning (a-c) and the radial arm 
water maze. Each outcome was assessed for publication bias using Egger 
regression (a,c), Funnel plot asymmetry (b,d) and Trim and Fill techniques (c,f). 
Missing studies from Trim and Fill techniques are shown in red. 
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7.3.13 T maze & Y maze 
 
 
Both Egger regression and Funnel plot asymmetry suggested a degree of 
publication bias for T maze and Y maze data (Figure 7.13d and e). This was 
subsequently confirmed using Trim and fill analysis: a baseline efficacy of 0.382 SD 
(0.166 to 0.597) from 42 outcomes was reduced to 0.299 SD (0.068 to 0.530) after the 
inclusion of  3 missing studies (figure 7.13f).  
 
7.3.14 Other pathological outcomes 
 
To ensure those datasets analysed for publication bias were not unduly influenced 
by the absence of data previously excluded (e.g. congo red and thioflavins S stained 
plaques, total amyloid beta and oligomer species) I grouped such data together for 
another publication bias analysis. Both Egger regression and funnel plot asymmetry 
suggested a degree of publication bias (See Table 7.9 for summary and Figure 7.14). 
I identified 328 studies which had had a baseline efficacy of 0.927(0.800 to 1.054) 
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7.3.15 Other neurobehavioral outcomes  
 
Equally, to ensure the exclusion of data which did not feature in 10 or more 
publications did not induce a bias in results I performed a sensitivity analysis on 
such data hereafter termed “other neurobehavioral outcomes”. This analysis was 
performed excluding data from the elevated plus maze or open field test (see 
methods) I found a suggestion of publication bias within both Egger regression and 
funnel plotting (Figure 7.14, Table 7.6 for summary) and trim and fill analysis of 85 
outcomes suggested that there were 14 missing outcomes; reducing efficacy from 
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Figure 7.13 Publication bias analyses for novel object recognition task (a-c) and 
combined data from the T-maze and Y-maze. Each outcome was assessed for 
publication bias using Egger regression (a,c), Funnel plot asymmetry (b,d) and Trim 
and Fill techniques (c,f). Missing studies from Trim and Fill techniques are shown in 
red. 
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Figure 7.14: Publication bias analyses for pathological (a-c) and behavioural 
outcomes (d-f) extracted but which were not previously analysed. Each outcome 
was assessed for publication bias using Egger regression (a,c), Funnel plot 
asymmetry (b,d) and Trim and Fill techniques (c,f). Missing studies from Trim and 
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Table 7.9: Summary table of assessing neurobehavioural outcomes for the 
presence of publication bias through Egger regression, Funnel plot asymmetry 
and Trim and fill techniques. Where Trim and fill identified publication bias 
both the unadjusted and adjusted estimates of efficacy are given alongside the 
percentage of experiments which are hypothesised missing. 
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While publication bias was suggested from the pathological dataset overall I 
assessed whether this could be explained by differences between transgenic mouse 
model groups (Table 7.10 and Figures 7.16 to 7.18). I identified that within the APP 
transgenic mouse model group, both Egger regression and funnel plot asymmetry 
suggested publication bias. Such suggestions were also confirmed using trim and 
fill estimates where 1666 comparisons suggested a baseline efficacy of 0.785 (0.727 to 
0.842) which was reduced to 0.447 (0.383 to 0.511) after the inclusion of 331 missing 
studies. 
 
APPS1, 3xTgAD and ‘other ’ transgenic mice all indicated publication bias through 
Egger regression (Figure 7.16d, 7.17a, 7.17d and 7.18a respectively) and funnel plot 
asymmetry (Figure 7.16e, 7.17b, 7.17e and 7.18b respectively). Likewise, trim and fill 
estimates suggested missing negative of neutral studies for APPS, 3xTgAD and 
‘other’ transgenic mice with the largest relative reduction observed in 3xTgAD mice 
where a 332 comparisons suggested a baseline efficacy of 0.504 (0.380 to 0.629) 
which was reduced to 0.261 (0.124 to 0.398) after the inclusion of 47 missing studies 




























































































































Figure 7.16: Publication bias analyses for the APP transgenic group (a-c) and the 
APPPS1 transgenic goup (d-f). Each outcome was assessed for publication bias 
using Egger regression (a,c), Funnel plot asymmetry (b,d) and Trim and Fill 
techniques (c,f). Missing studies from Trim and Fill techniques are shown in red. 
 
































































































































Figure 7.17: Publication bias analyses for the 3xTgAD transgenic group (a-c) and 
the Tau transgenic goup (d-f). Each outcome was assessed for publication bias 
using Egger regression (a,c), Funnel plot asymmetry (b,d) and Trim and Fill 
techniques (c,f). Missing studies from Trim and Fill techniques are shown in red. 
 























































































































Figure 7.18: Publication bias analyses for the ‘other’ transgenic group (a-c). Each 
outcome was assessed for publication bias using Egger regression (a), Funnel plot 
asymmetry (b) and Trim and Fill techniques (c). Missing studies from Trim and Fill 
techniques are shown in red. 
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(0.468 to 0.905) 
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Table 7.10: Summary table of assessing pathological outcomes by individual 
transgene across Egger regression, Funnel plot asymmetry and Trim and fill 
techniques. Where Trim and fill identified publication bias both the unadjusted and 
adjusted estimates of efficacy are given alongside the percentage of experiments 
which are hypothesised missing. 





After identifying publication bias collectively across neurobehavioral outcomes I 
additionally assessed for publication by transgenic model group in order to assess 
whether this could account for potential differences (see Table 7.11 and Figures 
7.19). Within the APP transgenic mouse model group, both Egger regression and 
funnel plot asymmetry suggested publication bias. Such suggestions were 
confirmed using trim and fill where a baseline efficacy of 0.663 SD (0.580 to 0.746) 
from 346 studies was reduced to 0.471 (0.374 to 0.567) after the inclusion of 52 
missing studies. 
 
Similarly, I identified publication bias in both APPPS and 3xTgAD where both 
funnel plotting and Egger regression suggested publication bias was present (Figure 
7.19). For tau, PS and ‘other’ outcomes it was not possible to assess the impact 
publication bias using Trim and fill estimates as there were too few studies present 
for a reliable analysis (5, 7 and 9 comparisons respectively). 
 
 





























































































































































































Figure 7.19: Publication bias analyses for the APP transgenic group (a-c) and the 
APPPS transgenic group (d-f) and 3xTgAD transgenic group (g-i). Each outcome 
was assessed for publication bias using Egger regression (a,c.g), Funnel plot 
asymmetry (b,d,g) and Trim and Fill techniques (c,f,i) where  missing studies 
shown in red. 
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Table 7.11: I assessed whether publication bias was present in behavioural outcomes 
by individual transgene across Egger regression, Funnel plot asymmetry and Trim 
and fill techniques. Where trim and fill identified publication bias both the 
unadjusted and adjusted estimates of efficacy are given alongside the percentage of 
experiments which are hypothesised missing. 
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7.4. Interpreting study quality and publication bias 
analyses 
 
7.4.1 Summary of findings  
 
Overall, study quality across transgenic model experiments is relatively low. For 
individual pathological outcomes the direction of impact in terms of effect size was 
inconsistent across aggregate study quality and individual study quality items. 
 
 
For neurobehavioural outcomes, stratifying outcomes according to reported 
aggregate study quality was also inconclusive. Individual study quality items such 
as blinding and randomisation were frequently associated with smaller estimates of 
effect size but these rarely accounted for a significant proportion of the observed 
heterogeneity. It is likely that some outcomes are more susceptible to the impact of 
blinding, and it may be that behavioural outcome assessment is more subjective 
opposed to pathological outcomes. The presence of a wild type group was 
frequently associated with smaller estimates of effect but this did not prove 
statistically significant. 
 
I identified publication bias for pathological and neurobehavioural outcomes. 
Where I performed analyses on specific outcomes, transgenic model groups and 
brain areas I identified publication bias in all analyses with the exception of trim 
and fill for cellular infiltrates. Overall estimates suggest 1 in 5 pathological 
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experiments and 1 in 7 neurobehavioural remain unpublished which causes a 
relative reduction in efficacy of 78.8% and 48.4% respectively.  
 
 
7.4.2 Implications of findings  
 
I identified that the reporting of fundamental study quality items was relatively 
low. While the empirical data did not suggest statistically significant associations 
between study quality and effect size, randomised and blinded studies were 
consistently associated with smaller neurobehavioural effect sizes. Thus the impacts 
of blinding and randomisation, at least from the empirical data appear to be smaller 
than in animal models of stroke.  
 
The general message from publication bias analyses is clear; there remains a large 
body of missing negative or neutral studies and these substantially revise our 
estimates of efficacy. Such reading is concerning because missing data skews our 
perception of how well interventions perform and is problematic because it 
encourages; (a) clinical trials to be based on incomplete datasets and (b) needless 
repletion of animal experiments at the preclinical trial stage. 
 
To improve the situation I think there is an urgent need for the development of a 
freely accessible online database to summarise experiments conducted in preclinical 
trials in Alzheimer’s disease. In Chapter 8 I discuss efforts made through the work 
of this thesis to provide an online facility where researchers can report data (past or 
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present) from any experiment conducted (and in particular those studies with 
neutral or negative results).  We plan to use data collected for this thesis to help 
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8: Systematic review in other disease models and 
development of an online database in transgenic 
mouse models of Alzheimer’s disease 
 
Across this thesis I identified a number of prominent issues regarding the testing of 
interventions in transgenic mouse models of AD including study quality, study 
methodology and publication bias. Alongside the main focus of this thesis, there 
have been a number of significant projects I have been involved with concerning 
similar themes. For example, issues of study methodology and study quality were 
highlighted in two published articles, one focused on stem cell therapies and the 
other on a survey of studies published in the Journal of Cerebral Blood Flow and 
Metabolism (JCBFM). I have also written a submitted manuscript on the impacts of 
exercise in preclinical models of stroke which is also a proposed preventative 
strategy for AD. Finally, during the course of this PhD we have made some 
potential progress to help address publication bias concerns through providing an 
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8.1 Stem cell-based therapy for experimental stroke 
 
Across neurological disorders including Alzheimer’s disease considerable promise 
has emerged with the use of stem cells. As part of my studies I worked with 
colleagues to further our understanding of the potential weaknesses of the use of 
stem cells in experimental stroke. My specific role was to extract data from 
publications in order to permit subsequent analyses. 
 
From searching four online databases using a number of key search terms we 
identified an initial 6059 publications of which 117 met the inclusion criteria. Within 
these, 70 reported structural and functional outcomes, 11 reported infarct volume 
and 36 reported neurobehaviour alone. The reported study quality within these 
publications was 4 out of a possible 10 (IQR 3-6). For specific measures to avoid bias, 
the reporting of randomisation was stated in 46% of experiments whereas 42% 
reported the blinded assessment of outcome.  
 
In total 187 experiments were reported for infarct volume representing 2332 animals 
and 192 experiments were reported for neurobehavioural outcomes representing 
2704 animals. Interestingly, where we stratified infarct volume data according to 
whether experiments were randomised or not, we found significantly higher 
estimates of efficacy in non-randomised studies. We did not find an impact of 
blinded assessment of outcome or allocation concealment. 
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We assessed experimental data for the prevalence of publication bias across both 
structural and functional outcomes. For structural outcomes we identified 
publication bias using Egger regression and Funnel plot asymmetry and Trim and 
fill identified one missing study. For functional outcomes, Egger regression did not 
suggest publication bias however time and fill suggested 52 missing studies. 
 
We identified a number of aspects of methodology which significantly impacted 
upon observed effect size. For structural outcomes, the use of the 
immunosuppressant cyclosporine A was associated with greater improvements and 
the use of autologous opposed to allogeneic stem cells was also associated with 
greater improvements. Further, we identified that moderation of cells overall was 
associated with improvements in effect. For functional outcomes, the use of the 
immunosuppressant cyclosporine was also associated with greater improvements 
and the use of allogeneic opposed to autologous stem cells was also associated with 
greater improvements. Similar to structural outcomes, the moderation of stem cells 
was associated with significantly greater improvements in effect size. 
 
In summary, we identified a number of weaknesses in the use of stem cells in 
experimental stroke.  Measures to avoid potential bias were not frequently reported 
and there was substantial publication bias identified within the 117 studies. Results 
associated methodological variation with differences in observed effect size further 
demonstrating the need to perform experiments relevant to the clinical setting. 
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8.2: Systematic survey across a year in the Journal of 
Cerebral Blood Flow and Metabolism (JCBFM) 
 
The failure to translate experimental findings from bench to bedside has been a 
prominent issue across medical discipline in recent years. Due to the prominence of 
the issue in cerebrovascular research, concerns have been raised regarding the 
quality and validity of experimental cerebrovascular studies. Therefore, we set out 
to assess study design, statistical analyses, and general experimental reporting over 
a year of original articles within the JCBFM. My specific role was to extract the data 
across all publications which were subsequently directly used in the output within 
the publication. 
 
JCBFM articles from 2008 were subject to a pre-specified checklist which addresses 
issues across the design, age and statistics and reporting of experiments conducted 
(Figure 8.1 for study design questions). A total of 193 publications were published in 
the JCBFM year of 2008 of which 95 (49%) report animal studies, 49 (25%) report in 
vitro experiments, 34 (18%) report human studies, 8 (4%) were review articles and 
29 (15%) articles which were of other types. We therefore took 156 original 
experimental studies forward to checklist assessment. 
 
Results identified that while 97% reported the aim or purpose only 30% of 
publications stated a primary research hypothesis. Across publication identified 
measures to avoid bias such as randomisation, allocation concealment and blinding 
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were reported in less than 20% of publications and only 1% of studies reported 









For the reporting of analyses and statistics, we identified that wherever present 81% 
of publications used appropriate approaches and tests. For reporting variance, more 
than 90% of publications stated error on results of which 46% use standard error of 
the mean, 49% use standard deviation and 4% use conference intervals. 9% of 
publications did not state the variance reported. 
 
In summary this work identifies issues in the conduct and reporting of experimental 
studies in a wider context and is likely to be a reliable representative of published 
neurological research. Similar to work in AD, the lack of: measures to avoid bias 
(blinding, randomisation), sample size calculations and fundamental study 
methodologies are both prevalent and concerning.  
Figure 8.1: 15 principle questions were included in the systematic survey of the 
JCBFM of which 7 are demonstrated within the study design category. Questioned 
addressed aspects of study design, analysis and statistics and reporting. 
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8.3 Exercise in experimental stroke 
 
In recent years the benefits of regular exercise have been proposed as a preventative 
and therapeutic intervention across a range of neurological disorders including 
Alzheimer’s disease. In focal ischemia there have been similar associations, where 
exercise is thought to reduce the risk of stroke and smaller infarcts. However, the 
mechanisms by which this occurs are poorly defined and there is little consensus as 
to which dose would be most beneficial or whether benefits would continue after 
the stroke has occurred. A considerable body of literature exists within animal 
models of focal ischemia and questions such as these were the focus of a meta-
analysis conducted which I was involved with. Working alongside colleagues my 
role was to extract data from the identified publications, perform analyses and help 
write the manuscript. 
 
Our results revealed that the use of exercise either pre or post ischemic stroke is 
associated with statistically significant reductions in infarct volume. Furthermore, 
animals exercised either pre or post ischemic stroke perform significantly better on 
tests of neurobehavioural function than animals receiving no exercise. Exercise 
appeared to be more advantageous when administered prior to, compared with 
after ischemic stroke, both in terms of its effect on reducing infarct volume and 
facilitating the recovery of neurobehavioural function. 
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In accordance with similar systematic reviews of animal models of focal ischemia, I 
found the reporting of study quality items infrequent. While the relationship 
between study quality and effect size in this dataset was unclear, there remains a 
substantial presence of publication bias for neurobehavioural outcomes.  
 
Our stratified analyses suggest that both model- and exercise-specific methodology 
can influence observed outcomes. Examples of these included: type of ischemia and 
method of induction (model specific) alongside whether exercise was forced or 
voluntary or the mode of exercise itself (exercise specific). Further, meta-regression 
suggested that reductions in infarct volume were greatest when exercise was started 
before or soon after ischaemic stroke as opposed taking place much later after a 
stroke. 
 
This work provides the first systematic review and meta-analysis of the use of 
exercise in animal models of focal cerebral ischemia. In summary, I found 
significant structural and behavioural benefits of exercise regardless of whether 
exercise was initiated prior to or after ischemic stroke. Despite such findings, the 
reported study quality was concerning, as was the evidence of publication bias 
within the described literature. Similar to issues in AD, investigators designing 
future experiments of pre- and post- ischemic exercise must be careful to consider 
what is practical for the clinical setting. 
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8.4 An online reporting facility for published data 
 
Across pathological and neurobehavioural data I identified extensive publication 
bias and the creation of an online reporting facility for trials in preclinical AD   (past 
and present) would be a significant step to address this. During the course of my 
PhD studies I have begun the process of developing an online reporting facility in 
collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF). 
 
As part of the grant application for this, I have designed a user interface which 
allows users to choose a desired transgenic model group, outcome, intervention, 
dose or age of administration or assessment range (Figure 8.2). The online database 
is designed to help inform those conducting both preclinical and clinical trials in AD 
with the capacity to: (i) summarise existing data (Figure 8.3) and (ii) perform live 
meta-analyses to ascertain the likelihood of clinical efficacy (Figure 8.4).  
 
While the data included in this thesis provides a systematic overview of 
interventions tested in transgenic models up until January 2009 I appreciate that the 
field is fast developing.  I plan to expand to increase the relevance and scope of data 
collected by: (i) updating this dataset and perform monthly updates to ensure the 
database is current and (ii) extracting data across interventions tested across all pre-
clinical AD animal models. This system would provide a comprehensive and novel 
resource in order to maximise the use of existing data in pre-clinical AD. 
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One concern of such a system which must be taken into account is that individual 
companies may wish to keep their development plans and studies secret. For 
example, smaller companies may have few incentives to share previous 
experimental research with competitors. Therefore it could be that facilitating 










Figure 8.2: I designed a front end user interface for an online database of preclinical 
trials in Alzheimer’s disease which will provide summaries or meta-analyses of 
data selected. Users will be able to specify data according to transgenic model 
group, outcome measure, intervention, dose, units, age at administration and year 
of publication. 












Figure 8.3: Users can summarise existing data according to: intervention tested, 
dose, transgenic model, age at administration, year of publication and link to 
publication. 
Figure 8.4: Users can also summarise existing data using meta-analysis techniques. 
Estimates will be provided as standardised mean difference estimates alongside the 
number of animals, and upper and lower 95 % confidence limits. 
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Chapter 9: General Discussion  
 
The need for efficacious interventions capable of slowing, stopping or reversing 
Alzheimer’s disease symptoms looks certain to increase in the years ahead. The 
aims of this thesis were to inform translational failure through the use of systematic 
review and meta-analysis on interventions tested in transgenic mouse models of the 
condition. In this final chapter I discuss key findings which include; (i) study 
methodology, (ii) study quality, (iii) interventions, (iv) publication bias, (v) 
limitations and (vi) concluding remarks. 
 
In AD (and across neuroscience) the research community is becoming increasingly 
aware of critical shortcomings within pharmaceutical structures; drug discovery is 
high risk and long. It is estimated that 93% of all clinically tested CNS interventions 
fail to make it to the marketplace (7% worse than the market average) and for those 
which do, it takes an average of 12.6 years (Pangalos et al., 2007). 
 
Academia and industry cannot afford to invest indefinitely in AD without realistic 
prospects of return and examining pre-clinical data is only part of the translational 
road block. Insights may be found by scrutinising failed AD clinical trial data, or by 
combining preclinical data synthesis insights and clinical practicalities together as 
demonstrated in hypothermia in stroke (van der Worp et al., 2010). Such 
multidisciplinary approaches allow rational trial design based on empirical data 
and are thus likely to increase our chances of identifying clinical efficacy. 
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9.1 Study methodology  
 
The methodological variation present in studies is clearly extensive; particularly 
with respect to models used and the age at which interventions are administered 
and outcomes assessed. I was able to quantify the impact on a number of 
methodological aspects including: transgenic model group, age, sex, and inspect 
study design features within MWM experiments. 
 
Collectively, the empirical evidence suggests the transgenic model used has an 
impact on the efficacy of interventions, particularly for pathological outcomes, 
(stratifying by transgenic model proved significant for 4 out of 6 outcomes). 
Interestingly, this was not observed for neurobehavioural results where differences 
between transgenic model groups were found in only two of six paradigms. Such 
trends may reflect different spectrums and magnitudes of AD pathologies caused by 
transgenes (e.g. the Tg2576 mouse does not capture tau pathology) whereas 
behavioural deficits are ultimately similar.  Considering that authors are three times 
more likely to report pathological as opposed to neurobehavioural outcome, most 
data are vulnerable to those differences between transgenic models. Factoring that 
few interventions are tested in more than one transgenic model (24 % [84/357]) we  
may increase external validity of pre-clinical studies if interventions can 
demonstrate pathological efficacy across a number of transgenic models. This 
process could be aided through multi-centre animal trials similar to those planned 
in experimental stroke (multi-PART). 
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I identified a number of relationships when assessing the impact of age on outcome 
measures. In agreement with recent literature, experiments were conducted 
relatively early in the mouse lifespan and it was reassuring that neurobehavioural 
effects were smaller at earlier ages of administration and assessment (Zahs and 
Ashe, 2010). To understand this relationship further, I assessed whether 
neurobehavioural deficits changed over time within control animals. Overall, the 
presence of a transgene was associated with significantly worsened neurobehaviour 
at all ages assessed, but not in an age dependent manner. 
 
Defining transgenic model phenotypes (particularly with respect to behaviour) has 
caused controversy in recent years with some studies suggesting that transgenic 
mice have no observable behavioural deficits (Deacon et al., 2008, Westerman et al., 
2002).  While our own data have reflected such concerns, in house meta-analysis 
studies of transgenic data elsewhere have demonstrated the complexities of 
ascertaining a direction of impact for neurobehaviour over time. Despite this, 
experimental data (and indeed the clinical phenotype) suggest that neurobehaviour 
deficits worsen with age (Reed et al., 2010). Our differences observed may be 
attributed to combining control data from different laboratories, transgenic models 
and behavioural paradigms, frequently with low power. There are also significant 
weaknesses in calculating effect size using SMD (see limitations) which must be 
taken into account across all analyses. Thus while increases in neurobehavioural 
intervention efficacy over time do not coincide with an increased magnitude of 
control animal behavioural deficits, results should be interpreted with caution.  




For amyloid beta 40 and 42 intervention administration and assessment in older 
animals and longer durations between administration and assessment were 
associated with smaller intervention effects. Where I assessed the magnitude of 
transgene pathologies I identified that amyloid beta levels reduced  as the mice age, 
in contrast to findings elsewhere that amyloid species increase over time 
(Kawarabayashi. et al., 2001). Further investigation is warranted to try and improve 
our understanding of whether it is the sensitivity of the approach taken which 
implies such a relationship or whether amyloid beta levels do reduce as the 
transgenic mice age. 
 
For outcomes regarding neurodegeneration estimates of efficacy were smaller in 
older ages of administration and assessment but stratifying data did not prove 
statistically significant.  Where I examined APP mice the magnitude of 
neurodegeneration showed a modest increase over time which would be expected 
considering in clinical AD cell loss increases with advancing disease stage.  The 
increasing presence of neurodegeneration within control animals does not coincide 
with improved intervention efficacy (if anything data were suggestive of smaller 
estimates of efficacy at later time points) and reiterates that to prevent 
neurodegeneration, early intervention is required. 
 
For tau outcomes, the impact of age on intervention efficacies and magnitude of 
transgene effect were overall inconclusive. Similarly, data on cellular infiltrates did 
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not demonstrate a direction of effect for intervention analyses overall, or for the 
transgene effect.  
 
Collectively across age related analyses, it is clear that the age at which 
interventions are administered and outcomes assessed can impact on observed 
outcome. Therefore, declaring whether interventions are being tested as 
preventative or therapeutic strategies in preclinical trials is crucial to minimise 
overzealous interpretation of preclinical data. Recently published ADDF guidelines 
recommend such measures (Shineman et al., 2011), and across experimental science 
it is absolutely imperative that we can demonstrate efficacy under those conditions 
which reflect the clinical setting.  
 
For sex analyses, analyses conducted were inconclusive. For pathological outcomes, 
males were associated with higher estimates of efficacy for four out of six outcomes 
but these were frequently marginal, and there was considerable overlapping of 
confidence limits. For neurobehavioural outcomes female transgenic mice were 
associated with greater improvements than males, however the limitations of meta-
analyses were evident as estimates of efficacy for both sexes (i.e. males and females) 
were considerably lower. There is a considerable proportion of literature which 
identifies differences between male and female transgenic mice and it could be that 
our results are inconclusive because I have amalgamated different transgenes 
together within a single transgenic model group. 
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For neurobehavioural experiments, it is clear that the MWM has become the gold 
standard memory test: 64% (165/259) of all neurobehavioural experiments reported 
changes from the paradigm. Within the probe phase of the MWM I observed 
smaller estimates of efficacy at higher water temperatures. Considering that the 
paradigm requires a natural drive for mice to leave the water, it could be that colder 
water temperatures provide a greater degree of negative reinforcement.   
 
Strengths and weaknesses arise when using any neurobehaviour paradigm and 
differences between groups in the MWM can differ according to the methodology 
used (Vorhees and Williams, 2006).  However, reducing the potential impact of 
methodological influence altogether  is complex: empirical evidence suggests that 
animal experiments results will differ even when standardised (Crabbe et al., 1999, 
Richter et al., 2009) and further, systematic variation present across preclinical 
studies is an asset for external validity (Richter et al., 2010). 
 
Therefore, it may be advantageous to embrace the idiosyncrasy of experimental 
research. We may wish however, to advance our understanding of how specific 
methodologies may influence observed differences and consider adjusting estimates 
of efficacy before embarking on clinical trials. What remains critical is that we can 
contextualise findings, which at present could be strengthened by testing wild type 
mice as a transgene negative controls and/or making previous in house 
experimental data available. 
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9.2 Study quality 
 
The lack of reporting of fundamental study quality items was concerning,: less than 
1 in 5 studies reported blinded assessment of outcome or random allocation to 
group and no studies performed a sample size calculation. Such findings are 
relatively similar to animal models of other neurological diseases (Vesterinen et al., 
2010, Sena et al., 2010a, Rooke et al., 2011). For pathological outcomes the 
relationship between study quality and effect was relatively inconsistent. 
Biologically, we might expect that valid hypothetical relationships would be 
reflected across all pathologies, which did not occur. For neurobehavioural 
experiments, the majority of blinded and randomised experiments reported smaller 
estimates of effect but did not prove statistically significant overall. Such results 
could reflect that neurobehavioural experiments are more susceptible to influence 
from such biases and one interpretation could be that the presence of fundamental 
study quality items should be performed as a precautionary measure.  
 
When interpreting the impact of study quality items such as blinding it is important 
to keep in mind that findings may often represent a proxy for another part of the 
study (i.e. it is not clear whether the observed differences are a direct measure of the 
conduct of the studies opposed to a more overall measure of general conduct and 
reporting). Further, blinding or randomisation were generally based on explicit 
statements regarding this, but were open to further scrutiny.   
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The absence of sample size calculations has been identified across experimental 
neuroscience, well beyond experimental AD (Vesterinen et al., 2011). Systematic 
review in multiple sclerosis has identified that animal experiments were 
insufficiently powered to assess differences between groups and across preclinical 
AD the lack of sample size calculations was reflected by low group sizes (Vesterinen 
et al., 2010). While it is accepted that spontaneous transgenic model attrition and 
local availability can pose major challenges to laboratory groups, it remains crucial 
for internal validity that I use sufficient numbers of animals to detect differences 
between groups. Such issues have been addressed in published experimental 
guidelines; the ARRIVE guidelines recommend (at the very least) an explanation of 
how experimental numbers arose (Kilkenny et al., 2010) and recently published 
guidelines from the ADDF promote the use of sample size calculation in 
experimental design (Shineman et al., 2011).  
 
I retrospectively inspected an additional study quality item concerning the use of a 
wild type group, the majority of paradigms (4 out of 6) reported smaller estimates of 
effect where wild type animals were present such findings did not reach statistical 
significance.  Even if findings are coincidental, behavioural paradigms between 
laboratory groups are almost always unique (alongside experimental design). 
Therefore defining differences between wild type and transgenic animals is useful 
to: (i) ensure measurable differences between wild type and transgenic phenotypes 
exist and, (ii) put intervention effects in context with maximal improvement. Again, 
such measures are recommended by the ADDF guidelines (Shineman et al., 2011). 








Our analyses suggested a number of relationships regarding outcome measures in 
particular with respect to amyloid beta and plaque burden. For example, I identified 
strong correlations between the different staining techniques used to assess plaque 
burden and changes in amyloid beta 40 were generally reflective of changes in 
amyloid beta 42. This implies that the clearance of plaques correlate well with the 
clearance of amyloid species and further that the clearance of amyloid beta species 
(at least with respect to amyloid beta 40 and 42) is generally not peptide length 
specific. Meta-regression analyses also identified that changes in plaque pathology 
correlated strongly with changes in tau and particularly prominently with changes 
in neurodegeneration. Such results reflect relationships identified from the amyloid 
cascade hypothesis previously in transgenic mice (Love, 2001, Urbanc et al., 2002) 
 
Thus,  it can be tempting to speculate that numerous results provide evidence in 
favour of the amyloid cascade hypothesis (Hardy, 2003, Pike et al., 1993). However, 
I must be cautious as our analyses do not imply causation- it could be that two 
outcomes are affected simultaneously either directly or indirectly through an 
intermediary. Across those outcome measure relationships identified (both within 
pathology, and between pathology and neurobehaviour), multivariate meta-
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regression or path analysis may help further our understanding of relationships 
identified.  
 
For neurobehavioural experiments, analyses identified a relatively strong 
correlation between the acquisition and probe phase within the use of the MWM. 
Where I analysed data from the acquisition phase at different time points in 
isolation, I identified that as the acquisition phase progressed, observed changes 
became more reflective of those observed in the probe phase. Such results suggest 
that probe phase performance can be explained, at least in part by acquisition phase 
performance. Understanding how the methodology of the MWM impacts on 
detecting differences between groups has been investigated previously, where 
researchers were able to identify that ‘proximity to platform’ within the probe phase 
was the most sensitive outcome measure (Maei et al., 2009). Here, our results 
suggest that there is a strong relationship between the acquisition and probe phase. 
Such hypotheses emphasise the need for both the acquisition and probe results to be 
reported both in full, regardless of whether efficacy is demonstrated or not. 
 
Overall, data suggested 20% of the variation in neurobehaviour could be explained 
by variation in pathological outcomes. Where I looked more specifically within 
pathologies I found that improvements in plaque burden and amyloid beta 40 and 
42 correlated with changes in neurobehaviour (<30%). Such relationships have been 
described in APP Tg2576 mice previously (Westerman et al., 2002) but I did not 
have sufficient data to inspect associations between specific oligomers species which 
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have been frequently suggested to provide associations with behavioural 
performance (Lesne et al., 2006). 
 
For tau pathologies it was surprising that I did not identify a relationship between 
changes in structural outcome and change in functional outcomes as this is often 
perceived to be a better predictor of neurobehaviour than amyloid (Walsh and 
Selkoe, 2004). What our results may reflect are that: (i) few experiments (and 
models) report changes in tau and neurobehaviour and, (ii) for studies which do, 
there appears to be little consensus on how to measure changes in tau (e.g. selecting 
the number of specific phosphorylation sites). There may be benefits if the field 
could reach a consensus on which tau phosphorylation sites are the most important. 
 
Interestingly, the strongest pathological predictor of changes in neurobehaviour was 
neurodegeneration, a finding similar to a number of clinical studies (Terry et al., 
1991, Sze et al., 1997). While I must accept that data overall were limited (20 
experiments) this finding was also shown within APP transgenic models in 
isolation. Thus, data suggest that if I are measuring pathologies as surrogate 
measures of neurobehaviour within AD models, markers of neurodegeneration may 









Across the 357 individual interventions identified, the depth of information 
available for any single intervention was extremely limited. Experiments are 
generally conduced with relatively low group sizes and only one in four 
interventions were tested in more than one transgenic model. In truth, studies were 
more indicative of proof of concept as opposed to studies conducted to reliably 
quantify the likelihood of clinical efficacy. 
 
Hypotheses frequently drive experimental research and this was well represented 
within specific outcomes assessed for given interventions.  For example, of the 22 
experiments which report pathological outcomes on the anti-inflammatory 
intervention LY-411575, 22 report changes in amyloid beta 40 whereas no 
publications reported changes in tau or neurodegeneration. Further, until the AD 
community definitively establishes which pathology (or pathologies) causes 
memory loss, clinical trial design is likely to benefit from establishing portfolios of 
evidence across a range of pathological outcomes. Using existing data on specific 
interventions I are able to (i) identify outcomes where few or no experiments have 
been conducted and (ii) where data do exist, use cumulative meta-analysis to guide 
where experiments are needed most. It is accepted that I face biological limits to the 
range and depth by which AD models capture symptoms. Nevertheless, 
synthesising evidence across a range of AD outcomes is likely to provide greater 
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depth in the external validity of intervention efficacy and further, has the potential 
highlight potential combination therapies. 
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9.5 Implications of publication bias 
 
Publication bias was identified using all techniques extensively across pathological 
and neurobehavioral datasets, regardless of: brain region, outcomes or transgenic 
model group. Findings are similar to other disease models (such as experimental 
stroke and MS) where preclinical datasets have also indicated publication bias.  
 
It is disconcerting  that AD experiments provide yet another example of the 
relentless drive to selectively publish efficacious interventions (Sena et al., 2010b). 
The ‘everything works approach’ is not only biologically improbable but encourages 
the use of limited resources on false leads, in an industry where the odds are 
already slender.  The point that publication bias exists indiscriminately across 
experimental medicine suggests that current structures in the pharmaceutical 
industry need to be reconsidered. It is likely that the solution lies in a 
multidisciplinary approach where authors, journal editors and funding bodies 
collectively ensure neutral and negative studies are reported and published in full. 
 
Some early signs of change may already be upon us.  For example, there are now  
journals which only accept neutral or negative results (e.g. Journal of negative 
results in biomedicine) and it is becoming increasingly common for universities to 
develop and share open data repositories (Sandercock, 2012).  I find it encouraging 
to have made significant progress in developing a comprehensive open data 
repository for preclinical studies of AD and would encourage similar systems to be 
designed across experimental medicine to maximise the use of existing data. 





Analyses conducted within this thesis are post hoc and  one must interpret all 
findings as empirically guided hypotheses. Within analyses, I have made substantial 
efforts to take account of differences between transgenic models expressed, however 
I was not able to quantify the impact of zygosity or promoter and our analyses face 
considerable challenges balancing specificity and power. Throughout this work I 
have designed analyses around the spread of the data identified, not a hypothesis, 
outcome or individual transgenic model.  
 
While this approach maximises power, this could cause us to miss crucial subtleties 
within data analysed. For neurobehavioural analyses, performing analyses on 
individual paradigms does not take into account specific cognitive processes (and/or 
those brain regions involved). This is clearly a very important area, and it could be 
possible to categorise data in terms of the types of neuropsychological assessments 
made. However, while I considered categorising data according to specific 
processes, this requires assumptions to be made on the strategies used (which there 
may be no consensus on) and our own analyses have suggested that within the 
MWM multiple processes may be at play simultaneously. Further, I have attempted 
to reduce the impact of such weaknesses by conducting behavioural analyses on the 
overall data, as it is unlikely that a given clinical trial would require paradigm 
specific improvements. 
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I identified articles using a systematic search as a methodology which reduce bias 
but it is still possible that I have missed publications which should be included. We 
did not use Explode, focus or truncation codes in the search conducted and this may 
have increased the number of publications included overall. Further, data are likely 
to be missing due the effects of publication bias. If analyses concerning study 
quality and characteristics were conducted including such experiments then results 
may substantially differ.  
 
For the calculation of effect sizes there are two main approaches used; standardised 
mean difference and normalised mean difference. For our datasets analyses the 
standardised mean difference was used almost universally across the dataset. While 
this technique is good for combining data from different scales I cannot always 
assume that observed relationships are consistently reflective of true biological 
efficacies. For example, if the mean values in a given cohort became broader over 
time, effect sizes would suggest that efficacy decreased which is somewhat 
deceptive. Additionally, a particular weakness of animal studies is that the variance 
used is an estimate of an infinite population rather than a true measurement and 
thus small study effects may also impact on observed results 
 
Overall it must be accepted that theoretical relationships identified may not 
necessarily be true if I used alternative techniques (e.g. meta-regression/stratified 
meta-analysis, or specific calculation of effect size).  Thus the collective use of meta-
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analysis in animal models needs a degree of refining, in particular to determine the 
sensitivities of possible approaches. 
 
 
Throughout the analyses conducted, statistical power was lost due to missing or 
unclear data regarding: the number of animals used variance and also study 
methodology (e.g. age at assessment). While I emailed 16 authors for further 
information in order to address such issues it is plausible that this may directly 
impact on observed relationships.  
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9.7 Concluding remarks 
 
The aims of this thesis were to describe and explore interventions tested in 
transgenic mouse models of Alzheimer’s disease in order to provide evidence to 
develop evidence based Good Laboratory Practice guidelines. Analyses identified: 
(i) pre-clinical studies are characteristically diverse and few studies report 
fundamental study quality items (e.g. blinding, randomisation), (ii) study 
characteristics and study quality impact on the observed efficacy, and (iii) extensive 
publication bias is present across transgenic mouse model literature. Additionally, I 
have identified a number of interesting hypotheses both within and between 
outcomes measures which may be informative to trial design and disease 
hypotheses. Collectively, empirical data suggest that we cannot take evidence from 
preclinical trials at face value and further demonstrate the utility of systematic 
review and meta-analysis. The message from preclinical studies is clear: 
experiments at the bench must begin, and end, at the bedside. Furthermore, if we 
are to accelerate AD drug discovery it remains imperative that the wider scientific 
community maximises the use of existing data from pre-clinical trials to inform, 
educate and ultimately improve our translational hit rate. The words of C.S Lewis 
are as true now as ever,  
 
“Failures are finger posts on the road to achievement.” 
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Mori 2006 + + - + - 3 
Morihara 2005 - - - - - 0 
Mottin 2002 - - - - - 0 
Mouri 2007 - - - + - 1 
Movsesyan 2008 + - - + + 3 
Mucke 2002 - - - - - 0 
Muhs 2007 - + - + + 3 
Nakashima 2004 + + - + - 3 
Nakashima 2005 + + - + - 3 
Nelson 2007 - - - + - 1 
Nichol 2007 + - - + - 2 
Nichol 2008 - - - + + 2 
Nicolakakis 2008 + - - + - 2 
Nicolau 2002 - - - - - 0 
Nikolic 2007 - - - - + 1 
Nikolic 2008 + - - + + 3 
Noble 2005 - - - + - 1 
Nordberg 2002 + - - - - 1 
Oddo 2004 - - - + - 1 
Oddo 2005 + - - - - 1 
Oddo 2006 - + - - - 1 
Oddo 2006 - - - + - 1 
Oddo 2008 + + - + - 3 
Oksman 2006 + - - + - 2 
Okura 2006 + - - + + 3 
Okura 2008 + - - + - 2 
Onozuka 2008 + + - + - 3 
Page 2008 - - - + - 1 
Parachikova 2008 - - - + - 1 
Paris 2003 - - - - - 0 
Paris 2004 - - - - - 0 
Park 2003 + - - + - 2 
Park 2006 - - - - - 0 
Patel 2005 - + - - - 1 
Paul 2007 - - - + + 2 
Pedersen 2004 - - - + - 1 
Pedersen 2006 + - - + - 2 
Peretto 2005 - - - + - 1 
Permanne 2002 - - - - - 0 
Petanceska 2002 - - - - - 0 
Petrushina 2007 + - - + - 2 
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Petrushina 2008 + - - - - 1 
Pihlaja 2008 - - - + - 1 
Pillay 2008 - + - + - 2 
Plattner 2006 - - - + - 1 
Prada 2007 - - - + - 1 
Prasad 2007 - - - - - 0 
Pratico 2002 + + - + - 3 
Pugh 2007 - - - + + 2 
Puglielli 2005 - - - + + 2 
Qin 2008 - + - + - 2 
Qing 2008 - - - + + 2 
Qu 2004 - - - - + 1 
Qu 2006 - - - + - 1 
Qu 2007 - - - + - 1 
Quinn 2003 - - - + - 1 
Quinn 2005 - - - + - 1 
Quinn 2007 - - - - + 1 
Racke 2005 - - - - - 0 
Rakover 2007 - - - - - 0 
Refolo 2000 - - - - - 0 
Refolo 2000 + - - - - 1 
Refolo 2001 + - - - - 1 
Ren 2007 - - - + - 1 
Rezai-Zadeh 2008 + - - + - 2 
Ribes 2006 - - - + - 1 
Ribes 2008 - - - + - 1 
Ribes 2008 - - - + - 1 
Richter 2008 - - - + - 1 
Riddell 2007 - - - - - 0 
Rockenstein 2002 - - - - - 0 
Rockenstein 2002 - - - + - 1 
Rockenstein 2003 + - - - + 2 
Rockenstein 2004 - - - - - 0 
Rockenstein 2005 - - - + - 1 
Rockenstein 2006 - - - + - 1 
Rockenstein 2007 - - - - - 0 
Rockenstein 2007 - - - + - 1 
Rockenstein 2007 + - - + - 2 
Rosario 2006 - - - - - 0 
Rosenmann 2007 - - - - + 1 
Ryder 2003 - - - + - 1 
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Sabbagh 2008 - - - + - 1 
Sadowski 2004 - + - - - 1 
Sadowski 2006 - + - + + 3 
Sankaranarayanan 2008 - - - + - 1 
Sastre 2006 - - - - + 1 
Schafer 2007 - - - + - 1 
Schenk 1999 - - - - - 0 
Schilling 2008 - - - + + 2 
Scholtzova 2008 + - - + - 2 
Schroeter 2008 + - - - + 2 
Schultz 2004 - - - - - 0 
Seabrook 2004 - - - + - 1 
Seabrook 2006 - - - + + 2 
Seabrook 2006 - - - + - 1 
Seabrook 2007 - - - + - 1 
Senechal 2008 - - - - - 0 
Seubert 2008 - - - - - 0 
Sheng 2002 - + - + - 2 
Shie 2002 - + - + - 2 
Shim 2007 - - - + - 1 
Shim 2008 - - - + - 1 
Shineman 2008 - - - + - 1 
Sigurdsson 2001 + - - + - 2 
Sigurdsson 2004 + - - + - 2 
Singer 2005 + - - + + 3 
Snow 2002 - - - - - 0 
Snow 2004 - - - - - 0 
Soderman 2008 + - - + - 2 
Solomon 2004 - - - - - 0 
Solomon 2007 - + - - - 1 
Sood 2007 - - - + - 1 
Spencer 2008 - - - + - 1 
Stackman 2003 + - - + - 2 
Stahl 2006 - - - + - 1 
Stein 2004 - - - + - 1 
Stoltenberg 2007 + - - + - 2 
Su 2003 - - - - - 0 
Su 2004 - + - + - 2 
Sung 2003 - + - + - 2 
Sung 2004 + + - + - 3 
Tabira 2008 - + - - - 1 
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Takata 2007 - - - + - 1 
Tamura 2005 - - - - - 0 
Tchantchou 2007 - - - + - 1 
Tian 2008 - - - - - 0 
Town 2002 + - - - - 1 
Trinchese 2008 + - - + + 3 
Tsai 2007 - - - + + 2 
Tucker 2006 - - - - - 0 
Tucker 2008 - - - + - 1 
Um 2008 - - - + - 1 
Unger 2006 - + - + - 2 
Uryu 2002 + - - + - 2 
Van Dam 2005 + + - + - 3 
Van Dam 2006 - + - + - 2 
Van Dam 2008 - + - + - 2 
Van Groen 2008 - - - + - 1 
Van Vickle 2007 - - - - - 0 
Vasilevko 2007 + - - + + 3 
Vehmas 2001 + - - + - 2 
Velliquette 2005 - + - + - 2 
Vloeberghs 2008 - - - + - 1 
Volmar 2000 - - - - - 0 
Wang 2005 - + - + - 2 
Wang 2006 - + - - - 1 
Wang 2007 - - - + - 1 
Wang 2007 - + - + + 3 
Wang 2008 - - - + - 1 
Weiner 2000 - + - + + 3 
Westerman 2002 - - - - + 1 
Wilcock 2001 - + - - - 1 
Wilcock 2003 - - - - - 0 
Wilcock 2004 - - - - - 0 
Wilcock 2006 - - - - - 0 
Wilcock 2007 - - - + - 1 
Windisch 2004 - - - - - 0 
Windisch 2007 - - - - - 0 
Wisniewski 2004 - - - - - 0 
Wisor 2005 - - - + - 1 
Wolf 2006 - + - + - 2 
Wong 2004 - - - + - 1 
Yamamoto 2005 - - - - - 0 
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Yan 2003 - - - - - 0 
Yang 2005 - - - - - 0 
Yang 2008 - - - + - 1 
Yoshiike 2008 - - - + + 2 
Youm 2005 - - - - - 0 
Zamora 2006 - - - + + 2 
Zhang 2003 - - - + - 1 
Zhang 2004 - - - - - 0 
Zhang 2005 + - - - - 1 
Zhang 2006 - - - - - 0 
Zhang 2006 - + - + - 2 
Zhang 2007 - - - - - 0 
Zhao 2004 - + - + - 2 
Zheng 2002 + - - - - 1 
Zheng 2004 - - - + - 1 
Zheng 2006 - - - + - 1 
Zhou 2003 - - - - - 0 
Zhu 2004 - - - - - 0 
Zou 2007 + - - - - 1 
Zou 2008 - - - + - 1 
Zurbriggen 2005 + + - - - 2 
 
 
Appendix II: Table explains the number of publications which reported each 
study quality item: (1) blinded assessment of outcome, (2) random allocation 
to group, (3) sample size calculation, (4) compliance with animal welfare 
legislation and (5) statement regarding potential conflicts of interest. 
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Appendix III: Study Characteristics of included studies 
 
Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
Boyett et al. (2003) C1q N/A   multiple U APPPS >336 and <504.1 >336 and <504.1 Plaque area 10 
Butovsky et al. (2007) Glatiramer acetate N/A   SubCut U APPPS <168.1 >168 and <336.1 Plaque area 6 
Cancino et al. (2008) ST1571 12.5 mg/kg Iperitoneal U APPPS >168 and <336.1 >168 and <336.1 Acquisition 6 
                  Neurodegeneration 6 
                  TAU 6 
Cao et al. (2007) Sucrose Sweetened Water 10 % Oral M APPPS <168.1 >168 and <336.1 Acquisition 14 
                  Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  Plaque area 14 
                  Probe 14 
                  T/Y maze 15 
Carroll et al. (2007) Estrogen 0.25 mg SubCut F 3xTgAD <168.1 <168.1 Plaque area 14 
                  TAU 14 
                  T/Y maze 14 
  Progesterone 25 mg SubCut F 3xTgAD <168.1 <168.1 Plaque area 14 
                  TAU 14 
                  T/Y maze 14 
Carty et al. (2006a) 
Endothelin Converting 
Enzyme (ECE) 
N/A   iCranial U APPPS <168.1 >168 and <336.1 Plaque area 16 
Cavalli et al. (2007) memoquin 7 mg/kg/day Iperitoneal U other >336 and <504.1 >336 and <504.1 Plaque area 8 
                  TAU 8 
  memoquin 7 mg/kg/day Iperitoneal U other <168.1 >168 and <336.1 Plaque area 8 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
                  TAU 8 
  memoquin 7 mg/kg/day Iperitoneal U other <168.1 <168.1 TAU 8 
Chauhan (2007) Antibody A11 10 ug/10 ul intraventriclular U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
                  Plaque area 7.5 
  Antibody Amy-33 10 ug/10 ul intraventriclular U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
                  Plaque area 7.5 
Cho et al. (2003) Exercise 2520 mins N/A U other >168 and <336.1 >336 and <504.1 Amyloid beta 42 6 
                  Probe 6 
Dedeoglu et al. (2004) Compound XH1 25 mg/kg Oral F APPPS <168.1 >168 and <336.1 Amyloid beta 40 8 
DiCarlo et al. (2001) LPS N/A   iHippocampus B APPPS >168 and <336.1 >168 and <336.1 Plaque area 9 
  LPS N/A   iHippocampus B APPPS >336 and <504.1 >336 and <504.1 Plaque area 13 
Dodart et al. (2005) apoE2 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Amyloid beta 42 8 
  apoE2 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 8 
  apoE2 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 7.5 
  apoE2 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 7.5 
  apoE2 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 9 
  apoE3 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Amyloid beta 42 10 
  apoE3 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 10 
  apoE4(Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 9 
  apoE4(Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Amyloid beta 42 9 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
  apoE4(Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 7.5 
  apoE4(Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 7.5 
  apoE4(Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 10 
  apoE2 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >336 and <504.1 Plaque area 11.67 
  apoE2 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 11.67 
  apoE3 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 10.67 
  apoE3 (Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >336 and <504.1 Plaque area 10.67 
  apoE4(Lenti-vector) N/A   iHippocampus U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 7.667 
                  Plaque area 7.667 
Dong et al. (2004) Isolation Stress N/A   Iperitoneal B APP <168.1 <168.1 Fear conditioning 16 
                  Neurodegeneration 16 
                  Plaque area 10 
Frazer et al. (2008) A beta 1-42 N/A   SubCut M 3xTgAD <168.1 >168 and <336.1 TAU 9 
  A beta 1-42 N/A   SubCut M 3xTgAD <168.1 >168 and <336.1 TAU 9 
Frye & Walf (2008) Progesterone N/A   SubCut F APPPS <168.1 >168 and <336.1 NORT 10 
                  T/Y maze 10 
Fukuchi et al. (2006) Antibody scFv N/A   multiple U APP >336 and <504.1 <168.1 Plaque area 12 
Fuso et al. (2008) B-vitamin Deprivation N/A   Oral B APP <168.1 <168.1 Amyloid beta 40 30 
                  Amyloid beta 42 30 
                  Plaque area 20 
  B-vitamin Deprivation N/A   Oral B APP <168.1 <168.1 Amyloid beta 40 30 
                  Amyloid beta 42 30 
                  Plaque area 20 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
  B-vitamin Deprivation N/A   Oral M APP <168.1 <168.1 Acquisition 19 
Gong et al. (2006) Uch-L1 0.03 g/kg Iperitoneal B APPPS <168.1 <168.1 Amyloid beta 42 12 
  Uch-L1 0.03 g/kg Iperitoneal B APPPS <168.1 <168.1 Amyloid beta 42 15 
  Uch-L1 0.03 mg/kg Iperitoneal B APPPS <168.1 <168.1 Fear conditioning 28 
  Uch-L1 0.03 mg/kg Iperitoneal B APPPS <168.1 <168.1 Fear conditioning 34 
  LDN-57444 0.4 mg/kg Iperitoneal B APPPS <168.1 <168.1 Fear conditioning 38 
Green et al. (2006) Dexamethasone 1 mg/kg Iperitoneal M 3xTgAD <168.1 <168.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
  Dexamethasone 5 mg/kg Iperitoneal M 3xTgAD <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 16 
                  TAU 6 
  Dexamethasone 5 mg/kg Iperitoneal M 3xTgAD >336 and <504.1 >336 and <504.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  TAU 8 
Green et al. (2005) Estrogen N/A   Unknown F APP <168.1 >168 and <336.1 Amyloid beta 40 15 
                  Amyloid beta 42 14.33 
Greig et al. (2005) 
N-
phenethnorcymserine(PEC) 
3 mg/kg/day Iperitoneal M APPPS <168.1 <168.1 Amyloid beta 40 24 
                  Amyloid beta 42 24 
Heikkinen et al. (2004) Estrogen N/A   SubCut F APPPS <168.1 <168.1 Acquisition 26 
                >168 and <336.1 Probe 26 
                  RAWM 26 
                  T/Y maze 26 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
  Estrogen N/A   SubCut F APPPS <168.1 <168.1 Amyloid beta 40 19 
                  Amyloid beta 42 19 
                >168 and <336.1 Acquisition 30 
                  RAWM 30 
                  T/Y maze 30 
  Estrogen N/A   SubCut F APPPS <168.1 >168 and <336.1 Acquisition 38 
                  Probe 30 
                >336 and <504.1 RAWM 34 
                  T/Y maze 34 
  Estrogen N/A   SubCut F APPPS <168.1 >168 and <336.1 Amyloid beta 40 19 
                  Amyloid beta 42 19 
                  Plaque area 16 
  Estrogen N/A   SubCut F APPPS <168.1 >336 and <504.1 Probe 38 
  Estrogen N/A   SubCut F APPPS <168.1 >168 and <336.1 Amyloid beta 40 25 
                  Amyloid beta 42 25 
  Estrogen N/A   SubCut F APPPS <168.1 >336 and <504.1 Amyloid beta 40 29 
                  Amyloid beta 42 29 
                  Plaque area 29 
Horikoshi et al. (2004) Antibody 82E1 10 mg/kg Iperitoneal U APP >336 and <504.1 >504 Amyloid beta 42 5 
                  Plaque area 5 
Hu et al. (2008) A beta 1-15 N/A   multiple U APP <168.1 >336 and <504.1 Acquisition 10.66 
                  Probe 10.67 
  A beta 36-42 N/A   multiple U APP <168.1 >336 and <504.1 Acquisition 10.66 
                  Probe 10.67 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
  A beta 1-42 N/A   multiple U APP <168.1 >336 and <504.1 Acquisition 10.66 
                  Probe 10.67 
Hwang et al. (2006) Furin N/A   Icortex U APP <168.1 <168.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
  Furin N/A   Icortex U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
Jacobsen et al. (2008) PAZ-417 20 mg/kg/day Oral M APPPS <168.1 >168 and <336.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
  PAZ-417 20 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 16 
                  Amyloid beta 42 16 
  PAZ-417 10 mg/kg/day Oral M APP <168.1 <168.1 Fear conditioning 10.67 
  PAZ-417 30 mg/kg/day Oral M APP <168.1 <168.1 Fear conditioning 10.67 
  PAZ-417 100 mg/kg/day Oral M APP <168.1 <168.1 Fear conditioning 10.67 
  PAZ-417 10 mg/kg/day Oral M APP <168.1 <168.1 Fear conditioning 16 
  DAPT 100 mg/kg/day Oral M APP <168.1 <168.1 Fear conditioning 16 
Kim et al. (2008a) BRI2 N/A   IVentricular B APP <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
  BRI-Abeta1-40 N/A   IVentricular B APP <168.1 <168.1 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Plaque area 15 
  BRI2 N/A   IVentricular B APP <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  BRI2-del244-266 N/A   IVentricular B APP <168.1 <168.1 Amyloid beta 40 17 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
                  Amyloid beta 42 17 
                  Plaque area 17 
Kitazawa et al. (2005) LPS 0.5 mg/kg Iperitoneal B 3xTgAD <168.1 <168.1 Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Plaque area 10 
                  TAU 10 
Kulic et al. (2006) A beta 1-42 N/A   Iperitoneal F Tau >168 and <336.1 >168 and <336.1 TAU 18 
Liskowsky & Schliebs 
(2006) 
Scolopamine Hydorbromide 2 mg/kg/day Iperitoneal U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
Matsubara et al. (2003) Melatonin 1.5 mg/day Oral U APP <168.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 8 
  Melatonin 1.5 mg/day Oral U APP <168.1 >168 and <336.1 Amyloid beta 40 12 
                  Amyloid beta 42 13.5 
  Melatonin 1.5 mg/day Oral U APP <168.1 >168 and <336.1 Amyloid beta 40 14 
                  Amyloid beta 42 14 
  Melatonin 1.5 mg/day Oral U APP <168.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
Melnikova et al. (2006) celecoxib N/A   Oral F APPPS <168.1 >168 and <336.1 Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  Plaque area 14 
                  T/Y maze 17 
  celecoxib N/A   Oral M APPPS >168 and <336.1 >168 and <336.1 Amyloid beta 40 14 
                  Amyloid beta 42 14 
   Appendix III: Study characterstics report 
427 
 
Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
                  Plaque area 14 
                  T/Y maze 17 
  celecoxib N/A   Oral M APPPS >168 and <336.1 >168 and <336.1 T/Y maze 32 
Mohajeri et al. (2004) A beta 1-42 1 ul/350 uM Icortex U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 7 
                  Plaque area 8 
  A beta 1-42 35 ul/350 uM Icortex U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 8 
                  Plaque area 7 
Mohajeri, Wollmer, & 
Nitsch (2002) 
A beta 1-42 N/A   iCranial U APP <168.1 >168 and <336.1 Plaque area 8 
Mouri et al. (2007) A beta 1-42 N/A   Oral F APP >168 and <336.1 >336 and <504.1 Acquisition 28 
                  Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Fear conditioning 28 
                  NORT 28 
                  Plaque area 13 
                  Probe 28 
Nichol et al. (2008) Exercise N/A EE N/A U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
                  Cellular infiltrates 12.75 
Oddo et al. (2006b) Antibody 20.1 (monoclonal) N/A   Iperitoneal U 3xTgAD >504 >504 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Fear conditioning 15 
                  TAU 15 
                  T/Y maze 15 
  Antibody 20.1 (monoclonal) N/A   Iperitoneal U 3xTgAD >504 >504 Amyloid beta 40 20 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
                  Amyloid beta 42 20 
                  Fear conditioning 20 
                  TAU 20 
                  T/Y maze 20 
  A beta 1-42 N/A   SubCut U 3xTgAD >504 >504 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Fear conditioning 15 
                  TAU 15 
                  T/Y maze 15 
Park et al. (2006) Nogo-66 receptor -ecto-Fc 0.27 mg/kg/day SubCut U APPPS >168 and <336.1 >168 and <336.1 Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Cellular infiltrates 16 
                  Neurodegeneration 16 
                  Plaque area 16 
                  RAWM 16 
Paul, Strickland, & 
Melchor  
Tranexamic 100 U/day SubCut U APP <168.1 <168.1 Cellular infiltrates 6 
 (2007)  acid               Plaque area 6 
  Ancrod 4 mg/day SubCut U APP <168.1 <168.1 Plaque area 5 
Pratico et al. (2002) Aluminium 2 mg/kg/diet Oral B APP <168.1 >168 and <336.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
                  Plaque area 12 
Refolo et al. (2000) High Cholesterol N/A   Oral M APPPS <168.1 <168.1 Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  Plaque area 16 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
Ribes et al. (2008a) Aluminium 17 mg/kg/day Oral M APP <168.1 >168 and <336.1 Acquisition 16 
                  Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Neurodegeneration 16 
                  Probe 16 
Ribes et al. (2008b) Aluminium 0.09 mg/g Oral U APP not known not known Amyloid beta 40 14 
                  Amyloid beta 42 14 
  Aluminium 0.09 mg/g Oral U APP not known not known Neurodegeneration 6 
Richter et al. (2008) Exercise N/A   N/A M APP <168.1 <168.1 NORT 22 
                  Plaque area 21 
Sabbagh et al. (2008) nicotine 200 ug/mL Oral B APP <168.1 >168 and <336.1 Amyloid beta 40 40 
                  Amyloid beta 42 40 
                  Cellular infiltrates 40 
                  Neurodegeneration 40 
Sadowski et al. (2004) Amyloid beta-12-28P 100 µmol/L Iperitoneal U APPPS <168.1 <168.1 Plaque area 12 
Sheng, Price, & Koliatsos 
(2002) 
ERC lesion N/A   Oral U APPPS >168 and <336.1 >168 and <336.1 Amyloid beta 40 22 
                  Amyloid beta 42 22 
                  Plaque area 22 
Shie et al. (2002) High Cholesterol N/A   Oral F APP <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
  High Cholesterol N/A   Oral F APP <168.1 >168 and <336.1 Plaque area 8 
Stein et al. (2004) TTR antibody N/A   SubCut U APP >504 >504 Neurodegeneration 8 
Stoltenberg et al. (2007) Zinc deficiency N/A   Oral U APPPS >168 and <336.1 >168 and <336.1 Plaque area 18 
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Age at assessment 
(days) 
Outcome measure N 
Su, Ryder, & Ni (2003) H89 103 uM IVentricular U APP <168.1 <168.1 Amyloid beta 42 20 
Tsai, Tsai, & Shen (2007) G-CSF N/A   SubCut M APP >168 and <336.1 >336 and <504.1 Acquisition 10 
                  Neurodegeneration 10 
                  Plaque area 10 
Uryu et al. (2002) Mild brain trauma N/A   N/A B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
      single N/A B APP >168 and <336.1 >336 and <504.1 Acquisition 19.5 
  Mild brain trauma N/A   N/A B APP >168 and <336.1 >336 and <504.1 Acquisition 17.5 
                  Amyloid beta 40 6 
                  Amyloid beta 42 6 
  Mild brain trauma N/A   N/A B APP >168 and <336.1 >168 and <336.1 Plaque area 6 
  Mild brain trauma N/A   N/A B APP >168 and <336.1 >168 and <336.1 Plaque area 6 
  Mild brain trauma N/A   N/A B APP >168 and <336.1 >336 and <504.1 Plaque area 6 
  Mild brain trauma N/A   N/A B APP >168 and <336.1 >336 and <504.1 Plaque area 6 
Velliquette, O'Connor, & 
Vassar (2005) 
Kainic acid 30 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  Kainic acid 30 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  Kainic acid 30 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  2-deoxyglucose(2DG) 1 g/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  2-deoxyglucose(2DG) 1 g/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  2-deoxyglucose(2DG) 1 g/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  3-Nitropropionic acid (3NP) 100 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  3-Nitropropionic acid (3NP) 100 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  3-Nitropropionic acid (3NP) 100 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
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  Insulin 18 U/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  Insulin 18 U/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
  Insulin 18 U/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 5 
Wilcock et al. (2001) A beta 1-42 N/A   SubCut U APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 12 
  A beta 1-42 N/A   SubCut U APP >336 and <504.1 >504 Cellular infiltrates 10 
  A beta 1-42 N/A   SubCut U APP >168 and <336.1 >336 and <504.1 Cellular infiltrates 12 
Windisch et al. (2004) MDVFMKGLSMAKE 5 mg/day INasal U APP not known not known Acquisition 12 
Yoshiike et al. (2008) Picrotoxin N/A   Iperitoneal M APPPS >168 and <336.1 >168 and <336.1 Neurodegeneration 12 
                  NORT 12 
                  Probe 12 
Zheng et al. (2002) Estrogen 5 ug/mL Oral F APPPS <168.1 <168.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
  Estrogen 1.7 mg SubCut F APP <168.1 >168 and <336.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
  Estrogen 5 mg SubCut F APP <168.1 >168 and <336.1 Amyloid beta 40 12 
Zou et al. (2007) captopril 30 mg/kg/day Oral M APP <168.1 >336 and <504.1 Amyloid beta 40 26 
                  Amyloid beta 42 26 
                  Plaque area 26 
Koenigsknecht-Talboo et 
al. (2008) 
IgG2b N/A   Iperitoneal U APP >504 >504 Cellular infiltrates 5 
  M3D6 N/A   Iperitoneal U APP >504 >504 Cellular infiltrates 5 
  M3D6 N/A   Iperitoneal U APP >504 >504 Cellular infiltrates 8 
  M3D6 N/A   Iperitoneal U APP <168.1 <168.1 Cellular infiltrates 8 
  m3D6 Fab Fragments N/A   Iperitoneal U APP >504 >504 Cellular infiltrates 5 
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  mHJ5.1 N/A   Iperitoneal U APP >504 >504 Cellular infiltrates 5 
van Groen et al. (2008) D3 0.25 mg/pump iHippocampus U APPPS <168.1 <168.1 Cellular infiltrates 15 
                  Plaque area 15 
  D1 N/A   iHippocampus U APPPS <168.1 <168.1 Cellular infiltrates 14 
                  Plaque area 14 
Spencer et al. (2008) Neprilysin 2 µl multiple U APP <168.1 >336 and <504.1 Acquisition 16 
                  Neurodegeneration 16 
                  Plaque area 16 
                  Probe 16 
                  TAU 16 
Oddo et al. (2008) A beta 1-42 N/A   iHippocampus B 3xTgAD <168.1 >336 and <504.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
                  TAU 9 
  CHIP expressing lentivirus 3 ul iHippocampus B 3xTgAD >504 >504 TAU 8 
  CHIP expressing lentivirus 3 ul iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 TAU 8 
Qing et al. (2008) Valproic acid 30 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 60 
  Valproic acid 30 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 24 
  Valproic acid 30 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 60 
      mg/kg/day Iperitoneal U APP >168 and <336.1 >168 and <336.1 Acquisition 60 
                  Probe 60 
  Valproic acid 30 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 60 
  Valproic acid 30 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 60 
  Valproic acid 30 mg/kg Iperitoneal U APPPS <168.1 <168.1 Plaque area 54 
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Green et al. (2008) Nicotinamide 200 mg/kg/day Oral U 3xTgAD <168.1 >168 and <336.1 Acquisition 16 
                  Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Fear conditioning 16 
                  NORT 16 
                  Probe 16 
                  TAU 16 
  Nicotinamide 200 mg/kg/day Oral U 3xTgAD >504 >504 Amyloid beta 40 10 
                  Amyloid beta 42 10 
                  TAU 10 
  Sodium butyrate 800 mg/kg/day Oral U 3xTgAD >336 and <504.1 >336 and <504.1 Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  TAU 16 
Ding et al. (2008) Retinoic-acid 20 mg/kg/day Iperitoneal M APPPS <168.1 >168 and <336.1 Acquisition 12 
                  Cellular infiltrates 12 
                  Neurodegeneration 12 
                  Plaque area 12 
                  Probe 12 
Okura et al. (2008) A beta (unspecified length) 50 ug/week intramuscular U APP <168.1 >336 and <504.1 Plaque area 6 
  A beta (unspecified length) 50 ug/week intramuscular U APP <168.1 >336 and <504.1 Cellular infiltrates 7 
                  Plaque area 6 
  A beta (unspecified length) 50 ug/week intramuscular U APP <168.1 >168 and <336.1 Cellular infiltrates 6 
Dong et al. (2008) Memantine 5 mg/kg/day Oral B APP <168.1 >168 and <336.1 Fear conditioning 14.67 
                  Neurodegeneration 14.67 
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                  Plaque area 14.67 
  Memantine 10 mg/kg/day Oral B APP <168.1 >168 and <336.1 Fear conditioning 19.67 
                  Neurodegeneration 19.67 
                  Plaque area 19.67 
  Memantine 20 mg/kg/day Oral B APP <168.1 >168 and <336.1 Fear conditioning 11.67 
                  Neurodegeneration 11.67 
                  Plaque area 11.67 
Um et al. (2008) Exercise 4850 mins N/A U Tau >336 and <504.1 >336 and <504.1 Amyloid beta 42 10 
                  Neurodegeneration 10 
                  Probe 10 
Scholtzova et al. (2008) Memantine 10 mg/kg/day Iperitoneal U APPPS <168.1 >168 and <336.1 Cellular infiltrates 14 
                  NORT 14 
                  Plaque area 14 
Nicolakakis et al. (2008) Pioglitazone 20 mg/kg/day Oral U APP >336 and <504.1 >336 and <504.1 Acquisition 8 
                  Amyloid beta 40 10 
                  Amyloid beta 42 10 
                  Cellular infiltrates 8 
                  Plaque area 10 
                  Probe 8 
Carty et al. (2008) 
Endothelin Converting 
Enzyme (ECE) 
2 µl iCranial U APPPS <168.1 >168 and <336.1 Plaque area 16 
Onozuka et al. (2008) Nobiletin 10 mg/kg Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 17 
                  Amyloid beta 42 17 
                  Fear conditioning 16 
                  Plaque area 17 
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Karlnoski et al. (2008) Antibody D-2H6 3 
mg/kg/we
ek 
Iperitoneal U APP >504 >504 Cellular infiltrates 6.667 
                  Plaque area 6.667 
                  RAWM 6.667 
  Antibody D-2H6 10 
mg/kg/we
ek 
Iperitoneal U APP >504 >504 Cellular infiltrates 6.667 
                  Plaque area 6.667 
                  RAWM 6.667 
  Antibody D-2H6 30 
mg/kg/we
ek 
Iperitoneal U APP >504 >504 Cellular infiltrates 6.667 
                  Plaque area 6.667 
                  RAWM 6.667 
Nikolic et al. (2008) Umbilical Cord Blood Cells N/A   Ivenous B APPPS >168 and <336.1 >336 and <504.1 Cellular infiltrates 20 
                  Plaque area 20 
Wang et al. (2008) Grape Polyphenolics 200 mg/kg/day Oral F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
  Grape Polyphenolics 200 mg/kg/day Oral F APP <168.1 >168 and <336.1 Acquisition 12 
                  Probe 12 
Gortz et al. (2008) Environmental Enrichment N/A   N/A F APP <168.1 <168.1 NORT 13 
Li et al. (2008) A beta 16-20 3 nmol iHippocampus U APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 10 
                  Neurodegeneration 9.5 
                  Plaque area 9.5 
  A beta 16-22 0.3 nmol iHippocampus U APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 10.5 
                  Plaque area 16.5 
McKee et al. (2008) Ibuprofen 375 ppm Oral U 3xTgAD <168.1 >168 and <336.1 Acquisition 10 
                  Plaque area 10 
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                  Probe 10 
                  TAU 10 
Shineman et al. (2008) SQ 2 mg/kg intraventriclular F APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
                  Plaque area 7 
  iPF2a-11 (IsoP) 1 ug/kg intraventriclular F APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
                  Plaque area 8 
El Amouri et al. (2008) Neprilysin 3 µl multiple U APPPS <168.1 >168 and <336.1 Amyloid beta 40 38 
                  Amyloid beta 42 38 
                  Cellular infiltrates 38 
                  Plaque area 38 
                  Probe 38 
Van Dam, Coen, & De 
Deyn (2008) 
Donepezil 0.27 mg/kg/day SubCut M APP <168.1 <168.1 Acquisition 14.5 
                  Probe 14.5 
  Donepezil 0.58 mg/kg/day SubCut M APP <168.1 <168.1 Acquisition 14.5 
                  Probe 14.5 
Sankaranarayanan et al. 
(2008) 
Merk-3 30 mg/kg/day IVentricular U APP <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  Merk-3 7.5 mg/kg/day IVentricular U APP <168.1 <168.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
  Merk-3 7.5 mg/kg/day IVentricular U APP <168.1 <168.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
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  Merk-3 30 mg/kg/day IVentricular U APP <168.1 <168.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
Windisch et al. (2007) KEGV 5 mg/kg INasal U APP >168 and <336.1 >168 and <336.1 Plaque area 4.667 
  KEGV 50 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 4.667 
  SMAKEGV 5 mg/kg INasal U APP >168 and <336.1 >168 and <336.1 Plaque area 4.667 
  SMAKEGV 50 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 4.667 
  MDVFMKGLSMAKE 5 mg/kg INasal U APP >168 and <336.1 >168 and <336.1 Plaque area 4.667 
  MDVFMKGLSMAKE 50 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 4.667 
Kotilinek et al. (2008) Ibuprofen 375 ppm Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 20.67 
                  Amyloid beta 42 20.17 
                  Probe 24.67 
  Naproxen 375 ppm Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 20.67 
                  Amyloid beta 42 20.17 
                  Probe 23.67 
  MF tricyclic 13 ppm Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 20.17 
                  Amyloid beta 42 20.67 
                  Probe 23.67 
  Ibuprofen 375 ppm Oral U APP <168.1 <168.1 Amyloid beta 42 16 
  Ibuprofen 375 ppm Oral U APP <168.1 >168 and <336.1 Probe 32 
                  T/Y maze 32 
  MF tricyclic 13 ppm Oral U APP <168.1 <168.1 Amyloid beta 42 10 
  Naproxen 375 ppm Oral U APP <168.1 <168.1 Amyloid beta 42 10 
Klausner et al. (2008) Oxybutynin 3.75 mg/ml Oral F APPPS <168.1 >168 and <336.1 Amyloid beta 42 9 
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  Oxybutynin 3.75 mg/ml Oral M APPPS <168.1 >168 and <336.1 Amyloid beta 42 8 
Herring et al. (2008) Environmental Enrichment N/A   N/A F APP <168.1 <168.1 Amyloid beta 40 18 
                  Amyloid beta 42 18 
Yang et al. (2008) Coenzyme Q10 1200 mg/kg/day Oral F PS1 >336 and <504.1 >504 Amyloid beta 40 10 
                  Amyloid beta 42 10 
Page et al. (2008) MRK-560 3 mg/kg/day Oral U APP <168.1 <168.1 Amyloid beta 40 4.5 
                  Amyloid beta 42 4.5 
  GSM-1 3 mg/kg/day Oral U APP <168.1 <168.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  GSM-1 10 mg/kg/day Oral U APP <168.1 <168.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  GSM-1 30 mg/kg/day Oral U APP <168.1 <168.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  MRK-560 3 mg/kg/day Oral U APPPS <168.1 <168.1 Amyloid beta 40 4.5 
                  Amyloid beta 42 4.5 
  GSM-1 3 mg/kg/day Oral U APPPS <168.1 <168.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  GSM-1 10 mg/kg/day Oral U APPPS <168.1 <168.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  GSM-1 30 mg/kg/day Oral U APPPS <168.1 <168.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
Vasilevko et al. (2007) A beta 1-42 100 µg SubCut U APP <168.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  A beta 1-11 50 µg SubCut U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7.5 
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                  Amyloid beta 42 7.5 
  A beta 1-11 50 µg SubCut U APP <168.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  A beta 1-40 100 µg SubCut U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
Nichol, Parachikova, & 
Cotman (2007) 
Exercise N/A   N/A B APP >336 and <504.1 >336 and <504.1 RAWM 22 
Petrushina et al. (2007) A beta 1-11 N/A   SubCut F APP >168 and <336.1 >504 Amyloid beta 40 19 
                  Amyloid beta 42 19 
                  Cellular infiltrates 19 
                  Plaque area 19 
  A beta 1-42 N/A   SubCut F APP >168 and <336.1 >504 Amyloid beta 40 10 
                  Amyloid beta 42 10 
                  Cellular infiltrates 10 
                  Plaque area 10 
Chang et al. (2007) Memapsin 2 N/A   SubCut F APP <168.1 >336 and <504.1 Acquisition 13 
                  Amyloid beta 40 24 
                  Amyloid beta 42 24 
                  Plaque area 24 
                  Probe 13 
  Memapsin 2 N/A   SubCut F APP >168 and <336.1 >336 and <504.1 Acquisition 9 
                  Amyloid beta 40 17 
                  Amyloid beta 42 17 
                  Plaque area 17 
                  Probe 9 
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Qu et al. (2007) A beta 1-42 N/A   SubCut U APPPS <168.1 >336 and <504.1 Amyloid beta 42 12 
                  Cellular infiltrates 12 
                  Plaque area 12 
Hirko et al. (2007) Gelsolin N/A   Ivenous U APPPS >168 and <336.1 >168 and <336.1 Plaque area 12.33 
  Gelsolin N/A   Ivenous U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 6 
                  Plaque area 6 
Ren et al. (2007) 40H-GTS-21 1 mg/kg Iperitoneal M APPPS >168 and <336.1 >168 and <336.1 Plaque area 20 
Asuni et al. (2007) Tau379–408 N/A   SubCut M Tau <168.1 <168.1 TAU 13 
  Tau379–408 N/A   SubCut M Tau <168.1 >168 and <336.1 TAU 12 
  Tau379–408 N/A   SubCut F Tau <168.1 <168.1 TAU 13 
  Tau379–408 N/A   SubCut F Tau <168.1 >168 and <336.1 TAU 12 
  Tau379–408 N/A   SubCut B Tau <168.1 >168 and <336.1 NORT 24 
Garcia-Alloza et al. 
(2007a) 
Curcumin 7.5 mg/kg/day Ivenous B APPPS >168 and <336.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Neurodegeneration 6 
Berardi et al. (2007) Environmental Enrichment N/A   N/A B other <168.1 >168 and <336.1 NORT 24 
                  Probe 24 
  Environmental Enrichment N/A   N/A B other <168.1 >168 and <336.1 Plaque area 22 
                  TAU 24 
Herber et al. (2007) LPS 10 ug Iperitoneal B APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 10.5 
  LPS 10 ug iCranial B APP >336 and <504.1 >336 and <504.1 Plaque area 10.5 
  Dexamethasone 5 mg/kg Iperitoneal B APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 10.5 
                  Plaque area 10.5 
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Prasad et al. (2007) BMS-433796 30 umol/kg Oral U APP not known not known Amyloid beta 40 14 
Chauhan & Sandoval 
(2007) 
Garlic extract 0.2 % Oral U APP <168.1 >168 and <336.1 Acquisition 20 
                  Amyloid beta 40 20 
                  Amyloid beta 42 20 
                  Probe 20 
                  T/Y maze 20 
  Garlic extract 0.2 % Oral U APP <168.1 >168 and <336.1 Acquisition 20 
                  Amyloid beta 40 20 
                  Amyloid beta 42 20 
                  Probe 20 
                  T/Y maze 20 
Kukar et al. (2007) Flurbiprofen 10 mg/kg/day Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 45 
                  Amyloid beta 42 45 
                  Plaque area 45 
  Flurbiprofen 10 mg/kg/day Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 45 
                  Amyloid beta 42 45 
  Flurbiprofen 10 mg/kg/day Oral U APP >336 and <504.1 >504 Amyloid beta 40 43 
                  Amyloid beta 42 43 
                  Plaque area 45 
                  Probe 28 
  Flurbiprofen 10 mg/kg/day Oral U APP >168 and <336.1 >168 and <336.1 Probe 45 
Mamikonyan et al. (2007) Antibody anti-beta-11 2 copies iHippocampus U 3xTgAD >504 >504 Plaque area 8 
Muhs et al. (2007) a beta 1-16 N/A   Iperitoneal F APPPS <168.1 <168.1 NORT 7.5 
  A beta 1-15 N/A   Iperitoneal F APPPS <168.1 <168.1 NORT 7.5 
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Zhang et al. (2007) 
Soybean 
phosphatidylinositol 
500 nM iHippocampus U Tau <168.1 <168.1 Neurodegeneration 4 
  A beta 25-35 100 nM iHippocampus U Tau <168.1 <168.1 Neurodegeneration 4 
  A beta 25-35 1 uM iHippocampus U Tau <168.1 <168.1 Neurodegeneration 4 
Seabrook et al. (2006b) A beta 40/42 N/A   multiple U APP <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
  A beta 1-15 N/A   multiple U APP <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
  A beta 1-15 N/A   multiple U APP <168.1 >168 and <336.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
                  Plaque area 9 
Carty et al. (2006b) 
Antibody 2h6 
(deglycosylated) 
N/A   iCranial U APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 6 
                  Plaque area 6 
  Antibody 2h6 N/A   iCranial U APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 9 
                  Plaque area 9 
Nelson et al. (2007) paroxetine 5 mg/kg/day Iperitoneal M 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 10 
                  TAU 10 
  paroxetine 5 mg/kg/day Iperitoneal F 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 10 
                  TAU 10 
  paroxetine 5 mg/kg/day Iperitoneal B 3xTgAD <168.1 >168 and <336.1 Acquisition 20 
                  Probe 20 
Seabrook et al. (2007) A beta 1-15 N/A   INasal M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 10 
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                  Amyloid beta 42 10 
                  Plaque area 10 
Costa et al. (2007) Environmental Enrichment N/A   N/A B APPPS <168.1 <168.1 Acquisition 29.5 
                  Plaque area 16 
                  RAWM 30 
  Environmental Enrichment N/A   N/A B APPPS <168.1 <168.1 Plaque area 22 
  Rolipram 0.03 mg/kg/day SubCut U APPPS >168 and <336.1 >336 and <504.1 RAWM 9 
Caccamo et al. (2007) Lithium N/A   Iperitoneal U 3xTgAD >336 and <504.1 >336 and <504.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
                  TAU 20 
                  T/Y maze 20 
Green et al. (2007) DHA-diet 1 1.3 per 100g Oral B 3xTgAD <168.1 <168.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
                  TAU 8.5 
  DHA-diet 1 1.3 per 100g Oral B 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  TAU 8 
  DHA-diet 1 1.3 per 100g Oral B 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  TAU 8.667 
  DHA-diet 2 N/A   Oral B 3xTgAD <168.1 <168.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
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                  TAU 8.75 
  DHA-diet 2 N/A   Oral B 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  TAU 8 
  DHA-diet 2 N/A   Oral B 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  TAU 8 
  DHA-diet 3 N/A   Oral B 3xTgAD <168.1 <168.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
                  TAU 8 
  DHA-diet 3 N/A   Oral B 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  TAU 8 
  DHA-diet 3 N/A   Oral B 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  TAU 8 
Riddell et al. (2007) TO901317 10 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
  TO901317 30 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
  TO901317 50 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
                  Fear conditioning 18 
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Hemming, Selkoe, & 
Farris (2007) 
captopril 2 g/l Oral U 3xTgAD <168.1 <168.1 Amyloid beta 40 17.5 
                  Amyloid beta 42 17.5 
  Losartan 0.6 g/l Oral U 3xTgAD <168.1 <168.1 Amyloid beta 40 17.5 
                  Amyloid beta 42 17.5 
  captopril 2 g/l Oral U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 19 
                  Amyloid beta 42 19 
  captopril 2 g/l Oral U APP >336 and <504.1 >336 and <504.1 Plaque area 8 
Chen et al. (2007) A beta 1-42 N/A   SubCut M APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 34 
  A beta 1-42 N/A   SubCut M APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 42 
Matsuoka et al. (2007) NAP 0.5 µg INasal U 3xTgAD >168 and <336.1 >336 and <504.1 Amyloid beta 40 22 
                  Amyloid beta 42 22 
                  TAU 22 
Nikolic et al. (2007) A beta 1-42 200 µg SubCut B APPPS <168.1 >168 and <336.1 Amyloid beta 40 18 
                  Amyloid beta 42 18 
                  Plaque area 18 
Rockenstein et al. (2007b) Lithium 20 mg/kg/day Iperitoneal U APP <168.1 >168 and <336.1 Acquisition 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
                  Probe 12 
                  TAU 12 
Becker, Lavie, & Solomon 
(2007) 
EFRH N/A   Iperitoneal B APP <168.1 >336 and <504.1 Cellular infiltrates 24 
                  Neurodegeneration 24 
Billings et al. (2007) Learning N/A   N/A B 3xTgAD <168.1 >168 and <336.1 Amyloid beta 40 15 
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Age at assessment 
(days) 
Outcome measure N 
                  Amyloid beta 42 15 
                  Plaque area 15 
                  TAU 15 
  Learning N/A   N/A B 3xTgAD <168.1 >504 Acquisition 18 
  Learning N/A   N/A B 3xTgAD <168.1 >504 Acquisition 18 
  Learning N/A   N/A B 3xTgAD <168.1 >336 and <504.1 Acquisition 18 
  Learning N/A   N/A B 3xTgAD <168.1 >336 and <504.1 Probe 18 
  Learning N/A   N/A B 3xTgAD <168.1 >336 and <504.1 Probe 14 
  Learning N/A   N/A B PS1 <168.1 >504 Acquisition 18 
  Learning N/A   N/A B PS1 <168.1 >336 and <504.1 Probe 18 
  Learning N/A   N/A B 3xTgAD <168.1 >504 Acquisition 21 
  Learning N/A   N/A B 3xTgAD <168.1 >336 and <504.1 Acquisition 11 
  Learning N/A   N/A B 3xTgAD <168.1 >504 Acquisition 18 
  Learning N/A   N/A B 3xTgAD <168.1 >336 and <504.1 Probe 21 
  Learning N/A   N/A B 3xTgAD <168.1 >336 and <504.1 Probe 11 
Best et al. (2007) MRK-560 3 mg/kg/day Oral B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 44 
                  Amyloid beta 42 44 
                  Cellular infiltrates 6 
                  Plaque area 24 
  MRK-560 3 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 6 
Liu et al. (2007) nicotine 195 ug/day Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
                  Plaque area 10 
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Outcome measure N 
Li et al. (2006) Simvastatin 50 mg/kg/day Oral F APP >168 and <336.1 >336 and <504.1 Acquisition 40 
                  Amyloid beta 40 40 
                  Amyloid beta 42 40 
                  Plaque area 40 
                  Probe 40 
                  T/Y maze 40 
Wolf et al. (2006) Exercise N/A   N/A F APP <168.1 >168 and <336.1 Acquisition 10 
                  Probe 10 
                >336 and <504.1 Neurodegeneration 9 
                  Plaque area 10 
  Environmental Enrichment N/A   N/A F APP <168.1 >168 and <336.1 Acquisition 9 
                  Probe 9 
                >336 and <504.1 Neurodegeneration 9 
                  Plaque area 9 
Chauhan (2006) Garlic extract 20 mg/kg Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 6.667 
                  Amyloid beta 42 6.667 
                  Plaque area 6.667 
                  TAU 6.667 
  SAC 20 mg/kg Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 6.667 
                  Amyloid beta 42 6.667 
                  Plaque area 6.667 
                  TAU 6.667 
  DADS 20 mg/kg Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 6.667 
                  Amyloid beta 42 6.667 
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Age at assessment 
(days) 
Outcome measure N 
                  Plaque area 6.667 
                  TAU 6.667 
Hartman et al. (2006) Pomegranate juice 5 ml/day Oral U APP <168.1 >168 and <336.1 Acquisition 41 
                >336 and <504.1 Amyloid beta 40 38 
                  Amyloid beta 42 40 
                  Plaque area 47 
                  Probe 41 
Wang et al. (2006) Cabernet Sauvignon N/A   Oral F APP <168.1 >168 and <336.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
Holcomb et al. (2006) Bacopa Monniera 40 mg/kg/day Oral U APPPS <168.1 <168.1 Amyloid beta 40 15 
                  Amyloid beta 42 15 
  Bacopa Monniera 160 mg/kg/day Oral U APPPS <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  Bacopa Monniera 40 mg/kg/day Oral U APPPS <168.1 >168 and <336.1 Amyloid beta 40 14.5 
                  Amyloid beta 42 14.5 
                  T/Y maze 14.5 
  Bacopa Monniera 160 mg/kg/day Oral U APPPS <168.1 >168 and <336.1 Amyloid beta 40 12.5 
                  Amyloid beta 42 12.5 
                  T/Y maze 12.5 
Oksman et al. (2006) DHA N/A   Oral M APPPS <168.1 >168 and <336.1 Acquisition 21.66 
                  Amyloid beta 40 21.67 
                  Amyloid beta 42 21.67 
  Typical Western Diet N/A   Oral M APPPS <168.1 >168 and <336.1 Acquisition 21.66 
                  Amyloid beta 40 21.67 
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(days) 
Outcome measure N 
                  Amyloid beta 42 21.67 
  Lipid Neutral Diet N/A   Oral M APPPS <168.1 >168 and <336.1 Acquisition 21.66 
                  Amyloid beta 40 21.67 
                  Amyloid beta 42 21.67 
  Fish oil-based diet N/A   Oral F APPPS <168.1 >168 and <336.1 Amyloid beta 42 10.5 
                  Cellular infiltrates 10.5 
  Corn oil N/A   Oral F APPPS <168.1 >168 and <336.1 Amyloid beta 42 10.5 
                  Cellular infiltrates 10.5 
Carro et al. (2006) Insulin-like Growth factor 1 50 
micro 
g/day 
SubCut U APPPS >168 and <336.1 >336 and <504.1 Acquisition 24 
                  Amyloid beta 40 10 
                  Amyloid beta 42 10 
                  Cellular infiltrates 24 
                  Neurodegeneration 24 
                  Plaque area 10 
Ethell et al. (2006) T cells N/A   Ivenous U APPPS >168 and <336.1 >168 and <336.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
                  Cellular infiltrates 11 
                  RAWM 11 
  T cells N/A   Ivenous U APPPS >168 and <336.1 >168 and <336.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
                  Cellular infiltrates 13 
  T cells N/A   Ivenous U APPPS >168 and <336.1 >168 and <336.1 RAWM 15 
                  T/Y maze 15 
Mori et al. (2006) Arundic Acid 10 mg/kg Oral M APP >168 and <336.1 >504 Amyloid beta 40 29 
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(days) 
Outcome measure N 
                  Amyloid beta 42 29 
                  Cellular infiltrates 29 
                  Plaque area 29 
Okura et al. (2006) A beta 1-42 N/A   intramuscular U APP <168.1 >168 and <336.1 Plaque area 20 
  A beta 1-42 N/A   intramuscular U APP <168.1 >168 and <336.1 Plaque area 20 
  A beta 1-42 N/A   intramuscular U APP <168.1 >336 and <504.1 Plaque area 24 
  A beta 1-42 N/A   intramuscular U APP <168.1 >168 and <336.1 Plaque area 20 
  A beta 1-42 N/A   intramuscular U APP <168.1 >336 and <504.1 Plaque area 24 
Wilcock et al. (2006) Antibody 2h6 10 
mg/kg/we
ek 
Iperitoneal U APP >504 >504 Cellular infiltrates 7.5 
                  Plaque area 7.5 







Iperitoneal U APP >504 >504 Cellular infiltrates 8.5 
                  Plaque area 8.5 
                  RAWM 8.5 
Maier et al. (2006) A beta 1-15 N/A   INasal U APP <168.1 <168.1 Acquisition 13 
                  Amyloid beta 40 13 
                  Amyloid beta 42 13 
                  Plaque area 13 
                  Probe 13 
Caccamo et al. (2006) AF267B 2 mg/kg/day Iperitoneal U 3xTgAD <168.1 >168 and <336.1 Acquisition 20 
                  Amyloid beta 40 20 
                  Amyloid beta 42 20 
                  Plaque area 20 
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Age at assessment 
(days) 
Outcome measure N 
                  Probe 20 
                  TAU 20 
  Dicyclomine 8 mg/kg/day Iperitoneal U 3xTgAD <168.1 >168 and <336.1 Acquisition 14 
                  Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  Plaque area 14 
                  Probe 14 
                  TAU 14 
Unger et al. (2006) Galantamine 2 mg/kg/day SubCut U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 5.333 
                  Amyloid beta 42 5.333 
                  Neurodegeneration 6.667 
  Memantine 10 mg/kg/day SubCut U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 5.333 
                  Amyloid beta 42 5.333 
                  Neurodegeneration 6.667 
  nicotine 0.42 mg/kg SubCut U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6.667 
                  Amyloid beta 42 6.667 
                  Neurodegeneration 6.667 
Van Dam & De Deyn 
(2006) 
Galantamine 2.6 mg/kg/day SubCut M APP <168.1 <168.1 Acquisition 13.5 
                  Probe 13.5 
  Galantamine 7.2 mg/kg/day SubCut M APP <168.1 <168.1 Acquisition 13.5 
                  Probe 13.5 
  Memantine 7.2 mg/kg/day SubCut M APP <168.1 <168.1 Acquisition 13.5 
                  Probe 13.5 
  Memantine 14.4 mg/kg/day SubCut M APP <168.1 <168.1 Acquisition 12.5 
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Age at assessment 
(days) 
Outcome measure N 
                  Probe 12.5 
Asai et al. (2006) KMI-429 10 nM iHippocampus M APP <168.1 <168.1 Amyloid beta 40 5.333 
                  Amyloid beta 42 5.333 
  KMI-358 10 nM iHippocampus M APP <168.1 <168.1 Amyloid beta 40 5.333 




2.5 nmol iHippocampus M APP <168.1 <168.1 Amyloid beta 40 5.333 
                  Amyloid beta 42 5.333 
Nakashima et al. (2005) Lithium 2 LICL/kg Oral U Tau <168.1 <168.1 TAU 7.5 
  Lithium 2 LICL/kg Oral U Tau <168.1 >168 and <336.1 TAU 6 
  Lithium 2 LICL/kg Oral U Tau <168.1 >168 and <336.1 TAU 6 
Tamura et al. (2005) Antibody Fc fragment N/A   Iperitoneal U APP >336 and <504.1 >504 Amyloid beta 40 9 
                  Amyloid beta 42 9 
  Antibody Fc fragment N/A   intracranial U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
  Antibody Fc fragment N/A   intracranial U APP >504 >504 Amyloid beta 40 6.667 
                  Amyloid beta 42 6.667 
  Antibody p-F(ab')2 N/A   Iperitoneal U APP >336 and <504.1 >504 Amyloid beta 40 9 
                  Amyloid beta 42 9 
  Antibody p-F(ab')2 N/A   intracranial U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 10.33 
                  Amyloid beta 42 10.33 
  Antibody p-F(ab')2 N/A   intracranial U APP >504 >504 Amyloid beta 40 7.667 
                  Amyloid beta 42 7.667 
  Antibody anti-beta-13 N/A   Iperitoneal U APP >336 and <504.1 >504 Amyloid beta 40 8 
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(days) 
Outcome measure N 
                  Amyloid beta 42 8 
  Antibody anti-beta-13 N/A   intracranial U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 10.33 
                  Amyloid beta 42 10.33 
  Antibody anti-beta-13 N/A   intracranial U APP >504 >504 Amyloid beta 40 6.667 
                  Amyloid beta 42 6.667 
Zurbriggen et al. (2005) a beta 1-16 N/A   intramuscular B APPPS <168.1 >168 and <336.1 Amyloid beta 40 36 
                  Amyloid beta 42 36 
                  Plaque area 36 
Buttini et al. (2005) A beta 1-42 N/A   Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 20 
                  Neurodegeneration 14.67 
                  Plaque area 20 
  Antibody 12B4 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 24 
                  Neurodegeneration 24 
                  Plaque area 24 
  Antibody 3d6 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 24 
                  Neurodegeneration 24 
                  Plaque area 24 
  A beta 15-24 N/A   Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 20 
                  Neurodegeneration 20 
                  Plaque area 20 
  A beta 3-9 N/A   Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 20 
                  Neurodegeneration 14.67 
                  Plaque area 20 
  a beta 1-5 N/A   Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 42 20 
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Age at assessment 
(days) 
Outcome measure N 
                  Neurodegeneration 14.67 
                  Plaque area 20 
Comery et al. (2005) DAPT 100 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Fear conditioning 12 
  DAPT 100 mg/kg/day Oral M APP >168 and <336.1 >168 and <336.1 Fear conditioning 16 
  DAPT 100 mg/kg/day Oral M APP >336 and <504.1 >336 and <504.1 Fear conditioning 16 
  DAPT 100 mg/kg/day Oral M APP <168.1 <168.1 Fear conditioning 16 
  Rolipram 0.1 mg/kg/day Iperitoneal M APP >168 and <336.1 >168 and <336.1 Fear conditioning 16 
Dong et al. (2005) Donepezil 0.1 mg/kg/day SubCut B APP >168 and <336.1 >168 and <336.1 Fear conditioning 7.667 
  Donepezil 0.3 mg/kg/day SubCut B APP >168 and <336.1 >168 and <336.1 Fear conditioning 7.667 
  Donepezil 1 mg/kg/day SubCut B APP >168 and <336.1 >168 and <336.1 Fear conditioning 7.667 
                  Plaque area 10 
  Physostigmine 0.03 mg/kg/day SubCut B APP >168 and <336.1 >168 and <336.1 Fear conditioning 6.667 
  Physostigmine 0.1 mg/kg/day SubCut B APP >168 and <336.1 >168 and <336.1 Fear conditioning 6.667 
  Physostigmine 0.3 mg/kg/day SubCut B APP >168 and <336.1 >168 and <336.1 Fear conditioning 6.667 
                  Plaque area 10 
Frenkel et al. (2005) A beta 1-40 N/A   Iperitoneal U APP >336 and <504.1 <168.1 Cellular infiltrates 15 
Calon et al. (2005) DHA N/A   Oral B APP >336 and <504.1 >504 Neurodegeneration 7.5 
  DHA-diet 1 N/A   Oral B APP >336 and <504.1 >504 Neurodegeneration 7.5 
Hartman et al. (2005) Antibody 10d5 N/A   Iperitoneal B APP >336 and <504.1 >336 and <504.1 Acquisition 23 
                >504 Amyloid beta 40 18 
                  Amyloid beta 42 18 
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Outcome measure N 
                  Plaque area 18 
Dam et al. (2005) Donepezil 0.3 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 12.87 
                  Probe 12.88 
  Donepezil 0.6 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 12.87 
                  Probe 12.88 
  Galantamine 1.25 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 15.87 
                  Probe 15.88 
  Galantamine 2.5 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 15.87 
                  Probe 15.88 
  Rivastigmine 0.5 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 16.87 
                  Probe 14.21 
  Rivastigmine 1 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 12.87 
                  Probe 12.88 
  Memantine 2 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 14.87 
                  Probe 13.88 
  Memantine 10 mg/kg/day Iperitoneal M APP <168.1 <168.1 Acquisition 11.87 
                  Probe 11.88 
Noble et al. (2005) Lithium 10 
microlitres 
per gram 
Iperitoneal B Tau >168 and <336.1 >168 and <336.1 Neurodegeneration 12 
                  TAU 10.67 
  AR-A014418 10 
microlitres 
per gram 
Iperitoneal B Tau >168 and <336.1 >168 and <336.1 TAU 20 
Adlard et al. (2005) Exercise N/A   N/A F APP <168.1 >168 and <336.1 Acquisition 10 
                  Plaque area 10 
Quinn et al. (2005) Melatonin 16 ug/mL Oral F APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 14 
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Outcome measure N 
                  Amyloid beta 42 14 
                  Plaque area 14 
Lim et al. (2005) DHA 0.02 w/w Oral B APP >336 and <504.1 >504 Amyloid beta 40 10 
                  Amyloid beta 42 10 
  DHA 0.6 w/w Oral B APP >336 and <504.1 >504 Amyloid beta 40 10 
                  Amyloid beta 42 10 
Lazarov et al. (2005) Environmental Enrichment N/A   N/A U APPPS <168.1 <168.1 Amyloid beta 40 13 
                  Amyloid beta 42 13 
  Environmental Enrichment N/A   N/A U APPPS <168.1 <168.1 Plaque area 16 
De Rosa et al. (2005) NGF N/A   INasal U other not known not known NORT 42 
  NGF N/A   INasal U other not known not known NORT 36 
Billings et al. (2005) Antibody 1560 N/A   IVentricular B 3xTgAD <168.1 <168.1 Acquisition 8 
                  Fear conditioning 8 
                  Probe 8 
  Antibody 1560 N/A   IVentricular B 3xTgAD <168.1 <168.1 Acquisition 11 
                  Fear conditioning 11 
                  Probe 11 
  Learning N/A   N/A B PS1 <168.1 >168 and <336.1 Probe 24 
  Learning N/A   N/A B 3xTgAD <168.1 >168 and <336.1 Probe 30 
  Learning N/A   N/A B 3xTgAD <168.1 >168 and <336.1 Probe 29 
Yang et al. (2005) Curcumin 500 ppm Oral U APP >336 and <504.1 >504 Plaque area 10 
Anderson et al. (2005) 
BMS-289948 (also known as 
SIB-3399) 
5 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
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Age at assessment 
(days) 
Outcome measure N 
  
BMS-289948 (also known as 
SIB-3399) 
25 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-289948 (also known as 
SIB-3399) 
50 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-289948 (also known as 
SIB-3399) 
100 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-289948 (also known as 
SIB-3399) 
175 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-289948 (also known as 
SIB-3399) 
100 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-299897 (also known as 
SIB-3520) 
1.5 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-299897 (also known as 
SIB-3520) 
5 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-299897 (also known as 
SIB-3520) 
15 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-299897 (also known as 
SIB-3520) 
50 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-299897 (also known as 
SIB-3520) 
150 mg/kg/day Oral U APP not known not known Amyloid beta 40 9.6 
  
BMS-299897 (also known as 
SIB-3520) 
100 mg/kg/day Oral U APP not known not known Amyloid beta 40 16 
Bowers et al. (2005) A beta 1-42 N/A   SubCut U APP <168.1 >168 and <336.1 Plaque area 7 
Wang et al. (2005) Caloric restriction N/A   Oral F APP <168.1 >168 and <336.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
Rockenstein et al. (2005) Cerebrolysin 5 mg/kg Iperitoneal U APP >168 and <336.1 >168 and <336.1 Plaque area 12 
  Cerebrolysin 5 mg/kg Iperitoneal U APP >168 and <336.1 >336 and <504.1 Plaque area 12 
Zhang et al. (2005) paclitaxel 25 
mg/m 
squared 
Iperitoneal U Tau >168 and <336.1 >168 and <336.1 Neurodegeneration 4.5 
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Age at assessment 
(days) 
Outcome measure N 
                  TAU 18 
  paclitaxel 10 
mg/m 
squared 
Iperitoneal U Tau >168 and <336.1 >168 and <336.1 Neurodegeneration 4.5 
                  TAU 18 
Jensen et al. (2005) A beta 1-42 N/A   SubCut U APPPS <168.1 >336 and <504.1 Acquisition 8 
                  Plaque area 8 
                  Probe 8 
                  RAWM 8 
                  T/Y maze 8 
Chauhan, Siegel, & Lichtor 
(2004) 
Antibody Amy-33 N/A   intraventriclular U APP <168.1 <168.1 Plaque area 10 
  Antibody Amy-33 N/A   intraventriclular U APP >168 and <336.1 >168 and <336.1 Plaque area 10 
Arendash et al. (2004) Environmental Enrichment N/A   N/A U APP >336 and <504.1 >504 Acquisition 9 
                  Plaque area 9 
                  Probe 9 
Schultz et al. (2004) Antibody 16E6 N/A   Ivenous U APP <168.1 <168.1 Amyloid beta 42 8 
  Antibody 16G1 N/A   Ivenous U APP <168.1 <168.1 Amyloid beta 42 8 
Herber et al. (2004) LPS 4 ug/ul iHippocampus U APP >336 and <504.1 >336 and <504.1 Plaque area 6 
  LPS 10 ug/ul iHippocampus U APP >336 and <504.1 >336 and <504.1 Plaque area 6 
  LPS 4 ug/ul iHippocampus U APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 8 
                  Plaque area 8 
Lee et al. (2004) DP-109 5 mg/kg Oral F APP >504 >504 Amyloid beta 40 28 
                  Amyloid beta 42 28 
                  Plaque area 28 
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(days) 
Outcome measure N 
Minkeviciene, Banerjee, & 
Tanila (2004) 
Memantine 30 mg/kg/day Oral M APPPS >168 and <336.1 >168 and <336.1 Acquisition 45 
Bussiere et al. (2004) Antibody 10d5 10 
mg/kg/we
ek 
Iperitoneal U APP >336 and <504.1 >504 Plaque area 14.67 
  Antibody 12B4 10 
mg/kg/we
ek 
Iperitoneal U APP >336 and <504.1 >504 Plaque area 14.67 
  Antibody 12A11 10 
mg/kg/we
ek 
Iperitoneal U APP >336 and <504.1 >504 Plaque area 17 
Seabrook et al. (2004) A beta 40/42 N/A   Iperitoneal U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
  A beta 40/42 N/A   Iperitoneal U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
Oddo et al. (2004) Antibody 1560 N/A   iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 6 
                  TAU 6 
  Antibody 1560 N/A   iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 6 
                  TAU 6 
  Antibody 1560 N/A   iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 12 
                  TAU 9 
  Antibody 1560 N/A   iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 6 
                  TAU 6 
  Antibody HT7 N/A   iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 6 
                  TAU 6 
  Antibody 4G8 N/A   iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 6 
                  TAU 6 
  Antibody 1560 N/A   iHippocampus B 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 6 
                  TAU 6 
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Outcome measure N 
  Antibody 1560 N/A   iHippocampus B 3xTgAD <168.1 >168 and <336.1 Plaque area 10 
                  TAU 10 
Etcheberrigaray et al. 
(2004) 
bryostatin 1 1 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 40 8 
  bryostatin 1 40 ug/kg Iperitoneal B APPPS <168.1 >168 and <336.1 Amyloid beta 40 30 
                  Amyloid beta 42 30 
Sigurdsson et al. (2004) A beta 1-30 N/A   SubCut U APP >168 and <336.1 >504 Plaque area 36 
                  RAWM 32 
  A beta 1-30 N/A   SubCut U APP >168 and <336.1 >504 RAWM 14 
Wilcock et al. (2004) Antibody 2286 10 mg/kg Iperitoneal U APP >504 >504 Cellular infiltrates 7 
                  Plaque area 5 
                  T/Y maze 7 
Nakashima et al. (2004) alpha-tocopherol 160 IU/kg Oral U Tau <168.1 <168.1 TAU 4.5 
  alpha-tocopherol 1500 IU/kg Oral U Tau <168.1 <168.1 TAU 4.5 
  alpha-tocopherol 160 IU/kg Oral U Tau <168.1 >168 and <336.1 TAU 4.5 
  alpha-tocopherol 1500 IU/kg Oral U Tau <168.1 >168 and <336.1 TAU 4.5 
Chang et al. (2004) OMOO-3 DR9 8 mg/kg/day Iperitoneal U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 12 
Su et al. (2004) Lithium 300 mg/kg Oral U APP <168.1 <168.1 Amyloid beta 42 20 
  Lithium 600 mg/kg Oral U APP <168.1 <168.1 Amyloid beta 42 15 
  Lithium 300 mg/kg Oral U APP <168.1 <168.1 Amyloid beta 42 15 
  Lithium 2.4 mg/kg Oral U APP <168.1 >168 and <336.1 Amyloid beta 42 15 
                  Plaque area 20 
  Valproic acid 400 mg/kg Oral U APP <168.1 <168.1 Amyloid beta 42 15 
  Lithium N/A     U Tau >168 and <336.1 >168 and <336.1 Amyloid beta 40 20 
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Age at assessment 
(days) 
Outcome measure N 
George et al. (2004) High Cholesterol N/A   Oral F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Plaque area 15 
Hellstrom-Lindahl et al. 
(2004) 
nicotine 0.42 mg/kg SubCut U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 10 
                  Amyloid beta 42 11 
  nicotine 200 ug/mL Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
                  Plaque area 9 
Bergamaschini et al. 
(2004) 
Enoxaparin (a Heparin) 60 µg Iperitoneal M APP <168.1 >168 and <336.1 Amyloid beta 40 14 
                  Plaque area 12 
Wong et al. (2004) LY-411575 1 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 8.75 
                  Amyloid beta 42 8.75 
  LY-411575 10 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 8.75 
                  Amyloid beta 42 8.75 
  LY-D 1 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 8.75 
                  Amyloid beta 42 8.75 
  LY-D 10 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 8.75 
                  Amyloid beta 42 8.75 
Iwata et al. (2004) Neprilysin 0.6 µl iHippocampus U APP <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  Neprilysin 0.6 µl iHippocampus U APP >504 >504 Plaque area 12 
Sung et al. (2003) Vitamin E 2 I.U./g Oral B APP <168.1 >336 and <504.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
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(days) 
Outcome measure N 
                  Plaque area 20 
  Vitamin E 2 I.U./g Oral B APP >336 and <504.1 >504 Amyloid beta 40 20 
                  Amyloid beta 42 20 
                  Plaque area 20 
Zhang et al. (2003) A beta 1-42 N/A   Oral U APP >168 and <336.1 >336 and <504.1 Acquisition 10.33 
                  Amyloid beta 40 10.33 
                  Amyloid beta 42 10.33 
                  Plaque area 10.33 
                  Probe 9.333 
  A beta 1-42 N/A   INasal U APP >168 and <336.1 >336 and <504.1 Acquisition 10.33 
                  Amyloid beta 40 10.33 
                  Amyloid beta 42 10.33 
                  Plaque area 10.33 
                  Probe 10.33 
  A beta 1-42 N/A   intramuscular U APP >168 and <336.1 >336 and <504.1 Acquisition 10.33 
                  Amyloid beta 40 10.33 
                  Amyloid beta 42 10.33 
                  Plaque area 10.33 
                  Probe 10.33 
  A beta 1-42 N/A   Oral U APP <168.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
                  Probe 12 
  A beta 1-42 N/A   INasal U APP <168.1 >336 and <504.1 Amyloid beta 40 12 
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Outcome measure N 
                  Amyloid beta 42 12 
                  Plaque area 12 
        intramuscular U APP <168.1 >336 and <504.1 Probe 12 
  A beta 1-42 N/A   INasal U APP <168.1 >336 and <504.1 Probe 11 
        intramuscular U APP <168.1 >336 and <504.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
                  Plaque area 11 
  A beta 1-42 N/A   intramuscular U APP <168.1 >336 and <504.1 Acquisition 11 
  A beta 1-42 N/A   INasal U APP <168.1 >336 and <504.1 Acquisition 12 
  A beta 1-42 N/A   Oral U APP <168.1 >336 and <504.1 Acquisition 12 
  A beta 1-42 N/A   Oral U APP >168 and <336.1 >336 and <504.1 Acquisition 9.33 
                  Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
                  Plaque area 9.333 
                  Probe 10.33 
  A beta 1-42 N/A   INasal U APP >168 and <336.1 >336 and <504.1 Acquisition 10.33 
                  Amyloid beta 40 10.33 
                  Amyloid beta 42 10.33 
                  Plaque area 10.33 
                  Probe 10.33 
  A beta 1-42 N/A   intramuscular U APP >168 and <336.1 >336 and <504.1 Acquisition 10.33 
                  Amyloid beta 40 10.33 
                  Amyloid beta 42 10.33 
                  Plaque area 10.33 
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(days) 
Outcome measure N 
                  Probe 10.33 
Ryder et al. (2003) Lithium 200 mg/kg Oral U APP <168.1 <168.1 Amyloid beta 42 16 
  Roscovitine 30 nM IVentricular U APP <168.1 <168.1 Amyloid beta 42 20 
  Roscovitine 50 nM IVentricular U APP <168.1 <168.1 Amyloid beta 42 20 
Hasegawa et al. (2003) A beta 1-42 N/A   Unknown U APP <168.1 <168.1 Acquisition 21 
                >168 and <336.1 Plaque area 21 
Lombardo et al. (2003) Antibody 10d5 N/A   icerebral U APP >504 >504 Plaque area 16 
  Antibody 10d5 N/A   icerebral U APP >504 >504 Plaque area 16 
Bayer et al. (2003) Copper 0.25 grams/liter Oral F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
                  Plaque area 11 
  Copper 0.25 grams/liter Oral M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Plaque area 15 
Stackman et al. (2003) Gingko Biloba 70 mg/kg/day Oral F APP >168 and <336.1 >336 and <504.1 Acquisition 16 
                  Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Plaque area 16 
                  Probe 16 
Rockenstein et al. (2003) Cerebrolysin 5 ml/kg Iperitoneal U APP <168.1 >168 and <336.1 Acquisition 24 
                  Neurodegeneration 24 
                  Plaque area 24 
  Cerebrolysin 5 ml/kg Iperitoneal U APP <168.1 >168 and <336.1 Acquisition 24 
                  Neurodegeneration 24 
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Age at assessment 
(days) 
Outcome measure N 
                  Plaque area 24 
Zhou et al. (2003) Y-27632 2 mg/kg/day IVentricular U APP <168.1 <168.1 Amyloid beta 42 20 
Lemere et al. (2003) A beta 40/42 200 ug/week multiple B APPPS <168.1 <168.1 Amyloid beta 40 10 
                  Amyloid beta 42 10.5 
                  Plaque area 10 
Yan et al. (2003) Ibuprofen 62.5 mg/kg/day Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
                  Cellular infiltrates 7 
                  Plaque area 7 
  Pioglitazone 20 mg/kg/day Oral U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 6.5 
                  Amyloid beta 42 6.5 
                  Cellular infiltrates 6 
                  Plaque area 6 
Park et al. (2003) Lovastatin 100 mg/kg/day Oral M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  Plaque area 14 
  Lovastatin 100 mg/kg/day Oral F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  Plaque area 14 
Joseph et al. (2003) Blueberry supplementation 20 g/kg/day Oral U APPPS <168.1 >168 and <336.1 T/Y maze 6 
Austin et al. (2003) A beta 1-42 N/A   SubCut B APPPS >336 and <504.1 >504 RAWM 26 
Wilcock et al. (2003) Antibody anti-beta 1-16 N/A   multiple U APP >336 and <504.1 >336 and <504.1 Cellular infiltrates 13 
                  Plaque area 13 
Quinn et al. (2003) Indomethacin 2.24 mg/kg/day Oral F APP >168 and <336.1 >504 Plaque area 8 
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(days) 
Outcome measure N 
  Indomethacin 2.24 mg/kg/day Oral F APP >168 and <336.1 >336 and <504.1 Plaque area 5.333 
  LPS 25 mg/kg Iperitoneal F APP >336 and <504.1 >336 and <504.1 Plaque area 5.333 
  LPS 25 mg/kg Iperitoneal F APP >336 and <504.1 >336 and <504.1 Plaque area 5.333 
Marr et al. (2003) Neprilysin 15000000 TU icerebral U APP >336 and <504.1 >336 and <504.1 Plaque area 25 
Bard et al. (2003) A beta 15-24 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Plaque area 37.75 
  Antibody 6C6 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Neurodegeneration 35.67 
  a beta 1-5 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Plaque area 35.75 
  A beta 5-11 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Plaque area 38.75 
  A beta 3-9 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Plaque area 42.75 
  Antibody 2C1 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Neurodegeneration 31.67 
  Antibody 3A3 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Neurodegeneration 34.67 
  Antibody 10d5 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Neurodegeneration 36.67 
  Antibody 12B4 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Neurodegeneration 34.67 
  Antibody 12A11 10 
mg/kg/we
ek 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Neurodegeneration 39.67 
Matsuoka et al. (2003) GM1 ganglioside 15 
mg/kg/bod
y  
IVentricular B APPPS <168.1 <168.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 




Iperitoneal B APPPS <168.1 <168.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
  Gelsolin N/A   Iperitoneal B APPPS <168.1 <168.1 Amyloid beta 40 14.5 
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Age at assessment 
(days) 
Outcome measure N 
                  Amyloid beta 42 14.5 
                  Plaque area 10 
Town et al. (2002) A beta 1-42 N/A   Iperitoneal B APP <168.1 >504 Plaque area 8 
Capsoni, Giannotta, & 
Cattaneo (2002) 
Galantamine 3.5 mg/kg/day Iperitoneal U other <168.1 >168 and <336.1 Plaque area 6.25 
  Galantamine 3.5 mg/kg/day Iperitoneal U other <168.1 <168.1 Plaque area 6.25 
  NGF 48 ul Iperitoneal U other <168.1 >168 and <336.1 Plaque area 5.25 
  NGF 48 ul Iperitoneal U other <168.1 <168.1 Plaque area 5.25 
Rockenstein et al. (2002) Cerebrolysin 4 mg/kg Iperitoneal U APP <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
Petanceska et al. (2002) atorvastatin N/A   Oral B APPPS <168.1 <168.1 Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Plaque area 16 
Kotilinek et al. (2002) Antibody BAM-10 N/A   Iperitoneal B APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 37 
                  Amyloid beta 42 37 
  Antibody BAM-10 N/A   Iperitoneal B APP >168 and <336.1 >168 and <336.1 Probe 27 
Chauhan & Siegel (2002) Antibody Amy-33 N/A   intraventriclular M APP >168 and <336.1 >168 and <336.1 Cellular infiltrates 10 
                  Plaque area 10 
Nordberg et al. (2002) nicotine 30 mg/kg Oral B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
Permanne et al. (2002) iA-beta-5 N/A mg/week Iperitoneal U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 22 
                  Amyloid beta 42 22 
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(days) 
Outcome measure N 
                  Plaque area 22 
  iA-beta-5 N/A mg/week intraventriclular U APPPS >168 and <336.1 >168 and <336.1 Neurodegeneration 9 
                  Plaque area 9 
  iA-beta-5 N/A mg/week Iperitoneal U APPPS >168 and <336.1 >168 and <336.1 Neurodegeneration 11 
                  Plaque area 11 
Dodart et al. (2002) Antibody m266 200   Iperitoneal M APP >504 >504 NORT 16 
                  Plaque area 16 
  Antibody m266 10   Iperitoneal M APP >168 and <336.1 >168 and <336.1 NORT 10.67 
  Antibody m266 50   Iperitoneal M APP >168 and <336.1 >168 and <336.1 NORT 10.67 
  Antibody m266 250   Iperitoneal M APP >168 and <336.1 >168 and <336.1 NORT 10.67 
  Antibody m266 360   Iperitoneal M APP >168 and <336.1 >168 and <336.1 NORT 16 
Jantzen et al. (2002) Ibuprofen 62.5 mg/kg/day Oral U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 9.333 
                  Plaque area 9.333 
  celecoxib 30 mg/kg/day Oral U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 9.333 
                  Plaque area 9.333 
  NCX-2216 62.5 mg/kg/day Oral U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 9.333 
                  Plaque area 9.333 
  NCX-2216 62.5 mg/kg/day Oral U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 14 
Liu et al. (2002) Metrifonate 100 mg/kg/day Oral M APPPS >168 and <336.1 >336 and <504.1 Acquisition 56 
                  Amyloid beta 40 36 
                  Amyloid beta 42 36 
                  Plaque area 36 
Vehmas et al. (2001) A beta 1-42 100 mg Iperitoneal U APPPS <168.1 >168 and <336.1 Amyloid beta 40 7 
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Outcome measure N 
                  Amyloid beta 42 7 
                  Plaque area 7 
  A beta 1-42 100 mg Iperitoneal U APPPS <168.1 >168 and <336.1 Plaque area 10.5 
Arendash et al. (2001) A beta 1-42 N/A   SubCut U APPPS >168 and <336.1 >336 and <504.1 Plaque area 8 
                  RAWM 8 
                  T/Y maze 20 
Das et al. (2001) A beta 1-42 N/A   Iperitoneal U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
  A beta 1-42 N/A   Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
  A beta 1-42 N/A   Iperitoneal U APP >504 >504 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
Refolo et al. (2001) BM15-766 250 mg/kg/day Oral B APPPS <168.1 <168.1 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Plaque area 15 
Lim et al. (2001) Curcumin 160 ppm Oral B APP >168 and <336.1 >336 and <504.1 Cellular infiltrates 17 
                  Plaque area 17 
Sigurdsson et al. (2001) A beta 1-30 N/A   SubCut U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
DeMattos et al. (2001) Antibody m266 N/A   Iperitoneal U APP <168.1 >168 and <336.1 Amyloid beta 42 28 
                  Plaque area 27 
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Janus et al. (2000) A beta 1-42 N/A   Iperitoneal U APP <168.1 <168.1 Acquisition 16 
                >168 and <336.1 Plaque area 16 
Morgan et al. (2000) A beta 1-42 N/A   SubCut B APP >168 and <336.1 >336 and <504.1 Plaque area 5 
                  RAWM 5 
  A beta 1-42 N/A   SubCut B APPPS >168 and <336.1 >336 and <504.1 Plaque area 9 
                  RAWM 9 
Weiner et al. (2000) A beta 1-40 10 ug/week Oral U APP <168.1 >168 and <336.1 Amyloid beta 42 6 
                  Plaque area 13.5 
  A beta 1-40 10 ug/week Oral U APP <168.1 >168 and <336.1 Plaque area 13.5 
  A beta 1-40 5 ug/week INasal U APP <168.1 >168 and <336.1 Amyloid beta 42 5 
                  Plaque area 11.5 
  A beta 1-40 25 ug/week INasal U APP <168.1 >168 and <336.1 Amyloid beta 42 6 
                  Plaque area 13.5 
  A beta 1-40 100 ug/week Oral U APP <168.1 >168 and <336.1 Amyloid beta 42 6 
Lim et al. (2000) Ibuprofen 56 mg/kg/day Oral B APP >168 and <336.1 >336 and <504.1 Cellular infiltrates 14 
                  Neurodegeneration 15 
                  Plaque area 12 
Schenk et al. (1999) A beta 1-42 N/A   Iperitoneal F APP <168.1 >336 and <504.1 Plaque area 14 
  A beta 1-42 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Plaque area 18 
  A beta 1-42 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Plaque area 19 
  SAP protein N/A   Iperitoneal F APP <168.1 >336 and <504.1 Plaque area 9 
Asami-Odaka et al. (2005) Antibody BC05 0.95 
mg/kg/we
ek 
Iperitoneal M APP <168.1 >168 and <336.1 Amyloid beta 40 19 
                  Amyloid beta 42 19 
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Outcome measure N 
                  Plaque area 19 
Backer et al. (2008) CNI-1493 8 mg/kg/day Iperitoneal M APP <168.1 <168.1 NORT 25 
                  Plaque area 9 
Chauhan (2003) Garlic extract 40 mg/kg/day Oral U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
Cherny et al. (2001) Clioquinol 30 mg/kg/day Oral B APP >504 >504 Plaque area 27 
Czirr et al. (2007) LY-411575 10 mg/kg/day Oral U APP <168.1 <168.1 Amyloid beta 40 10 
                  Amyloid beta 42 9 
  LY-411575 10 mg/kg/day Oral U APPPS <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
Gong et al. (2004) Rolipram 0.03 mg/kg/day SubCut B APPPS <168.1 >168 and <336.1 Fear conditioning 24 
                  Probe 24 
                  RAWM 31 
  Rolipram 0.03 mg/kg/day SubCut B APPPS <168.1 >168 and <336.1 Acquisition 24 
                  Amyloid beta 40 34 
                  Amyloid beta 42 20 
  Rolipram 0.03 mg/kg/day SubCut B APPPS <168.1 <168.1 Fear conditioning 24 
                  RAWM 31 
Hemming et al. (2007) Neprilysin 4 µl iHippocampus U APP >504 >504 Cellular infiltrates 8 
                  Plaque area 8 
Kim et al. (2007a) Resveratrol N/A 5 ug/ml IVentricular U Tau <168.1 <168.1 Fear conditioning 14 
  Resveratrol N/A mg/week IVentricular U Tau <168.1 <168.1 Cellular infiltrates 5 
                  Neurodegeneration 5 
Levites et al. (2006b) Antibody scFv9 N/A   IVentricular U APP <168.1 <168.1 Amyloid beta 40 7.5 
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                  Amyloid beta 42 7.5 
  Antibody scFv9 N/A   IVentricular U APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
                  Plaque area 9.333 
  Antibody scFv42.2 N/A   IVentricular U APP <168.1 <168.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  Antibody scFv42.2 N/A   IVentricular U APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
                  Plaque area 9.333 
  Antibody scFv40.1 N/A   IVentricular U APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
                  Plaque area 9.333 
Abramowski et al. (2008) LY-411575 10 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 12 
  LY-411575 10 mg/kg/day Oral M APP <168.1 >168 and <336.1 Amyloid beta 40 40 
                  Amyloid beta 42 40 
                  Plaque area 38 
  LY-411575 10 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
  LY-411575 10 mg/kg/day Oral F APPPS <168.1 <168.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
  LY-411575 3 mg/kg Oral F APPPS >336 and <504.1 >336 and <504.1 Amyloid beta 40 30 
                  Amyloid beta 42 30 
Adlard et al. (2008) Clioquinol 30 mg/kg/day Oral B APPPS >504 >504 Amyloid beta 40 9 
                  Amyloid beta 42 9 
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Outcome measure N 
  Clioquinol 30 mg/kg/day Oral B APPPS >504 >504 Neurodegeneration 9 
                  TAU 9 
  PBT2 30 mg/kg/day Oral F APPPS >168 and <336.1 >168 and <336.1 Acquisition 25 
                  Probe 16 
  Clioquinol 30 mg/kg/day Oral F APPPS >168 and <336.1 >168 and <336.1 Acquisition 16 
                  Probe 16 
  PBT2 10 mg/kg/day Oral M APPPS >336 and <504.1 >336 and <504.1 Acquisition 13 
                  Probe 13 
  PBT2 30 mg/kg/day Oral B APPPS >168 and <336.1 >168 and <336.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
                  Neurodegeneration 9 
  PBT2 30 mg/kg/day Oral B APPPS >168 and <336.1 >168 and <336.1 TAU 9 
  PBT2 30 mg/kg/day Oral B APPPS >168 and <336.1 >168 and <336.1 TAU 12 
  PBT2 30 mg/kg/day Oral B APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 18 
                  Amyloid beta 42 18 
  PBT2 30 mg/kg/day Oral B APP >336 and <504.1 >336 and <504.1 Neurodegeneration 18 
                  TAU 18 
  PBT2 30 mg/kg/day Oral F APP >336 and <504.1 >336 and <504.1 Plaque area 12 
Ambree et al. (2006) Environmental Enrichment N/A   N/A F APP <168.1 <168.1 Amyloid beta 40 18 
                  Amyloid beta 42 18 
                  Cellular infiltrates 18 
                  Plaque area 18 
Arendash et al. (2006) Caffeine 1.5 mg/day Oral B APP <168.1 >168 and <336.1 Acquisition 41 
                  Probe 41 
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Outcome measure N 
  Caffeine 1.5 mg/day Oral B APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
Arendash et al. (2007) High Fat diet N/A   Oral U APPPS <168.1 >168 and <336.1 Acquisition 17 
                  Amyloid beta 40 17 
                  Amyloid beta 42 17 
                  Probe 17 
                  T/Y maze 17 
Asuni et al. (2006) A beta 1-30 N/A   SubCut B APP >168 and <336.1 >504 Amyloid beta 40 28 
                  Amyloid beta 42 28 
                  Plaque area 28 
                  RAWM 33 
  A beta 1-30 N/A   SubCut B APP >504 >504 Amyloid beta 40 18 
                  Amyloid beta 42 18 
                  Plaque area 18 
                  RAWM 19 
Barten et al. (2005) 
BMS-299897 (also known as 
SIB-3520) 
N/A   Oral M APP <168.1 <168.1 Amyloid beta 40 6 
  
BMS-299897 (also known as 
SIB-3520) 
N/A   Oral M APP <168.1 >168 and <336.1 Amyloid beta 40 6 
  
BMS-299897 (also known as 
SIB-3520) 
N/A   Oral M APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6 
  
BMS-299897 (also known as 
SIB-3520) 
N/A   Oral M APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6 
  
BMS-299897 (also known as 
SIB-3520) 
N/A   Oral M APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 6 
Boado et al. (2007) antibody (fusion) 20 pmol icerebral M APPPS >336 and <504.1 >336 and <504.1 Plaque area 6 
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Brendza et al. (2005) Antibody 10d5 N/A   ibrain U APP >336 and <504.1 >336 and <504.1 Neurodegeneration 17 
Butovsky et al. (2006) Glatiramer acetate N/A   SubCut U APPPS >168 and <336.1 >168 and <336.1 Acquisition 13 
                  Plaque area 13 
  Glatiramer acetate N/A   SubCut U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 13 
                  Neurodegeneration 13 
Casadesus et al. (2006) Leuprolide 7.5 mg/kg intramuscular F APP >504 >504 Plaque area 13 
                  T/Y maze 13 
Chauhan, Siegel, & 
Feinstein (2004) 
Pravastatin 0.5 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
                  Plaque area 5.625 
  Pravastatin 1 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
                  Plaque area 5.625 
  Pravastatin 5 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
                  Plaque area 5.625 
  Pravastatin 10 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
                  Plaque area 5.625 
  Lovastatin 0.5 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
                  Plaque area 5.625 
  Lovastatin 1 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
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                  Plaque area 5.625 
  Lovastatin 5 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
                  Plaque area 5.625 
  Lovastatin 10 mg/kg/day Oral M APP <168.1 <168.1 Amyloid beta 40 5.625 
                  Amyloid beta 42 5.625 
                  Plaque area 5.625 
Chauhan & Siegel (2005) 





intraventriclular U APP <168.1 <168.1 Plaque area 5.833 
  





intraventriclular U APP <168.1 <168.1 Plaque area 5.833 
  





intraventriclular U APP <168.1 <168.1 Plaque area 5.833 
  Antibody anti-beta 3-6 10 
ugl10ul/an
imal 
intraventriclular U APP <168.1 <168.1 Plaque area 5.833 
  Antibody anti-beta-11 10 
ugl10ul/an
imal 
intraventriclular U APP <168.1 <168.1 Plaque area 5.833 
  Antibody anti-beta 1-28 10 
ugl10ul/an
imal 
intraventriclular U APP <168.1 <168.1 Plaque area 5.833 
  Antibody beta-CTF 10 
ugl10ul/an
imal 
intraventriclular U APP <168.1 <168.1 Plaque area 5.833 
Chauhan & Siegel (2007) Antisense Gamma-site ODN 10 nM/wk IVentricular U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6.25 
                  Amyloid beta 42 6.25 
  Antisense Beta-site ODN 10 nM/wk Iperitoneal U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6.25 
                  Amyloid beta 42 6.25 
  Gamma-secretase site ODN 10 nM/wk IVentricular U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6.25 
                  Amyloid beta 42 6.25 
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  Beta-secretase site ODN 10 nM/wk Iperitoneal U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6.25 
                  Amyloid beta 42 6.25 
Chen, Eckman, & Eckman 
(2006) 
LY-411575 25 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 21.5 
                  Amyloid beta 42 21.5 
  Ginsenoside Rg3 25 mg/kg Oral F APP <168.1 <168.1 Amyloid beta 40 14.5 
                  Amyloid beta 42 14.5 
  Ginsenoside Rg1 25 mg/kg Oral F APP <168.1 <168.1 Amyloid beta 40 15.5 
                  Amyloid beta 42 15.5 
  Ginsenoside Re 25 mg/kg Oral F APP <168.1 <168.1 Amyloid beta 40 23.5 
                  Amyloid beta 42 23.5 
Cracchiolo et al. (2007) Environmental Enrichment N/A   N/A B APPPS <168.1 >168 and <336.1 Plaque area 8.667 
                  Probe 8.667 
                  RAWM 8.667 
  Exercise N/A   N/A B APPPS <168.1 >168 and <336.1 Plaque area 7.667 
                  Probe 7.667 
                  RAWM 7.667 
  impoverished housing N/A   N/A B APPPS <168.1 >168 and <336.1 Plaque area 10.67 
                  Probe 10.67 
                  RAWM 10.67 
DaSilva et al. (2006) A beta 1-42 N/A   SubCut U APP <168.1 >168 and <336.1 Cellular infiltrates 18 
                  Plaque area 20 
  A beta 1-42 N/A   SubCut U APP <168.1 >168 and <336.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
Dickstein et al. (2006) A beta 1-40 N/A   Ivenous U APP >168 and <336.1 >336 and <504.1 Plaque area 12 
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  A beta 1-40 N/A   Ivenous U APP <168.1 >168 and <336.1 Plaque area 12 
Dineley et al. (2007) FK506 10 mg/kg Iperitoneal B APP <168.1 <168.1 Amyloid beta 42 10 
                  Fear conditioning 20 
Dvir et al. (2006) Indomethacin 50 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 10.5 
                  Amyloid beta 42 10.5 
  Indomethacin 16.66 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 17.5 
                  Amyloid beta 42 17.5 
  DP-115 135 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 11.5 
                  Amyloid beta 42 11.5 
  DP-115 45 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 17.5 
                  Amyloid beta 42 17.5 
Engel et al. (2006) Lithium 1.98 g/kg Oral U Tau >504 >504 TAU 8 
Esposito et al. (2008) A beta 2-6 N/A   Iperitoneal U APPPS <168.1 >168 and <336.1 Plaque area 4.5 
  A beta 2-6 N/A   Iperitoneal U APPPS <168.1 >336 and <504.1 Plaque area 8 
  A beta 1-7 N/A   Iperitoneal U APPPS <168.1 >168 and <336.1 Plaque area 4.5 
Fan et al. (2007) Minocycline 5 mg/kg/day Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 18 
                  Amyloid beta 42 18 
                  Cellular infiltrates 10 
Feng et al. (2004) Melatonin 10 mg/kg Oral U APP <168.1 >168 and <336.1 Neurodegeneration 20 
Feng et al. (2006) Melatonin 10 mg/kg Oral B APP <168.1 >168 and <336.1 Neurodegeneration 10 
Fenili et al. (2007) Scyllo-inositol 25 mg/animal Oral U APP <168.1 >168 and <336.1 Amyloid beta 40 18 
                  Amyloid beta 42 18 
                  Plaque area 18 
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Frenkel et al. (2008) Protollin 1 ug/mouse INasal U APP >504 >504 Amyloid beta 40 9.5 
                  Amyloid beta 42 9.5 
                  Cellular infiltrates 13 
  Glatiramer acetate 25 ug/mouse INasal U APP <168.1 >336 and <504.1 Cellular infiltrates 13.5 
Garcia-Alloza et al. (2006) Egb- 761 100 mg/kg Oral U APPPS >168 and <336.1 >168 and <336.1 Plaque area 66 
  Trolox 210 mg/kg/day Oral U APPPS >168 and <336.1 >168 and <336.1 Plaque area 66 
Garcia-Alloza et al. 
(2007b) 
Antibody 10d5 N/A   Icortex U APPPS >168 and <336.1 >168 and <336.1 Plaque area 4.5 
  Antibody 10d5 N/A   Icortex U APPPS >168 and <336.1 >168 and <336.1 Plaque area 4.5 
  Antibody 10d5 N/A   Icortex U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 4.5 
                  Plaque area 6 
  Antibody 10d5 N/A   Icortex U APPPS >168 and <336.1 >168 and <336.1 Plaque area 6 
  Interferon-gamma N/A   Icortex U APPPS >168 and <336.1 >168 and <336.1 Cellular infiltrates 4.5 
                  Plaque area 4.5 
  Interferon-gamma N/A   Icortex U APPPS >168 and <336.1 >168 and <336.1 Plaque area 4.5 
Halagappa et al. (2007) Intermittent Fasting 0.5 restricted Oral B 3xTgAD <168.1 >336 and <504.1 Amyloid beta 40 19.5 
                  Amyloid beta 42 19.5 
                  Probe 24 
                  TAU 19.5 
  Intermittent Fasting 0.5 restricted Oral B 3xTgAD <168.1 >168 and <336.1 Acquisition 25.5 
                  Probe 24 
  Caloric restriction 0.4 resricted Oral B 3xTgAD <168.1 >336 and <504.1 Amyloid beta 40 19.5 
                  Amyloid beta 42 19.5 
                  Probe 24 
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                  TAU 19.5 
  Caloric restriction 0.4 resricted Oral B 3xTgAD <168.1 >168 and <336.1 Acquisition 25.5 
                  Probe 24 
  Intermittent Fasting 0.5 resricted Oral M 3xTgAD <168.1 >336 and <504.1 Acquisition 10.5 
  Intermittent Fasting 0.5 resricted Oral F 3xTgAD <168.1 >336 and <504.1 Acquisition 9 
  Caloric restriction 0.5 resricted Oral M 3xTgAD <168.1 >336 and <504.1 Acquisition 10.5 
  Caloric restriction 0.4 resricted Oral F 3xTgAD <168.1 >336 and <504.1 Acquisition 9 
Heneka et al. (2005) Pioglitazone 62.5 mg/kg/day Oral U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
                  Cellular infiltrates 9 
                  Plaque area 9 
  Ibuprofen 40 mg/kg/day Oral U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
                  Cellular infiltrates 9 
                  Plaque area 9 
Hooijmans et al. (2007) DHA N/A   Oral M APPPS <168.1 >336 and <504.1 Plaque area 12 
  Typical Western Diet N/A   Oral M APPPS <168.1 >336 and <504.1 Plaque area 13 
Hook, Kindy, & Hook 
(2008) 
CA074Me 0.006 mg/kg/day SubCut M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7 
                  Amyloid beta 42 12 
                  Plaque area 12 
  E64d 0.006 mg/kg/day SubCut M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
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  CA074Me 0.006 mg/kg/day SubCut M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
  E64d 0.006 mg/kg/day SubCut M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
Hussain et al. (2007) GSK-188909 250 mg/kg/day Oral M APPPS <168.1 <168.1 Amyloid beta 40 29 
                  Amyloid beta 42 29 
  GSK-188909 250 mg/kg/day Oral M APPPS <168.1 <168.1 Amyloid beta 40 27 
                  Amyloid beta 42 26 
  GF120918 250 mg/kg/day Oral M APPPS <168.1 <168.1 Amyloid beta 40 30 
                  Amyloid beta 42 30 
Hyde et al. (2006) LY-411575 0.1 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 0.3 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 1 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 3 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 10 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 0.1 mg/kg/day SubCut B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 0.3 mg/kg/day SubCut B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 1 mg/kg/day SubCut B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 3 mg/kg/day SubCut B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 10 mg/kg/day SubCut B APP <168.1 <168.1 Amyloid beta 40 7.636 
  LY-411575 10 mg/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 8 
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  LY-411575 10 mg/kg/day Oral B APP >504 >504 Amyloid beta 40 8 
  LY-D 10 g/kg/day Oral B APP <168.1 <168.1 Amyloid beta 40 7.636 
Imbimbo et al. (2007) CHF5074 61 mg/kg/day Oral B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 22 
                  Amyloid beta 42 26 
                  Cellular infiltrates 16 
                  Plaque area 16 
Jankowsky et al. (2005) Environmental Enrichment N/A   N/A F APP <168.1 >168 and <336.1 Acquisition 16 
                  Amyloid beta 40 17 
                  Amyloid beta 42 17 
                  Probe 16 
                  RAWM 16 
  Environmental Enrichment N/A   N/A F APPPS <168.1 >168 and <336.1 Acquisition 16 
                  Amyloid beta 40 19 
                  Amyloid beta 42 19 
                  Plaque area 19 
                  Probe 16 
                  RAWM 16 
  Environmental Enrichment N/A   N/A F PS1 <168.1 >168 and <336.1 Acquisition 16 
                  Probe 16 
                  RAWM 16 
Kim et al. (2004) A beta 1-42 N/A   INasal U APP >168 and <336.1 >336 and <504.1 Plaque area 9 
Kim et al. (2007b) A beta 1-6 N/A   INasal U APPPS <168.1 >168 and <336.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Plaque area 12 
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Kim et al. (2008b) 
BMS-562492 (TACE 
INHIBITOR) 
0 unknown SubCut U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  TAPI-I 0   SubCut U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
Koldamova et al. (2005) TO901317 50 mg/kd/day Oral U APP <168.1 <168.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
Lanz, Fici, & Merchant 
(2005) 
Flurbiprofen 25 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 12.5 
                  Amyloid beta 42 12.5 
  Flurbiprofen 50 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  Flurbiprofen 100 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  Ibuprofen 50 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
  Sulindac Sulfide 25 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
  Sulindac Sulfide 50 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
  Ibuprofen 50 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
  Flurbiprofen 10 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 20 
                  Amyloid beta 42 20 
  Flurbiprofen 25 mg/kg/day Oral F APP <168.1 <168.1 Amyloid beta 40 20 
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                  Amyloid beta 42 20 
Lanz et al. (2008) hIGF 500 ug/kg/day SubCut U APP >168 and <336.1 >168 and <336.1 TAU 13.5 
  hIGF 50 ug/kg/day SubCut U APP >168 and <336.1 >168 and <336.1 TAU 13.5 
Lavie et al. (2004) EFRH 10 
phage 
copies 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Acquisition 7 
                  Amyloid beta 40 7 
                  Amyloid beta 42 7 
  EFRH 150 
Phage 
copies 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Acquisition 9 
                  Amyloid beta 40 9 
                  Amyloid beta 42 9 
  EFRH 300 
phage 
copies 
Iperitoneal U APP >168 and <336.1 >336 and <504.1 Acquisition 8 
                  Amyloid beta 40 8 
                  Amyloid beta 42 8 
Le Corre et al. (2006) K252a 100 mg/kg Oral F Tau >168 and <336.1 >168 and <336.1 TAU 58 
Lee et al. (2006) Antibody NAB61 62.5 µg Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 17 
                  Amyloid beta 42 17 
  Antibody NAB61 62.5 µg Iperitoneal U APP >504 >504 Amyloid beta 40 30 
                  Amyloid beta 42 30 
  Antibody NAB61 62.5 µg Iperitoneal U APP >504 >504 Acquisition 30 
                  Probe 30 
  Antibody NAB61 62.5 µg iHippocampus U APP >168 and <336.1 >168 and <336.1 Plaque area 10 
Levites et al. (2006a) Antibody Ab2 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
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  Antibody Ab5 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  Antibody ab9 N/A   Iperitoneal F APP <168.1 <168.1 Amyloid beta 40 10.5 
                  Amyloid beta 42 10.5 
                  Plaque area 10.5 
  Antibody Ab42.2 N/A   Iperitoneal F APP <168.1 <168.1 Amyloid beta 40 10.5 
                  Amyloid beta 42 10.5 
                  Plaque area 10.5 
  Antibody Ab40.1 N/A   Iperitoneal F APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
  Antibody Ab40.1 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
  Antibody Ab42.2 N/A   Iperitoneal F APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
  Antibody Ab42.2 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
  Antibody ab9 N/A   Iperitoneal F APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 8 
                  Amyloid beta 42 8 
                  Plaque area 8 
  Antibody ab9 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
  Antibody ab9 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 8 
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                  Amyloid beta 42 8 
  Antibody Ab3 N/A   Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
Ma et al. (2006) Antibody anti-beta 1-15 N/A   intraventriclular U APP >168 and <336.1 >168 and <336.1 Plaque area 13 
Malm et al. (2007) Pyrrolidine Dithiocarbamate 20 mg/kg/day Oral U APPPS >168 and <336.1 >336 and <504.1 Acquisition 28 
                  Amyloid beta 40 28 
                  Amyloid beta 42 28 
                  Cellular infiltrates 28 
                  Plaque area 28 
                  Probe 28 
Marutle et al. (2007) Phenserine 25 mg/kg/day Iperitoneal U APP >168 and <336.1 >168 and <336.1 Cellular infiltrates 6 
Matsuoka et al. (2008) NAP 5 ul/day INasal B 3xTgAD >168 and <336.1 >336 and <504.1 TAU 24 
  NAP 5 ul/day INasal B 3xTgAD >168 and <336.1 >504 Probe 22 
                  TAU 22 
McLaurin et al. (2006) Epi-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 <168.1 Acquisition 12 
                  Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Cellular infiltrates 15 
                  Plaque area 15 
  Epi-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 >168 and <336.1 Acquisition 12 
                  Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Cellular infiltrates 15 
                  Plaque area 15 
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  Epi-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 >168 and <336.1 Acquisition 15 
                  Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Plaque area 15 
                  Probe 15 
  scyllo-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 <168.1 Acquisition 12 
                  Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Cellular infiltrates 15 
                  Plaque area 15 
  scyllo-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 >168 and <336.1 Acquisition 12 
                  Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Neurodegeneration 20 
                  Plaque area 15 
  scyllo-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 >168 and <336.1 Acquisition 15 
                  Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Cellular infiltrates 15 
                  Neurodegeneration 20 
                  Plaque area 15 
                  Probe 15 
  scyllo-cyclohexanehexol 0.3 mg/kg/day Oral B APP <168.1 <168.1 Acquisition 10 
                  Plaque area 10.67 
  scyllo-cyclohexanehexol 1 mg/kg/day Oral B APP <168.1 <168.1 Acquisition 10 
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                  Plaque area 10.67 
  scyllo-cyclohexanehexol 3.3 mg/kg/day Oral B APP <168.1 <168.1 Acquisition 10 
                  Plaque area 10.67 
  scyllo-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 <168.1 Acquisition 10 
  scyllo-cyclohexanehexol 10 mg/kg/day Oral B APP <168.1 >168 and <336.1 Amyloid beta 42 10.67 
  scyllo-cyclohexanehexol 30 mg/kg/day Oral B APP <168.1 >168 and <336.1 Amyloid beta 42 10.67 
  scyllo-cyclohexanehexol 5 mg/kg/day Oral B APP <168.1 >168 and <336.1 Amyloid beta 42 10.67 
  scyllo-cyclohexanehexol N/A   Oral B Tau not known not known Cellular infiltrates 20 
                  Neurodegeneration 20 
Movsesyan et al. (2008) A beta 1-11 N/A   SubCut U 3xTgAD <168.1 >504 Acquisition 14 
                  Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  Cellular infiltrates 14 
                  Plaque area 14 
                  Probe 14 
                  TAU 14 
Oddo et al. (2005) nicotine 490 ug/mL Oral U 3xTgAD <168.1 <168.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
                  Neurodegeneration 10 
                  Plaque area 10 
                  TAU 10 
Oddo et al. (2006a) Antibody A11 N/A   iHippocampus U 3xTgAD >168 and <336.1 >336 and <504.1 Plaque area 8 
                  TAU 8 
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Parachikova, Nichol, & 
Cotman (2008) 
Exercise N/A   N/A U APP >336 and <504.1 >336 and <504.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
      day N/A U APP >336 and <504.1 >336 and <504.1 RAWM 12 
Patel et al. (2005) Caloric restriction 0.4 restriction Oral M APPPS <168.1 <168.1 Cellular infiltrates 8 
                  Plaque area 8 
  Caloric restriction 0.4 reduction Oral M APP <168.1 <168.1 Plaque area 8 
Pedersen et al. (2006) Rosiglitazone 30 mg/kg Oral M APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 14 
                  Amyloid beta 42 14 
                  RAWM 14 
  Metyrapone 50 mg/kg SubCut M APP >168 and <336.1 >336 and <504.1 RAWM 14 
Petrushina et al. (2008) a beta 1-28 N/A   SubCut B APP <168.1 >336 and <504.1 Cellular infiltrates 13 
                  Plaque area 13 
Pugh et al. (2007) DSP-4 5 mg/kg Iperitoneal M APPPS <168.1 >168 and <336.1 Fear conditioning 12 
                  Plaque area 12 
  DSP-4 5 mg/kg Iperitoneal M APPPS <168.1 >168 and <336.1 Fear conditioning 12 
                  Plaque area 12 
Qu et al. (2006) A beta 1-42 N/A   SubCut F APPPS <168.1 >336 and <504.1 Amyloid beta 42 8 
                  Plaque area 8 
Quinn et al. (2007) Lipoic acid 0.1 % of diet Oral F APP >168 and <336.1 >336 and <504.1 Acquisition 15 
                  Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Fear conditioning 15 
                  Plaque area 15 
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                  Probe 15 
Rakover, Arbel, & 
Solomon (2007) 
Antibody BBS1 2 mg/kg Iperitoneal F APP <168.1 >168 and <336.1 Amyloid beta 40 8.5 
                  Amyloid beta 42 8.5 
                  Cellular infiltrates 8.5 
                  NORT 8.5 
                  Plaque area 8.5 
  Antibody BBS1 16 mg/kg Iperitoneal F APP <168.1 >168 and <336.1 Amyloid beta 40 10.5 
                  Amyloid beta 42 10.5 
                  Cellular infiltrates 10.5 
                  NORT 10.5 
                  Plaque area 10.5 
Rezai-Zadeh et al. (2008) 
epigallocatechin-3- 
50 mg/kg Oral F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 20 
gallate 
                  Amyloid beta 42 20 
                  Plaque area 10 
  
epigallocatechin-3- 




50 mg/kg Oral F APP >168 and <336.1 >336 and <504.1 RAWM 10 
gallate 
Rockenstein et al. (2006) Cerebrolysin 5 ml/kg Iperitoneal U APP <168.1 >168 and <336.1 Acquisition 24 
                  Neurodegeneration 24 
                  Plaque area 24 
Rockenstein et al. (2007a) Cerebrolysin 5 ml/kg Iperitoneal U APP <168.1 <168.1 Cellular infiltrates 12 
                  Neurodegeneration 12 
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Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
                  Plaque area 12 
  Cerebrolysin 5 ml/kg Iperitoneal U APP <168.1 <168.1 Cellular infiltrates 12 
                  Neurodegeneration 12 
                  Plaque area 12 
Rosario et al. (2006) Testosterone 10 mg SubCut M 3xTgAD <168.1 >168 and <336.1 Plaque area 12 
                  T/Y maze 12 
Sadowski et al. (2006) Amyloid beta-12-28P 1 mg Iperitoneal F APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 22 
                  Amyloid beta 42 22 
                  Plaque area 22 
                  RAWM 22 
  Amyloid beta-12-28P 1 mg Iperitoneal F APPPS <168.1 >168 and <336.1 Amyloid beta 40 22 
                  Amyloid beta 42 22 
                  Plaque area 22 
  Amyloid beta-12-28P 1 mg Iperitoneal F APPPS <168.1 >168 and <336.1 Amyloid beta 40 22 
Schilling et al. (2008) PBD150 7.2 mg/kg/day Oral B APP <168.1 >168 and <336.1 Acquisition 10.5 
                  Amyloid beta 40 16 
                  Amyloid beta 42 16 
                  Probe 14 
  PBD150 7.2 mg/g Oral B APP <168.1 >168 and <336.1 Plaque area 8 
  PBD150 2.4 mg/kg/day Oral B APP <168.1 >168 and <336.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  PBD150 7.2 mg/kg/day Oral B APP <168.1 >168 and <336.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
  PBD150 2.4 mg/kg/day Oral B APP <168.1 >336 and <504.1 Amyloid beta 40 12 
   Appendix III: Study characterstics report 
492 
 
Author and (Year) Intervention Dose Unit 








Age at assessment 
(days) 
Outcome measure N 
                  Amyloid beta 42 12 
                  Fear conditioning 7.5 
                  Plaque area 6 
  PBD150 7.2 mg/kg/day Oral B APP <168.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Fear conditioning 7.5 
                  Plaque area 6 
  PBD150 2.4 mg/kg/day Oral B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Fear conditioning 6 
  PBD150 7.2 mg/kg/day Oral B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Fear conditioning 6 
  PBD150 2.4 mg/kg/day Oral B APP >168 and <336.1 >336 and <504.1 Plaque area 6 
  PBD150 7.2 mg/kg/day Oral B APP >168 and <336.1 >336 and <504.1 Plaque area 6 
Seabrook et al. (2006a) Minocycline 55 mg/kg/day Oral U APP <168.1 >168 and <336.1 Acquisition 12 
                  Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Cellular infiltrates 12 
                  Plaque area 12 
  Minocycline 55 mg/kg/day Oral U APP >168 and <336.1 >336 and <504.1 Acquisition 12 
                  Amyloid beta 40 12 
                  Amyloid beta 42 12 
                  Cellular infiltrates 12 
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Age at assessment 
(days) 
Outcome measure N 
                  Plaque area 12 
Shim et al. (2007) Lithium 60 mg/kg/day Iperitoneal B Tau >504 >504 TAU 9 
  Lithium 300 mg/kg/day Iperitoneal B Tau >504 >504 TAU 9 
Shim et al. (2008) nicotine 5 mg/kg/day Oral B APP >168 and <336.1 >504 Acquisition 20 
                  Probe 20 
  nicotine 30 mg/kg/day Oral B APP >168 and <336.1 >504 Acquisition 20 
                  Probe 20 
  nicotine 180 mg/kg/day Oral B APP >168 and <336.1 >504 Acquisition 20 
                  Probe 20 
Singer et al. (2005) Lenti-siBACE1-6 0 mg/kg/day iHippocampus U APP >168 and <336.1 >168 and <336.1 Acquisition 10 
                  Probe 10 
  Lenti-siBACE1-6 0 mg/kg/day iHippocampus U APP >168 and <336.1 >168 and <336.1 Amyloid beta 42 16 
                  Plaque area 16 
Sung et al. (2004) Indomethacin N/A   Oral B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Plaque area 12 
  Nimesulide N/A   Oral B APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 15 
                  Amyloid beta 42 15 
                  Plaque area 12 
Trinchese et al. (2008) BDA-410 30 mg/kg Iperitoneal U APPPS <168.1 >168 and <336.1 Fear conditioning 23 
                  RAWM 23 
        Oral U APPPS <168.1 >168 and <336.1 Amyloid beta 40 8.5 
                  Amyloid beta 42 8.5 
  BDA-410 30 mg/kg Oral U APPPS >168 and <336.1 >168 and <336.1 Fear conditioning 15 
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Age at assessment 
(days) 
Outcome measure N 
                  RAWM 15 
  e64 6.4 mg/kg Iperitoneal U APPPS <168.1 >168 and <336.1 RAWM 20 
        Oral U APPPS <168.1 >168 and <336.1 Amyloid beta 40 7.5 
                  Amyloid beta 42 7.5 
Tucker et al. (2006) N-acetyl cystine 5 g/l Oral U APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
  paroxetine 250 ng/mouse Oral U APP <168.1 <168.1 Amyloid beta 40 7.333 
                  Amyloid beta 42 7.333 
  erythromycin N/A   Oral U APP <168.1 <168.1 Amyloid beta 40 9.333 
                  Amyloid beta 42 9.333 
Tucker, Borchelt, & 
Troncoso (2008) 
Antibody 6E10 2 µg icerebral B APPPS >168 and <336.1 >336 and <504.1 Plaque area 10 
  Antibody 6E10 5 µg icerebral B APPPS >336 and <504.1 >336 and <504.1 Plaque area 12 
  Antibody 6E10 5 µg icerebral B APP <168.1 >168 and <336.1 Plaque area 8 
  antibody Ib3 5 µg icerebral B APP <168.1 >168 and <336.1 Plaque area 8 
  Antibody 7b6 5 µg icerebral B APP <168.1 >168 and <336.1 Plaque area 8 
Wang et al. (2007) Valsartan 10 mg/kg/day Oral F APP <168.1 >168 and <336.1 Acquisition 10.5 
                  Amyloid beta 40 10.5 
                  Amyloid beta 42 10.5 
  Valsartan 40 mg/kg/day Oral F APP <168.1 >168 and <336.1 Acquisition 10.5 
                  Amyloid beta 40 10.5 
                  Amyloid beta 42 10.5 
  Valsartan 10 mg/kg/day Oral F APP <168.1 >168 and <336.1 Acquisition 10.5 
                  Probe 10.5 
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Age at assessment 
(days) 
Outcome measure N 
  Valsartan 40 mg/kg/day Oral F APP <168.1 >168 and <336.1 Acquisition 10.5 
                  Probe 10.5 
Wilcock et al. (2007) NCX-2216 187 ppm Oral U APPPS >168 and <336.1 >504 Plaque area 22 
  A beta 1-42 N/A   SubCut U APPPS >168 and <336.1 >504 Plaque area 19 
Yamamoto et al. (2005) 3F1 (FAB fragment) N/A   Iperitoneal U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
  4396C (FAB fragments) N/A   Iperitoneal U APP >168 and <336.1 >168 and <336.1 Amyloid beta 40 6 
                  Amyloid beta 42 6 
  4396C (FAB fragments) N/A   Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
                  Plaque area 9 
  4396C (FAB fragments) N/A   Iperitoneal U APP >168 and <336.1 >336 and <504.1 Amyloid beta 40 9 
                  Amyloid beta 42 9 
Zamora et al. (2006) a beta 1-9 N/A   intramuscular B APPPS <168.1 >168 and <336.1 Amyloid beta 40 11 
                  Amyloid beta 42 11 
                  Cellular infiltrates 10 
                  Plaque area 10 
Zhang et al. (2006) TSG 120 umol/kg/d Oral B APP <168.1 >168 and <336.1 NORT 24 
                  Probe 24 
  TSG 240 umol/kg/d Oral B APP <168.1 >168 and <336.1 NORT 24 
                  Probe 24 
  TSG 120 umol/kg/d Oral B APP >168 and <336.1 >336 and <504.1 NORT 24 
                  Probe 24 
  TSG 240 umol/kg/d Oral B APP >168 and <336.1 >336 and <504.1 NORT 24 
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Age at assessment 
(days) 
Outcome measure N 
                  Probe 24 
Zou et al. (2008) A beta 1-15 N/A   INasal U APP >168 and <336.1 >504 Acquisition 9 
                  Amyloid beta 42 9 
                  Plaque area 9 
                  Probe 9 
  A beta 1-42 N/A   INasal U APP >168 and <336.1 >504 Acquisition 9 
                  Amyloid beta 42 9 
                  Plaque area 9 
                  Probe 9 
Cao & et al (2009) T cells 150000 cells Unknown U APPPS >168 and <336.1 >336 and <504.1 Amyloid beta 40 10 
                  Amyloid beta 42 10 
                  Cellular infiltrates 10 
                  RAWM 18 
 
 
Age at administration (days) 
 
 
Appendix III: Table explains experiments included in analyses conducted. For each publications are listed by author and year, intervention, dose, 
dose units, route of administration, sex (where U, unknown, M, male, F, female, and B, both), age at intervention administration (days), age at 
outcome assessment (days), outcome measure reported and number of animals used (N). Novel object recognition task (NORT), Radial arm water 
maze (RAWM) 
 




Appendix IV: Notes from working in the Morris 
laboratory 
 
Mice were handled extremely carefully and there were specific efforts to 
reduce both noise and distress. The task I had to do was to announce which 
mouse had to be assessed (identified by a hole in specific ear/coat colour), start 
the operating system by clicking “reference” on the specific mouse for a 
specific training trial. Vassilis would then start the experiment by pushing the 
button as the mice enter the pool. The software dictated the direction the 
mouse should enter the pool and where the platform should be positioned. 
When planning the experiments for the acquisition phase careful 
consideration was given as to whether mice had to turn “right” or “left” to 
avoid the mice learning where the platform was from a memory of specific 
movements. The system would take 0.1 seconds away from the measured time 
as an approximate response time from experimenters. 
 
The mice were inserted into the pool facing the outside wall and Vassilis was 
often in the room at the same time as the mice began their search for the 
platform. Interestingly, he alternates the way he leaves the room each time to 
try to reduce the influence he may have on mouse behaviour. No noise was 
allowed when the mice were searching for the platform in case this influences 
behaviour. At the start of the specific experiment I was working on, the mice 
were trained to find the visible platform and were in the maze for up to 90 




seconds. Upon completion of finding the platform, mice would remain there 
for 30 seconds and in the case that they did not find the platform mice would 
be placed on it for 30 seconds.  It’s an interesting point that knowing where 
the platform is doesn’t show the mouse how to get there- I rely on the mouse 
processing the surrounding environment in order to find the platform on the 
next trial. 
 
It was quite remarkable to note that some of the mice didn’t seem interested in 
finding the platform, even after multiple trials and although these mice would 
be included for the visible analysis of the MWM they would not be taken 
further in the experimental setup. It is unclear exactly why individual mice 
behave in this way as it could be that they do not understand the task set or 
conversely that they do understand the task set but lack the motivation to 
complete it. 
 
The next stage of the experiment was the acquisition phase where the mice 
were trained for 6 trials a day for a minimum of 3 days and a maximum of 10 
days, stopping on the day that they reached the criterion, which is average 
latency of <20 seconds for the 6 trials of the day. There was one probe trial 10 
min after that, another one 24 h later (both using the Atlantis platform) and a 
final one 7 d later, with no platform at all. Each time the mice reached the 
criterion (<20 seconds, which was quite stringent) they were given a probe 




trial using the Atlantis platform. The advantage of using the Atlantis platform 
is that it rises up at the end of the probe phase test and thus reduces the 
confusion for the mouse. Although time in target quadrant was being used for 
statistical assessment it was quite clear that different mice used different 
strategies to find the platform. Some mice would use spirals around the pool, 
whereas others would take relatively straight lines around the pool. Some 
mice appeared to understand the visible platform task extremely well but a 
number could not locate the platform in these 90 second trials.  
 
When mice left the pool they were put under a hot lamp to warm up before 
being put back into cages- and tubes for running around in with water/food 
were present at all times. Mice were given an active or control drug once per 
week. 
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